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The incidence of childhood asthma in the kingdom of Saudi Arabia (KSA) ranges 
from 4% in some regions to 23% in others. Although international and national 
guidelines have been issued to improve the management of asthma, their 
implementation has not been as expected or hoped for. For instance, while the 
guidelines recommend the use of inhaled corticosteroids (ICS) as the first choice in 
chronic asthma treatment, international research shows that the use of these agents is 
suboptimal. This holds true in KSA. Many reasons have been suggested for the lack 
of implementation of guidelines and the inappropriate use of corticosteroids, 
including poor patient knowledge, attitudes and education, physician confidence and 
performance, health care costs, and available facilities.  
This research consists of four phases investigating the current practice of asthma 
management among both patients (children and adolescents) and physicians in 
primary health care in KSA with regard to the Saudi National Protocol for the 
Management of Asthma; it identifies barriers affecting young and adolescent 
patients’ and their families’ adherence with asthma management protocols and 
adherence with ICS use. It also evaluates the effects of education intervention and 
the provision of asthma action plans (AAPs).  
The first phase documents current patterns of management of asthma in children and 
adolescents in KSA, to assess the pattern and appropriateness of corticosteroid use in 
childhood asthma and to evaluate asthma management practice in primary health 
care centres (PHCCs) against the national protocol. A total of 230 respondents 
(56.1% male and 43.9% aged 5 to <10 years), comprising patients (or their carers) 
from Asser and Riyadh, completed a survey using a translated hybrid of the FACCT 
quality measures (Adult Asthma Measurement Survey-version 2.0) and Asthma 
Therapy Assessment Questionnaire (ATAQ) to provide data on patterns of asthma 
treatment, degree of asthma control, use of AAPs and PFMs (peak flow meters), and 
levels of patient education and knowledge. The majority of respondents in both 
regions had asthma classified as either mild or moderately severe (85.7%). Only 
34.8% used ICS, while around two thirds (60.6%) used a β2 agonist only. Low 




as were regional variations. The conclusion is that asthma management tends to be 
inconsistent with national guidelines. Poor knowledge, attitudes, behaviours and self-
efficacy, as well as lack of communication between patients/ carers and 
professionals, contribute to unsatisfactory management outcomes. The majority of 
study subjects did not have well controlled asthma. 
The second phase investigates physicians’ compliance with the National Protocol 
Asthma Guidelines in two regions of KSA. A total of 87 physicians from Riyadh 
(44) and Asser (43) completed a survey of strategies for management of asthma. The 
majority reported access to The National Protocol for the Management of Asthma at 
the point of care. Information about medication was provided by 78.2% of physicians 
to patients with moderate asthma and by 85.1% to those with severe asthma. AAPs 
were provided by 36.8% of physicians for patients with mild asthma, 55.8% for 
patients with moderate asthma, and 69.0% for those with severe asthma. 
Recommendations to use ICSs varied from 16.1% to 88.5% amongst six vignettes 
reviewed by the physicians. Bronchodilators were commonly recommended, and in 
some cases oral corticosteroids were deemed inappropriate. Compliance with 
national guidelines was found to be less than optimal. Poor communication between 
health care providers and patients/ carers was observed.  
A third survey uses The Illness Management Survey (IMS) and ICS scales for the 
purpose of identifying the barriers affecting Saudi asthma patients; it finds that 40% 
of participants believed that medications were unhelpful and doctors did not involve 
the patient in decision-making. Fewer than 40% of respondents reported adequate 
access to information. Low use of AAPs and PFMs, with inappropriate treatment, 
was observed; and ICS use adherence in this phase was low, with less than one third 
of respondents reporting daily use of ICSs. A majority reported more than five 
barriers to adherence with asthma management in general and ICS use especially, 
including lack of knowledge, patient behaviours and attitudes, lack of self-efficacy, 
misconceptions, misunderstandings among patients/ carers, poor communication, and 
lack of motivation and social support. 
The fourth phase evaluates the impact of an educational intervention and the 
provision of AAPs on asthma management outcomes. One group of patients was 




Both groups A (n = 105) and B (n = 99) completed pre-intervention and post-
intervention surveys. Both groups completed three steps: (1) a baseline self-
administered questionnaire, (2) an education program, (3) a three-month follow-up 
period with the re-administration of the baseline questionnaire at the conclusion. 
Group A patients were also provided with an AAP. The education program improved 
patients’/ carers’ knowledge, behaviours/ attitudes, and self-efficacy, as well as their 
ability to communicate with health care providers; and resulted in improved asthma 
management outcomes. Use of controller medication and adherence increased. 
Furthermore, patients in the intervention stages had fewer asthma symptoms and 
better control of their asthma, which resulted in better quality of life. The conclusion 
is that the education program coupled with the provision of AAPs and follow-up 
achieved significantly better results. 
The overall of the study has found a number of differences in asthma management in 
KSA. In particular, an intervention and provision of AAPs and follow-ups led to 
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Medication issues, consisting of 6 variables (alpha=0.74);  
Doctor and other relationships, with 7 variables (alpha=0.76);  
Adherence influences, with 6 variables (alpha=0.64);  
Self-efficacy, with 4 variables (alpha=0.60);  
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Chapter 1   
Background 
This chapter provides the background on asthma among children and adolescents, 
backed by an in-depth literature review on patient self-management, patient 
education, and the role of physicians and the KSA primary healthcare service in 
asthma management.  
Asthma is considered one of the highest-incidence disorders in the world and is 
becoming more common in both adults and children, with about 300 million people 
worldwide suffering from it now and 400 million expected to suffer from it in 20 
years’ time (1). In Australia, 11.2 to 13.5% of children and 10 to 17.5% of adults 
have asthma (2). In 2002, 20 million Americans, more than 6 million of them 
children aged between 0-17, were diagnosed with asthma (3). KSA is an Asian 
country located in the Middle East. It is divided into 13 regions. In 2006 the KSA 
total population was 23,678,849, with 5,751,559 occupying the Riyadh region and 
1,733,845 the Asser region. The prevalence of asthma in general ranges between 4-
23%. The prevalence of asthma in Riyadh was 10% while in Asser it was 13% (4). It 
is one of the most common diagnoses made in health care centres (5). The total 
number of primary health care centre visitors in Saudi Arabia during 2004 was 
911,999, of whom 183,718 were aged 5 to14, and 456,551 were aged 15 to 44 (6). 
Most people who are hospitalized because of asthma are children, or those aged 65 
and over (5).  
There has been a decline in mortality from asthma in some parts of the world. For 
example, in Australia mortality declined from 397 in 2002 to 314 in 2003 (7). The 
numbers of deaths in which asthma was a secondary cause in the United States 
decreased from 5637 in 1995 to 4657 in 2002 (3, 7). In KSA during 2001, 1305 died 
of respiratory system disease, compared with 1718 in 1999 (6). Nevertheless, the 
mortality rate remains high in many parts of the world: WHO statistics show that 
180,000 people die each year from asthma (8). However, it has  been shown that the 
most of the deaths are preventable (9). One study reveals that 90% of asthma deaths 
in the United Kingdom were from avoidable factors (10). According to other studies, 
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the high level of morbidity is due to a number of factors, such as negative personal 
perception of patients about their own condition, lack of knowledge about asthma 
and medications, poor practice in the use of inhaler devices, and non-compliance 
with self-management. These strongly suggest that patient education has a role in 
decreasing morbidity and mortality amongst asthma sufferers (11-13).  
Asthma, like other chronic diseases, is associated with high social and financial costs 
(12). In addition to health care costs, there is loss of valuable time, whether of school 
or work. A greater proportion of people with asthma have been found to have days 
away from work or study (11.4%) than people without asthma (7.9%) (14). The 
estimated direct and indirect costs of asthma in Australia range from $585 to $720 
million annually (15); in 1998, the total cost in the United States was put at $11.3 
billion (3).  
1.1 Definition of Asthma 
Asthma is defined as  
A chronic inflammatory disorder of the airways in which many cells and 
cellular elements play a role, in particular, mast cells, eosinophils, T 
lymphocytes, macrophages, neutrophils and epithelial cells. In susceptible 
individuals this inflammation causes recurrent episodes of wheezing, 
breathlessness, chest tightness and coughing, particularly at night or in the 
early morning. These episodes are usually associated with widespread but 
variable airflow obstruction that is often reversible either spontaneously or with 
treatment. The inflammation also causes an associated increase in the existing 
bronchial hyper-responsiveness to a variety of stimuli. (14)  
Asthma may be classified as intrinsic (non-allergic) or extrinsic (allergic), as 
intermittent or persistent (mild, moderate or severe), according to severity and the 
presence and frequency of daytime and night-time symptoms; and as acute or 
chronic. Asthma symptoms are shared with other diseases such as viral infections, 
particularly in young children and the elderly. This feature makes it difficult to 
differentiate asthma from other wheezing disorders and to obtain an accurate 
measurement of how many children have asthma.  
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The causes of asthma are not fully understood, but some potential causal factors 
include atopy (allergy) and a family history of asthma, hay fever, or eczema. Some 
factors increase the risk of asthma development or trigger symptoms in people with 
asthma, including both internal and external environmental elements such as 
infections, air pollutants, inhaled allergens, weather changes, chemicals, living in 
disadvantaged areas, occupational hazards, drugs, smoking, levels of exercise, 
educational status, economic status, emotional stress and certain foods (4, 14, 16-18). 
Indoor factors (in the home, school, and work place) are most commonly cited, as 
most asthmatic patients tend to spend more time indoors (19-27). Other factors that 
aggravate asthma include under-diagnosis, lack of education, and poor health 
facilities and choice of treatment (28-35).  
Asthma treatment and optimal asthma control are affected by patient knowledge, 
education level, behavioural changes, adherence to management components, 
physician experience and confidence, and the availability of health care facilities. 
International and national guidelines have been developed to assist health care 
providers and patients achieve optimal asthma control; their recommendations 
include enhancing corticosteroid prescription, minimizing β2 agonist use, educating 
patients, and developing self-management skills. 
1.2 Asthma Management  
1.2.1 Asthma guidelines 
Asthma cannot be cured. However, symptoms can be prevented and controlled in 
most cases when the disease is diagnosed during the early stages, therapy guidelines 
are adhered to, and patient education is improved (36). To improve care, 
international guidelines (such as GINA, Australia and Canada guidelines) and 
national guidelines (KSA guidelines) for asthma diagnosis and treatment have been 
developed and updated over the past decade to help physicians and patients achieve 
treatment goals such as preventing chronic symptoms, decreasing morbidity and 
mortality, normalizing the patient’s daily activity levels, decreasing hospital 
admissions and emergency visits, reducing exacerbations of disease, maximizing 
lung function levels, prescribing suitable drugs to minimize adverse effects, reducing 
patients’ negative perceptions, and promoting physician and patient education; these 
also save time and money (4, 37, 38). The question is: have the international and 
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national guidelines achieved these goals in the world generally, and in KSA in 
particular? In specific, have these guidelines been disseminated to health care 
providers, and implemented? 
Scholars are divided. The guidelines are based upon strong, clear evidence, and 
studies show that they have helped to achieve the main objectives as far as 
diagnosing and treating asthma (39, 40). However, other studies such as Asthma in 
America, Asthma Insights and Reality in Europe (AIRE) and Asthma Insights and 
Reality in the Asia-Pacific (AIRIAP) indicate that asthma management falls well 
short of that recommended by the guidelines (10, 38, 41). For example, only 35% of 
American children can totally control their asthma (42). Furthermore, numerous 
studies indicate that the guidelines are not fully implemented by health care 
providers: two studies in KSA alone reflect this: the first conducted in the 
Emergency Department in King Fahd National Guard Hospital and the second in the 
National Guard Iskan Primary Care Centre (41, 43). Reasons for the lack of 
implementation as well as adherence to guidelines components are identified; they 
include under-diagnosis of asthma, patient perceptions of asthma and its 
management, inappropriate medication choice, and the type and quality of the health 
care centre – including the qualifications of its professionals, facility and costs, 
culture, communication, and health education (10, 42, 44-46).  
1.2.2 Asthma control 
Asthma control is the main goal of treatment underpinning asthma management 
guidelines, yet even its definition, classifications (from total to poor control), and 
assessment tools are controversial. Within guidelines, suggested measures of asthma 
control include minimizing day and night symptoms, bronchodilator use, and 
hospitalization or emergency room visits; preventing asthma attacks, and maintaining 
normal activity levels as well as normal lung function (47-50).  
Assessment of both asthma control and severity can depend on one or more of the 
following: symptoms, changes in expiratory flow, and airway inflammation. 
Assessment of results vary depending on the methods used, as asthma is a chronic 
disease with varying severity and levels of control over time, making it difficult to 
accurately assess it with one method at a particular point in time (51-53); hence, the 
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use of more than one method has been suggested in asthma control. Asthma control 
and degree of severity are related, yet, practically, they are different. Control is 
defined as sufficient disease treatment; severity is concerned with the fundamental 
process of the disease (54-56). However, some studies support the use of asthma 
control based on an asthma management approach rather than on severity (50, 54-
57). Five symptoms, namely being awoken at night, limitations of daily activities, 
morning waking with symptoms, dyspnoea, and wheezing, as well as short β2 agonist 
use and deficiency of lung function, are listed as the most important indications for 
control assessment in national guidelines across different countries (1, 4, 14, 49, 50). 
Despite the existence of such guidelines, achievement of optimal control is still lower 
than expected (57-63). A study conducted in Turkey, which involved children and 
adult asthma patients, used the Asthma Insights and Reality (AIR) surveys to 
estimate asthma control levels based on the Global Initiative for Asthma (GINA) 
guideline classifications. Only 1.3% of patients were found to have achieved an 
optimum control level, and around 75% and 90% of children and adults respectively 
were experiencing daytime symptoms (59). Patients tend to underestimate the 
severity of their asthma while overestimating their control level, and this 
phenomenon seems to yield similar results in several countries where AIR surveys 
have been carried out (57, 59). Inhaled corticosteroids (ICSs) have been 
recommended in persistent (mild, moderate, and severe) asthma, but the success of 
asthma control is largely dependent on adherence to ICS daily use (9, 64). Other self-
management activities, such as education, peak flow meter (PFM) use, monitoring of 
medication, trigger avoidance, inhaler practice, and use of asthma action plans 
(AAPs) are also mentioned as contributory factors (9, 61, 65, 66). 
The underestimation of asthma symptoms and severity level as well as 
overestimation of control level (reported among many asthma patients) (59) is one of 
several factors, which also include professional deficiencies in asthma care practices 
(diseases estimate, illness causes/ allergens, treatment, education, and follow-up of 
patients), comorbidities and the use of other medication, lack of self-management 
and lack of patient knowledge, low behavioural adjustment, economic, social and 
environmental factors, and poor adherence to asthma management guidelines (67). 
Research has found that the main factors contributing to patient noncompliance were 
costs of medication and time lost waiting at the pharmacy (68). Social and 
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environmental factors including lifestyle factors such as smoking, diet, and low 
physical activity, and less controllable elements like air pollution, have been 
associated with uncontrolled asthma.  
1.3 Corticosteroids 
1.3.1 Steroid use  
Corticosteroids are the cornerstone of asthma management, as asthma is now 
regarded as an inflammatory airway disease. The most common medical condition in 
children is viral infection inflammation combined with allergy (22, 69-72). In the 
past, asthma management used to be concentrated on asthma symptom treatment 
with the use of bronchodilators, and this method (that is, the use of β agonists) 
remained common in some areas despite the possibility of it causing fatal or near 
fatal asthma (38, 73-78). Currently, international and national guidelines focus on the 
use of corticosteroids as the first line of defence in asthma management. Studies 
indicate that corticosteroids have a positive effect on inflammation control, 
symptoms prevention, lung function, and quality of life, with a related reduction in 
asthma exacerbations, emergency department utilization, and hospitalization (79-82). 
Corticosteroids are widely reported to be more effective than other asthma drugs as 
long–term control agents (37, 50, 83, 84), yet they are used less frequently than 
expected (38, 85-87). International surveys show that inhaled corticosteroid (ICS) 
use ranges from 5.5% to 26% (57-59, 88). While some studies report an increase in 
the use of ICSs, their use is still considered suboptimal (38, 54, 85, 89, 90). A British 
study showed that the daily dose of ICS prescriptions increased from 69 million in 
1992 to 124.7 million in 1998, compared with 2 agonist, which increased from 130 
million to 170 million during the same period (75). Not only was low use of ICSs 
reported, but also non-adherence to regular daily use (74, 82, 85, 90-92). Such non-
adherence to treatment could be due to a number of factors such as lack of 
knowledge, poor self-efficacy, poor communication, misperceptions of the patient, 
age, level of education, health beliefs, accuracy of diagnosis, availably of health care 




1.3.2 Dosage and dosage form 
There is controversy over the most appropriate dosage and dosage form of 
corticosteroids, especially in regard to early treatment, dosage doubling, combination 
therapies (ICS and LABA), and route of administration. The National Asthma 
Education and Prevention Program (NAEPP) reported that the use of inhaled 
corticosteroids in mild or moderate persistent asthma in children was effective in 
controlling asthma with appropriate dose adjustment (37). Studies have shown that 
the most effective dosage for fluticasone and beclomethasone dipropionate (BDP) or 
the equivalent is 250 micrograms and 400 micrograms daily, respectively. Using a 
higher dosage, in the case of both drugs, or adding salmeterol to beclomethasone, 
slightly improves effectiveness (96, 97). However, the study by Reddel (33) noted 
that patients achieved total control with low doses. The percentage of exacerbation 
reduction was obvious in all groups, including those groups without total control. 
Rodrige’s study showed that early treatment using ICS and repeated doses of inhaled 
fluticasone of more than 3000 micrograms/ hour over 3 hours, compared with 500mg 
IV hydrocortisone, produced best results and earlier improvement for acute asthma 
patients (98).  
Despite some of the previous guideline recommendations that doubling the 
maintenance ICS dose may prevent and treat exacerbations, a study has shown that 
40% of both patient groups, those using maintenance (MS) doses and those doubling 
doses (DP), suffered from exacerbations (78). Interestingly, another study also 
reported that using four times the dosage of MS prevented exacerbations (99). In 
studies comparing inhaled, oral, and systematic (IV or IM) routes of corticosteroids 
for acute asthma treatment in children from 1–18 years, the systemic route was found 
to be more effective, capable of reducing both time spent in the emergency 
department and hospitalization (100). 
Although both international and national guidelines recommend regular ICS use as 
long-term control in asthma management, Boushey et al. (101) have shown that it is 
possible to treat mild asthma with short, discontinuous courses when needed. In 
contrast, Fabbri (83) has suggested that such irregular use may result in a change of 
asthma severity, and may affect lung function. One study that involved a comparison 
between adjustable maintenance and fixed doses with ICS/ LABA found that 
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adjustable maintenance doses minimized exacerbations, reduced the number of 
inhalations per patient per day, and increased the control of asthma and so could 
lower treatment costs (102). The addition of LABA to ICS as long-term medication 
to control moderate asthma has many advantages, such as improving lung function 
and alleviating symptoms, and reducing the need for short-acting 2 agonists (61, 
84). Bateman et al. (40, 84) found that total control was reached by 41% of those on 
fluticasone and salmeterol (FS), compared to 21% for those on fluticasone alone (F), 
while good control was achieved for 71% on FS compared to 59% of those on F. 
Fluticasone and salmeterol’s low dose and fast reaction resulted in a reduction in the 
exacerbation rate. Varying results were found in the OPTIMA study, where 
budesonide combinations and budesonide alone were compared as treatments of mild 
asthma patients. The difference in exacerbation reduction was negligible, but the 
investigators found that adding formoterol for patients who used an ICS was more 
effective than doubling the corticosteroid dose (103). Lemiere et al. recommended 
that initial mild asthma should be treated with ICS alone. This same study showed 
that combinations increased treatment costs, and that non-response to corticosteroids 
could have resulted from other factors (104). 
1.3.3 Adverse effects 
The side effects of corticosteroids range from local effects such as mouth infections 
and hoarseness of the voice to systemic effects such as endocrine abnormalities, fluid 
and electrolyte imbalance, and problems of the eyes, bones, muscles, immune 
system, and skin. Not all patients suffer these adverse effects, as their development is 
dependent on the dosage of corticosteroid, the dosage form used, and the duration of 
usage (105-108). There is clear evidence to suggest that ICSs are safe and effective 
in children when used at the recommended dose. Studies show that ICSs have a 
slight effect on growth in the initial stage of use (37, 84, 109), although it is 
suggested that their effects increase with higher doses and longer duration of use 
(109-111). However, there is also evidence that this effect may be due to other 
factors such as the illness itself or genetic or socioeconomic factors (106, 110, 111). 
Some research suggests that high doses of ICSs may result in adrenal suppression 
(105, 112). Studies differ in their findings regarding adverse effects of ICS on bone 
and eye (37, 84, 113). Tattersfeld et al. (112) found that moderate and high doses of 
ICS increased the risk of fractures with long-term use, but recommended that ICS 
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should be used to reduce the requirement for oral corticosteroid administration and to 
improve the quality of life of asthma sufferers. Calam et al. suggested that 
psychological problems were common among asthma patients, but noted that this 
may have been caused by general lack of health rather than by asthma itself (114).  
1.4 Inhaler technique  
The preferred mode of administration of asthma medications is by inhalation, which 
has been proven to be better than oral administration in terms of cost, effectiveness, 
rapidity of onset of action, and minimization of side effects (115, 116). However, 
these benefits may not be fully recognized by many patients, who lack knowledge, 
asthma education, understanding of their disease and its management, and the ability 
to use inhaler devices appropriately (68, 115-119). These problems may contribute to 
poor asthma management, including misuse of medications, overdose, poor asthma 
control and repeat hospitalizations, resulting in increases in both direct and indirect 
treatment costs (115, 116, 120). Suboptimal use and inadequate inhaler technique 
have been reported in many studies, even amongst patients who were educated (68, 
116, 117, 120, 121). A review by Cochrane found that, overall, patients took the 
recommended doses of their inhaled medication on 20% to 75% of days, and that the 
frequency of efficient inhalation technique ranged from 46% to 59% (117). Another 
study reported that 28% to 68% of patients were unable to use their inhaler properly 
(115). Factors contributing to such outcomes may relate to patients and their 
families, the physician, the illness, or the inhaler itself (117, 119). Lack of 
knowledge, education, and understanding of instructions, combined with a lack of 
skill amongst patients and their families, were considered to be the main contributors 
to non-compliance with inhaler use. A study conducted in the Netherlands involving 
66 patients (newly referred) aged 1–14 years, and a control group with 29 patients 
aged 5–10 years, evaluated the skills needed for inhaler use (101). Almost 91% of 
the 66 newly referred patients had been given some inhaler instruction, and 97% 
believed they demonstrated inhaler technique properly; however, just over half 
(58%) of the 66 children correctly applied all the steps necessary to get optimal 
inhalation, compared with 93% from the control group, who were educated more 
than once and received a six-week follow-up (121). Similar results were obtained in 
a study performed on a sample of 331 patients over 7 years of age in Trinidad, West 
Indies. Respondents were 10% children, 8% teenagers, 62% adults, and 20% elderly. 
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The study showed that 49% of children and 23% of teenagers had obtained 
instruction on correct inhaler technique, compared to 6% of the elderly group. While 
90% of the total sample reported that they had had a demonstration of the appropriate 
inhaler technique and 92% believed they were applying the appropriate technique, in 
fact only 41% applied all the correct steps (68). Education, training, and follow-up 
showed an increase of patients’/ carers’ ability to use inhalers correctly (117, 122). In 
another recent study, 81% of the children surveyed demonstrated improved inhaler 
technique at the end of an education session combined with demonstrations and 
follow-up by health care providers, compared with 8% before (120).  
In addition, education, demonstrations, written instructions, motivation, and follow-
up may improve patient compliance. A return to old behaviour or developing new 
errors over time was found in 50% of patients who reported poor compliance (120). 
Other factors reported to contribute to the failure of patients and their families to 
adhere to proper inhaler technique include patient/ family and health care provider 
relationships, their beliefs and preferences, psychosocial and economic factors, and 
the total number of inhalers in use (68, 115, 117, 120). Calculating remaining doses 
is another problem for patients using Metered Dose Inhalers (MDI) (68, 115).  
While health care providers’ qualifications, confidence, and understanding of proper 
inhaler technique enabled patients to use their inhalers properly and encouraged 
compliance with their medication, researchers have found that in some cases there is 
a lack of knowledge on the part of the physician and other staff (115, 123, 124). 
Comparison studies on the knowledge of health care providers, including house staff, 
nurses, GPs, pharmacists, and respiratory therapists (RTs), in MDI technique found 
that consultant staff (RTs) were more likely to understand the steps in the correct 
order of inhalation technique compared to others, but that most health care providers 
in all groups could not outline all steps accurately (123-125). Another study 
compared the use of MDI among patients who received prescriptions from the 
hospital and from their GP. Results indicated that hospital patients were likely to be 
more knowledgeable (126). 
Time pressure and lack of information sources were reported as the major factors 
influencing the health care provider (127). Kamps et al. reported on 29 patients who 
had been educated about inhaler use in a pharmacy and 31 patients who had been 
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educated in GP offices. They found 79% and 39% respectively were using their 
inhalers appropriately. The main difference between two groups was the education 
time (121).  
Regardless of the type of inhaler device, treatment efficiency is expected to be 
similar (115, 116, 128). It has been reported that there may be some confusion 
caused by having different types of inhalers, which may increase misuse among 
patients. Patients have demonstrated correct inhaler technique more often when they 
were using only one type of inhaler device than if they had to switch between two or 
more devices (115). Further, recent studies have found that patients are more likely 
to be tolerant of combination therapy (ICS and LABA) using a single inhaler than 
when using two inhalers (129-131).  
Inappropriate use of inhalers is primarily due to lack of knowledge and 
understanding about inhaler technique, combined with differences in the various 
types of inhalers. For example, inhalers that have a holding chamber (spacer) have 
advantages in that they simplify the process of receiving the inhalant and reduce the 
oropharyngeal airway drug deposition; yet spacers may affect the cost, cause patient 
error, and increase the size of the inhaler (68). In one study, only 18% of patients in 
the sample had advice about spacers (68). These examples demonstrate the need to 
educate patients with simple instructions together with demonstrations, with follow-
up by health care providers. The cost of medication also influences adherence of 
inhaler use (132, 133).  
International and national guidelines suggest that health care providers need to 
demonstrate accurate medication techniques and educate their patients in the type of 
medication delivery system used. Asthma guidelines recommend the steps that health 
professionals may use to educate their patients about inhaler technique, including 
coaching their patients through written instructions, giving practical demonstrations 
by a professional, requesting that the patient demonstrate the steps, and providing 
follow-up sessions to observe skills and deliver feedback to patients on how they 




1.5 Asthma Self-management 
Because asthma is a chronic disease, patients play a major role in controlling their 
condition, in partnership with health care providers (84). Through self-management, 
the patients and their carers can make day-to-day decisions about actions to be taken 
to control and to minimize the impact of the disease. The actions to be performed in 
order to prevent and treat asthma attacks are usually included in the self-management 
process (134). Self-management, in this thesis, is defined as   
effective behaviour regarding asthma, based on sufficient knowledge about 
asthma and its provoking factors, adequate coping behaviour, compliance with 
inhaled medication, attention to changes in disease severity, adequate 
inhalation technique, and the correct use of a peak flow meter. (135)  
Changes to the behaviours, skills, and understanding of patients, combined with 
emotional support, may affect their ability self-manage their condition. Self-
management, developed through patient–health professional relationships, may 
improve patients’ and their carers’ self-efficacy by providing and developing skills 
such as problem solving and goal setting, and by influencing behaviour which will 
help to improve asthma management outcomes and reduce both mortality and 
morbidity (136, 137). Self-management may also affect the socioeconomic factors of 
asthma for both patients and their families and for asthma carers. Achieving better 
asthma management is not easy. Barriers which may have a negative impact on 
successful self-management of the condition include patients’ emotional state, 
psychological influences, knowledge, literacy, race, language, and socioeconomic 
status, in addition to poor communication between patients and their family or health 
care provider (138, 139). A successful self-management intervention may reduce 
these barrier effects and improve management outcomes (13, 137, 140). Self-
management interventions may include self-monitoring, regular asthma and 
medication review,
 
a written asthma action plan, and exchange of information (8, 14, 
73, 141). These may lead to improvements in treatment outcomes, and reduce 
disease-related events including hospitalization, emergency room visits, unplanned 
doctors’ visits, and absence from school or work, as well as improving the quality of 
life (141, 142). Gibson reported that risk of hospital admission was reduced by 39% 
when asthma self-management interventions were introduced (143). Interventions 
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based on PFMs and adequate follow-up were found to have the greatest effect (142). 
An asthma self-management plan, coupled with education and regular follow-up, has 
been proposed as a key strategy in achieving the best possible outcomes in asthma 
management (1, 135, 144). Further, direct or indirect costs can be reduced with self-
management interventions combined with self-monitoring, asthma action plans 
(APPs) and regular reviews (141, 142).  
1.5.1 Self-monitoring 
Symptom and lung function monitoring are important issues in asthma management 
(84). The chance of having an asthmatic attack during the succeeding year, in a 
sample of children, doubled when the child was suffering from significant airway 
obstruction [Forced Expiratory Volume in one second (FEV1) < 60%] (145). 
Monitoring processes can assist patients and physicians or other health care providers 
to recognize an asthma attack early and control the disease. This may significantly 
influence health care costs and the value of health services (144). Monitoring may be 
used to determine disease severity, identify trigger factors, and assess response to 
treatment and the need for medication adjustment. As such, monitoring provides the 
necessary information for decision-making (90, 146).  
Airflow measurement by Peak Expiratory Flow (PEF) or FEV1 has been 
recommended by guidelines as a tool for self-monitoring. A PFM is cheap, easy to 
use, and ready available, which contributes to its wide use and popularity (18, 147). 
A PFM is used for initial diagnoses especially in patients with poor symptoms, for 
the detection of exacerbating factors, and in patient follow-up (18, 84, 148). PFM can 
help to evaluate the efficacy of treatment and the need for any dosage adjustment. 
PFM when combined with other interventions may also improve patients’ 
compliance with asthma self-management (147, 148); however, it has been found to 
be less reliable than other tools such as FEV1. Variations in PEF values among 
patients, and disagreement between some different types of PEF monitoring 
equipment values, have been reported (84, 143, 147).  
Guidelines recommend regular home monitoring of PEF to assess airway 
obstruction. The use of these devices encourages patients to actively engage in their 
care management, which may contribute to more effective decision-making. 
 
14 
However, low use of PFMs and low compliance with usage among both adults and 
children with asthma have been reported in several studies (87, 118, 143, 147, 149). 
Other studies have argued that the regular use of PEF measurement is not important 
in all cases (144, 146, 147), and some have reported that PFM is of no value in 
accurately predicting asthma severity and nor are asthma diaries; and that asthma 
action plans based on symptoms alone are as effective as those reliant on PFM, 
indicating that routine monitoring of PEF may not be necessary in all children (147, 
150). Whilst it has been suggested that having AAPs based on symptoms and PFM 
together may help to achieve better health management outcomes and reduce adverse 
effects such as patient poor perception of symptoms and over treatment (1), studies 
do not support this (143, 144). PEF monitoring may increase the cost of treatment, 
and so may lead to low adherence to self-management plans (18, 144). Other 
potential problems with PFM are the lack of conformity and dependability of written 
PEF diaries (144, 146, 147), time effectiveness (144), lack of compliance, data 
misrepresentation, and inconsistency of PEF charts (146). Studies have shown that 
compliance with PFM is high during the early stages of use amongst patients, but 
reduces to nil over a short duration (146, 147). Recently, electronic PEF monitoring, 
provisional communications through the Internet and SMS, and patient education 
have been suggested as ways to enhance adherence (143, 146, 151). Patients should 
be educated and trained about self-monitoring tools such as how to use and read, 
record, and express (communicate) the results, as well as be motivated to use them; 
and they should be followed up (118, 143).  
1.5.2 Asthma Action Plans (AAP) 
Although some studies have found that an AAP based on PFM is helpful, a plan 
based on PFM or symptoms or both is recommended (37). Turner and colleagues 
compared PFM-based and symptoms-based AAPs coupled with education amongst 
adult patients (118). Although some improvements were found in asthma 
management outcomes, there were no significant differences between groups. AAP 
compliance in both groups (PFM and symptoms) was less than optimal (65% vs. 
52%) (144). Jin et al. reported that patients with an AAP based on PFM required 
fewer emergency room visits than groups with no AAP or with AAPs based on 
symptoms. Although asthma control was improved in all intervention groups, the 
effectiveness of the peak flow-based action plan as a short-term protection from 
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asthma severe exacerbations was indicated (152). Bhogal et al. found similar results 
for children when reviewing five studies comparing patients with AAPs based on 
symptoms and PFM results (128). No differences in outcomes were found between 
groups, including rate of exacerbations requiring oral steroids or hospital admission, 
absence from school, lung function, symptom score, and quality of life (153). 
Lefevre et al. reviewed nine studies which compared the effect of AAP with or 
without peak flow monitoring or action plan on asthma management outcomes. They 
reported that the effect of AAPs on the outcomes did not support their use in all 
patients, so that to insist upon them might be a waste of resources (154). Zemek et al. 
found that using AAPs based on symptoms was more helpful, and favoured by 
children over a PFM-based AAP; however, other studies have found that there is no 
difference in outcome between AAPs based on PFM or on symptoms (1, 155, 156). 
As the asthma experience differs from one patient to another, a tailored AAP needs 
to be developed to suit an individual’s needs (156). Guidelines recommend a self-
management plan as an important component of asthma treatment. It may be based 
on PFM, or symptoms, or both. Improvement in asthma management outcomes such 
as asthma control, quality of life, medication use and modification, reduction in 
disease morbidity, and health care consumption, were found when a written AAP and 
patient education were part of the treatment, among both adults and children (156). 
AAPs have been recommended to all patients. One study showed a significant 
decline in asthma attacks requiring urgent treatment in a group of patients who used 
AAPs based on PFM after six months: p=0.002 (152). Adams et al. reported that the 
use of an AAP was more likely to reduce a patient’s hospital admissions and re-
admissions (157). Another study reported a significant decrease in β2 agonist daily 
use (p=0.008) and an increase in daily ICSs (p=0.001) with patients who had an AAP 
based either on PFM or on symptoms, combined with education (144).  
Additional information included in an AAP includes trigger factors, emergency 
contact numbers, and exercise instructions; these are aimed at improving outcomes 
of asthma management and enhancing communication between patients and parents 
or physicians. There was some indication that patient behaviour can be changed with 
the use of an action plan: Adams et al. found that patients who had an AAP were 
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more likely to interact and participate in decision-making (158). At least 53% of a 
sample of 228 coronary heart disease patients reported continued behaviour change 
three weeks after the date when they were provided with an action plan (159). 
Furthermore, a recent study of 70 participants, conducted to estimate exacerbation 
frequency and usefulness of an AAP, divided responses into a yellow zone in which 
albuterol was used more than three times a day and/ or more than two nights episode; 
and a red zone where systematic corticosteroid or urgent health care visit were 
required; it revealed that nearly 80% had persistent asthma. More than 66% of the 
sample had experienced yellow-zone exacerbation at least once during the three-
month period of the study, and 27% had experienced red- zone exacerbation. Ninety 
percent of the patient carers in this study agreed that the asthma action plan was 
helpful in asthma exacerbation treatment (160); however, use and adherence to AAP 
still remains suboptimal (38, 61, 87, 89, 90, 158, 161-163). Wilson et al. found that 
the use of self-management asthma plans in South Australia decreased from 42.3% in 
1995 to 22.2% in 2001, while the disease prevalence increased from 8% to 12.8% for 
the same period (164).  
There is evidence that physicians have a role to play in the lack of AAP deployment 
and guideline implementation (153, 165, 166), as do patients and their families who, 
while having an AAP, question its usefulness either because they do not have enough 
information about asthma and possess inadequate self-management skills, or because 
they have a low level of communication with health care providers and limited 
involvement in decision-making (153, 160, 166-168). A number of studies have 
suggested that self-management behaviour and asthma management outcomes may 
be improved by providing intervention programs for patients and/ or their family as 
well as for professionals, influencing patient-provider partnerships and medical 
review (156, 165-169).  
1.6 Education 
Asthma management is not limited to medication: as Fink declared, ‘Management of 
asthma disease is 10% medication and 90% education’ (170). Education is 
instrumental in encouraging the implementation of guidelines to manage chronic 
diseases such as asthma. For best results, education should be aimed at all concerned 
parties: patients, families, and health service providers.  
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Education can include aspects of the pathophysiology of the disease, symptoms, 
triggers, medication function, monitoring, device techniques, and self-management 
skills. Patients and their families should be educated in how to present information 
and discuss their issues with health care professionals. Improvement in asthma 
management outcomes have been reported after education programs, compared to 
usual care (171). 
The objectives of education are broad-ranging and include not only delivering 
information but also implementing behaviour change and encouraging patients and 
health care professionals to incorporate this change into their daily practice. As the 
sole intervention, education may not improve some aspects such as self-efficacy and 
outcome expectancy; so it is suggested that intervention programs should also 
include workshops, focus groups, feedback, and follow-up (172). 
A study in New York which surveyed 6,672 patients and parents found that 78% 
could recognize primary asthma symptoms and 87% knew how to manage an asthma 
exacerbation (85). The study found that 89% of participants were provided with good 
or very good information from their health providers, while more than 80% were 
supplied with a written action plan, and were taught about inhaler and PFM use. 
However, 84% of participants reported using their medication only when they had 
symptoms; of the 75% who used ICS, only 38% reported daily use; and while 51% 
reported PFM possession only 18% of these had changed their medication as a result 
of PFM monitoring (85). From these results, the authors indicated that a relationship 
between communication and education as well as compliance with management 
regimens could be inferred; they suggested focusing on the quality of education. 
Guidelines consider education to be part of asthma management, but a lack of 
education among asthma patients has been reported: a lack of knowledge about 
asthma, the disease and its management, as well as misunderstandings regarding 
device use, have been reported (59, 65, 68, 77, 90, 161, 173-176). A study conducted 
in 29 countries revealed that 39–70% of patients believed that their asthma was well 
controlled or under complete control, when in fact they had moderate symptoms 
(58). One survey showed that 67% of respondents reported familiarity with reliever 
medications, yet only 59% of these correctly identified the one they used and 24% 
believed that it should be used daily. Further, 74% of respondents reported controller 
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term knowledge, with 63% of these correctly identifying the one they had and 26% 
believing that it should be used on an as-needed basis (90).  
Patients’ attitudes, perceptions, beliefs and behaviour skills have been reported as 
another concern. Patients make decisions depending on their knowledge, beliefs, and 
experience. A number of studies have reported low ICS use and/ or adherence among 
asthma patients (38, 57, 58, 65, 177). It has been suggested that patient/ family 
concerns about the disease and medication, such as side effects, lack of 
understanding the role of medications, inhaler technique problems and poor 
communication with their professionals, are all reasons behind the low adherence to 
ICS use (54, 65, 85, 90, 177-179). Boulet (179) found that 59% of respondents were 
afraid of using ICSs, and 39% reduced the prescribed dose. Low ICS use was 
reported amongst patients with severe asthma, with 50% or fewer having had the 
chance to contact a health care professional in the previous three months (180). 
Burkhart et al. found that 92% of respondents were incorrectly using their inhaler 
during a pre-intervention or test; 19% made mistakes even after an intervention. It is 
indicated that one-time instruction may be inadequate (176) .  
Any shortfall in education may result in mortality, morbidity, and high health care 
costs. One study showed that 90% of asthma deaths in the United Kingdom were 
avoidable. In some cases, patients and/ or their family did not believe that asthma is 
chronic disease (9, 58, 173). Forty per cent of asthmatic patients reported they had a 
chronic disease while 53% reported they had asthma only when they had symptoms, 
and they were less adherent with ICS use and other self-management skills (65). 
Further, increased consumption of health resources may associate with a lack of 
education. Lack of self-management may lead to unscheduled clinic visits, hospital 
admissions, and emergency room attendances. It has been reported that the frequency 
of unscheduled clinic visits ranges from 25% in Western Europe to 47% in Japan 
(58); further, 13% and 23% of Japanese and United States patients respectively 
present to the emergency room each year (58). Another study has shown that 44.2% 
and 30% of participants had unscheduled clinic visits or emergency attendances 
respectively during a single year (54). Of 206 children involved in a study in KSA, 




Parents’ knowledge, beliefs, worries and psychosocial issues may be important 
factors affecting asthma management, particularly in young children (134, 160, 181-
183). It has been suggested that parents often lack necessary information about how 
their child should use their medication and inhalation device. This is a concern; in 
one study which reported a lack of patient knowledge regarding some aspects of 
asthma and its managements, a number of patients reported that they usually received 
their education from their family and/ or friends, and in 21% of cases these were the 
only sources for education (161). 
A recent study was conducted on 67 patients and parents to determine the correlation 
between parents’ concerns about preventer medication and adherences: 75% of 
parents strongly believed that their child’s medication was necessary for their health 
and 34% reported that they worried about the medication. Poor adherence among 
patients whose parents held greater concerns was recorded (183). An Australian 
study found that more than half (51%) of parents reported they lacked adequate 
information about asthma triggers, 60% of children had low adherence to preventer 
medication and 48% did not have an AAP (162). These findings support the need to 
involve parents in asthma education programs. 
Lack of knowledge about asthma diagnosis, its management, and the use of inhalers, 
self-efficacy and outcomes expectancy, together with poor communication skills and 
compliance with management guidelines and variations amongst the practices of 
health care providers, have been reported in several studies (90, 115, 184-195). Some 
of these investigators and others suggest that education programs for health care 
providers may improve asthma management outcomes (55, 90, 190-192, 196-199). 
One study in Canada showed that only 6% of physicians (specialists and primary 
care) always, and 33% sometimes, followed the guideline recommendations (90). 
Cloutier et al. found that physicians’ adherence to recommendations, such as 
prescribing ICSs, improved amongst those who undertook an education program, and 
this contributed to reduced hospital admissions and emergency room attendances 
among child with asthma (199). Further, educating health care providers improved 
their relationship with patients and their communication skills, which positively 
affected asthma management outcomes and compliance among patients/ family (180, 
182, 187, 189, 196). Poor education is expected to result in poor management 
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adherence, strained patient-physician relationships, and suboptimal asthma care 
outcomes.  
It is evident that patient knowledge, literacy level, socioeconomic status, 
psychological and cultural factors, and familiarity with asthma care may all affect 
patient participation, which, in turn, influences compliance with asthma management 
(58, 90, 197, 200, 201). Simplifying the education materials, utilizing the available 
resources, using supporting media, and encouraging the participation of health care 
providers may positively influence the education process (202, 203). 
1.7 Barriers to Adherence to Asthma Management Guidelines 
ICSs are recommended in international and national asthma management guidelines 
based upon evidence that they can improve treatment outcomes. A number of studies 
have found that there is a correlation between non-adherence to controller medication 
(corticosteroids) and both morbidity and mortality among asthmatic patients, as well 
as an increase in health care service utilization and cost (79, 80, 82, 204, 205). Suissa 
et al. found that hospital admission and readmission rates were reduced by 31% and 
39% respectively amongst patients adherent to their ICS regimen (80). However, 
numerous studies have shown that the use of ICS amongst patients is low, and that 
adherence to therapy is also poor (38, 54, 57-59, 74, 85-88). Several studies have 
reported barriers that may reduce patient adherence to asthma treatment in general 
and to treatment with ICS in particular. These barriers are related to the medication 
(corticosteroid), the patients and their families, and physicians and other health 
workers (34, 183, 206-214). Lack of knowledge, misconceptions, beliefs, concerns 
and attitudes regarding asthma and its management, coupled with patients’ and 
carers’ characteristics such as lack of self-efficacy, limited physical ability, and 
socioeconomic and psychological barriers may contribute to low adherence, as may 
poor communication between patients/ carers and health care providers. Patients and/ 
or carers may be affected by one or more of these barriers (85, 86, 91, 93, 207, 214, 
215). Bender et al., when reviewing 29 studies conducted to evaluate patients’ (adult, 
adolescent, children and/ or their parents) barriers to adherence income status 
classified the most common of these barriers according to their significance (i.e. 
either having low or high patients emphasis). In addition there were differences in 
the barriers reported and emphases placed on barriers by adults, children and/ or 
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parents as well as those in the low income group. Stigmatization barriers were found 
to have the most influence on children, while concerns about medication side effects 
were reported among all groups as one of the most common barriers (204). Steroid 
phobia has been reported as the most important barrier in a number of studies (177, 
179, 204, 209, 215). Mothers who feared there would be corticosteroid side effects 
were less likely to let their children use ICSs and more likely to reduce the dose 
when they did (215). Drug and health service costs also tended to reduce ICS use 
(133, 204, 216) (14, 17, 19-21). For example, one study found that families with low 
incomes were less likely to use ICS (216).  
Knowledge is a further barrier. Patients’ understanding of their disease and its 
severity, together with the function of medication, influences treatment adherence 
(65, 177, 179, 209, 212). Some patients believe that they have to use their medication 
only when they have symptoms (65). It has been found that misunderstanding of the 
drugs’ side effects (i.e. the belief that it causes addiction) may cause patients to 
reduce ICS use (215). Lack of education, low income, type of information sources, 
culture, time, age, gender, patient-physician relationship, and poor perceptions of the 
utility of ICS are other barriers relating to patients or families that have been reported 
as factors contributing to decreased ICS use (179, 210, 211, 213, 215, 217): Gazala et 
al. reported that mothers with concerns about ICSs tended to be influenced by 
information received from unqualified sources (215). In addition, patients’ or their 
carers’ psychological, social and personality barriers such as forgetfulness, 
reluctance or denial, difficulty using an inhaler, peer or family influence, absence of 
motivation, inconvenience, time, and embarrassment were found to be barriers to 
adherence (93, 204, 207-209, 218). Rhee et al. found that 63% and 53% respectively 
of participants reported reluctance and forgetfulness as the main barriers affecting 
their adherence (207).  
Health care providers also have an effect on ICS use. Physician–patient relationships, 
good communication, patient discussion, and follow-up are factors noted in several 
studies as important elements which may affect ICS prescription and adherence (93, 
177, 218, 219). Boulet found that while most participants reported concerns about 
their medication, only one third of respondents had discussed their ICS concerns with 
their health care providers (179). Logan et al. grouped adherence barriers in four 
 
22 
domains: disease/ regimen issues, cognitive difficulties, lack of social/ self-efficacy, 
peer/ family issues, and denial/ distrust factors (206).  
1.8 Value of Asthma Education Programs and Asthma Action 
Plans 
Daily responsibility for chronic disease management lies mostly with patients and 
their family members. As the majority of the patient’s time is spent away from health 
care centres, self-management is an important component of chronic disease 
management. Through effective self-management, patients are able to assess their 
current health status and make whatever clinical, cognitive, behavioural and 
emotional adjustments are needed to sustain a reasonable quality of life (140, 142, 
220, 221). Traditional patient education may improve chronic disease management 
outcomes; however, intervention programs based on both social learning and self-
regulation theories have proven to provide better results in terms of clinical outcomes 
and improvement in self-management skills than traditional education programs 
(140, 142, 221-223). In addition, a strong sense of self-efficacy, which is definition 
by Bandura as ‘one’s capabilities to organize and execute the course of action 
required to manage prospective situations’ (142), has proven to be beneficial for 
patients’ ability to manage their own chronic illness, which in turn has been related 
to a range of positive outcomes such as improved health, better accomplishment, and 
social integration (223-225). Furthermore, collaborative care, where the health care 
decision is taken by both the patient and his/ her health care provider through a 
continual working relationship that results from understanding of roles and tasks, 
sharing goals, and acquiring skills for executing their roles combined with self-
management education, is more valuable than traditional advice (140, 220, 223, 226). 
Knowledge, self-efficacy, involvement in decision-making, and behaviour have 
improved among patients and carers who undertook intervention programs. These 
factors contribute to enhancing asthma management outcomes (35, 67, 135, 173, 
203, 225, 227-235). From the previous studies, it should be noted that intervention 
programs may differ, depending on who delivers them (such as a health care provider 
or peer), the setting (clinic, school, home) and presentation methods (computer, 
DVD, chalkboard). Knowledge has also been reported to improve among family 
members who undertake intervention programs (134, 135, 203, 234). The influence 
of knowledge and understanding is illustrated by a study in which patients answered 
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80.7% of a questionnaire in a correct manner after undertaking an education 
program, compared with 60.4% before the program (135). Furthermore, 
improvement in asthma control, symptom-free days and/ or nights, enhancement of 
quality of life and better health care usage were found among asthma patients who 
had been educated (134, 223, 227, 228, 230-239). Studies have indicated that patients 
with AAPs and a training program reported fewer hospital and unscheduled 
physician visits, emergency room attendances, school or work absences, all of which 
resulted in reduction in asthma-related costs compared with patients receiving 
normal care (67, 173, 228, 230, 232, 233, 235, 237, 240-243). Kelly et al. found that 
emergency room attendance and hospital admission rates amongst an intervention 
group declined from 3.6 to 1.7 and 0.6 to 0.2 per patient/ year, respectively (241). 
Costs for the intervention group reduced by $721 per patient/ year compared with 
$178 in the control group; most of this saving was due to reductions in hospital 
admissions (241). Evans et al. found that the patients’ school performance improved 
more amongst the educated group than the control group, although no significant 
differences in school attendance were reported; the authors suggested that this might 
be because the majority of the sample had only mild severity asthma (227). Similar 
results were reported by Clark et al. (238).  
Intervention programs may influence compliance with medication and improve 
inhaler technique (135, 173, 223, 232, 233, 237, 239, 241). For example, in an 
educational intervention study, ICS daily usage as a controller drug increased from 
58.8% to 91.8% and inhaler technique improved from 38.2% to 95.6% amongst 
patients after the education program (173). Another study found that using anti-
inflammatory drugs increased from 34% at baseline to 95% after a year amongst the 
intervention group, but only from 60% to 65% in the control group, although the 
latter reported higher percentage use at baseline than the intervention group (241). 
Turner et al. found similar results, with adult patients using AAPs who were 
educated for a period of six months showing a reduction in their daily use of 2 
agonist and increased use of ICS (144). AAPs and education with follow-up are 
recognized as major factors in achieving best asthma treatment outcomes. 
Intervention programs and asthma self-management plans may improve the asthma 
and medication knowledge of patients and carers, as well as self-efficacy and 
behaviour (134, 135, 225, 234, 239, 244). Recent studies suggest that while 
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knowledge is influenced by education, sharing decisions with the patient/ carer and 
providing AAPs improve health outcomes as result of better compliance with asthma 
management (203, 235, 239, 245). It is clear that when it comes to chronic disease 
control, not just medication but education plays an important role. Education 
duration and follow-up, the suitability of programs (whether interview, individual 
consultation, written instruction), delivery method and content, facility and setting, 
plus the age, culture, socioeconomic and education level of the patient have been 
demonstrated as factors that can influence the outcomes of intervention programs 
(13, 67, 173, 203, 225, 234, 235, 239, 246).  
1.9 Quality of Primary Health Care Centres 
Worldwide, many patients suffer chronic illnesses. One study shows that 120 million 
Americans suffer from one or more chronic diseases, with the cost of treatment 
representing 70–80% of total health care costs (221). In general, primary health care 
centres (PHCs) are the first choice of patients. Recent studies in KSA found that 
primary health care centres were preferred by 60% of participants for the 
management of their illness (247). Worldwide, it is evident that most patients do not 
have good quality health services (41, 43, 248-251). Lack of, or wide variance in the 
quality of, primary health care has been reported within and between countries (247, 
252-254). Poor health care may be the result of one or more problems of access and 
effectiveness, which may affect some or all services in PHCs (255, 256). A review of 
31 studies evaluating the quality of PHCs in KSA regarding access to and 
effectiveness of clinical and interpersonal care found that while good access and 
effectiveness were reported of some services such as immunization programs, there 
was poor access to and low effectiveness of other services, including chronic disease 
management and education programs as well as specialist referral and prescribing 
patterns (247). Interpersonal care was affected by differences in culture and language 
between patients and health care providers, contributing to poor communication 
(247, 256). A study of PHCs in Riyadh, Saudi Arabia, found that while patients and 
their families reported satisfaction with some aspects of their care, there was 
dissatisfaction with other aspects such as PHC locations, working hours, waiting 
times, overcrowding, lack of specialized clinics, inadequate medicine and equipment, 
unsatisfactory health care provider skills, language barriers with professionals, poor 
communication, and inadequate consultation times (255-257). Other studies have 
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reported a number of barriers to health care quality (41, 247, 254, 256). These 
barriers may relate to PHC settings and the organization or patients and their 
families, as well as of health care providers. They include poor implementation and 
adherence to guidelines and recommendations such as prescribing patterns, lack of 
follow-up, patient education or referral to specialists, poor qualifications and 
training, lack of motivation among administrative and professional staff, inadequate 
care environments, poor team work, language and cultural differences, short 
consultation times which may lead to insufficient communication between patients 
and professionals, and a lack of resources and facilities such as essential medications, 
laboratory items, devices, information system access and care centre access (166, 
247, 250, 252, 255). Added to these, patients’ and their families’ knowledge, 
satisfaction and compliance with management care plans are other potential barriers 
to the quality of PHC care, particularly with chronic diseases (166, 247, 250, 252).  
Facilities at PHCs may also not be suitable for treating patients of chronic diseases if 
there is a lack of proper medicine and equipment (42). One study evaluated the 
concerns of 49 GPs divided into six groups, from urban and rural areas, regarding the 
achievement of optimal outcomes in asthma patients and the care delivery barriers 
they faced (141). It was reported that education for both patients and professionals 
was the major priority of all groups. Medication availability and safety, regular 
treatment review, consultation time, and costs were other concerns (165). 
Worldwide, health services may be inadequate in some areas due to the lack of 
facilities and/ or capable health staff (50, 187, 247). For example, in the United 
Kingdom, 58% of the asthma patients in one study were prescribed inappropriate 
medication and were treated primarily by GPs in PHCs (258).  
1.10 Physicians’ Use of Guidelines 
Guidelines have been developed to assist health care providers in clinical practice to 
provide quality asthma care. Attributes such as adequate knowledge, experience, 
communication skills, and confidence are all identified as essential. These attributes 
are important in all aspects of asthma management practice, including diagnosis, 
treatment, caregiver–patient collaboration, patient education, and follow-up. Health 
care providers’ adherence to such guidelines may improve the quality of care, and so 
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lead to optimal asthma management outcomes including improved patient knowledge 
and behaviour, self-management, adherence to treatment regimens, quality of life, 
asthma control, and a decrease in the socioeconomic effects of asthma. However, 
adherence to guidelines amongst health care providers remains limited. Physicians’ 
non-adherence can be observed in their inadequate assessment of asthma severity and 
the consequent inadequate treatment, in addition to an increase in hospital 
admissions and ER attendance. A study of 101,544 consultations by 235 general 
practitioners across several countries found that asthma ranked as the sixth most 
common diagnosis, varying from 1.8% in Italy to 5.8% in Ireland (259). However, it 
was also found that most asthma outpatient clinics were inadequately managed (259). 
A study conducted in 15 health care facilities in the United States surveyed 254 adult 
asthma patients and found comparable results: about 15% of patients had been 
hospitalized for asthma at 1-year follow-up, and only 22.9% of these patients had 
PFMs; 56% of patients with allergies had been educated in how to avoid allergens, 
and had been recommended for official allergy testing (260). A high percentage of 
patients (94.6%) used β2 agonist inhalers either in overdose or in combination with 
an oral β2 agonist. Patients also tended to have a lack of understanding about acute 
asthma attacks (260).  
Often asthma patients present at Emergency Departments (ED) having had visits to 
the primary care facility where they may not have received appropriate management, 
exemplified by such problems as low use of ICS, lack of an AAP, no PFM, or 
delayed follow-up (161, 187). Reeves et al. in their evaluation of asthma care and 
management for children before their attendance at three ED locations (urban, 
suburban, and rural) found that 54% of the 197 participants had persistent asthma 
and 61.4% had attended ED at least once the previous year (187). They found that 
PHCs were the main setting for regular asthma management, with 187 (95%) of 
patients reporting they had access to a PHC. The authors reported that physicians did 
not always adhere to some of the NAEPP recommended guidelines (187). For 
example, only 18% of patients had seen a specialist; 61% and 43% had a PFM and an 
AAP, respectively. Only 14.5% of patients who had a PFM used it regularly. More 
than one third (36.5%) of the patients were considered undertreated (with no 
controller medication). While most patients reported they had been well educated 
about some issues such as medication, asthma triggers, nebulizer use, and asthma 
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attack management, 41% and 46% had received no instruction on how to use a PFM 
or an AAP, respectively. Differences were evident between primary clinic provider 
practices in aspects such as PFM use, hospitalization, and the use of preventer 
medications, although the authors noted that this could have been due to the small 
sample of participants from each site (187).  
Most the asthma patients are treated by general practitioners (GPs). No significant 
differences in medication use between patients treated in asthma clinics and those 
treated in non-specialist clinics were discovered in a study conducted in England at 
six general practices, five of which had asthma clinics (258); however, more than 
half (58%) of the patients were prescribed an inappropriate drug which was not 
consistent with the guidelines. The authors concluded that physicians’ experience, 
age, and education might affect their compliance with guideline recommendations 
(258). Other studies have shown that GPs’ practices often fail to comply with 
guideline recommendations (87, 184, 195, 261). In Belgium, a study comparing 356 
GPs’ assessment and treatment of 1376 patients with the GINA Guidelines found 
that the asthma severity of 78% of patients was correctly assessed, while 20% were 
under-estimated and 2% over-estimated (261). Only 37.5% of the sample were 
correctly treated accordingly to the GPs’ severity assessment and the guidelines, 
while 29.6% and 32.9% were under- and over-treated, respectively (261).  
Inaccurate assessment of asthma severity by physicians leads to inappropriate 
management. Studies conducted with asthmatic adults and children to assess the 
effect of asthma severity assessed by physicians found that patients with poor 
outcomes including asthma control, ICS prescription, and PFM use had had the 
severity of their asthma underestimated by their physicians (193, 262). 
Variation in asthma management practices between countries has been reported (38, 
259). Jepson et al. conducted a comparison of the prescribing patterns in primary 
care of 235 GPs from six European countries (259). Variations in asthma prescribing 
practices were found: for instance, the use of ICSs in children ranged from 12% in 
Portugal to 34% in Ireland, while in adults it ranged from 14% in Italy to 31% in 
Ireland. A wide range of ICSs, such as beclomethasone, fluticasone, and budesonide, 
were used. There were wide variations in the use of β2 agonist (short- and long-
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acting) in children and adults (259). These studies and others illustrate that poor 
adherence to guideline recommendations are common (38, 184, 187, 189, 260, 262). 
Practice has been shown to vary between physicians. It has been found that specialist 
physicians and experts are more likely to comply with asthma guidelines than their 
GP counterparts (115, 163, 186, 193-195, 263, 264).  
A number of issues which may relate to health care providers, patients and their 
families, primary health care facilities, and lack of resources have been recognized as 
probable barriers to effective guideline adherence among primary health care 
management. These constraints may have different effects on all or some of the 
guideline recommendations, such as use of ICSs, PFMs, written AAPs, avoidance of 
triggers, and patient education (172). 
1.11  Barriers Affecting Physicians’ Adherence to Guidelines 
There are many barriers influencing physicians’ adherence to practice guidelines. 
These barriers are classified into three groups: 1) physicians’ knowledge barriers 
(e.g. lack of awareness of or familiarity with the guidelines), 2) physicians’ approach 
and ability barriers (e.g. lack of agreement, self-efficacy, outcome expectancy, and 
motivation/ inertia of previous practices) and 3) external barriers (e.g. guidelines, 
environmental, and patient-related factors) (265). These groupings were constructed 
by Cabana and colleagues after reviewing 76 studies of barriers to physicians’ 
general guideline adherence (265). The study focused on barriers which might be 
changed by an intervention, and the grouping was based on the effect these barriers 
had on physicians’ knowledge, attitudes or behaviours. It concluded that barriers are 
dependent on practice settings and that findings in one setting cannot be generalized 
(265). 
As asthma is one of the chronic diseases, worldwide, several studies have been 
conducted to evaluate health care provider practices (163, 188, 190, 193-195, 198, 
259, 264, 266, 267). Some of these, and other studies, have identified barriers to 
compliance with guidelines, and most have similar findings (172, 190, 191, 266-
271): lack of physician knowledge, awareness, familiarity and agreement with 
guideline elements, in addition to lack of physician self-efficacy and outcome 
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expectancy, are the main barriers to successful implementation of asthma guidelines. 
Adherence to guideline recommendations may be affected by one or more barriers, 
(172), and associated factors may also influence compliance. For example, 
physicians’ lack of awareness may be associated with their lack of time to become 
informed; and poor access to guidelines may be a result of poor self-efficacy 
associated with lack of time and resources to advise and discuss guideline 
recommendations with patients and family, a lack of training programs, of 
reimbursement, or of structures to ensure continuity of care through follow-up (191).  
Lack of physician knowledge, awareness and familiarity of guidelines has been 
reported. Halterman et al. and Wolfenden et al. found that physicians underestimated 
the severity of asthma in most patients, and so provided them with insufficient 
therapy (189, 262). As few as 40% and 50% respectively of the participants in their 
studies were given an accurate estimation of their asthma severity and control 
medication (189). The primary reason was considered to be limited physician 
awareness of guideline recommendations. A study conducted in Karachi, Pakistan, to 
evaluate national guideline adherence among physicians’ current practices found that 
lack of knowledge, approach, and poor adherence to guideline recommendations 
including high use of short-acting 2-agonists and low prescribing of steroids with a 
variety of doses, forms, and routes of administration, contributed to poor adherence 
(184). Another study of 62 participants showed that more than half (33) did not have 
an AAP; of these 33, only 11 reported that AAP was prescribed to them by their 
physicians (168). In a further study, Cabana et al. found that physicians’ 
unfamiliarity with guideline recommendations was more likely to affect adherence 
than lack of awareness of guideline recommendations (172).  
There are variations in asthma care and management at different levels of health care 
professionals (187, 193, 263, 272); and it is possible that the qualifications of health 
care providers, their self-efficacy, and their confidence may hinder adherence. It has 
been reported that specialists, experts and well trained physicians are more likely to 
follow guidelines, including which maintenance medication to prescribe, the use of 
lung function monitoring, and instructions on avoiding asthma triggers, than are GPs 
(263, 268, 272). Laforest et al. found that patients treated by specialists were less 
likely to use short-acting beta agonists, antibiotics, or antitussive drugs, and more 
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likely to be prescribed a combination of long-acting beta agonists and ICSs (194). 
Further, the asthma control level was higher in patients treated by specialists than in 
other groups (194). Such variations in management practice have been found by 
other studies of asthma control and management practices in different countries (38, 
188, 190, 198, 259, 270).  
Primary health care professionals reported limited disagreement with some guideline 
recommendations (185, 264, 266), and physicians reported different barriers to 
compliance in their practices. Some of these differences were associated with factors 
such as age, specialities, training, and experience. One study of paediatricians in 
primary care investigated the barriers affecting adherence to four recommendations 
(ICS prescribing, PFM use, smoking cessation counselling and allergen exposure 
counselling); it examined three focus groups based on graduation year, including 21 
paediatricians and a nurse (191). Lack of agreement on the prescription of 
corticosteroids for long term use, lack of self-efficacy in using PFM, and lack of 
outcome expectancy of smoking cessation due to concerns about side effects of 
corticosteroids, how to interpret readings of PFM, and patient non-compliance were 
reported among senior physicians; less concern with using corticosteroids or 
provision of smoking cessation counselling were reported amongst younger 
physicians, due to a lack self-efficacy and training (191). The inertia of previous 
practice barriers was not addressed by younger physicians, but, all groups reported 
lack of agreement, self-efficacy and outcome expectancy as barriers to allergen 
counselling, and time limitations as a barrier for all four recommendations (191). 
Another self-report study estimated the barriers affecting 455 paediatricians’ 
adherence to ICS prescribing, PFM use, and patients’ and parents’ smoking cessation 
counselling (172). In the previous study, physicians’ adherence to all 
recommendations ranged from 39% to 53%. Both access to and awareness of 
guideline recommendations were reported by the majority of the 455 participants 
(81% and 88% respectively). Lack of familiarity and external barriers were also 
reported, with a significant association with all recommendations. Lack of agreement 
for both corticosteroid prescription and PFM use were recorded by 17.5% and 7.7% 
of respondents respectively, with 2.5% and 27.4% of the same respondents reporting 
a lack of confidence in the outcomes. Lack of outcomes expectancy for both patients’ 
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and parents’ smoking counselling affected 61% and 67% of respondents’ decisions, 
respectively (172). 
In an evaluation of specialists (allergists and pulmonologists), a high proportion of 
respondents disagreed with the current asthma severity classifications (185). In 
contrast, physicians may have an awareness of and/ or agreement with the guidelines, 
yet their practices may still reflect poor adherence to them (38, 172, 188). In East 
Harlem, New York, a study evaluating the practices of primary health care providers 
was undertaken to identify the barriers to various guideline components, including 
use of ICSs, PFM, AAPs, allergy testing and influenza vaccination. Of the 202 health 
care professionals surveyed, 79% had received training in asthma guidelines, and 
70% reported awareness of these guidelines (268). Moderate to strong agreement 
with ICS, PFM, AAP use and influenza vaccination were reported as follows: 66% 
(95% CI, 59–73%), 63% (95% CI, 56–70%), 55% (95% CI, 48–62%) and 70% (95% 
CI, 63–77%). However, more than half (54%) of respondents did not use the 
guidelines to manage their asthmatic patients, with 62% and 73% reporting 
adherence to ICS use and influenza vaccination, while low adherence was reported 
with PFM use (34%), AAP use (9%), and allergy testing (10%). Low adherence to all 
five recommendations was associated with lack of familiarity, lack of provider self- 
efficacy, and outcomes expectancy barriers (268).  
Limited time and restricted resources have also been identified as potential barriers 
which may lead to poor health care provider adherence to guideline 
recommendations (77, 163, 172, 182, 186, 187, 190, 191, 265, 268). 
Medications and device-related barriers such as beliefs, perceptions, and cost may 
also affect health care providers’ practices. Their awareness of medication costs, 
treatment fears, and misunderstanding may contribute to their non-compliance (68, 
77, 191, 258, 266, 273). A better understanding of medication function has been 
shown to change behaviour and lead to better asthma care outcomes (274). Long 
waiting periods at pharmacies have been suggested as a reason for 34% of non-
compliance among patients, with 30% of non-compliance attributed to medication 
costs (68). In addition, both the complexity of the guidelines and the number of 
practice guidelines provided may affect professionals’ adherence rates (261, 265). 
 
32 
As the compliance process is dependent on patients, families, and health care 
providers, it can be expected that good relationships between these parties will 
improve care outcomes. These relationships are dependent on the quality of 
communication (182). A barrier to professionals’ guideline compliance is inadequate 
communication with their patients and/ or families due to inadequate consultation 
time or poor communication skills (163, 166, 181, 182, 201, 272). The lack of 
communication may also be related to patients’ or their family’s knowledge, beliefs 
and perceptions of asthma and its management. It has been found that patients do not 
present their symptoms accurately, which may lead to inappropriate diagnosis (182, 
189, 261). In addition, it has been reported that patients who visit their physician at 
least every six months receive proper diagnosis (189).  
Collaboration between health care providers and patients/ families is required to 
improve self-management of asthma (169, 182, 220). Collaborative care and self-
management education are the basis for a partnership, distinct from traditional care, 
with better use of behavioural and social learning theory, greater recognition of the 
problem, of goal setting, problem solving, shared decision-making and internal 
motivation (140, 169, 220, 221). For instance, collaborative goal-setting coupled 
with action plans has been reported to be valuable in changing coronary heart disease 
patients’ behaviours in a primary care setting (169).  
Ferguson et al. have found that culture and language may affect patients’ 
involvement in decision-making (201). Patients’ and their families’ education level 
may also be considered a factor affecting health care provider–patient relationships, 
and may result in low compliance with asthma care and management by both patients 
and professionals. This is because most health care literature is written in 
sophisticated language that may not be the primary language of either health care 
providers or patients, making it challenging for many patients and their families with 
a low to medium literacy level to understand, while physicians may assume that 
patients have higher literacy than they possess; patients may be too shy to clarify 
doubts with their physicians (275, 276).  
Adherence to guidelines can be improved by addressing a number of barriers 
including lack of awareness, knowledge, agreement, and familiarity with guideline 
recommendations, as well as professionals’ self-efficacy, outcome expectancy and 
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communication skills. These may be modified through education interventions 
tailored for individual health care providers, a course that has the potential to 
contribute directly to the enhancement of asthma care management and patient 
outcomes such as adequate diagnosis, proper treatment, and reduced health care costs 
(38, 55, 172, 184, 187, 188, 191, 196, 198). Physicians can improve asthma care and 
self-management by following the guideline, particularly regarding appropriately 
prescribing ICSs, developing AAPs, utilizing lung function monitoring, educating 
patients, referring patients to specialists, ensuring regular follow-up visits, building 
good communication channels with their patients, and taking into consideration their 
socioeconomic status (38, 198, 272). Physicians should also provide support for self-
management by scheduling group meetings for interested patients. Efforts in this area 
by health care providers are considered to contribute to better outcomes in asthma 
care (221). A team approach to asthma management may also be useful, especially in 
cases where physicians’ lack of knowledge or training in some aspects of asthma 
management, or their time limitations, hinder their application of guideline 
recommendations (144, 277).  
1.12 Summary 
Asthma is a chronic disease that affects both adults and children world-wide. There 
have been advancements in medications used to treat the disease, and guidelines have 
been developed in an attempt to standardize practice and improve treatment 
outcomes. However, adherence to recommended asthma practices remains limited 
amongst both patients and physicians, and many patients fail to achieve optimal 
control of their disease, the primary goal of asthma management. 
In order to attain greater success in control, both patients and their families and 
physicians should take more responsibility, to limit morbidity and mortality as well 
as reduce the burden of health care costs.  
Poor asthma care and self-management in some parts of the world are associated 
with lack of knowledge, understanding, and education, exacerbated by 
communication barriers between patients and health providers; all these result in 
poor outcomes. Low numbers of ICS prescriptions, high use of short-acting beta 
agonists, irregular medication use, inappropriate inhaler technique, and poor 
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adherence to self-management components such as self-monitoring have been 
reported as contributors to poor disease management. Several barriers affecting 
patient and/ or family adherence have been identified, including patients’ and carers’ 
knowledge, their behaviours, and their self-efficacy; asthma management outcomes 
have been improved in those who have participated in interventions programs built 
around education. 
The literature reveals that to improve asthma care and self-management, the 
following need to be addressed: patients’ and their families’ knowledge of and 
understanding about asthma, treatment regimens, and self-management, which result 
in changes in behaviours and attitudes, increasing confidence in and adherence to 
management components. These outcomes depend largely on health care 
professionals’ practices and their relationship with their patients and their families. 
The lack of physician knowledge (awareness, familiarity), confidence (self-efficacy, 
outcome expectancy), and other external factors such as lack of time and resources 
have been associated with poor adherence to guidelines. The education process is an 
important aspect of asthma care that encourages the contributions of patients and 
their families as well as of health care providers to achieve better management 
outcomes. 
1.13 The Focus of this Study  
Chronic asthma in children and adolescents is a worldwide health phenomenon, and 
so are reports of poor asthma management. This thesis addresses the following 
questions: 
 What is the level of asthma management in KSA?  
 How are children and adolescents managed?  
 What are the current practices in the primary health care centres (PHCCs)?  
 What is the level of knowledge of patients/ families and physicians regarding 
asthma and its management?  




Another important question to consider is what factors contribute to low utilization 
of ICSs. 
The current study comprised four phases. The first phase was a patient survey 
administered through PHCCs in KSA, to identify current knowledge and 
understanding of asthma, attitudes towards the disease, and management practices 
among children and adolescents. The second phase was to ascertain physicians’ 
patient education strategies, asthma treatment practices, their involvement of patients 
in management decisions, and patient and physician compliance with the KSA 
asthma guidelines. A third phase was conducted to identify the barriers affecting 
Saudi asthma patients’ management adherence generally, and adherence to ICS use 
specifically, in PHCCs. The last phase evaluated the impact of an education program 
and provision of AAPs on Saudi asthma patients’ and their carer’s knowledge, self-
efficacy and behaviour, in addition to asthma management health outcomes. 
1.14 Reasons for the Study 
As asthma is one of the most common diseases in KSA, it was expected that 
corticosteroids would be widely prescribed: in particular, that corticosteroids would 
be the drugs of first choice for the management of chronic asthma in accordance with 
the Saudi National Protocol for the Management of Asthma. However, poor asthma 
management compliance including inaccurate diagnoses, inappropriate medication 
use, poor patient knowledge, low understanding of the disease, unsatisfactory self-
management adherence, incorrect technique in administering inhalant medications, 
and insufficient education were known to exist. Although a national protocol for 
asthma management was developed in 1995, data on the level of its implementation, 
patient and practitioner compliance, and the outcomes of the guidelines in health 
centres, are lacking. This research provided a useful insight into current patterns of 
asthma management in children and adolescents in KSA, the extent of guideline 
implementation in PHCCs, and the use of corticosteroids by chronic asthma patients. 
The research also provided information about the barriers affecting KSA’s asthmatic 
patients’ ICS use. The use of AAPs, patient education and PFMs have been 
recommended as there is evidence that they improve asthma management outcomes 
by encouraging better compliance with treatment. Interventions in this study were 
designed to enhance guideline implementation and increase the use of ICSs, AAPs 
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and PFMs, with the aim of improving appropriate medication use, knowledge, and 
asthma control, and of reducing disease morbidity and enhancing the quality of life 




Chapter 2    
Aims and Hypotheses 
This chapter includes the aims and hypotheses for the research phases. 
2.1 Phase 1: A Survey of Children and Adolescents with Chronic 
Asthma (or of their Carers)  
2.1.1 The aims of this study  
 To compare the current practice of asthma management in Saudi Arabian 
primary health care centres against the national protocol for asthma 
management. 
 To document current patterns of asthma management in children and 
adolescents in KSA. 
 To assess the patterns and appropriateness of corticosteroid use in childhood 
asthma.  
 To assess patients’ and/ or their relatives’ understanding of the level of asthma 
management. 
2.1.2 Null hypotheses 
The study aimed to test the following three null hypotheses: 
H0: current patterns of asthma management in children and adolescents in KSA are 
not influenced by gender 
H0: current patterns of asthma management in children and adolescents in KSA are 
not influenced by geographical region [Riyadh versus Asser]. 
H0: the current practice of asthma management in Saudi Arabia primary health care 





2.2 Phase 2: A Survey of Physicians in Primary Health Care in 
Riyadh and Asser, KSA 
2.2.1 The aims of this study  
 To identify current physicians’ practices for asthma management in KSA. 
 To compare the current practice of asthma management in Saudi Arabian 
primary health care centres (PHCCs) with The National Protocol for the 
Management of Asthma. 
 To assess the patterns and appropriateness of medication description.  
  
2.2.2 Null hypotheses 
The study aimed to test the following three null hypotheses: 
H0: Current practice of asthma management in Saudi Arabia PHCCs is not in 
compliance with the national protocol for asthma management. 
H0: Current practices for asthma management in PHCCs in KSA are not influenced 
by physicians’ gender. 
H0: Current practices for asthma management in PHCCs in KSA are not influenced 
by geographical region (Riyadh vs. Asser). 
2.3 Phase 3: Barriers Affecting Inhaled Corticosteroid (ICS) Use 
and Patient Adherence  
2.3.1 The aims of this study  
 To identify the barriers affecting Saudi asthma patients’ management 
adherence generally in PHCCs. 
 To identify the barriers affecting Saudi asthma patients’ management 




2.4 Phase 4: Impact of an Education Program and Provision of 
Asthma Action Plans on the Knowledge and Health Outcomes 
of Asthmatic Patients 
2.4.1 The aims of this study  
 To assess the impact of an education program and provision of asthma action 
plan (AAP) on Saudi asthma patients’ and their carers’ knowledge, self-
efficacy, and behaviour. 
 To assess the impact of an education program and provision of asthma action 
plan (AAP) on asthma management outcomes among Saudi asthma patients 
and their carers. 
 To assess the impact of an education program and provision of asthma action 
plan (AAP) on Saudi asthma patients’ and their carers’ adherences.  
 To compare the impact of an education program and provision of asthma 
action plan (AAP) with education alone on asthma management outcomes 
among Saudi asthma patients and their carers.  
2.4.2 Null hypotheses 
The study aimed to test the following five null hypotheses: 
H0: children and adolescents or their carers’ knowledge, self-efficacy and behaviour 
are not improved after attending intervention programs and being provided with 
asthma action plans (AAPs).  
H0: asthma management outcomes among children and adolescents or their carers are 
not influenced by any education program and provision of asthma action plans 
(AAPs)  
H0: Children’s and adolescents’ or their carers’ adherences are not improved after 
attending intervention programs and being provided with asthma action plans 
(AAPs) in the Riyadh region of KSA.  
H0: Asthma management intervention outcomes in children and adolescents or their 
carers in Riyadh are not influenced by the provision of asthma action plans (AAPs)  
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Chapter 3   
Methodology 
This chapter will describe the methodology of the research phases. Four phases were 
conducted: among children and adolescents (and their families) with chronic asthma, 
to estimate their current management (Phase 1); among physicians working in 
PHCCs to estimate their current practices and adherence to guidelines, involving 
children and adolescents (and their families) with chronic asthma (Phase 2); to 
estimate barriers affecting asthma management in general and inhaled corticosteroid 
(ICSs) adherence barriers in particular (Phase 3); and to evaluation the impact of an 
education program and provision of AAP on the knowledge, behaviour, self-efficacy 
and asthma management health outcomes of asthmatic patients in KSA (Phase 4). 
Data were collected via self-administered questionnaires.  
3.1 Phase 1: Patient Survey  
3.1.1 Aims  
The aims of Phase 1 of the study were to assess patterns of asthma treatment and 
control through self-management, such as the use of asthma action plans and PFMs, 
and patients’ education, knowledge, and behaviours. 
3.1.2 Participants and procedures 
Equivalent groups were surveyed in primary health care centres in two regions in 
KSA (Riyadh and Asser regions) during the period January–May 2006. The selection 
of these particular regions was to take advantage of prima facie differences in 
customs, geography, climate, education and health service provision in the two areas.  
Outpatients (or their relatives, where appropriate) with chronic asthma, aged between 
6 and18 years, were included in Phase 1. This group was chosen because of their 
high number of visits to PHCC services: according to the Ministry of Health, in 2004 
5–14-year-olds with asthma accounted for 20% of total PHCC visits (183,718 out of 
911,999 total visits) (278). Furthermore, the health system in KSA has separate 
clinics for each gender with staff of the same gender. The research was designed to 
explore differences in services, education and management offered through both 
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gender clinics. Two hundred patients were recruited from each region, and PHCC 
directors were contacted two or three times to encourage responses. Anonymous 
responses were solicited to encourage truthful answers. No compensation was 
offered. The exclusion criteria were patients who had not been diagnosed by a 
physician as asthmatic, who were aged 5 and under or over 18, or who failed to 
answer five or more questions. 
3.1.3 Survey instrument and data collection 
 Data were collected by questionnaires administered to outpatients, using ATAQ 
(Asthma Therapy Assessment Questionnaire) (279) categories which reflect five 
asthma management domains: patients’ control, knowledge, behaviour/ attitude, self-
efficacy, and patient–health provider communication (279); plus FACCT quality 
measures (Adult Asthma Measurement Survey–version 2.0) (280) after modification 
to suit the study sample. Three questions on current medication used, medication side 
effects and whether there had been visits to the emergency room or hospital during 
the last three months were added. The general objective of the questionnaire was to 
estimate current asthma management, adherence to asthma guidelines, any effects of 
changes in behaviour and daily practice, patient knowledge and understanding, self-
efficacy, and the impact of these on management outcomes. It was composed in 
English, translated into Arabic and back-translated into English by native Arabian 
speakers who were fluent in the English language [see Appendixes A and M for both 
versions of the questionnaire]. This required the revision of some questions to suit 
the different languages: for instance, one response, ‘does not apply’ from the answer 
options of questions 5, 6, 7, and 8 of section IV, was deleted as it created confusion 
in the Arabic translation. 
A covering letter contained brief information about the study and its aims, plus 
contact details and confirmation that the collected information would be used for 
research purposes only. An appendix containing most of the medication used in 
asthma treatment (as a list and scanned box image) together with illustrations of 
spacer types, was attached. The phrase ‘blue inhaler’ was added in question Y: ‘Does 
your child use a blue inhaler or a nebulizer for quick relief from asthma symptoms?’ 
to simplify identification. Similar questions with different possible responses were 
used in order to test the following: estimates of current practices, patients answering 
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as accurately as possible, and estimates of patients’ knowledge, understanding and 
behaviours. For example, the participants were asked about their asthma action plan, 
steroid use, control drug, and current medication. 
The patient questionnaire contained the following sections: demographic details (age, 
gender), asthma symptoms, asthma severity and frequency, frequency of hospital 
admissions or ED visits for the last three months, medical history, treatment regimen, 
history of corticosteroid (usage level compliance, side effects), asthma education 
history (patient’s and his/ her carers’), patient/ carer knowledge, attitude and 
behaviour regarding asthma management, presence of written asthma action, PFM, 
and patient/ health care provider communication. 
3.1.4 Face validity  
The questionnaires were examined by two consultants, a specialist, a health 
education specialist, a statistician from the health field, and an Arabic linguist.  
3.1.5 Questionnaire administration 
The questionnaire was self-administered. In Riyadh, copies were handed to each 
health centre director, who passed them out to physicians who distributed them 
randomly to patients or carers. In Asser, the questionnaire was handed to the region’s 
professional supervisors, and it was passed along to health care centre directors, 
physicians, and patients. Where a child could not complete the questionnaire, it was 
done by a parent or carer. 
3.1.6 The setting  
Primary heath care centres in two regions (Riyadh and Asser) were the settings. 
PHCCs are considered the front line in health care. According to the Saudi protocol 
of asthma management, patients with intermittent asthma should be managed at their 
PHCC, while patients with moderate or more severe asthma should be referred to 
secondary (SHCC) or tertiary clinics (THCC) for asthma treatment, then attend 
follow-up sessions at the PHCC. 
Saudi Arabia is divided into thirteen regions. Research was conducted in two 
regions, Riyadh and Asser, which differ in geography, education level, facilities, and 
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to some extent in culture and customs, as well as pollution, moisture in the air, pollen 
count, average temperature, etc. For example, Riyadh is 608m above sea level, while 
Abha, the centre of Asser, rises 2190m above. The average temperature during 




, while in Abha which the main 




 (281, 282). Riyadh is the 
capital city of Saudi Arabia, with a population over 4 million people, and there is a 
variety of health care settings, including private and military hospitals and outpatient 
clinics in addition to MOH care settings. The majority of the Asser area is considered 
rural, with less population and limited health care settings. 
In 2003, according to the Ministry of Health Annual Report (278), Riyadh and Asser 
had 336 and 229 PHCCs, and 35 and 13 public hospitals, respectively. Riyadh had 
336 PHCCs divided into 2 divisions (central and rural), the central division 
consisting of 125 PHCCs divided into 5 sectors and covering all Riyadh suburbs. 
Participants in this survey were selected randomly across all of these. Asser had 253 
PHCCs divided into 16 sectors, and participants were selected from four: Abha, 
Magardah, Khames Meshait, and Mohail. There were 101 PHCCs in these sectors. 
3.1.7 Outcomes 
Comparison of responses was by gender and region. The primary desired outcome 
was an assessment of use in accordance with asthma management guidelines by 
patients receiving ICS. The second outcome expected was an assessment of the 
knowledge of patients. The third outcome was the evaluation of self-management 
aspects of asthma treatment such as asthma action plans, use of PFM meters, and 
education intervention.  
3.1.8 Data analysis  
Data were entered into SPSS version 14. Data were randomly checked to ensure 
accuracy, and double-checked to avoid entering mistakes. Appropriate statistical tests 
were used, including frequency estimates, cross tabulation, Fisher’s exact test, 
students t-test and Chi-square tests, to find associations between the variables and the 
regions and gender. Logistic regression analysis was applied in order to estimate the 
relation between dependent variables (inhaled ICS, control, asthma action plan, 
possession of PFM and education) and the independent variables. Results were 
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considered to be significant at ≤ 0.05 level. The Kappa test was executed to evaluate 
agreement between participants’ responses to the question, ‘Do you/ does your child 
use inhaled steroids?’ with the current list of medication used.  
3.1.9 Ethical considerations 
Prior to the commencement of the study, approval was obtained from the Human 
Research Ethics Committee of Curtin University of Technology. Ethical approval 
was also sought from the Ministry of Health in Riyadh, Saudi Arabia. All 
information collected by the questionnaires remains confidential. All data are coded 
by number and stored on a password-protected computer hard disk. After completion 
of the study all materials will be stored in a secure archive at the School of Pharmacy 
for a minimum of five years. 
3.2 Phase 2: Physician Survey 
3.2.1 Objective  
Phase two of the research aimed at identifying current physicians’ practice in PHCCs 
in two regions in KSA with regard to asthma management (patient education 
strategies, treatment, and patient involvement), and areas of agreement and 
disagreement. Adherence to Saudi National Protocol for the Management of Asthma 
by PHCC physicians was also targeted. 
3.2.2 Participants and procedure  
Participants were working in PHCCs in the Asser and Riyadh regions during the 
period January–June 2006. The survey covered 120 physicians, 60 from each region, 
to determine current practices and differences in health service provision. Inclusion 
criteria were  
 The physicians worked in PHCCs. 
 The physicians had worked in PHCCs for a minimum of one year.  
3.2.3 Survey instrument and data collection 
Data were collected by questionnaires administered to physicians (Appendix B) 
(283). The questionnaire was administered in English. A covering letter was attached 
containing brief information about the study aims and contact details, and confirming 
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that collected information would remain anonymous and be used for research 
purposes only. The physician questionnaire consisted of both direct questions and 
case studies. It was designed to collect demographic data (age, gender, qualification, 
experience, and training) and to determine each physician’s knowledge of asthma 
and use of patient educational activities in accordance with the national asthma 
guidelines. Model case scenarios were used to estimate both these and patients’ 
involvement in their treatment decisions. 
3.2.4 Face validity 
Face validity of the questionnaires was assessed by two consultants, one specialist 
working as a physician in PHCCs and SHCCs, one health education specialist and 
one statistician from the health field. 
3.2.5 Questionnaire contents 
3.2.5.1 Practice characteristics 
Demographic data (age, gender) and experiences, specialization, practice category, 
training, personal experience with asthma symptoms, professional assistance and 
practice load were collected. Four more questions concerned working place 
(government or private sector), nationality, access to national guidelines (hard copy, 
electronic), and access to other guidelines.  
3.2.5.2 Asthma education section  
This section aimed to determine physicians’ involvement in patients’ education. This 
section determined the extra information provided to patients about medication for 
mild, moderate and severe asthma: 1) General information about asthma. 2) 
Prescribed asthma medication. 3) Demonstrating the proper use of inhalation 
devices. 4) Information on avoiding asthma triggers, and on environmental control. 
5) Information on the warning signs of worsening or uncontrolled asthma. 6) An 
asthma action plan based upon symptoms. 7) Information about monitoring peak 
flow rates. 8) An asthma action plan based upon peak expiratory flow rates in 
conjunction with symptoms. 9) Information about community non-profit 
organizations that provided further information about asthma. The physicians were 
asked to report their usual practices. Each question had three response options for 
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each degree of asthma severity (mild, moderate and severe): a) I do not provide this 
information; b) I provide this information only if the patient asks; and c) I provide 
this information without waiting for the patient to ask. 
3.2.5.3 Treating asthma  
Six model case scenarios ranging in severity were presented to assess each 
physician’s approach and compliance with guidelines. Each scenario included 
options to initiate treatment, delay treatment, or refer patient to ED. If treatment was 
initiated, there were six options to choose from: 1) inhaled B2 agonist; 2) inhaled 
Iprotropium bromide; 3) inhaled corticosteroid; 4) non-steroid anti-inflammatory; 5) 
oral theophylline; and 6) oral corticosteroid. 
3.2.5.4  Individual practice section  
This section contained two questions about usual and ideal patients’ involvement in 
asthma management decisions. Each question had five-answer options to reflect 
physicians’ perceptions of the patient role in asthma management, ranging from low 
to high involvement. 
Work place and nationality were included to determine any differences in asthma 
management practice between government and private sectors, as well as between 
Saudi and non-Saudi physicians.  
3.2.6 Questionnaire administration  
The questionnaires were self-administered. In Riyadh, the questionnaire was handed 
to health centre directors, who passed it on to physicians. In Asser, the questionnaire 
was handed to the region’s sector supervisors, then passed on to the health care 
centre directors and then to the physicians. 
3.2.7 The setting  
PHCCs are considered the front line in health care. According to the Saudi Protocol 
of Asthma Management, patients with intermittent asthma should be managed 
through PHCCs, while patients with moderate or more severe asthma should be 
referred to the secondary or tertiary clinics for asthma treatment and return to the 
PHCC for follow-up visits. 
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3.2.8  Outcomes  
The results were analysed for gender and region interaction. The main focus was the 
level of physicians’ compliance with the current Saudi National Protocol for the 
Management of Asthma. The second expected outcome was an assessment of 
physicians’ knowledge on asthma management.  
3.2.9 Data analysis  
Data were entered into SPSS version 14. Data were randomly checked. Results were 
analysed with cross tabulation and Chi-square tests. Results were deemed to be 
significant at ≤ 0.05 level. The current physicians’ practices regarding the valid full 
sample (for both regions), and the differences between the two regional assessments, 
depended on self-reports using frequency estimates, cross tabulation and Chi-square 
tests. Assessment of physician agreement and disagreement with the option of case 
scenarios was only undertaken if at least 75% of the full study group or subgroups 
respondents agreed or disagreed with the action. The relationship between current 
physicians’ practices for the full response and others’ practice characteristics were 
assessed by using cross tabulation and the Chi-square test.  
The focus was on  
1. The level of physicians’ awareness of the asthma guidelines. 
2. The level of physicians’ use of the guidelines in prescribing for and educating 
patients. 
3. The influence of age, gender, experience, and training on physician’s 
awareness and use of the guidelines and their components. 
4. The level of physician compliance with the guidelines based on 
i. Their assessment of test case prescribing; 
ii. Their pattern of prescribing amongst PHCC outpatients. 
3.2.10 Ethical considerations 
Prior to the commencement of the study, approval was obtained from the Human 
Research Ethics Committee of Curtin University of Technology. Ethical approval 
was also sought from the Ministry of Health in Riyadh, Saudi Arabia. All 
information collected by questionnaires will remain confidential, and no identifying 
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information will be used in this thesis or any subsequent publication. The 
information has only been made available to the researcher and his supervisor. All 
data are coded by number and stored on a password-protected computer hard disk. 
After completion of the study all materials will be stored in a secure archive at the 
School of Pharmacy for a minimum of five years.  
3.3 Phase Three: Barriers Affecting Inhaled Corticosteroid (ICS) 
Use and Patient Adherence  
3.3.1 Aims  
The aims of Phase 3 of the study were to identify the barriers affecting Saudi asthma 
patients’ management of their asthma in general and adherence to ICS use in 
particular.  
3.3.2 Survey instrument 
The survey was divided into three parts. Part One contained questions related to 
demography (age, gender, level of education of patient and parents, level of income, 
presence of health insurance), asthma severity and symptoms, medication use and 
adherence, possession of AAP, PFM, patients’/ carers’ beliefs about the usefulness of 
their medication, their involvement in treatment plans, and their access to 
information. Data in Part Two was collected by using the Illness Management 
Survey (IMS) (206), modified to suit the study sample,; patients/ carers rated the 
degree to which they were affected by each barrier on a 5-point Likert scale (strongly 
disagree to strongly agree). The IMS’s reliability was evaluated by its authors and 
showed high internal consistency (Cronbach’s alpha =0.87. The authors of the IMS 
suggest a subclass of five factors solution accounting for 52.4% of variance: disease/ 
regimen, cognitive difficulties, lack of social support/ self-efficacy, denial/ distrust, 
and peer influences. In Part Three, a questionnaire was developed by the primary 
investigator to estimate barriers to ICS adherence in particular, in order to identify 
Saudi patients’ non-adherence barriers; this was because although ICS is the 
cornerstone in asthma treatment, worldwide non-adherence to ICS use has been 
indicated. Patients may be confused between the steroid (the main control 
medication) and control expression, due to lack of knowledge and their 
understanding of relevant terminology.  
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Part Three contained 18 items related to knowledge, perception, social status, 
economic status, and education: those aspects relating to patients and family, 
medication and health care providers:  
 Patients’ knowledge of their disease and the function of their medication. 
 Fear of medication, and their perception of its worth. 
 Cost of medication and health services. 
 Patient sources of information. 
 Patient–physician relationship and communication. 
 Social support 
ICS’s reliability was estimated and showed high internal consistency (Cronbach’s 
alpha = 0.87. The patient questionnaire was translated and administered in the Arabic 
language, the main language of the Saudis, and the responses translated back into 
English by native Arabian speakers who were fluent in the English language.  
3.3.3 Validity test  
In order to test the reliability and validity of the questionnaire: 
 Face validity was conducted by proof reading by 15 experienced physicians in 
PHCCs. 
 A pilot study was conducted with 60 students from departments of the Riyadh 
Health College. 
The pilot study investigated to what extent the items and instructions for the 
measurements were clear to the participants, to determine what or where practical 
problems occurred, and to develop the measurements to be used in the main study; in 
these ways it was used to investigate the validity and reliability of the measurements. 
3.3.3.1  Participants and procedure  
The pilot sample consisted of 60 college students recruited from various disciplines 
within the College of Health Sciences at Riyadh, all aged between 18 and 25 years. 
The researcher informed them about the aim of the study and read them the 
instructions for the scales. Each one who agreed to take part signed a consent form; 
then the researcher handed them the questionnaire booklets in person.  
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3.3.3.2 Statistical analyses 
To assess whether the same psychometric properties and analyses of each test were 
evident when administrated to Arabic participants, the researcher used Cronbach’s 
alpha to assess internal consistency. The results for the reliability of scales in the 
pilot study were: Cronbach’s alpha for IMS scale = 0.79 and for ICS scale =0.87. 
3.3.4 Setting  
A self-administered questionnaire was distributed by the primary researcher to 
outpatients (or their carers in the event that patients could not answer for themselves) 
in PHCCs in KSA, during the period between April and September, 2008. Patient (or 
carer) written consent was obtained prior to the administration of the questionnaire. 
3.3.5 Participants  
To determine the proportion of subjects who experienced different barriers to ICS 
use, a sample size of 92 respondents was required to achieve a 95% confidence 
interval equal to the proportion +/- 10%. Assuming that only 40% of respondents 
would complete and return their questionnaire, a sample size of 230 respondents was 
issued with the questionnaire. The respondents were either patients with chronic 
asthma aged between 5–18 years or their carers. Anonymous responses were 
solicited to encourage truthful answers. No compensation was offered. The exclusion 
criteria included patients who had not been diagnosed by a physician as asthmatic, 
those who were under 5 or over 18 years old, and those who failed to answer five 
questions or more. 
3.3.6 Expected outcomes  
It was expected that this phase of the study would provide information on 
 Barriers affecting Saudi asthma patient’s management adherences. 
 Levels of patients’ knowledge, behaviour and self-efficacy related to 
asthma medication, such as drug function, goals of drug treatment, side 
effects, and how to use the medications. 
 Barriers affecting Saudi asthma patients’ adherence to ICS use  
 Patients’ sources of information (and their quality and reliability), and the 
quality of the patient–physician relationship. 
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3.3.6 Data analysis  
Data were entered into SPSS version 17. Data were randomly checked to ensure 
accuracy, and double-checked to avoid entering mistakes. Appropriate statistical tests 
were used, including descriptive statistics, mean, standard, deviation, independent 
sample t-test and one-way ANOVA, to find an association between the variables 
with regard to age and gender. Factor analysis for IMS and ICS was also performed. 
Results were deemed to be significant at the 0.05 level.  
3.3.7 Ethical considerations 
Prior to the commencement of the study, approval was obtained from the Human 
Research Ethics Committee of Curtin University of Technology. Ethical approval 
was also sought from the Ministry of Health in Riyadh, Saudi Arabia. All 
information collected by questionnaires remains confidential and no identifying 
information will be used in this thesis or any subsequent publication. The 
information was available only to the researcher and his supervisor. All data were 
coded by number and stored on a password-protected computer hard disk. After 
completion of the study all materials will be stored in a secure archive in the school 
of pharmacy for a minimum of five years. 
3.4 Phase 4: Impact of an Education Program and Provision of 
Asthma Action Plans on the Knowledge and Health Outcomes 
of Asthmatic Patients 
3.4.1 Objectives 
The aims of Phase 4 of the study were to assess the impact of an education program 
and the provision of an asthma action plan (AAP) on asthma management outcomes 
among Saudi asthma patients and their carers, through self-management components 
including adherence to long-term treatment, use of asthma action plans and PFMs, 
and patients’ knowledge and behaviour. 
3.4.2 Procedure 
Participants were divided into two groups. One group was provided with education 
alone and the other with education plus an AAP based on symptoms, and/ or a PFM, 
to see if it improved management outcomes. The research comprised three steps: (1) 
a self-administered questionnaire to participants, (2) an education program (of two 
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sessions), and (3) a three-month follow-up period, with the re-administration of the 
baseline questionnaire at the end of the three months.  
3.4.2.1 Step 1: administration  
A self-administered questionnaire was issued, similar in purpose, design and content 
to the questionnaire used in Phase 1 (Asthma Therapy Assessment Questionnaire 
ATAQ), and reflecting five asthma management domains: patients’ control, 
knowledge, behaviour/ attitude, self-efficacy, and communication with health 
provider. Additional elements regarding quality of life were included: 
a. Disease severity and history. 
b. Patient’s/ relative’s knowledge and beliefs concerning disease, medication and 
illness management. 
c. Medication adherence or compliance. 
d. Asthma action plan (AAP). 
e. Peak flow meter (PFM). 
f. Perception of inhaler technique. 
g. Quality of life, such as limitations on physical activity, school absences, 
psychological and emotional stressors. 
h. Health care utilization (emergency room attendances and hospital visits). 
The patient questionnaire was created in English, but translated and administered in 
the Arabic language, the main language of the Saudis. The responses were translated 
back into English by native Arabian speakers who are fluent in the English language. 
All patients/ carers provided written consent before participation in the study. 
3.4.2.2 Step 2: education program  
Individual educational interventions (face to face consultation) was coupled with the 
provision of both electronic and written information in the form of a booklet 
compiled from the National Asthma Management Guidelines and other sources. 
3.4.2.3 Step 3: follow-up 




3.4.3 Intervention programs 
3.4.3.1 Intervention content 
The first session focused on the following: 
 Disease pathophysiology: asthma was defined to patients, together with 
respiratory system structure and function, and the difference between episodic 
and non-episodic airway, symptoms, triggers and classifications of asthma 
were clarified. 
 Treatment regime: treatment aims and trigger avoidance were defined with 
each patient, with advice on how to avoid triggers.  
 Medication: this section covered asthma medication and devices, the function 
and goal of medication, when and how long to use it, medication concerns, 
types of inhalers, how to use them and how to avoid side effects, as well as 
lung function monitoring, PFM types, and diary use, with explanation of the 
importance of an asthma action plan.  
 Patient and family role in asthma management: adherence to asthma 
management pros and cons, improving disease control and quality of life, 
were addressed, in addition to the effect of misconceptions, how to identify 
appropriate information resources, problems arising from lack of social 
support, and communication with the health care provider. 
The second session focused on barriers that could affect the individual patient’s 
asthma management, such as concerns about medication side effects, the cost of 
medication, the inconvenience associated with using medication, and lack of 
understanding about how and why asthma needs to be managed, as identified in Step 
1, together with any queries raised by the patient and/ or their carers during the 
session. The second session was planned to take place at least three weeks from the 
first; it was delivered by the investigator. 
3.4.3.2 Tools 
1. Models and pictures of two airways before and after an asthma episode. 
2. Samples and models of medication and device (inhaler type and PFM). 
3. Visual medication and device list. 
 
55 
3.4.3.3 Education procedure 
Patients and/ or family were encouraged to ask about, discuss, or identify personal 
problems relating to them and their disease as a method of sharing decision-making 
about their situation. 
1. Evaluation of patients’/ family’s knowledge and behaviour regarding asthma 
and its medication. Patients were asked to use the samples provided to 
differentiate between normal airways and airways during an asthma episode, 
and to discuss the effect of triggers. They also were asked to identify triggers 
which stimulated their asthma, using the pictures provided, and encouraged to 
avoid them.  
2. Patients were asked to identify their medication from the demonstrated 
samples and discuss its functionality, whether a reliever or controller, and to 
reveal their beliefs regarding side effects, and why, when, and how they 
should use medication. 
3. Inhaler technique steps were explained using placebo samples and pictures, 
and patients were asked to repeat the steps and demonstrate the use of the 
inhaler using their own medication. The same method was used to explain 
PFM and diary use. 
4. The advantages of an asthma action plan were described, and attendees were 
instructed in how to use it.  
Patients/ family were asked after each section to indicate any point which was 
unclear or causing confusion.  
At the end each patient was presented with a bag containing two CDs, one including 
information about asthma (pathology, symptoms, medications types, inhalers, 
triggers), the other containing a video explanation in Arabic on how to use an inhaler 
produced by the Saudi Pharmaceutical Association, PFM, brochures from the Saudi 
Thoracic Society (STS), a booklet, pen, and note book. The booklet contained, in 
addition to the actual CDs, a written manuscript of the CDs for patients/ carers who 
did not have PCs, as follows: 
a. Disease pathophysiology: definition, symptoms, structure and function of the 
lungs, classification of asthma, trigger avoidance. 
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b. Treatment regimens: role and goal of medication (reliever and preventer or 
controller), side effects, compliance with and adherence with treatment 
regime, technique advice (inhaler and PFM).  
c. Management skills: the Asthma Action Plan, managing asthma attacks.  
d. Barriers to effective asthma management: such as a lack of knowledge and of 
information sources. The importance of asking, discussing, and sharing 
concerns with professionals.  
e. Diary: to report daily symptoms, school absences, PFM, hospital or ED visits.  
3.4.4 Face validity  
Face validity was conducted by proofreading by15 physicians experienced in PHCC.  
3.4.5 Setting 
A self-administered questionnaire was distributed by the researcher to outpatients (or 
their carers in the event that patients could not answer for themselves) in primary and 
secondary outpatient clinics in KSA, between April and November, 2008. Patient (or 
carer) written consent was obtained by the researcher prior to the administration of 
the questionnaire.  
3.4.6 Participants  
To assess the effects of the asthma education program and asthma action plan, an 
intervention and a control group were used; 93 subjects in each group were required, 
to enable the detection of a difference of 20% at the 95% level of confidence and 5% 
level of significance. Assuming a dropout rate of 30%, 133 subjects were recruited in 
each group. The total sample for this Phase Four study was 266. 
An entirely different sample of asthma patients aged 6–18 who had been prescribed 
with steroids or had started using steroids, or their carers, were recruited for this 




3.4.7 Expected outcomes 
 The following were the expected outcomes: 
 That patient/ family knowledge about the disease, medication, illness 
treatment and triggers would be improved. 
 That there would be changes in patients’ behaviour and an increase in 
compliance with the following asthma treatment elements: 
o medication  
o use of AAPs  
o use of PFM and spacer  
o correct inhaler technique. 
 That there would be an increase in the percentage of patients using ICS as 
controller. Phase One of the study demonstrated only 22(19.5%) of patients in 
Asser and 58(49.6%) in Riyadh used ICS. 
 That asthma control would be enhanced (for example with symptom-free 
days, or no waking up at night). 
 That there would be improved quality of life in areas such as daily physical 
activity, emotional and social improvement, and fewer school absences. 
 That there would be reduced health care utilization, such as hospital visits and 
emergency room attendances. 
3.4.8 Data analysis  
Data were entered into SPSS version 17. Data were randomly checked to ensure 
accuracy, and double-checked to avoid entering errors. Appropriate statistical tests 
were used, including descriptive statistics, Chi-square test, independent sample t-test 
and one-way ANOVA, to describe the results and to find any associations between 
the variables and patient demographics such as age and gender. In addition, these 
were used to compare responses before and after program implementation, within 





3.4.9 Ethical issues 
Prior to the commencement of the study, approval was obtained from the Human 
Research Ethics Committee of Curtin University of Technology. Ethical approval 
was also sought from the Ministry of Health in Riyadh, Saudi Arabia. 
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Chapter 4   
 Phase One Results and Discussion 
4.1 Patient Survey Response 
Survey response data in Table 4.1 show that two hundred questionnaires were 
administered in each region (Asser and Riyadh) with 152 (77.5%) and 162 (81%) 
returned respectively. Of these, 87 (21.8%) were excluded because of the 
respondent’s age (under 5 or over 18 years) or were incomplete. There were 230 
participants: 129 males and 101 females. The largest group of respondents was the 
under-10 year’s segment (43.9%). 









Questionnaires administered 200 200 400 
Responses  151(75.5) 162(81.0) 313(78.3) 
Usable 
responses  
Male 58(51.3) 71(60.7) 129(56.1) 
Female 55(48.7) 46(39.3) 101(43.9) 
Total 113 (56.5) 117 (58.5) 230 (57.5) 
Age of 
respondents 
5 - < 10 yrs. 39(34.5) 62(53.0) 101(43.9) 
10 - <15 yrs. 36(31.9) 35(29.9) 71(30.9) 
15 - <18 yrs. 38(33.6) 20(17.1) 58(25.2) 
4.2 Severity of Disease 
4.2.1 Self-reported severity 
Respondents were asked to classify their or their child’s asthma severity across a 




Figure 4.1 Patient self-assessment severity 
 
Figure 4.1 illustrates that the majority of respondents from both regions, Asser and 
Riyadh, classified their asthma as moderately severe or less: 121 (52.6%) and 76 
(33.1%) respectively reported their asthma as moderate, mild, or very mild. A 
significant difference was found between both regions. Riyadh patients were more 
likely to classify their asthma as severe than were Asser patients (p=0.000). While 22 
(18.8%) Riyadh patients classified their asthma as severe, 8 (7.1%) Asser patients 
did so; 2 (1.7%) and 12 (10.6%) respectively reported their asthma as very mild. 
There was no significant difference across gender (see Appendix E). 
4.2.2 Self-reported asthma severity according to patient answers to symptoms 
question (at least one symptom) 
Based on patients’ or their carers’ responses to a series of five questions, their 
asthma severity score was calculated. Scores ranged from 3 to 18, with a score of 3 




Figure 4.2 Self-reported asthma severity classification according to patients’ answers to 
symptoms question 
 
Figure 4.2 shows approximately two thirds (65.8%) of respondents from both 
regions, Asser and Riyadh, had asthma classified as mild, while 15.1% and 9.8% of 
respondents were classified as having moderate or severe asthma. There was no 
significant difference across regions or gender, although Riyadh patients were more 






























4.2.3 Patients’ seasonal asthma symptoms 
Table 4.2 Patients’ seasonal asthma symptoms 








Asser (112)* 10(8.9) 45(40.2) 57(50.9) 
NS Riyadh(117) 4(3.4) 39(33.3) 74(63.2) 
Total (229) 14(6.1) 84(36.7) 131(57.2) 
Summer 
Asser (112) 25(22.3) 52(46.4) 35(31.3) 
NS Riyadh(117) 32(27.4) 63(53.8) 22(18.8) 
Total (229) 57(24.9) 115(50.2) 57(24.9) 
Spring 
Asser (112) 10(8.9) 78(69.6) 24(21.4) 
0.001 Riyadh(117) 21(17.9) 52(44.4) 44(37.6) 
Total (229) 31(13.5) 130(56.8) 68(29.7) 
Fall 
Asser (112) 29(25.9) 59(52.7) 24(21.4) 
NS Riyadh(117) 24(20.5) 60(51.3) 33(28.2) 
Total(229) 53(23.1) 119(52.0) 57(24.9) 
*One set of data missing 
Respondents were asked if their asthma symptoms differed across seasons. As can be 
seen from Table 4.2, there was significant difference between patients in Riyadh and 
Asser during spring (p=0.001). Both regions reported similar increases in symptoms 
during winter, and reduced symptoms in both summer and fall. The results were not 
influenced by gender (see Appendix E). 
4.2.4 Asthma medication management (clinical category) 
(See Appendix A: scoring instructions) 
Respondents were asked about their asthma management, in particular their use of 
reliever and controller medication, using two questions, ‘Does your child use an 
inhaler or nebulizer for quick relief from asthma symptoms?’ and ‘Has your child 
ever had a prescription for asthma medicine that is NOT used for quick relief, but is 
used to control your child’s asthma?’. Responses can be seen in Table 4.3. They 
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were also asked about their level of use of controller medication if they had one, as 
can be seen in Table 4.4. 














Use of an inhaler or 
nebulizer for quick relief 
from asthma symptoms. 
  








Use of quick reliever 
only 




Use of a quick reliever 
and has a controller 
65(57.5) 66(56.4) 131(57.0) 
 
Table 4.4 Patients’ adherence to controller medication 
Questions Answer options Clinical category Regions Total 











































The data in Table 4.3 shows of the 21 (9.1%) of patients with no asthma medications, 
15 were from Asser and 6 from Riyadh (13.3% vs. 5.1%). The proportion of Riyadh 
patients who only used quick reliever medications was double that of Asser (24.8% 
vs. 12.4%). With regard to use of a quick reliever and having a controller, both 
regions reported nearly the same percentage (57% approximately). From the data 
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summarized in Table 4.4 it can be seen that both regions showed low daily controller 
usage: Riyadh at 22.2% and Asser at 15.9%, p= 0.16.  
4.3  Use of Inhaled Corticosteroids (Clinical Category)  
In this instance rather than being asked if they used a controller, patients were asked 
if they used an inhaled steroid (with exceptions which were given); this was done to 
avoid confusion about the term ‘controller’ (as can be seen in Tables 4.5 and 4.6). 
Table 4.5 Clinical classification of patients based on reliever and inhaled corticosteroid 
(ICS) medication usage. 
Questions Answer 
option 
Clinical category Regions Total 




Use of an inhaler or nebulizer 
for quick relief from asthma 
symptoms.  
 





















Use of a quick 
reliever and has a 
ICs 
22(19.5) 51(43.6) 73(31.7) 
 

































Table 4.5 categorizes patients based on their answers to the questions ‘Does your 
child use an inhaler or nebulizer for quick relief for asthma symptoms?’ and ‘Does 
your child use inhaled steroids for his/ her asthma?’ A total of 49 (21.3%) 
respondents had no asthma medication. Of these, 34 (30.1%) were from Asser and 15 
(12.8%) from Riyadh. Most patients (101: 43.9%) in both regions were using a quick 
reliever only. Asser patients (50.4%) were more likely to use relievers only than 
Riyadh patients (37.6%); however, more than twice as many Riyadh patients (43.6%, 
than Asser’s 19.5%) fell into the ‘Use of a quick reliever and has a controller’ 
category. From the data represented in Table 4.6 it can be seen that both regions’ 
patients (10.4%) showed low daily ICS usage, with Riyadh patients slightly ahead of 
Asser patients (12.8% vs. 8.0%, p= 0.28).  
4.4 Disease Management  
4.4.1 Medication used in the past 12 months 
Respondents were asked if they had used asthma medication in the past 12 months. 
Table 4.7 Number of patients using medication over the past 12 months.  
Region Use an asthma medication over the past year p value 
Yes No Total 
N (%) N (%) N (%) 
Asser N=113 109(96.5) 4(3.5) 113(100.0) NS 
Riyadh N=117 112(95.7) 5(4.3) 117(100.0) 
Total N=230 221(96.1) 9(3.9) 230(100.0) 
 
The data in Table 4.7 illustrate that the majority of patients (>95%) had used asthma-
related medications in the previous 12 months. Chi Square analysis shows no 





4.4.2 Quick relief medication  
Respondents were asked if they had used medication to relieve their symptoms.  
Table 4.8 Number of patients using an inhaler or nebulizer for quick relief from 
asthma symptoms. 
Region Use of an inhaler or nebulizer for quick relief from asthma 
symptoms 
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser N=113 79(69.9) 31(27.4) 3(2.7) 113(100.0) 
Riyadh N=117 95(81.2) 21(17.9) 1(0.9) 117(100.0) 
Total N=230 174(75.70 52(22.6) 4(1.7) 230(100.0) 
 Difference between Gender p value NS 
Difference between Region p value NS 
 
The data presented in Table 4.8 illustrate the use of an inhaler or nebulizer for quick 
relief from asthma symptoms among the study cohort. In both regions, more than 
two thirds (Asser 69.9%, Riyadh 81.2%) of patients were using an inhaler or 
nebulizer. While the patients in Riyadh were more likely to be doing this than those 
in Asser, the difference was not statically significant. Gender did not influence the 




4.4.3 Control medication 
Respondents were asked if they had used any control medication such as 
corticosteroids. 
 
Figure 4.3 Number of patients using control medication 
 
The data presented in Figure 4.3 illustrate the use of control medication. The 
majority of respondents (72.2%) reported they used a control medication. Response 
































4.4.4 Classes of asthma medications used 
Patients and their carers were asked to list their asthma medications. These were 
categorized by the investigator as shown in Table 4.9. 
Table 4.9 Classes of medication used 














   
Adrenoceptor agonist (select β2 Agonist) 107(94.7) 110(94.0) 217(94.3) NS 
Anticholinergic 1(0.9) 4(3.40) 5(2.2) NS 
Corticosteroid 21(18.6) 47(40.2) 68(29.6) 0.000 
Theophylline 6(5.3) 0(0.0) 6(2.6) 0.013 
Antihistamine 3(2.7) 8(6.8) 11(4.8) NS 
Sodium cromoglycate 1(0.9) 4(3.4) 5(2.2) NS 
Antibiotics 1(0.9) 0(0.0) 1(0.4) NS 
Anti-leukotriene receptor  2(1.8) 4(3.4) 6(2.6) NS 
 
Table 9 indicates that in both regions at least 94% (Asser 94.7%, Riyadh 94.0%) of 
patients were using a β2 agonist. There were significant differences in the proportion 
of patients receiving corticosteroids and theophylline in each region: Riyadh patients 
were 2.2 times (p=0.000) more likely to use corticosteroids than those in Asser. In 
Asser, 21 of 113 (18.6%) patients were receiving a corticosteroid, compared to 47 of 
117 (40.2%) in Riyadh. In the case of theophylline, six patients in Asser received the 
drug (5.3%) and none in Riyadh (P=0.013). There were no significant differences in 
the use of other asthma-related medications, including Anticholinergic, 
antihistamines, sodium cromoglycate and leukotriene receptor antagonists. There 





4.4.5 Treatment schedules (confirmed use by investigator)  
Respondents were asked to list their asthma medications; the list was grouped and 
classified by the researcher and appears in in Table 4.10. 










N (%) N (%) N (%) 
 β2 agonist only 80(70.8) 60(51.3) 140(60.9) 0.003 
 β2 agonist + Corticosteroid 14(12.4) 34(29.1) 48(20.9) 0.002 
 β2 agonist +Corticosteroid + others 1(0.9) 8(6.8) 9(3.9) 0.036 
 β2 agonist + other (Non-Corticosteroid) 12(10.6) 10(8.5) 22(9.6) NS 
Corticosteroid only 4(3.5) 5(4.3) 9(3.9) NS 
Corticosteroid + other (Non β2 agonist) 2(1.8) 0(0.0) 2(0.9) NS 
 
The data in Table 4.10 indicate that less than two thirds (60.6%) of respondents used 
β2 agonist alone. There were significant differences in use of β2 agonists in both 
regions, with Asser at 70.8% compared with Riyadh at 51.3% (p=0.003). In addition, 
there were significant differences between both regions in corticosteroid and β2 
agonist use with or without other medications. Thirty-four (29.1%) Riyadh patients 
were receiving a corticosteroid and β2 agonist compared with 14 (12.4%) Asser 
patients, p=0.002. However, there were no significant differences between regions in 
the prescribing of corticosteroid, whether alone or combined with other medications 
(non β2 agonist). Further, a significant difference was seen in the combined use of β2 
agonists and corticosteroids with or without other drugs. Riyadh patients were more 
likely to use a β2 agonist combined with a corticosteroid than Asser patients 
(p=0.036). There was no significant different in the treatment schedule across 
genders (See Appendix E). 
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4.5 Inhaled Corticosteroid (ICS) 
4.5.1 Self-report 
Patients were asked whether or not they used an inhaled corticosteroid (ICS). 




Yes No I don’t 
know 
Total 
N (%) N (%) N (%) N (%) 
Asser N=113 22(19.5) 80(70.8) 11(9.7) 113(100.0) 
Riyadh N=117 58(49.6) 41(35.0) 18(15.4) 117(100.0) 
Total N=230 80(34.8) 121(52.6) 29(12.6) 230(100.0) 
Difference between gender p value NS 
Difference between region p value 0.0001 
 
The data presented in Table 4.11 illustrate low-level use of ICS in the two study 
cohorts. In both regions, fewer than 35% of the respondents reported using ICS, with 
use in Asser statistically significantly less than in Riyadh (19.5% vs. 49.6%; 
P=0.0001). The response was not influenced by gender (see Appendix E). While the 
KSA Guidelines recommend the use of ICS in patients with mild persistent asthma 
and above, only 32.4%, 52.9% and 50.05 of patients with mild, moderate and severe 




4.5.2 Patients’ adherence to ICS daily use 
Respondents were asked about their level of adherence to ICS daily use. 
Table 4.12 Patients’ adherence to ICS daily usage 





N (%) N (%) N (%) NS 
Inhaled steroids every day  9(40.9) 15(25.9) 24(30.0) 
Inhaled steroids less often.  5(22.7) 10(17.2) 15(18.8) 
Inhaled steroids several times a week.  1(4.5) 5(8.6) 6(7.5) 
Inhaled steroids when having asthma 
symptoms. 
7(31.8) 28(48.3) 35(43.8) 
 
Patients in both cohorts reported a low level of regular ICS use, as shown in Table 
4.12. Only 30.0% of patients from both regions used their ICS on a regular basis (i.e. 
daily) while more than two-thirds (70.0%) used it intermittently. There were no 
significant differences in the use of ICS by region or gender, but there was a 
difference in the level of corticosteroid used when self-reported (according to the 
question ‘Do you/ Does your child use inhaled steroids for his/ her asthma?’) and 
according to the response to the question analysing drug use (‘confirmed use by 
investigator’). This will be considered in detail later in the discussion section. 
4.5.3 Adverse effects 
Patients and their carers were asked if they had suffered from adverse effects such as 
weight gain, change of mood, diabetes, or slowed growth rate since they commenced 
their asthma treatment. 
Table 4.13 Self-reported side effects 









N (%) N (%) N (%)  
A. Weight gain Yes 15(13.4) 24(20.7) 39(17.1) NS 
No 97(86.6) 92(79.30 189(82.9) 
B. Change of mood Yes 83(36.4) 47(40.9) 36(31.9) NS 
No 145(63.6) 68(59.1) 77(68.1) 
C. Diabetes Yes 1(0.9) 2(0.9) 1(0.9) NS 
No 110(99.1) 224(99.1) 114(99.1) 
D. Slowed growth rate Yes 46(20.2) 25(21.6) 21(18.8) NS 
No 182(79.8) 91(78.4) 91(81.3 
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Table 4.13 summarizes the adverse effects reported. There were no significant 
differences between regions. Approximately 13% and 21% of the respondents in 
Asser and Riyadh respectively reported weight gain, while 31.9% in Asser and 
40.9% in Riyadh stated their mood had change since commencing corticosteroid 
treatment. One patient in each region reported having diabetes. Twenty percent of 
patients in both regions indicated a slowed growth rate (See Appendix E). 
4.5.4 Hospital or emergency room visits 
Respondents were asked if they had been admitted to hospital or attended the ER at 
the hospital during the last three months, and if so, how many times.  
Table 4.14 Number of patients admitted to hospital or attending ER. 
Region  Number of times admitted to hospital or attended the Emergency Room at 
the hospital in the last 3 months 
p value 
1 To 2 times 
N (%) 
3 To 4 times 
N (%) 






Asser 19(55.9) 11(32.4) 3(8.8) 1(2.9) 34(100.0) 
NS Riyadh 32(71.1) 7(15.6) 5(11.1) 1(2.2) 45(100.0) 
Total 51(64.6) 18(22.8) 8(10.1) 2(2.5)% 79(100.0) 
 
Table 4.14 presents the frequency of hospital admissions and ER attendances in the 
three months prior to the survey. Only 34.3% of patients were admitted to hospital or 
attended the ER. Riyadh patients (45: 38.5%) were more likely to be admitted to 
hospital or visit ER than Asser patients (34: 30.1%), but this difference is not 




4.5.5 Relationship between dependent variable (using inhaled steroids) and 
other independent variables (logistic regression)  
Table 4.15 Relationship between inhaled corticosteroid use and other variables 




Dissatisfied with current asthma 
treatment component. 
No / unsure vs. Yes  2.29 0.93-5.63 0.072 
Use of an inhaler or nebulizer as a 
reliever  
Yes vs. No / unsure  5.06 2.17-11.81 0.000 
Average number of inhaler/nebulizer 
daily use. 
Over 6 vs. 0 to 2  6.30 1.33-29.95 0.021 
Number of inhaler/nebulizer daily use 
over the past 12 months. 
Over 6 vs. 0 to 2 11.79 2.04-68.06 0.006 
Chest tightness (difficulty taking a deep 
breath). 
Daily vs. Never 8.25 1.89-36.05 0.005 
Wheezy or whistling sound in the chest. Daily vs. Never 9.00 2.71-29.89 0.000 
Wheezing or difficulty breathing when 
exercising. 
4-7 vs. None  5.27 1.97-14.08 0.001 
Wheezing during the day when not 
exercising. 
4-7 vs. None 7.04 2.15-23.04 0.001 
Waking up at night. 1-3 vs. None 2.33 1.28-4.25 0.006 
Missing days of school. 1-3 vs. None 4.53 2.43-8.45 0.000 
Missing any daily activities. 1-3 vs. None 2.76 1.54-4.98 0.001 
Average of asthma attacks. Once or twice a week vs. 
Not at all 
7.03 2.81-17.57 0.000 
Three or more times a 
week vs. Not at all. 
6.11 1.75-21.27 0.004 
Asthma severity (self-reported) Moderate vs. Very mild 10.69 2.15-53.21 0.004 
Severe vs. Very mild 9.50 1.77-50.96 0.009 
Home peak flow meter accessibility 
 
Has and used regularly vs. 
Does not have PFM  
5.50 1.99-15.24 0.001 
Spacer accessibility Yes vs. No 2.19 1.25-3.85 0.006 
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Inhaler use demonstration Yes vs. No 1.85 1.01-3.38 0.047 
Inhaler use observation by professional  Yes vs. No 2.25 1.22-4.13 0.010 
Medication adjustment 
 
Yes, and completely 
understood vs. No, not at 
all vs. No, not at all  
3.36 1.30-8.70 0.012 
Yes, and completely 
understood vs. Yes, and 
he/she (I) pretty well 
understood. 
2.11  1.02-4.33 0.043 
 
Table 4.15 illustrates the relationships between patients’ use of an inhaled 
corticosteroid and other independent variables. Satisfaction with current asthma 
treatment was more likely to be reported amongst ICS users, and use of ICS was 
reported more commonly (5.06 times) amongst patients using relievers (95% CI, 
2.17-11.806; p=0.000). Inhaled corticosteroid use was also more common (6.30 
times) amongst patients with high inhaler/ nebulizer use (> 6 times daily) than 
among these with low use (0-1 times daily; p=0.02). ICS use was also 11.79 times 
more likely amongst these who had used quick relief inhalers six or more times daily 
in the past 12 months (95% CI, 2.04-68.06; p=0.006). 
Patients with a high frequency of asthma symptoms reported more use of ICS than 
patients with a low frequency: for example, patients with daily symptoms over the 
past four weeks including chest tightness (difficulty taking a deep breath) and 
wheezy or whistling sounds in the chest were 8.25 and 9 times more likely to have 
used ICS than patients with no symptoms (95% CI, 189-36.01; p=0.005) and (95% 
CI, 2.71-29.89; p=0.000 respectively). Patients who experienced wheezing or 
difficulty breathing when exercising or without exercising, within the frequency 
range of four to seven, were more likely to use ICS than patients with no symptoms 
(OR 5.3; 95% CI, 1.97-14.08; p=0.001) and (OR 7.04; 95% CI, 2.15-23.04; p=0.001 
respectively). Patients who woke up once to three times at night with wheezing or 
difficult breathing, and who missed days of school and daily activities as a result of 
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asthma, were more likely to use ICS more than other patients (OR 2.3; 95% CI, 1.28-
4.25; p=0.006), (OR 4.5; 95% CI, 2.43-8.45; p=0.000), and (OR 2.8; 95% CI, 1.54-
4.98; p=0.001). In addition, use of ICS amongst patients with severe asthma was 
higher than amongst those with less severe asthma. Patients with moderate and 
severe asthma were more likely to use ICS than were very mild asthma patients (OR 
10.7; 95% CI, 2.15-53.21; p=0.004 and OR 9.5; 95%CI, 1.77-50.96; p=0.009 
respectively), while patients who had suffered once or twice, or three or four times a 
week from asthma attacks over the past four weeks were more likely to use ICS than 
patients who did not have asthma attacks at all (OR 7.03; 95%CI, 2.81-17.57; 
p=0.000) and (OR 6.11; 95%CI, 1.75-21.27; p=0.004).  
Possession of a peak flow meter at home was implicated in patients’ use of ICS, 
which was reported 5.5 times more often amongst patients having peak flow meter 
and using it regularly (p=0.001). Further, patients who used a spacer with an inhaler 
were 2.2 times more likely to use ICS than patients who did not (p=0.006). 
Patients who were educated and followed up were more likely to use ICS. Patients 
shown how to use an inhaler properly by their health providers and observed doing 
so were more likely to use ICS than patients who were not (OR 1.85; 95% CI, 1.01-
3.38; p=0.047 and OR 2 .24; 95% CI, 1.22-4.13; p=0.010 respectively). In addition, 
patients who were taught how to adjust their medication when their asthma grew 
worse, and completely understood the instructions, were 3.4 times more likely to use 
ICS than non-educated patients (95%CI, 1.30-8.70; p=0.012), and 2.11 times more 
likely to use ICS than patients who were understood ‘pretty well’ (95% CI, 1.02-
4.33; p=0.043). However, the regression multivariate analysis only demonstrated the 
following to be significant: Have wheezing during the day when not exercising (OR 
1.9; CI, 1.14-3.15; p=0.014), number of inhaler/ nebulizer daily uses over the 12 
months (OR 2.02; CI, 1.2-3.41; p=0.008), asthma severity self- reported (OR 2.2; CI, 
1.78-3.67; p=0.004), home peak flow meter accessibility (OR 3.1; CI, 1.45-6.64; 




4.6 Asthma Control  
4.6.1 Patient response 
Respondents were asked about their asthma control beliefs over the past four weeks. 
Table 4.16 Patients’ asthma control beliefs 
Region/ sex 
 
Do you believe your or your child’s asthma was well controlled in 










Asser males 33(56.9) 12(20.7) 13(22.4) 58(100.0) 
0.035 
Asser females 32(58.2) 13(23.6) 10(18.2) 55(100.0) 
Asser total 65(57.5) 25(22.1) 23(20.4) 113(100.0) 
Riyadh males 25(35.2) 31(43.7) 15(21.1) 71(100.0) 
Riyadh females 26(56.5) 14(30.4) 6(13.0) 46(100.0) 
Riyadh total 51(43.6) 45(38.5) 21(17.9) 117(100.0) 
Total 116(50.5) 70(30.4) 44(19.1) 230(100.0) 
 
The data in Table 4.16 indicate that more than half (50.5%) of respondents from both 
regions believed their asthma was well controlled over the past four weeks, although 
self-reported control amongst Asser patients (57.5%) was slightly higher than among 
Riyadh patients (43.6%; p=0.035). This result was not influenced by gender. 
4.6.2 Relationship between the belief that the disease had been controlled in 
the past four weeks and other elements 
Table 4.17 Relationship between belief that asthma is well controlled and other 
variables 
Variable  Comparison Odds 
Ratio 
95% CI p 
value 
Dissatisfied with current asthma 
treatment component. 
Unsure vs. Yes  2.26 1.05-4.86 0.036 
Medication administration ability: 
patient’s beliefs 
Yes vs. unsure  .09 0.01-.69 0.021 
Adequate asthma management 
information accessibility beliefs 
Yes vs. No/unsure  5.67 2.90-11.09 0.000 
Medication usefulness: patients beliefs Yes vs. No/ unsure 10.63 5.34-21.13 0.000 
Acting upon physician’s given plan Yes vs. No 2.31 1.18-4.53 0.014 
Asthma triggers recognition and 
avoidance 
Yes vs. No 2.16 1.06-4.39 0.034 
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Variable  Comparison Odds 
Ratio 
95% CI p 
value 
Ability to act with asthma attack  Yes vs. No 2.74 1.50-5.03 0.001 
Asthma treatment decision 
involvement  
Yes vs. No 4.46 2.11-9.43 0.000 
Physician’s attentiveness to patient’s 
medication preference 
Yes vs. No 3.62 1.25-10.42 0.017 
Medication use followed up over the 
past 12 months 
Yes vs. No 4.61 1.79-11.91 0.002 
Asthma management education quality Excellent vs. Fair 5.68 1.92-16.80 0.002 
Very good vs. Fair 8.75 3.25-23.57 0.001 
AAP availability (when having asthma 
attack) 
Yes vs. No/unsure  3.68 1.79-7.57 0.000 
AAP availability (when not having 
asthma attack) 
Yes vs. No/unsure 2.62 1.40-4.91 0.003 
Level of AAP understanding on how 
to take asthma medicine 
Yes, and completely 
understood vs. No, not 
at all  
7.41 1.59-34.48 0.011 
Level of AAP understanding on what 
to do when having a severe asthma 
attack 
Yes, and completely 
understood vs. No, not 
at all  
9.43 2.70-33.33 0.000 
Chest tightness (difficulty taking a 
deep breath) 
Never vs. 2 to 3 times a 
week 
5.10 2.1-12.35 0.000 
Wheezy or whistling sound in the 
chest. 
Never vs. 2 to 3 times a 
week 
3.46 1.55-7.75 0.003 
Wheezing or difficulty breathing when 
exercising 
None vs. Over 7 13.51 1.56-111.11 0.018 
Missing any daily activities None vs. Over 7 5.29 1.05-26.32 0.043 
Waking up at night Not at all vs. Once or 
twice a week Less than 
once a week 
2.42 1.26-4.63 0.008 
Asthma severity (self- reported). Very mild/mild vs. 
Moderate 
2.370 1.30-4.31 0.005 
Very mild/mild vs. 
Severe/very severe 
5.44 2.20-13.51 0.000 
Physician’s attention to patient’s 
concerns 
Excellent vs. Fair 6.33 2.17-18.47 0.001 
Very good vs. Fair 2.94 1.02-8.50 0.046 
Hospital admission or emergency room 
attendance in past three months 
No vs. Yes 1.84 1.06-3.20 0.030 
 
Table 4.17 illustrates the relation between the patients’ or their families’ belief that 
their asthma had been well controlled over the past four weeks, and other 
independent variables. Patients / families satisfied with their current asthma 
treatment were 2.3 times more likely to believe the asthma was well controlled than 
patients dissatisfied with any part of their current asthma treatment (95% CI, 1.05-
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4.86; p=0.036). Patients/ families believing the asthma was well controlled were 
more likely to be able to administer asthma medicine(s) as directed than those 
patients who did not believe that (OR 0.09, 95%CI, .01-.69; p=0.021). 
The effects of patients’ knowledge, behaviour and attitudes were reported. Patients/ 
families believing they had access to sufficient information, and that the medicine(s) 
prescribed were useful in controlling their asthma, were more likely to believe their 
asthma was well controlled than who were not sure or not confident (OR 5.67, 95% 
CI, 2.90-11.09; p=0.000) and (OR 10.63, 95% CI, 5.34-21.13; p=0.000) respectively. 
Those patients/ families who recognized they had the ability to follow the care plan 
given them by a health provider, could identify things that might trigger their asthma, 
and knew how to deal with an asthma attack were more likely to believe their asthma 
was controlled than patients who did not (OR 2.3, 95% CI, 1.18-4.53; p=0.014; OR 
2.2 95% CI, 1.06-4.39; p=0.034 and OR 2.7, 95% CI, 1.50-5.03; p=0.001 
respectively). 
The involvement of patients in their own asthma treatment affected their belief in 
their ability to control their asthma. Patients who were engaged in decision-making 
about their treatment, or whose physicians knew how they wished to take their 
medicine, were more likely to believe their asthma was controlled than patients who 
were not engaged or unsure (OR 4.5, 95% CI, 2.11-9.43; p=0.000 and OR 3.62, 95% 
CI, 1.25-10.42; p=0.017 respectively).  
Patients who were educated and followed up by their physician were more likely to 
believe their asthma was well controlled than others. Patients instructed on how to 
take their asthma medicine(s) by their health providers over the past 12 months were 
more likely to believe their asthma was well controlled than patients with no follow-
up (OR 4.6, 95% CI, 1.79-11.91; p=0.002). Patients/ families who classified the 
quality of the asthma education they received as excellent and very good were more 
likely to believe their asthma was well controlled than patients who rated their 
education poorly (OR 5.7, 95% CI, 1.92-16.80; p=0.002 and OR 8.8, 95% CI, 3.25-
23.56; p=0.001 respectively). 
Having an asthma action plan (AAP) and knowing how to take medications had a 
positive influence on patients’ belief that their asthma was well controlled (OR 3.7, 
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95% CI, 1.79-7.57; p=0.000 and OR 2.6, 95% CI, 1.40-4.91; p=0.003 respectively); 
patients who completely understood their AAP and how to take their asthma 
medicine, and what to do if they had a severe asthma attack, were significantly more 
likely to believe their asthma was well controlled than those with no AAP (OR 7.4, 
95% CI, 1.59-34.48; p=0.011 and OR 9.4, 95% CI, 2.70-33.33; p=0.000 
respectively). 
Patients with a low frequency of asthma symptoms believed their asthma was well 
controlled more than patients with a high frequency of symptoms. For example, 
patients who had had no symptoms over the past four weeks, including chest 
tightness (difficulty taking a deep breath) and wheezy or whistling sounds in the 
chest, were more likely to believe their asthma was under control than patients who 
had faced these symptoms two to three times (OR 5.1, 95% CI 2.10-12.35; p=0.000 
and OR 3.5, 95% CI, 1.55-7.75; p=0.003 respectively). Patients who had never 
experienced wheezing or difficult breathing when exercising, and had never missed 
daily activities as a result of asthma in the past four weeks, were more likely to 
report their asthma was controlled than patients who had suffered more than seven 
times from these symptoms (OR 13.51, 95% CI 1.56-111.11; p=0.018 and OR 5.3, 
95% CI, 1.05-26.32; p=0.043 respectively), while patients who had never woken up 
at night as a result of asthma in the past four weeks were more likely to feel their 
asthma was under control than other patients (OR 2.42, 95% CI, 1.26-4.63; p=0.008). 
In addition, beliefs of good control among patients with very mild asthma were 
higher than among patients with more severe asthma. People with very mild and mild 
asthma were 2.4 and 5.4 times more likely, respectively, to believe their asthma was 
well controlled than moderate and severe asthma patients (95% CI, 1.30-4.31; 
p=0.005 and 95% CI, 2.20-13.51; p=0.000 respectively). 
Patients who felt that their health care professionals listened to their concerns were 
more likely to report their asthma was controlled. These who gave an excellent or 
very good rating to the skills of their doctors and nurses were 6.3 (95% CI, 2.17-
18.47; p=0.001) and 2.9 (95% CI, 1.02-8.502; p=0.046) times more likely to report 
good control. Patients who had neither been admitted to hospital nor attended the ER 
at the hospital during the past three months were 1.8 times more likely to believe 
their asthma was under control than other patients (95% CI, 1.06-3.20; p=0.030). 
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4.7 Asthma Self-management 
4.7.1 Asthma Action Plans (AAPs) 
4.7.1.1 Access to written asthma action plan. 
Respondents were asked if they had written instructions from their health provider on 
what to do during an asthma attack. 
Table 4.18 Number of patients with written instructions (AAPs)  
Region 
 
AAPs Availability, On what to do when 
having an asthma attack 
Yes No Total 
N (%) N (%) N (%) 
Asser* 98(93.3) 7(6.7) 
105(100.0) 
Riyadh** 86(77.5) 25(22.5) 
111(100.0) 
Total 184(85.2) 32(14.8) 
216(100.0) 
Difference between Gender p value 
NS 
Difference between Region p value 
0.014 
 *Eight sets of data missing 
 **Six sets of data missing 
 
Table 4.18 illustrates that 80.0% of patients from both regions had an AAP. Asser 
patients were 1.18 times more likely to have an AAP than Riyadh patients (86.7% vs. 
73.5%) explaining what to do if they had an asthma attack (95% CI, 1.192-4.651; 
p=0.014). Response rates were not influenced by gender (see Appendix E). 
Respondents were also asked if they had written instructions from their health 




Table 4.19 How to take medicine(s) on days when not having an asthma attack. 
Region 
 
AAP available on how to take medicine when not having an 
asthma attack 
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser 91(80.5) 11(9.7) 11(9.7) 113(100.0) 
Riyadh * 80(69.6) 23(20.0) 12(10.4) 115(100.0) 
Total 171(75.0) 34(14.9) 23(10.1) 228(100.0) 
Difference between Gender p 
value 
NS 
Difference between Region p 
value 
NS 
* 2 sets of data missing 
 
Table 4.19 illustrates that most patients in both regions (75.0%) had an AAP with 
regard to using medication when they were not having an asthma attack. There were 
no significant differences in responses based on region or gender (see Appendix E). 
4.7.1.2  Patient’s level of understanding of AAP 
4.7.1.2.1  Respondents’ understanding regarding AAP instructions on how to take 
medicine(s) on days when not having an asthma attack. 
Respondents were asked if they had an AAP on how to use their medications, to 
estimate their level of understanding. 
Table 4.20 Respondents’ understanding level of AAPs on how to use their medications 
when not having a severe asthma attack. 
Possession of AAP and understanding on how 
to take asthma medicine when not having a 








N (%) N (%) N (%) NS 
1. Yes, and completely understood  78(69.0) 84(71.8) 162(70.4) 
2. Yes, well understood 29(25.7) 19(16.2) 48(20.9) 
3. Yes, confused 3(2.7) 4(3.4) 7(3.0) 




The data presented in Table 4.20 illustrate that around 70% of patients in both 
regions had AAPs, and the majority felt they understood completely or very well 
how to use their medications. There were no significant differences in responses 
based on region or gender (see Appendix E). 
4.7.1.2.2 Patients’ level of understanding of AAPs regarding what to do when having a 
severe asthma attack  
Respondents were asked if they had an AAP on what to do when having a severe 
asthma attack, to estimate their level of understanding. 
Table 4.21 Respondents’ level of understanding of AAPs regarding having a severe 
asthma attack. 
Possession of AAP and level of understanding 









N (%) N (%) N (%) 
0.009 
1. Yes, and completely understood  81(71.7) 76(65.0) 157(68.3) 
2. Yes, well understood 26(23.0) 18(15.4) 44(19.1) 
3. Yes, confused 1(0.9) 4(3.4) 5(2.2) 
4. No, not at all 5(4.4) 19(16.2) 24(10.4) 
 
The data presented in Table 4.21 illustrate that the majority of patients (68.3%) in 
both regions who had AAPs reported completely understanding what to do if they 
suffered a severe asthma attack. However, there was a significant difference between 
regions, with a greater proportion of patients from Riyadh unclear on what to do in 
case of a severe asthma attack (p = 0.009). Responses rates were not influenced by 
gender (see Appendix E). 
4.7.1.3 Patients’ understating level of AAPs regarding how to adjust medication 
when asthma gets worse. 
Respondents were asked if they had an AAP on how to adjust medication when their 




Table 4.22 Number of respondents on medication adjustment category. 
Possession of AAP and 
level of understanding 
regarding how to 
adjust medication 









 Gender No N (%) N (%) N (%) region gender 
1. Yes, and completely 
understood  
Male 26(44.8) 39(54.9) 65(50.4) 0.003 0.036 
Female 33(60.0) 31(67.4) 64(63.4) 
Total 59(52.2) 70(59.8) 129(56.1) 
2. Yes, well 
understood 
  
Male 18(31.0) 11(15.5) 29(22.5) 
Female 17(30.9) 5(10.9) 22(21.8) 
Total 35(31.0) 16(13.7) 51(22.2) 
3. Yes, confused Male 7(12.1) 7(9.9) 14(10.9) 
Female 2(3.6) 0(0.0) 2(2.0) 
Total 9(8.0) 7(6.0) 16(7.0) 
4. No, not at all 
  
Male 7(12.1) 14(19.7) 21(16.3) 
Female 3(5.5) 10(21.7) 13(12.9) 
Total 10(8.8) 24(20.5) 34(14.8) 
 
Table 4.22 illustrates that just over half the patients across both regions (56.1%) with 
an AAP reported completely understanding how to adjust their medication when 
their asthma got worse. There was a significant difference based on regions 
(P=0.003), with more patients in Riyadh (20.5%) reporting not having received an 
AAP than in Asser (8.8%). Across genders there was also a significant difference. 
Males (50.4%) were less likely to have an AAP or to completely understand how to 
adjust medications than females (63.4%, p=0.036); 14 (10.9%) and 21(16.3%) of 
males were confused and had no AAP, compared with 2(2.0%) and 13(12.9%) of 




4.7.1.4 Relationship between AAPs and others variables 
Table 4.23 Relationship between AAPs on what to do if having an asthma attack, and 
other variables 




Dissatisfied with current asthma treatment 
component. 
Unsure vs. Yes  3.16 1.32-7.57 0.010 




understood vs. No, 
not at all  
12.35 5.03-30.30 0.000 




understood vs. No, 
not at all  
4.93 1.17-20.83 0.030 
Acting upon physician’s given plan Yes vs. No 3.41 1.68-6.94 0.001 
Ability to act with an asthma attack Yes vs. No .48 1.78-6.85 0.001 
Patient’s belief in being able to administer 
medication 
Yes vs. Unsure  5.46 1.58-18.87 0.007 
Belief that there is adequate accessible 
asthma management information 
Yes vs. No/unsure  6.27 3.13-12.56 0.000 
Patient’s belief in medication’s usefulness  Yes vs. No/unsure 2.73 1.40-5.32 0.003 
Spacer accessibility  Yes vs. No  2.78 1.27-6.10 0.011 
Involvement in decisions about asthma 
treatment  
Yes vs. No 2.82 1.33-5.99 0.007 
Physician’s attentiveness to patient’s 
medication preferences 
Yes vs. No 9.43 3.44-25.64 0.000 
Medication use followed up over the past 
12 months 
Yes vs. No 9.43 3.98-22.22 0.000 
Yes vs. Unsure  21.28 4.05-111.11 0.000 
Inhaler use demonstration Yes vs. No 2.55 1.31-4.95 0.006 
Inhaler use observation Yes vs. No 2.48 1.28-4.79 0.007 
Quality of asthma management education  Very good vs. OK 5.81 2.13-15.87 0.001 
Quality of health care in the past 12 
months  
Excellent vs. Poor 39.00 6.68-227.65 0.000 
Very good vs. Poor 17.02 5.07-57.12 0.000 
Use of an inhaler or nebulizer as reliever  Yes vs. No / unsure  2.18 1.09-4.37 0.028 
Use of a control medication Yes vs. No 2.17 1.11-4.27 0.024 
Change of mood  No vs. Yes 2.03 1.06-3.92 0.034 
Slowed growth rate  No vs. Yes 3.09 1.51-6.34 0.002 
 
Table 4.23 illustrates the relationship between patients with an AAP knowing what 
to do if they have an asthma attack, and other independent variables. The effects of 
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patients’ knowledge, behaviours and attitudes were reported against patients and 
their families possessing an AAP. Patients and their families satisfied with current 
asthma treatment were 3.2 times more likely to have an AAP (95% CI, 1.32-7.57; 
p=0.010) than others. AAPs were more often provided to patients who received 
education and follow-up from their health providers. Patients instructed on how to 
adjust their medication when their asthma got worse and who completely understood 
were more likely to use an AAP than non-educated patients (OR 12.35, 95% CI, 
5.03-30.30; p=0.000). Furthermore, patients who completely understood how to 
identify asthma triggers were 4.9 times more likely to have an AAP than other 
patients (95% CI, 1.17-20.83; p=0.03). Those who had the ability to follow the care 
plan given to them by their health provider, and predict how to deal with an asthma 
attack, were more likely to use an AAP than patients who did not (OR 3.4, 95% CI, 
1.68-6.94; p=0.001 and OR 3.5, 95% CI, 1.78-6.85; p=0.001 respectively).  
Good self-efficacy was reported among patients and their families with an AAP, who 
were 5.5 times more likely to be able to administer asthma medicine(s) as directed 
than other patients (95% CI, 1.58-18.87; p=0.007). Patients and their families who 
believed they had access to enough information and that the medicine(s) prescribed 
were useful for controlling their asthma were more likely to have an AAP than those 
who did not, or who were unsure (OR 6.3, 95% CI, 3.13-12.56; p=0.000 and OR 2.7, 
95% CI, 1.40-5.32; p=0.003 respectively). Patients who usually used a spacer when 
they used an inhaler were 2.78 times more likely to have an AAP than non-spacer 
users (95% CI, 1.27-6.10; p=0.001). 
A link between good communication between patients and their families and their 
health provider, and possession of an AAP, were documented. Patients who were 
engaged in decision-making about their asthma treatment and whose physicians 
knew how they desired to take their medicine were more likely to have an AAP than 
patients who were not engaged (OR 2.8, 95% CI, 1.33-5.99; p=0.007 and OR 9.4, 
95% CI, 3.44-25.64; p=0.000 respectively). Those patients instructed on how to take 
their asthma medicine(s) by their health providers in the past 12 months were 9.4 and 
21.3 times more likely to have an AAP than patients with no follow-up or who were 
unsure (95% CI, 3.98-22.22; p=0.000 and 95% CI, 4.05-111.11; p=0.000 
respectively). Patients shown how to use an inhaler properly by their health providers 
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and observed doing so were 2.55 and 2.48 times more likely to have an AAP than 
patients who did not (95% CI, 1.31-4.95; p=0.006 and 95% CI, 1.28-4.79; p=0.007 
respectively). 
Patients and their families who classified the quality of information received about 
their illness from their health care providers as very good were 5.8 times more likely 
to use an AAP than patients who rated their education poorly (95% CI, 2.13-15.87; 
p=0.001). Patients who had an AAP were more likely to report the level of care 
received as excellent (OR 39, 95% CI, 6.68-227.65; p=0.000) or very good (OR 17, 
95% CI, 5.07-57.12; p=0.000) than patients without an AAP.  
Use of an AAP was more common among patients using an inhaler or nebulizer for 
quick relief than among patients who were not using such or were unsure (OR 2.2, 
95% CI, 1.09-4.37; p=0.028). In addition, patients who were prescribed a control 
medication were 2.2 times more likely to have AAP than patients who did not (95% 
CI, 1.11-4.27; p=0.024). 
The use of an AAP was higher among patients not suffering from adverse effects 
such as change of mood and slowed growth rate than among those who were. 
Patients who reported that they did not suffer from changes of mood and slowed 
growth rate after commencing asthma medication were more likely to have an AAP 
than patients who experienced these adverse effects (OR 2.03, 95% CI, 1.06-3.92; 




4.7.2 Peak flow meter (PFM)  
4.7.2.1 PFM usage 
Respondents were asked if they had a PFM and how regularly they used it. 
Table 4.24 Number of patients with a peak flow meter  






N (%) N (%) N (%) 
Does not have a home PFM 101(89.4) 83(70.9) 184(80.0) 
Yes and uses it regularly. 3(2.7) 16(13.7) 19(8.3) 
Yes, but almost never uses it  9(8.0) 18(15.4) 27(11.7) 
Difference between region p value 0.001 
Difference between both regions’ patients’ adherence to 
PFM use p value 
*0.003 
 * P value between both regions adherences with PFM use 
 
Table 4.24 shows that the majority (80%) of respondents in both regions did not have 
a PFM at home. There were significant differences between both regions. More than 
89% and 70% of patients in Asser and Riyadh respectively did not have a PFM. 
Riyadh patients were more likely to have a PFM than Asser patients, p= 0.001. 
Furthermore, there were low levels of regular PFM usage: 27 patients across both 
regions had a PFM but almost never used it. Only 8.3% of patients from both regions 
who had a PFM used it regularly, with patients in Riyadh more likely to do so than 
those in Asser (13.7% vs. 2.7%; p=0.0031). Response rates were not influenced by 




4.7.2.2 Relationship between the dependent variable PFM and other variables  
Table 4.25 Relationship between dependent variable PFM and other variables  




Medication usage followed up over 
the past 12 months 
Yes vs. No  7.69 1.02-58.82 0.048 
Inhaler use demonstration Yes vs. No 2.42 1.10-5.32 0.028 
Patient uses a peak flow meter to 
monitor asthma 
Yes vs. No 18.87 6.41-55.56 0.000 
Uses an inhaler or nebulizer as 
reliever.  
No/ unsure vs. Yes 5.80 1.72-19.51 0.005 
Uses corticosteroid  Yes vs. No 2.45 1.26-4.79 0.009 
Uses medication  β2 Agonist +corticosteroid 
vs. β2 Agonist Only  
2.23 1.01-4.93 0.048 
β2 Agonist + corticosteroid + 
Other vs. β2 Agonist Only  
7.50 1.85-30.34 0.005 
Spacer accessibility  Yes vs. No 4.65 2.34-9.26 0.000 
Chest tightness (difficulty taking a 
deep breath) 
Daily vs. Never 14.80 2.78-78.71 0.002 
Wheezy or whistling sound in the 
chest 
Daily vs. Never 10.76 3.0-38.58 0.000 
Wakes up at night. Three or more times a week 
vs. Not at all 
6.66 1.73-25.66 0.006 
Symptom (wheezing or difficulty 
breathing with or without 
exercising, waking up at night, 
missing days of school and daily 
activities). 
Moderate vs. Very mild  3.90 1.42-10.73 0.008 
Asthma severity (self-reported) Severe/very severe vs. Very 
mild/mild  
2.87 1.06-7.78 0.038 
Hospital admission or emergency 
room attendance in past three 
months 





Table 4.25. illustrates the relationship between having a PFM and other independent 
variables. Patients who were observed and followed up by their physician were more 
likely to use a PFM than others. Patients instructed in how to use their asthma 
medicine(s) by their health providers in the past 12 months were more likely to have 
and use a PFM than patients who were not followed up (OR 7.7, 95% CI, 1.02-58.82; 
p=0.048). In addition, patients who were shown how to use an inhaler properly by 
their health providers were more likely to have a PFM and use it than those who 
were not (OR 2.42, 1.10-5.32; p=0.028). A high percentage of patients with a PFM 
were using it to monitor their asthma (OR 18.87, 95% CI, 6.41-55.56; p=0.000). 
PFM use was reported more by patients not using or unsure if they were using an 
inhaler or nebulizer for quick relief than by patients who were confident using it (OR 
5.8, 95% CI, 1.72-19.51; p=0.005). Patients who were prescribed a corticosteroid or 
β2 agonists plus corticosteroids, with or without other medication, were more likely 
to have and use a PFM than patients prescribed β2 agonists only (OR 2.45, 95% CI, 
1.26-4.79; p=0.009, OR 2.23, 95% CI, 1.01-4.93; p=0.048 and OR 7.5, 95% CI, 
1.85-30.34; p=0.005 respectively). In addition, patients using a spacer with an inhaler 
were more likely to use a PFM than patients who were not (OR 4.65, 95% CI, 2.34-
9.26; p=0.000). 
Patients with a high frequency of asthma symptoms reported more use of their PFM 
than others. For example, patients with daily symptoms which included chest 
tightness and wheezy or whistling sounds in the chest were 14.8 and 10.8 times more 
likely to have a PFM and use it than those without symptoms (95% CI, 2.78-78.71; 
p=0.002 and 95% CI, 3.00-38.58; p=0.000, respectively). Patients who woke up 
three or more times a week at night as a result of their asthma were 6.7 times more 
likely to use a PFM than other patients (95% CI, 1.73-25.65; p=0.006). 
Patients who had moderate symptoms including wheezing or difficulty breathing 
when exercising or without exercising, who woke up at night with wheezing or 
difficult breathing or missed days of school and daily activities, were 3.9 times more 
likely to use a PFM than patients with very mild symptoms (95% CI, 1.42-10.73; 
p=0.008). It is clear that the use of a PFM was dependent on asthma severity. 
Patients with severe asthma were 2.9 times more likely to use a PFM than these with 
very mild asthma (95% CI, 1.06-7.78; p=0.038), and patients who had been admitted 
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to hospital or had attended the ER in the last 3 months were 2.9 times more likely to 
use a PFM than patients who had not (95% CI, 1.48-5.56; p=0.002). 
4.7.2.3 Air chamber (spacer)  
4.7.2.3.1 Possession of spacer 
Respondents were asked if they used a spacer when taking medication. 




Yes No Total 
N (%) N (%) N (%) 
Asser* 27(24.1) 85(75.9) 112(100.0) 
Riyadh** 55(47.8) 60(52.2) 115(100.0) 
Total 82(36.1) 145(63.9) 227(100.0) 
Difference between gender p value NS 
Difference between region p value 0.000 
*One set of data missing  
**Two sets of data missing 
As can be seen from Table 4.26, around three quarters of the Asser patients and half 
of the Riyadh patients did not use a spacer. There was a significant difference based 




4.7.2.4 Relationship between spacer use and age  
Table 4.27 Age category and spacer use 
Age  
  







5 - < 10 yrs. 45(19.8) 54(23.8) 99 (43.6) 0.016 
10 - <15 yrs. 24(10.6) 47(20.7) 71 (31.3) 
 l5 - <18 yrs. 13(5.7) 44(19.4) 57 (25.1) 
Total 82(36.1) 145 (63.9) 227 
 
Table 4.27 demonstrates that younger patients were more likely to use a spacer, with 
usage falling with increasing age, p=0.016.  
4.8 Patients’ Education 
4.8.1 Accessible information  
Respondents were asked if they believed they had enough access to asthma-related 
information. 
Table 4.28 Level of accessible information across gender and region 
Region 
 
Access to adequate asthma management information 
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser* 88(78.6) 13(11.6) 11(9.8) 112(100.0) 
Riyadh** 75(65.2) 25(21.7) 15(13.0) 115(100.0) 
Total 163(71.8) 38(16.7) 26(11.5) 227(100.0) 
Difference between gender p value NS 
Difference between region p value 0.028 
*One set of data missing 
**Two sets of data missing 
 
Table 4.28 shows that more than two thirds of respondents reported they had access 
to enough information to help them control their asthma. However, a significant 
difference between regions was found, with Asser patients more likely to have access 
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to information than Riyadh patients (78.6% vs. 65.2%, p=0.028). There was no 
statistically significant difference across gender (see Appendix E). 
4.8.2 Inhaler use education 
Respondents were asked if they were shown the correct use of the inhaler by their 
health provider, to which they could respond Yes, No, or unsure (see Appendix E). 
Table 4.29 Respondents’ inhaler usage education  
Region 
 
Correct inhaler use demonstrated by health care 
providers 
Yes No Total 
N (%) N (%) N (%) 
Asser* 75(67.6) 36(32.4) 111(100.0) 
Riyadh** 76(65.5) 40(34.5) 116(100.0) 
Total 151(66.5) 76(33.5) 227(100.0) 
 Difference between Gender p value NS 
Difference between Region p value NS 
*Two sets of data missing  
** One set of data missing 
 
Table 4.29 illustrates the majority (66.5%) of patients had been educated on how to 
use their inhaler. There were no significant differences between region or gender. 
4.8.3 Quality of patients’ education  
Respondents were asked to evaluate the quality of education regarding their disease 
that they received from their health providers, to which they could respond Fair, 




Figure 4.4 Respondents’ assessment of education in asthma management  
 
Figure 4.4 shows that the majority of patients evaluated the quality of education they 
received to manage their asthma as good or better. There was a significant difference 
between regions: while only 7.1% of Asser patients classified the quality of 
education as fair, this percentage increased to 21.6% amongst Riyadh patients, 
p=0.009. There was no difference based on gender (see Appendix E). 
4.9 Communication between Patients and Health Care Providers  
4.9.1  Patients’ involvement  
Respondents were asked if they were involved with their health providers in making 
decisions about their asthma management. 
Table 4.30 Patients’ involvement  
Region 
 
Involvement in asthma treatment decisions with medical 
provider.  
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser 83(73.5) 16(14.2) 14(12.4) 113(100.0) 
Riyadh 83(70.9) 29(24.8) 5(4.3) 117(100.0) 
Total 166(72.2) 45(19.6) 19(8.3) 230(100.0) 
Difference between gender p value NS 








































Table 4.30 shows that most patients (72.2%) were involved in decision-making 
regarding their asthma treatment; Riyadh patients were more definite that they were 
not engaged in decision-making than Asser patients (24.8% vs. 14.2%, p=0.019). No 
statistically significant differences were observed across gender (see Appendix E).  
4.9.2 Patients’ assessment of their relationship with health care providers 
Respondents were asked to rate the level of attention their health care providers gave 
to their concerns. 
 
 
Figure 4.5 Level of health care provider’s attention to patients’ concerns 
 
Figure 4.5 shows that the majority of patients (88.8%) in both regions evaluated the 
level of attention given by their health providers regarding their care concern issues 
as good or above. There were no significant differences based on region or gender 
(see Appendix E). 
4.9.3 Physicians’ amenability to prescribing patients’ preferred medication  
Respondents were asked if their health care providers paid attention to their preferred 





























Table 4.31 Patients’ perception of physicians’ amenability 
Region 
 
Physician attentive to patient’s medication preference  
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser 96(85.0) 6(5.3) 11(9.7) 113(100.0) 
Riyadh 92(78.6) 13(11.1) 12(10.3) 117(100.0) 
Total 188(81.7) 19(8.3) 23(10.0) 230(100.0) 
Difference between gender p value NS 
Difference between region p value NS 
 
Table 4.31 illustrates that the majority of patients (81.7%) reported that their health 
providers were familiar with their preferred medication. There were no significant 
differences based on region or gender (see Appendix E). 
4.9.4 Medication usage instruction 
Respondents were asked whether their health provider had instructed them about 
their medications in the past year. 
Table 4.32 Number of respondents coached about medication in the past 12 months. 
Region 
 
Medication use follow-up 
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser 104(92.0) 6(5.3) 3(2.7) 113(100.0) 
Riyadh 90(76.9) 22(18.8) 5(4.3) 117(100.0) 
Total 194(84.3) 28(12.2) 8(3.5) 230(100.0) 
Difference between gender p value NS 
Difference between region p value 0.002 
 
Data in Table 4.32 shows that the majority of respondents (84.3%) reported they had 
been educated about their use of medication over the past 12 months. Not as many 
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Riyadh patients (76.9%) received instruction as Asser patients (92.0%): 18.8% and 
4.3% of Riyadh patients were not educated or were unsure, compared with 5.3% and 
2.7% of Asser patients respectively (p=0.002). There was no significant difference 
based on gender (see Appendix E). 
4.9.5 Patient follow-up 
 Respondents were asked if they had been observed by their health care providers 
when using their inhaler. 




Inhaler observation by health care provider 
Yes No Total 
N (%) N (%) N (%) 
Asser 69(62.7) 41(37.3) 110(100.0) 
Riyadh 78(67.2) 38(32.8) 116(100.0) 
Total 147(65.0) 79(35.0) 227(100.0) 
 Difference between gender p value NS 
Difference between region p value NS 
 
Table 4.33 illustrates that the majority of patients (65.0%) had been observed by 
their health providers when using their inhaler. There were no significant differences 
based on region or gender (see Appendix E). 
4.10 Patients’ Medication Knowledge  
The questionnaire asked the patients or their family members if they (the child) used 
an inhaler or nebulizer reliever. To validate the responses, the primary researcher 
asked the respondents to list the medication, to determine if they knew what it was 




Table 4.34 Difference between patients’ responses for quick relief 
Region Use of an inhaler or nebulizer as a 
quick reliever  










Asser N=113 79(69.9) 34(30.1) 107(94.7) 6(5.3) 
Riyadh N=117 95(81.2) 22(18.8) 110(94.0) 7(6.0) 
Total 
N=230 
174(75.7) 56(24.3) 217(94.3) 13(5.7) 
 
Table 4.34 demonstrates that the majority of patients used a β2 agonist; however, 
there was a poor understanding amongst some patients/ parents about what these 
were for. For example, patients who reported using an inhaler or nebulizer for quick 
relief were 69.9% and 81.2% in Asser and Riyadh respectively, although their 
responses indicated that 94.7% of Asser and 94.0% of Riyadh patients were using β2 
agonist treatments. 
The patients were asked if they used a controller medication and an inhaled 
corticosteroid. To validate the responses the researcher asked the respondents to list 
the medication to determine if they used an ICS, as can be seen in Table 4.35.  
Table 4.35 Differences in patients’ responses about control medications 
Region Control medication used Use of an inhaled 
corticosteroids 
Corticosteroid use based 















84(74.3) 29(25.7) 22(19.5) 91(80.5%) 21(18.6) 92(81.4) 
Riyadh 
N=117 
82(70.1) 35(29.9) 58(49.6) 59 (50.4) 47(40.2) 70(59.8) 
Total 
N=230 
166(72.2) 64(27.8) 80(34.8) 150(65.2) 68(29.6) 162(70.4) 
Table 4.35 demonstrates that patients (and/ or their parents) had a poor 
understanding of what medications were controllers. Whilst the majority of 
respondents from both regions reported use of a controller medication (72.2%), 
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fewer than 35% reported the use of an ICS and fewer than 30% were actually found 
to use a corticosteroid. In some cases respondents reported using an ICS when 
according to their medication list they did not. 
4.11 Patients’ Beliefs, Perceptions, and Self-efficacy  
4.11.1 Respondents’ self-efficacy in medicine administration 
Respondents were asked if they believed that they could administer their medication 
as directed by their health provider.  
Table 4.36 Number of patients able to administer medicine as directed. 
Region 
 
Patients believe they can administer their medication as 
directed 
Yes No Unsure Total 
 
N (%) N (%) N (%) N (%) 
Asser 103(91.2) 4(3.5) 6(5.3) 113(100.0) 
Riyadh 97(82.9) 15(12.8) 5(4.3) 117(100.0) 
Total 200(87.0) 19(8.3) 11(4.8) 230(100.0) 
 Difference between gender p value NS 
Difference between region p value 0.037 
 
Table 4.36 illustrates that 87.0% of patients believed they were able to administer 
their medicine as directed. There was a statistically significant difference based on 
region, with Asser patients (91.2%) feeling more able to administer their medicine 





4.11.2 Patient perceptions about the usefulness of medication 
Respondents were asked if they believed that the medications they used were useful. 
Table 4.37 Respondents’ perception about medication’s effectiveness. 
Region 
 
Medicine usefulness: patients’ beliefs 
Yes No Unsure Total 
N (%) N (%) N (%) N (%) 
Asser 81(71.7) 8(7.10 24(21.2) 113(100.0) 
Riyadh * 69(60.0) 17(14.8) 29(25.2) 115(100.0) 
Total 150(65.8) 25(11.0) 53(23.2) 228(100.0) 
Difference between gender p value NS 
Difference between region p value NS 
Two sets of data missing 
 
Table 4.37 illustrates that more than half (65.8%) the patients believed their 
medications were useful in controlling their asthma. There was no significant 
difference based on region, although there was a greater level of uncertainty amongst 
Riyadh patients (40% vs. 28.2%). There was no statistically significant difference 
across gender (see Appendix E).  
4.11.3 Patients’/ relatives’ self-efficacy 
(See Appendix A: Scoring Instructions) 
Using the Therapy Assessment Questionnaire (ATAQ), which scores patients’ 
responses to a series of three questions, individual patients’ self-efficacy was 
determined. Patients with a score of zero were deemed to have a high self-efficacy 
level whilst those with a score of three were classified as having poor self- efficacy 
(See Appendix A: Scoring Instructions). 
Table 4.38 Patients’ and their families’ self-efficacy 











Asser 68(60.7) 28(25.0) 11(9.8) 5(4.5) 112(100.0) 0.057 
Riyadh 52(45.6) 30(26.3) 22(19.3) 10(8.8) 114(100.0) 
Total 120(53.1) 58(25.7) 33(14.6) 15(6.6) 226(100.0) 
 
100 
Table 4.38 illustrates the patients ‘and their families’ self-efficacy. Most patients had 
high self-efficacy. Asser patients (60.7%) were more likely to have high self-efficacy 
than Riyadh patients (45.6%). There were no significant differences based on region 
or gender (see Appendix E). 
4.12 Patients’ Behaviours/ Attitudes 
Using the Therapy Assessment Questionnaire (ATAQ), which scores patients’ 
responses to a series of two questions, individual patients’ behaviours/ attitudes were 
determined. Patients with a score of zero were deemed to have no behaviour/ attitude 
barriers whilst those with score of two were classified as having two barriers.  
Table 4.39 Patients’ and their families’ behaviours/ attitudes 









Asser 30(26.5) 64(56.6) 19(16.8) 113(100.0) NS 
Riyadh 27(23.1) 67(57.3) 23(19.7) 117(100.0) 
Total 57(24.8) 131(57.0) 42(18.3) 230(100.0) 
 
Table 4.39 illustrates that there were no significant differences between the regions 
regarding patients’ behaviours or attitudes. More than half the patients (57.0%) 
reported one barrier, and 19.7% of Riyadh patients reported two barriers, compared 
with 19 (16.8%) patients from Asser. These responses were not influenced by gender 
(see Appendix E). 
4.13 Patients’ Asthma Control Level 
Using the Therapy Assessment Questionnaire (ATAQ), which scores patients’ 
responses to a series of three questions, individual patients’ control levels were 
determined. Patients with a score of zero were deemed well controlled, whilst those 




Table 4.40 Patients’ asthma control levels 
Asthma control level Region Total 





Well controlled 24(21.2) 9(7.7) 33(14.3) 
0.045 
One control problem 19(16.8) 13(11.1) 32(13.9) 
Two control problems 25(22.1) 24(20.5) 49(21.3) 
Three control problems 16(14.2) 26(22.2) 42(18.3) 
Four control problems 16(14.2) 23(19.7) 39(17.0) 
Five control problems 6(5.3) 13(11.1) 19(8.3) 
Six control problems 6(5.3) 8(6.8) 14(6.1) 
Poor control 1(0.9) 1(0.9) 2(0.9) 
Total 113(100.0) 117(100.0) 230(100.0) 
 
Table 4.40 reveals that only 14.3% had well controlled asthma. In Asser the 
proportion of patients with well controlled asthma was 21.2%, compared with 7.7% 
amongst Riyadh patients (p=0.045). In general, patients in Riyadh were more likely 
to have one or more control problems than those in Asser; however, in both cases 
fewer than 1% of patients reported poor control. These responses were not 
significantly influenced by gender (see Appendix E). 
4.14 Communication between Patients and their Health Care 
Providers 
Using the Therapy Assessment Questionnaire (ATAQ), which scores patients’ 
responses to a series of three questions, the level of communication between patients 
and health care providers was determined. Patients with a score of zero were deemed 
to have a high communication level with their health care provider, whilst those with 




Table 4.41 Patients’ and their health care providers’ communication level 
Patient/ provider communication in both regions 
Communication level Asser 






Poor 65(57.5) 50(43.5) 115(50.4) 
0.080 
Low 24(21.2) 28(24.3) 52(22.8) 
Fair 12(10.6) 14(12.2) 26(11.4) 
Medium 7(6.2) 6(5.2) 13(5.7) 
Good  1(.9) 8(7.0) 9(3.9) 
High  4(3.5) 9(7.8) 13(5.7) 
Total 113(100.0) 115(100.0) 228(100.0) 
 
Table 4.41 indicates that in general there was a lack of communication, with no 
significant difference between regions. More than half the patients (50.5%) classified 
their communication with their health providers as poor. Riyadh patients tended to 
report a better level of communication than Asser patients (see Appendix E). 
4.15 Discussion of Phase One: Patients’ Survey  
Asthma is one of the most common childhood diseases. Inadequate asthma 
management leads to an increase in both mortality and morbidity, imposing a 
significant burden on children and their families in addition to social and financial 
strains on the population. International and national guidelines have been developed 
to ensure optimal asthma management, but achieving the objectives of these 
guidelines is difficult.  
This study evaluated the current practice of asthma management and adherence to 
the guidelines recommended for outpatients in primary health care in Saudi Arabia. 
It found low adherence to guideline recommendations regarding ICS use, PFM use, 
AAP, and patient education. It also found that there was a lack of knowledge, allied 
with poor attitudes, behaviours and inadequate self-efficacy in patients and their 
families, and a lack of communication between them and their health care providers. 




Patients’ self-reports underestimate the severity of their asthma and overestimate 
their control (52, 58, 59). Rabe et al. found that of patients who believed that their 
asthma was well or completely controlled, 32% to 49% had severe symptoms, while 
another 39% to 70% had moderate symptoms (58). The findings of this study are 
consistent with Rabe et al. The majority of children from both Asser and Riyadh 
classified their asthma as moderately severe or less: 27.1% and 52.6% of respondents 
in both regions classified their asthma as mild and moderate respectively, with 
around 50.5% believing their asthma to be well controlled. However, 60.7% and 
53.5% respectively reported having woken up at night and having missed school 
more than once in the past four weeks. In addition, 75.7% reported using a quick 
relief, and of these 94.3% had used it three times daily or more in the previous four 
weeks. Seventy-nine of 230 had been admitted to hospital or attended an emergency 
department in the past three months, with 35.4% of them utilizing these services at 
least three times. Only 34.8% of participants reported they were using an ICS, and of 
these only 30% used it regularly. Based on self-reported symptoms, only 14.3% of 
patients had well controlled asthma, and the actual percentage of patients using 
corticosteroids, based on their medication list, was 29.6%. These results are in line 
with the findings of many studies, indicating that asthma management and control 
remain suboptimal (38, 52, 55, 57-60, 74, 88, 90).  
Numerous factors are reported to have a positive influence on asthma control, 
including patient/ family satisfaction, knowledge, beliefs, behaviour, confidence, 
ability, education, involvement, follow-up, patients’/ carers’ communication with 
their health care provider, and the availability of AAPs. Asthma control is correlated 
negatively with disease severity, symptoms, hospital admission and emergency 
attendance. These factors should be considered when aiming to achieve the main 
goals of asthma management guidelines.  
As a consequence of the underestimation of asthma severity and the subsequent 
imposition of an inadequate level of control, patients are likely to be inappropriately 
treated (38, 52, 54, 56, 57, 74). In several studies such as Asthma Insights and 
Reality (AIR) surveys, the use of 2 agonists was reported to be high, ranging from 
39% to 94% in different countries (57, 58). Our findings are no different, with the 
majority (94.3%) of participants using 2 agonists. This may indicate severity of 
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disease and/ or lack of control. Furthermore, undertreatment was identified, with 
61% of patients using 2 agonists only, compared to 24.8% of patients using both 2 
agonists and corticosteroids. 
Based on strong evidence, international and national guidelines recommend ICS as a 
long-term treatment for all patients with persistent asthma. Despite this, low 
prescribing of ICS is reported worldwide (38, 52, 54, 57-59, 74, 88, 89, 284). 
Findings of this study confirm this: based on self-reports, only 34.8% of patients 
used ICS, with 30% of this cohort using them daily; but the proportion actually using 
corticosteroids was only 29.6% when estimated from a review of the list of 
medications used. Jentzach et al. have found that the adherence percentage varies 
when different methods are used to monitor beclomethasone usage in children (for 
instance, self-reporting 97.9%, pharmacy records 70.0%, electronic monitoring 
devices [Dosers] 51.5% and canisters 46.3%); and that adherence is likely to decline 
over time (285). Winnick et al. reported that children’s compliance with medication 
regimens ranged between 10% and 90% (182).  
Adherence to ICS use is a concern in asthma management. A number of studies have 
reported poor adherence; this is most often found to be less than 50% among children 
and adolescents (54, 59, 74, 85, 89, 91, 204, 218). Anarella et al. found that 74.4% of 
respondents reported using ICSs; however, only 38.5% used them daily (85). This 
study also noted that adults were more likely to adhere to ICS use than children (85). 
Our study showed no significant difference in rates of adherence among respondents 
in different age groups. Many factors, relating to patients/ families, professionals, 
care settings, and the medication itself, have been found to contribute to low ICS 
adherence levels (59, 85). Although the current study did not determine reasons, a 
lack of knowledge about medication was observed.  
Patient knowledge and understanding of asthma – both the disease and its treatment 
– are essential elements for better quality care. In general, it has been reported that 
patients do not distinguish between different medications and the role of each (85). 
The current study found the same, noting inconsistencies between the patients’ 
responses to questions about control medications and ICS use and the actual 
medication list recorded. Similar findings were found regarding 2 agonists. For 
instance, some participants answered ‘yes’ to the question on current ICS use, yet 
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according to their medication list did not use any steroid medications; similar 
findings applied in the case of ‘no’ and ‘unsure’ answers. These findings were 
replicated in the responses to questions about control medication, even when a 
pictorial list of most asthma medications was attached to help patients and family 
identify their medication correctly.  
It was also observed that many patients recognized their medication by its colour 
only. While it is recommended that medications be prescribed by their generic 
names, some professionals use the brand names; this may confuse patients, 
especially if they are used to a different brand. For example, some patients described 
salbutamol products as ‘the blue inhaler’ or ‘Ventolin
®
’ even when they used a 
different brand. This clearly suggested that patients and/ or their families were 
ignorant of the meaning of ‘asthma control’ or the role of medications – and of the 
medication they actually used. Language is another concern: most drugs’ names are 
written in English, but Arabic is the mother language in Saudi Arabia. Most asthma 
medications available worldwide are registered in Saudi Arabia, and the vast range 
of medications and devices available may confuse patients and even professionals.  
Correlation tests show a significant positive relationship between ICS use and the use 
of a reliever and the frequency of its use, disease severity, symptoms, and possession 
of PFM and a spacer, as well as of patient/ family behaviour, confidence, education 
and follow-up. It is related negatively with the level of patient/ family satisfaction 
and the quality of the information supplied regarding their disease. 
Asthma Management Guidelines (national and international) recommend that asthma 
action plans to be used. In this study, 80% of respondents had an AAP, which is 
consistent with the findings of Dinakar et al. and Anarella et al. (85, 160), but higher 
than reported in other studies (38, 57, 89, 90, 149, 167). It was noted that AAPs were 
not routinely used even if they had been developed for individual patients (90, 168). 
Leffvre et al. in their review study reported that AAPs have a limited effect on 
outcomes, and suggested they might not be essential for every patient (154). Quite 
similar results were previously reported by Sunshine et al. (286). Moreover, patients 
may lack the confidence to use AAPs (85, 168). As an observation, some patients 
were under the impression that they had a written AAP while in fact they had a 
verbal one. A Canadian study found that 80% of physicians prefer verbal over 
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written AAPs (90). While participants reported a high percentage of having AAPs, 
the lack of adherence to them, and confusion in practice, may be reflected in this 
study by low rates of adherence to ICS use, the low use of PFMs, and the lack of 
medication knowledge among patients. This is despite findings that outcomes of 
asthma management can be improved with the use of educational programs, 
including AAPs, monitoring, and medical review. 
Even when AAPs are available, how to use them may be misunderstood. In this 
study, 68.3% of respondents reported that they completely understood their AAPs in 
regard to how to use their medication when having a severe asthma attack, but only 
56.1% completely understood how to adjust their medication. Riyadh patients’ 
answers to questions regarding 2 agonist and ICS use were more consistent with 
actual medication used as listed than were Asser patients, yet their reported use of 
AAPs was less than that of Asser patients, which may indicate low adherence to 
AAPs and/ or ineffective education. 
A logistic regression test indicated a significant positive correlation between having 
an AAP and patients’ satisfaction, beliefs, involvement and communication, 
education, understanding level, perceptions of both information and health care 
quality, and their use of a spacer. On the other hand, having an AAP had a negative 
correlation with controller use and side effects (mood change and slow growth rate). 
There is no relationship between having an AAP and the severity of asthma, 
admissions to hospital or attendance at EDs, of PFM and ICS use, or medication 
listed as used.  
Anarella et al. reported that 51% of participants in their study owned a PFM, yet only 
63% of those used it regularly (85). In the current study, the use of a PFM was found 
to be very low, with only 20% of participants having a PFM and only 41.3% of these 
using it regularly. These findings are consistent with several other studies (38, 57, 
88, 89, 118, 147, 284, 287). Brand et al. suggested that the majority of children may 
not need to use home peak flow monitoring (147). Bukstein et al. used PFM in their 
study to measure its effect on adherence to 2 agonists and on hospitalization among 
mild asthma patients, and found that the benefits of using a PFM daily was minimal 
and ineffective (288). In the current study, use of PFMs shows a positive correlation 
with the severity of asthma and its symptoms, follow-up, education, and medication 
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used, and a negative correlation with the use of quick reliever inhalers and ICS. 
Spacer use is reported only by 82 (36.1%) participants, of whom 43.6% are from the 
age group 5–10 years, compared with 56.4% from the other two groups (p=0.016). 
As with PFM and spacer use, the figure in this study was low. This may be due to the 
cost of both PFM and spacers, which must be met by the patients or their carers. The 
discomfort of daily use may be another factor (147); as may be a lack of knowledge 
on the part of health professionals about the benefits, and even the proper use, of 
PFMs (190). This is suggested in part by the fact that very few patients had been 
taught how to use their PFM.  
Although 71.8% of patients had access to enough information, only 38.6% rated the 
quality of education provided as ‘very good’ or ‘excellent’. This suggests that the 
quality of education and the way information was delivered to patients was poor and/ 
or inadequate. Of those surveyed, 65.8% of participants believed their medication to 
be useful, 87% reported they could administer the medication and 66.5% reported 
having been educated about inhaler use, yet only a low percentage were adherent 
with ICS use. This may indicate that patient self-reports do not reflect reality, and 
that patient education is not associated with any positive behaviour change. 
Interestingly, no relation was found between patients self-reporting their asthma was 
well controlled and their use of controllers, ICS, quick relievers or the medications 
listed as used; this may be a result of the low level of ICS prescribing. Nor was a 
relationship found between the use of an AAP or PFM and ICS and the medication 
listed as used.  
Health services tend to focus on severe asthma patients, although mild asthma is 
more common and can not only cause morbidity and mortality but may develop to a 
stage that is believed to be life-threatening (288). The findings of this study suggest 
that current management focuses on patients with more severe asthma. This is 
evident in the more frequent use of corticosteroids or other preventive medication by 
patients with moderate and severe asthma than by those with mild asthma, of whom 
79% used  agonists only and 12.9% used corticosteroids with or without β2 
agonists. This compared with 48.8% and 33.9% use among patients with moderate 
asthma. Similarly, patients with mild asthma were less likely to be provided with an 
AAP, or to use a PFM, than those with moderate or severe asthma. 
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4.15.1 Comparison between other studies and this research, considering that 
methodologies may differ 
When comparing the findings of the current study with other studies, such as the 
review of AIR surveys across in 29 countries (58), it should be noted that there are 
differences in the methodology together with cultural variations between the 
countries reviewed and Saudi Arabia that may affect the results. Despite such 
differences, it is generally found that patients’ self-reports underestimate the severity 
of their asthma and overestimate their level of control (58, 59). Self-classified 
severity in Saudi Arabia was higher than that reported in other places such as the 
United States, Western Europe, Asia-Pacific, Japan, and Central and Eastern Europe 
For instance, 6.1%, 27% and 52.6% of Saudi respondents classified their asthma as 
intermittent, mild, and moderate respectively, compared with 43%, 16% and 22% in 
the United States (58). Hospital admissions and ER attendances, limitations of daily 
activity and school absences were higher in KSA. Beta agonist use is considered high 
in some studies, yet in KSA it was found to be higher still. Using preventive 
medication such as ICS and possession of a PFM, as well as adherence, in the current 
study was low and in the main consistent with other studies’ findings. The current 
study’s findings indicate that there are large differences between patients’ symptoms 
and their estimates of requisite control levels.  
Health care for Saudi patients is available free of charge. It is compulsory for 
families to register with a single PHC centre, but adherence to this regulation is poor 
and patients may visit more than one setting, including ED – which some patients 
may use as a clinic. While this may reflect a high severity of asthma, it may also 
indicate lack of knowledge and poor behaviours in both patients and their families – 
perhaps a result of inadequate care. 
It is clear that the findings in this research are consistent with the third hypothesis of 
this study: that the current practice of asthma management in Saudi Arabia primary 
health care centres is not in compliance with the national protocol for asthma 
management. There are no significant differences discovered between gender 
responses, except in the possession of an AAP and the degree of understanding about 
how to adjust medication when asthma worsens. These findings support the second 
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hypothesis: current patterns of asthma management in children and adolescents in 
KSA are not influenced by gender. 
4.15.2 Differences and similarities between Asser and Riyadh regions 
Although this study was not designed to estimate prevalence, it did reveal that the 
prevalence of severe asthma in Riyadh patients was higher than in Asser patients 
(21.4% vs.7.1%; p=0.000). Studies have found differences between rural and urban 
populations (289, 290); Sapan et al. have suggested that differences in asthma 
prevalence between cities can be explained by air pollution and environment (291). 
Patients from both Riyadh and Asser reported similar increases in symptoms during 
winter, and similar reductions in both summer and fall; however, in spring Asser 
patients were more likely to suffer from asthma symptoms than Riyadh patients 
(p=0.001). Comparing two seasons, winter and spring, with respect to day and night 
symptoms, physical daily activity, and emergency attendance, Fueyo et al. found a 
high frequency of daytime symptoms and physical activity limitation in both seasons, 
although all manifestations of asthma were reported to be worse in winter. In 
general, it was found that asthma control among patients was slightly poorer in 
winter than in spring (60). In the current study, school absence and limitations on 
daily activities were reported to be significant during spring and summer, but there 
was no relationship with patients’ level of control. This may indicate a climate effect. 
A variation in practice in PHCs has been reported within and between countries. In 
both Riyadh and Asser there was lack of consistency in asthma management. Riyadh 
patients were users of both medication, particularly inhaler corticosteroids, and 
spacers and PFMs, suggesting that facilities and medication availability in Riyadh 
are better, and more choices are available, than in Asser. Moreover, the economic 
advantages of Riyadh include the availability of private health facilities. Despite this, 
patient education including the use of AAP was more common in Asser (p=014), and 
they were more likely to understand what they had to do in an asthma attack 
(p=0.009). Access to information and involvement in decision-making, as well as the 
level of attention of the health care provider, were all higher in Asser, positively 
affecting patient behaviour and ability. Asser patients had more confidence in 
adjusting their medications and high self-efficacy, with fewer control problems. 
Education combined with an AAP contributed positively to patients’ self-efficacy, 
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attitude, and communication, which led to improved asthma control levels. It is 
likely that a lower patient load on rural physicians allows them to spend more time 
with each patient, developing a good relationship with patients and carers.  
Riyadh patients were found to be more aware of the medications they used such as 2 
agonists and ICSs, shown by the greater consistency between their descriptions of 
medications used and their actual medication list. There were significant differences 
in the use of β2 agonists between regions, with Asser at 70.8% and Riyadh at 51.3% 
(p=0.003). In addition, there were significant differences between both regions in the 
use of corticosteroids and β2 agonists, with or without other medications. Thirty-four 
(29.1%) Riyadh patients were receiving a corticosteroid and β2 agonist, compared 
with 12.4% of Asser patients (p=0.002). However, self-reported good asthma control 
amongst Asser patients (57.5%) was higher than amongst Riyadh patients (p=0.035). 
Compliance with ICS use was found to be poor in both regions with no significant 
difference found, although of the 80 patients who reported using ICS, only 30% used 
their medication daily. These findings are not consistent with the study hypothesis: 
those current patterns of asthma management in children and adolescents in KSA are 
not influenced by geographical region. 
Some limitations to this study should be reported. Firstly, this study is based on self-
reports; it may not reflect the patients’ and/ or families’ actual situations, behaviours 
and practices. To counter this, some questions were repeated in a different style, in 
order to test patients’ responses for consistency. The four weeks prior to the survey 
were chosen as the test period, on the assumption that patients and carers would 
likely remember them most accurately. In addition, anonymous responses were 
accepted, to encourage truthful answers. It was expected that responses would reflect 
practices accurately as anonymity meant that patients were able to record negative 
responses. In fact, the findings were consistent with those of other studies in most 
aspects, such as low adherence to asthma management.  
This study was conducted in the PHCCs of two from a total of thirteen regions, so 
results may have limited generalizability for children and adolescent patients and 
families in different regions of KSA, or who may attend different kinds of clinics 
such as secondary clinics. However, these two regions combined share most of the 
characteristics of KSA, such as urban, suburban and rural populations, geography, 
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climate, high and low population densities and customs. Furthermore, the 
organization system recommends moderate and severe asthma patients may be 
treated at a secondary clinic than return to PHCCs for follow-up.  
Patients were unlikely to have electronic medical records in the PHCCs for the 
researcher to confirm that the information they provided, such as asthma severity and 
medication, were accurate. This is especially so as medication instructions and labels 
are written in English, which is not the main language. For this reason a visual colour 
copy of medication was attached as to help patients identify and list their 
medications.  
4.16 Conclusions 
Asthma control in children and adolescents in KSA is still suboptimal. Non-
adherence to guidelines in many patterns was reported. These can be clearly seen in 
the survey responses, in which most patients report that they continue to suffer from 
symptoms that limit their daily activities, affect school attendance, and require 
constant use of heath care facilities. The majority of participants (85.7%) had at least 
one control problem. Furthermore, low use of controller and other self-management 
skills such as PFM and spacer use was reported. A significant finding of this research 
is that while the Saudi National Protocol for the Management of Asthma (URL: 
http://www.sinagroup.org) recommend corticosteroids as the first-line treatment in 
chronic asthma, their use was suboptimal: only 21 of 113 (18.6%) Asser patients 
used inhaled steroids and 47 of 117 (40.2%) Riyadh patients (p = 0.0001).  
Not only low use was found, but low adherence. Slightly more than one third of 
participants reported using ICS, and only 30% of them used it daily. One fifth of 
participants owned PFMs, but only 42.3% of them used them regularly even though 
they are particularly recommended for patients with moderate to severe asthma. 
Although AAP ownership was high among participants, non-adherence and 
misunderstanding were observed. Variations in regional practice in PHCs have been 
reported. Moreover, patients’/ carers’ lack of knowledge, self-efficacy and 
behaviour, as well as limited involvement and lack of communication with heath 
care providers, were reported. An intervention programme coupled with an asthma 
action plan and motivation may improve knowledge and self-efficacy, and so change 
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the behaviours of patients and their carers, contributing to better self-management 
and, ultimately, improved health outcomes. 
 
113 
Chapter 5   
Phase Two: Physician Survey – 
 Results and Discussion 
5.1 Administration of Physician Survey 
Table 5.1 Administration of survey  
Region Asser Riyadh Total P value 







Responses  52 (86.7) 54 (90) 106 (88.3)  
Usable 
responses 
Male 30 (69.8) 26 (59.0) 56 (52.8)  
Female 13 (30.2) 18 (41.0) 31 (29.2)  
Total 43 (71.7) 44 (73.3) 87 (82.1)  
Nationality Saudi 0 (0.0) 5 (11.4) 5 (5.7) 0.023 
Non-Saudi 43 (100.0) 39 (88.6) 82 (94.3) 
Working place Government 43 (100.0) 40 90.9) 83 (95.4) 0.043 
Private 0 (0.0) 4 (9.1) 4 (4.6) 
Age 31-39 yrs. 14 (32.6) 13 (29.5) 27 (31) .082 
40-49 yrs. 20 (46.5) 19 (43.2) 39 (44.8) .905 
Over 50 yrs. 9 (20.9) 10 (22.7) 19 (21.8) .466 
Total 43 (100.0) 42 (95.5)* 85 (97.7)  
*Data missing for Riyadh physicians  
Sixty questionnaires were administered in each region (Asser and Riyadh), with 52 
(86.7%) and 54 (90%) returned respectively. Of these, 19 (18.0%) were excluded as 
they were incomplete. The overall response rate was 72.5% (87 of 120); the majority 
of respondents were male (male 56, female 31). The majority (94.3%) of 
participating physicians were non-Saudi. Only five Riyadh physicians were Saudi; 
none in Asser were (p=0.023). Eighty-three (95.4%) were working in government 
centres and 4 (4.6%) in private centres. There was no difference in age distribution 




5.1.1 Physicians’ characteristics 
5.1.1.1 Physicians’ characteristics by region 











Physician’s specialty  Family 13 (30.2) 16 (36.4) 29 (33.3) 
0.22 
General 25 (58.1) 27 (61.4) 52 (59.8) 
Other 5 (11.6) 1 (2.3) 6 (6.9) 
Total 43 44 87 
Duration of practice 0 -10 years 17 (39.5) 15 (34.1) 32 (36.8) 
0.61 
11- 20 years 17 (39.5 22 (50.0) 39 (44.8) 
Over 20 years 9 (20.9) 7 (15.9) 16 (18.4) 
Total 43 44 87 
Physician’s practice 
is predominantly 




24 (55.8) 19 (25.0) 43 (49.4) 
Community-based solo 
practice 
2 (4.7) 9 (20.5) 11 (12.6) 
Other 7 (16.3) 5 (11.4) 12 (13.8) 
Total 43 44 87 
Conference 
attendances 
None or one every 5 years 11 (25.6) 20 (45.5) 31 (35.6) 
0.02 
Once at least every 2 years 28 (65.1) 15 (34.1) 43 (49.4) 
Once a year or more 4 (9.3) 9 (20.5) 13 (14.9) 




Yes 11 (25.6) 13 (29.5) 24 (27.6) 
0.68 No 32 (74.4) 31 (70.5) 63 (72.4) 
Total 43 44 87 
 
Data in Table 2 reveal no significant difference between regions regarding 
physicians’ specialties. Family specialists numbered 16 (36.4%) and 13 (30.2%) in 
Riyadh and Asser respectively, and around 60% in both regions were general 
specialists while 7% practised in other specialties. Thirty-nine (44.8%) physicians 
had 11–20 years’ experience, and of these 22 (50.0%) were in Riyadh and 17 
(39.5%) in Asser; 9 (20.9%) and 7 (15.9%) from Asser and Riyadh had spent more 
than 20 years in the same practice. More than half of the Asser physicians (55.8%) 
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mainly worked in community-based group practices, as did 25% of Riyadh 
physicians. Around one quarter of both regions’ physicians had a university-
associated practice. Riyadh physicians (nine, or 20.5%) were more likely to have 
their own practice than those from Asser  (two, or 4.7%). There were no statistically 
significant differences between regions regarding medical experience. However, 
there was a significant difference in the number of conferences attended (p=0.015). 
Approximately half the physicians (49.4%) reported that they attended at least one 
conference every two years: 28 (65.1%) from Asser and 15 (34.1%) from Riyadh, 
while 4 (9.3%) and 9 (20.5%) attended one or more a year. More than one third of 
both regions’ physicians (25.6% in Asser and 45.5% in Riyadh) reported attending 
none or less than one every 5 years (35.6%). 
5.1.1.2 Physicians’ characteristics by gender 












Family 19 (33.9) 10 (32.3) 29 (33.3) 
0.15 General 31 (55.4) 21 (67.7) 52 (59.8) 
Other 6 (10.7) 0 (0.0) 6 (6.9) 
Total 56 31 87 
Duration of 
practice 
0 -10 years 17 (30.4) 15 (48.4) 32 (36.8) 
0.02 11- 20 years 24 (42.9) 15 (48.4) 39 (44.8) 
Over 20 years 15 (26.8) 1 (3.2) 16 (18.4) 








28 (50.0) 15 (48.4) 43 (49.4) 
Community-based solo 
practice 
5 (8.9) 6 (19.4) 11 (12.6) 
Other 8 (14.3) 4 (12.9) 12 (13.8) 
Total 56 31 87 
Conference 
attendances 
None or one every 5 
years 
15 (26.8) 16 (51.6) 31 (35.6) 
0.07 One at least every 2 
years 
32 (57.1) 11 (35.5) 43 (49.4) 
Once a year or more 9 (16.1) 4 (12.9) 13 (14.9) 





Yes 16 (28.6) 8 (25.8) 24 (27.6) 
0.78 No 40 (71.4) 23 (74.2) 63 (72.4) 
Total 




There was no significant difference between genders regarding physicians’ 
specialties. Of the family specialists, 33.9% were male and 32.3% female, and 67.7% 
of females were general physicians, compared with 55.4% of males. There were 
significant differences in the level of experience (p=0.019), particularly evident in 
the category of experience >20 years. Males were more than six times more likely to 
have this level of experience than their female counterparts (26.8% vs. 3.3%). 
Female physicians were also less frequent conference attendees, with more than 50% 
reporting attending none or less than one every 5 years (males 26.8%).  
5.1.2 Physicians’ access to guidelines and other assistance 











A nurse or other health care 
professional to assist 
N= 87 
Yes 34 (79.1) 16 (43.2) 53 (60.9) 0.001 
No 9 (20.9) 25 (56.8) 34 (39.1) 
Total 43 (100.0) 44 (100.0) 87 (100.0) 
Have access to The National 
Protocol for the Management of 
Asthma   
N= 87 
Yes 40 (93.0) 28 (63.6) 68 (78.2) 0.001 
No 3 (7.0) 16 (36.4) 19 (21.8) 
Total 43 (100.0) 44 (100.0) 87 (100.0) 
Type of access to national 
guideline 
N= 68 
Hard copy 27 (67.5) 24 (85.7) 51 (75.0) 0.16 
Internet 
access 
6 (15.0) 3 (10.7) 9 (13.2) 
Both 7 (17.5) 1 (3.6) 8 (11.8) 
Total 40 (100.0) 28 (100.0) 68 (100.0) 
Access to other guidelines 
N= 87 
Yes 16 (37.2) 17 (38.6) 33 (37.9) 0.89 
No 27 (62.8) 27 (61.4) 54 (62.1) 
Total 43 (100.0) 44 (100.0) 87 (100.0) 
 
As can be seen from the data presented in Table 5.12, Physicians in Asser (79.1%) 
had greater access to the assistance of a nurse or other health care worker than these 
in Riyadh (43.2%; p=0.001). Further there was a significant difference between 
regions regarding National Guideline access (p=0.001). A large majority of Asser 
physicians (93.0%) reported they had access to the guidelines, compared with 63.6% 
of Riyadh physicians; the majority in both regions accessed hard copy. Only 3.6% of 
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Riyadh physicians had both hard copy and Internet access, compared with 17.5% in 
Asser. Around one third of the physicians in both regions reported having access to 
alternative guidelines; however, Asser physicians had better access via Internet 
(15.0% versus 10.7%) 
5.2 Patient Education Strategies  
Physicians were asked about their usual approach to providing education on asthma 
management to their patients. 
5.2.1 General information about asthma 
Physicians were asked about their usual approach to providing general information 
about asthma to patients with different disease severity. 
Table 5.5 Asthma: general information 
Educational matter Region Physicians 
N=87 (Asser =43; Riyadh =44) 
What is your usual approach to providing general 
information about asthma (e.g. structure of the 
respiratory system, mechanisms of asthma, 








 N (%) 
 
I do not provide this information 
  
Asser 1 (2.3) 0 (0.0)  1 (2.3) 
Riyadh 2 (4.5) 1 (2.3) 1 (2.3) 
Total 3 (3.4) 1 (1.1) 2 (2.3) 
 
I provide this information only if the patient asks 
  
Asser 10 (23.3) 5 (11.6) 1 (2.3) 
Riyadh 11 (25.0) 6 (13.6) 3 (6.8) 
Total 21 (24.1) 11 (12.6) 4 (4.6) 
 
I provide this information without waiting for the 
patient to ask. 
Asser 32 (74.4) 38 (88.4) 41 (95.3) 
Riyadh 31 (70.5) 37 (84.1) 40 (90.9) 
Total 63 (72.4) 75 (86.2) 81 (93.1) 
Difference between regions p value  ---- 0.825 0.579 0.606 




Table 5.5 illustrates the usual approach of physicians to providing general 
information about asthma to patients with mild, moderate, and severe asthma. There 
was no significant difference based on region, although a significant difference based 
on gender (P=0.004) amongst Riyadh physicians was found in the case of mild 
asthma. Further, in Riyadh 81% of female physicians provided asthma patients with 
information only if they were asked, compared with 18.8% of males; 71% of male 
physicians took the initiative in providing information to patients without being 
asked, compared with 29.0% of females. 
5.2.2 Information about prescribed asthma medication  
Physicians were asked about their usual approach to providing information about 
prescribed asthma medication to patients with different disease severity. 
Table 5.6 Information about prescribed asthma medication  
Educational matter Regions Physicians 
N=87 (Asser =43 and Riyadh =44) 
What is your usual approach to providing 
information about prescribed asthma medication 
(e.g. mode of action, proper dose, side effects) to 







 N (%) 
 
I do not provide this information 
  
Asser 0 (0.0) 0 (0.0) 2 (4.7) 
Riyadh 4 (9.1) 1 (2.3) 1 (2.3) 
Total 4 (4.6) 1 (1.1) 3 (3.4) 
  
I provide this information only if the patient asks 
  
Asser 13 (30.2) 5 (11.6) 2 (4.7) 
Riyadh 15 (34.1) 13 (29.5) 8 (18.2) 
Total 28 (32.2) 18 (20.7) 10 (11.5) 
  
I provide this information without waiting for the 
patient to ask 
Asser 30 (69.8) 38 (88.4) 39 (90.7) 
Riyadh 25 (56.8) 30 (68.2) 35 (79.5) 
Total 55 (63.2) 68 (78.2) 74 (85.1) 
Difference between region p value ---- 0.101 0.064 0.126 
Note: more detailed data are presented in Appendix F 
 
Table 5.6 reveals no significant difference based on region or gender, although Asser 
physicians were generally more likely to provide information than Riyadh 
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physicians: for example, for patients with moderate and severe asthma respectively, 
29.5% and 45.5% of Riyadh physicians provided medication information only if they 
were asked, compared with 11.6% and 4.7% of Asser physicians; 88.4% and 90.7% 
of Asser physicians took the initiative in providing information without being asked, 
compared with 68.2% and 79.5% of Riyadh physicians for moderate and severe 
cases respectively. 
5.2.3 Demonstrating the proper use of inhalational device 
Physicians were asked about their usual approach to demonstrating the use of 
inhalational devices to patients with different disease severity. 
Table 5.7 Demonstrating the proper use of inhalational device 
Educational matter Region Physicians 
N=87 (Asser =43; Riyadh =44) 
What is your usual approach to demonstrating 
the proper use of inhalational device (e.g. 
metered dose inhaler, spacer device, turbuhaler) 





 N (%) 
Severe  
 N (%) 
I do not provide this information 
  
Asser 2 (4.7) 0 (0.0) 2 (4.7) 
Riyadh 2 (4.5) 1 (2.3) 1 (2.3) 
Total 4 (4.6) 1 (1.1) 3 (3.4) 
 I provide this information only if the patient 
asks 
  
Asser 5 (11.6) 3 (7.0) 3 (7.0) 
Riyadh 11 (25.0) 6 (13.6) 4 (9.1) 
Total 16 (18.4) 9 (10.3) 7 (8.0) 
I provide this information without waiting for 
the patient to ask 
Asser 36 (83.7) 40 (93.0) 38 (88.4) 
Riyadh 31 (70.5) 37 (84.1) 39 (88.6) 
Total 67 (77.0) 77 (88.5) 77 (88.5) 
Difference between region p value  _ ---- 0.271 0.349 0.788 
Note: more detailed data are presented in Appendix F 
 
Table 5.7 reveals no significant difference based on region or gender; however, 
Asser physicians were generally more likely to provide information than Riyadh 
physicians. For example, in mild and moderate asthma, 25.0% and 13.6% of Riyadh 
physicians demonstrated the inhalation device only if they were asked to, compared 
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with 11.6% and 7.0% of Asser physicians respectively, who were more likely to take 
the initiative and demonstrate the devices without being asked.  
5.2.4 Information about asthma triggers  
Physicians were asked about their usual approach to providing information about 
asthma triggers to patients with different disease severity. 
Table 5.8 Information regarding asthma triggers  
Educational matter Region Physicians 
N=87 (Asser =43; Riyadh =44) 
What is your usual approach to providing information 
on the avoidance of asthma triggers and 
environmental control (e.g. control of house dust 







 N (%) 
 
I do not provide this information 
  
Asser 0 (0.0) 0 (0.0) 2 (4.7) 
Riyadh 0 (0.0) 0 (0.0) 0 (0.0) 
Total 0 (0.0) 0 (0.0) 2 (2.3) 
  
I provide this information only if the patient asks 
  
Asser 3 (7.0) 2 (4.7) 0 (0.0) 
Riyadh 4 (9.1) 4 (9.1) 3 (6.8) 
Total 7 (8.0) 6 (6.9) 3 (3.4) 
  
I provide this information without waiting for the 
patient to ask 
Asser 40 (93.0) 41 (95.3) 41 (95.3) 
Riyadh 40 (90.9) 40 (90.9) 41 (93.2) 
Total 80 (92.0) 81 (93.1) 82 (94.3) 
Difference between region p value  _ ---- 0.717 0.414 0.083 
Note: more detailed data are presented in Appendix F  
Table 5.8 reveals no significant differences based on region or gender, with the 
majority of physicians in both regions providing information about the avoidance of 
asthma triggers and environmental control to patients without being asked.  
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5.2.5 Information about asthma warning signs  
Physicians were asked about their usual approach to providing information about 
warning signs to patients with different disease severity. 
Table 5.9 Information about asthma warning signs 
Educational matter Region Physicians 
N=87 (Asser =43 and Riyadh =44) 
What is your usual approach to providing 
information on the warning signs of worsening or 








 N (%) 
 
I do not provide this information 
  
Asser 1 (2.3) 0 (0.0) 0 (0.0) 
Riyadh 9 (20.5) 6 (13.6) 5 (11.4) 
Total 10 (11.5) 6 (6.9) 5 (5.7) 
  
I provide this information only if the patient asks 
  
Asser 13 (30.3) 5 (11.6) 1 (2.3) 
Riyadh 10 (22.7) 4 (9.1) 2 (4.5) 
Total 23 (26.4) 9 (10.3) 3 (3.4) 
  
I provide this information without waiting for the 
patient to ask 
Asser 29 (67.4) 38 (88.4) 42 (97.7) 
Riyadh 25 (56.8) 34 (77.3) 37 (84.1) 
Total 54 (62.1) 72 (82.8) 79 (90.8) 
Difference between region p value  ---- 0.029 0.042 0.060 
Note: more detailed data are presented in Appendix F 
 
Table 5.9 reveals significant differences based on region, regarding both mild and 
moderate asthma (p=0.029 and 0.042 respectively). Asser physicians provided 
information more frequently than Riyadh physicians: for example, for mild asthma, 
30.3% of physicians in Asser provided information only when asked, compared with 
22.7% of physicians in Riyadh. In contrast, with moderate asthma, 13.6% of Riyadh 
physicians did not provide information at all, compared with 0.0% of Asser 
physicians, while 77.3% of Riyadh physicians provided patients with information 
without being asked, compared with 88.4% in Asser. While there was no regional 
difference in practice based on gender, there was a gender difference in the case of 
moderate asthma within the groups as a whole (p = 0.015); see Appendix F. Female 
physicians were found to be less likely to provide information on asthma warning 
signs than their male counterparts.  
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5.2.6 Information about asthma action plans based upon symptoms  
Physicians were asked about their usual approach to providing patients with 
information about an asthma action plan based upon the severity of their symptoms. 




N=87 (Asser =43; Riyadh =44) 
What is your usual approach to providing an asthma 
action plan based upon symptoms (e.g. written plan 
that outlines steps to control/ regain control of 






* N (%) 
Severe N 
(%) 
I do not provide this information 
  
Asser 6 (14.0) 3 (7.1) 4 (9.3) 
Riyadh 19 (43.2) 12 (27.3) 9 (20.5) 
Total 25 (28.7) 15 (17.4) 13 (14.9) 
  
I provide this information only if the patient asks 
  
Asser 21 (48.8) 11 (26.2) 6 (14.0) 
Riyadh 9 (20.5) 12 (27.3) 8 (18.2) 
Total 30 (34.5) 23 (26.7) 14 (16.1) 
I provide this information without waiting for the 
patient to ask 
Asser 16 (37.2) 28 (66.7) 33 (76.7) 
Riyadh 16 (36.4) 20 (45.5) 27 (61.4) 
Total 32 (36.8) 48 (55.8) 60 (69.0) 
Difference between region p value ---- 0.003 0.034 0.247 
 Note: more detailed data are presented in Appendix F.  
* One set of data missing (Asser Moderate).  
 
Table 5.10 reveals significant differences in regional practices for both mild and 
moderate asthma (p=0.003 and 0.034, respectively). Asser physicians were more 
likely to provide their patients with an AAP than Riyadh physicians, and more likely 
to provide one without being asked. A statistically significant difference was seen in 
the responses of male and female physicians in Riyadh concerning severe asthma 
cases (p=0.017; see Appendix (F). There was also a significant difference in the 
provision of an AAP between male and female physicians within the groups as a 
whole, particularly in the case of severe asthma (p=0.037). Male physicians provided 
AAPs based upon symptoms to patients with severe asthma more than females did. 
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Statistically significant differences were also found between female physicians in 
each region in the case of mild asthma (p=0.024).  
5.2.7 Peak flow monitoring 
Physicians were asked about their usual approach to providing information about 
monitoring peak flow rates (e.g. purpose, use of peak flow meters and proper 
recording of peak flow rates) to patients with different disease severity. 
Table 5.11 Peak flow monitoring 
Educational matter Regions Physicians 
N=87 (Asser =43 and Riyadh =44) 
What is your usual approach to providing 
information about monitoring peak flow rates 
(e.g. purpose, use of peak flow meters and 
proper recording of peak flow rates) to 







 N (%) 
I do not provide this information 
  
Asser 9 (20.9) 5 (11.6) 4 (9.3) 
Riyadh 19 (43.2) 14 (31.8) 12 (27.3) 
Total 28 (32.2) 19 (21.8) 16 (18.4) 
  
I provide this information only if the patient 
asks 
  
Asser 15 (34.9) 6 (14.0) 7 (16.3) 
Riyadh 13 (29.5) 14 (31.8) 10 (22.7) 
Total 28 (32.2) 20 (23.0) 17 (19.5) 
  
I provide this information without waiting for 
the patient to ask  
Asser 19 (44.2) 32 (74.4) 32 (74.4) 
Riyadh 12 (27.3) 16 (36.4) 22 (50.0) 
Total 31 (35.6) 48 (55.2) 54 (62.1) 
Difference between region p value  ---- 0.071 0.002 0.041 
Note: more detailed data are presented in Appendix F 
 
Table 5.11 reveals significant regional differences regarding information about peak 
flow monitoring to both moderate and severe asthma sufferers (p=0.002 and 0.041 
respectively). Asser physicians provided information about monitoring peak flow 
rates to patients more often than Riyadh physicians; for example, in the case of 
moderate asthma, 74.4% of physicians in Asser provided information without 
request, compared with 36.4% of physicians in Riyadh. Further, 31.8% of Riyadh 
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physicians did not provide information at all compared with 11.6% of Asser 
physicians; in the case of severe asthma, 27.3% of Riyadh physicians did not provide 
information at all, compared with 9.3% of Asser physicians, 74.4% of whom 
provided information without waiting for patient requests. Only 50.0% of Riyadh 
physicians did so. Whilst there were no significant differences based on gender 
within or between regions, there were significant differences in the case of moderate 
asthma between female physicians, with those in Riyadh less likely to discuss peak 
flow monitoring with their patients than their Asser counterparts (p=0.01).  
5.2.7.1 Asthma action plan based upon peak exploratory flow rates in conjunction 
with symptoms 
Physicians were asked about their usual approach to providing information about an 
AAP based upon peak expiratory flow rates in conjunction with symptoms to 
patients with different severities of disease.  
Table 5.12 Asthma action plan based upon peak expiratory flow rates in conjunction 
with symptoms 
Educational matter Region Physicians 
N=87 (Asser =43 and Riyadh =44) 
What is your usual approach to providing an 
asthma action plan based upon peak expiratory 
flow rates in conjunction with symptoms (e.g. 
written plan that outlines steps to control 









I do not provide this information 
  
Asser 9 (20.9) 8 (18.6) 9 (20.9) 
Riyadh 23 (52.3) 17 (38.6) 14 (32.6) 
Total 32 (36.8) 25 (28.7) 23 (26.7) 
  
I provide this information only if the patient 
asks  
Asser 15 (34.9) 8 (18.6) 5 (11.6) 
Riyadh 11 (25.0) 13 (29.5) 9 (20.9) 
Total 26 (29.9) 21 (24.1) 14 (16.3) 
  
I provide this information without waiting for 
the patient to ask 
  
Asser 19 (44.2) 27 (62.8) 29 (67.4) 
Riyadh 10 (22.7) 14 (31.8) 20 (46.5) 
Total 29 (33.3) 41 (47.1) 49 (57.0) 
Difference between region p value  ---- 0.009 0.041 0.143 
 Note: more detailed data are presented in Appendix F.  
* One set of data missing (Riyadh severe) 
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Table 5.12 reveals significant differences based on region for both mild and 
moderate asthma (P=0.009 and 0.041 respectively). Asser physicians provided 
patients with an AAP, based upon peak expiratory flow rates in conjunction with 
symptoms, more often than Riyadh physicians: for example, for patients with mild 
asthma, 44.2% of physicians in Asser provided information without request, 
compared with 22.7% of physicians in Riyadh, 52.3% of whom did not provide 
information at all. Only 20.9% of Asser physicians provided no AAP. For patients 
with moderate asthma, 38.6% of Riyadh physicians provided no information at all, 
compared with 18.6% of Asser physicians. While 62.8% of Asser physicians 
provided patients with information without request, only 31.8% of physicians from 
Riyadh did so. Statistically significant differences are also revealed in the responses 
of male and female physicians in Riyadh in the cases of moderate and severe asthma 
(p=0.037 and 0.012 respectively; see Appendix F). Male physicians provided an 
asthma action plan to patients with severe asthma more frequently than females: for 
example, 13.8% of male physicians provided information when the patient asked, 
compared with 2.3% of females; and 44.8% did so without patient request, compared 
with 24.1% of female physicians.  
Further statistically significant differences between female physicians are shown 
below: 
 Asser female vs. Riyadh female physicians in the case of mild asthma; 
p=0.004. 
 Asser female vs. Riyadh female physicians in the case of moderate asthma: 
p=0.008. 
 Asser female vs. Riyadh female physicians in the case of severe asthma: 
p=0.049. Asser female physicians were more likely to provide AAPs than 





5.2.8 Community non-profit organizations information providers 
Physicians were asked about their usual practices in providing information about 
community non-profit organizations that offered support to asthma patients. 
Table 5.13 Information about community non-profit organizations  
Educational matter Region Physicians 
N=87 (Asser =43 and Riyadh =44) 
What is your usual approach to providing 
information about community non-profit 
organizations that provide information about 
asthma (e.g. The National Scientific Committee 










I do not provide this information 
  
Asser 11 (25.6) 9 (20.9) 9 (20.9) 
Riyadh 23 (52.3) 19 (43.2) 17 (38.6) 
Total 34 (39.1) 28 (32.2) 26 (29.9) 
  
I provide this information only if the patient 
asks 
  
Asser 20 (46.5) 20 (46.5) 15 (34.9) 
Riyadh 12 (27.3) 9 (20.5) 9 (20.5) 
Total 32 (36.8) 29 (33.3) 24 (27.6) 
  
I provide this information without waiting for 
the patient to ask  
Asser 12 (27.9) 14 (32.6) 19 (44.2) 
Riyadh 9 (20.5) 16 (36.4) 18 (40.9) 
Total 21 ( 24.1) 30 (34.5) 37 (42.5) 
Difference between region p value ---- 0.036 0.020 0.137 
Note: more detailed data are presented in Appendix F 
 
Table 5.13 reveals significant differences in how often physicians provided 
information about community non-profit organizations to patients with mild and 
moderate asthma (p=0.036 and 0.020 respectively). Asser physicians provided this 
information more often than Riyadh physicians; for example, with patients with mild 
asthma, 27.9% of physicians in Asser provided the information without request, 
compared with 20.5% of physicians in Riyadh. Further, 52.3% of Riyadh physicians 
provided no information at all, compared with 25.6% of Asser physicians. In 
contrast, for patients with moderate asthma, 43.2% of Riyadh physicians provided no 
information at all compared with 20.9% of Asser physicians, but 46.5% of Asser 
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physicians provided information when it was requested by patients, compared with 
20.5% in Riyadh. There were no significant differences based on gender, except in 
the case of mild asthma in Asser (p=0.034), when female physicians provided 
information to patients with mild asthma more frequently than males: 16.3% 
compared with 11.6%. In contrast, 39.5% of male physicians provided it when the 
patient asked, compared with 11.6% of females; and 18.6% of males did not provide 
the information, compared with 7.0% of female physicians.  
5.2.9 Regional physicians’ scores  
The answers to the nine questions in the educational section were given a numerical 
score and then summed to give a score of physicians’ performances, shown in Table 
5.14. Answers to each question were rated as follows: 1= ‘I do not provide this 
information’, 2= ‘I provide this information only if the patient asks’, and 3= ‘I 
provide this information without waiting for the patient to ask’. The minimum total 
scores is nine, indicating a lack of asthma education provided by physicians; the 





Table 5.14 Physicians’ educational performances based on the severity of patients’ 
asthma 
Score 




















0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 1 (1.2) 
13 1 (2.3) 0 (0.0) 1 (1.1) 
0 (0.0) 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0) 1 (1.2) 
14 
0 (0.0) 2 (4.5) 2 (2.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
15 
0 (0.0) 5 (11.4) 5 (5.7) 0 (0.0) 2 (4.5) 2 (2.3) 0 (0.0) 1 (2.3) 1 (1.2) 
16 1 (2.3) 5 (11.4) 6 (6.9) 
0 (0.0) 4 (9.1) 4 (4.7) 0 (0.0) 1 (2.3) 1 (1.2) 
17 
0 (0.0) 2 (4.5) 2 (2.3) 0 (0.0) 3 (6.8) 3 (3.5) 0 (0.0) 1 (2.3) 1 (1.2) 
18 
3 (7.0) 2 (4.5) 5 (5.7) 1 (2.4) 2 (4.5) 3 (3.5) 0 (0.0) 2 (4.7) 2 (2.3) 
19 2 (4.7) 3 (6.8) 5 (5.7) 4 (9.5) 0 (0.0) 4 (4.7) 1 (2.3) 4 (9.3) 
5 (5.8) 
20 1 (2.3) 4 (9.1) 5 (5.7) 2 (4.8) 4 (9.1) 6 (7.0) 2 (4.7) 3 (7.0) 
5 (5.8) 
21 4 (9.3) 2 (4.5) 6 (6.9) 1 (2.40 3 (6.8) 4 (4.7) 2 (4.7) 1 (2.3) 
3 (3.5) 
22 8 (18.6) 6 (13.6) 14 (16.1) 3 (7.1) 7 (15.9) 10 (11.6) 2 (4.7) 4 (9.3) 
6 (7.0) 
23 7 (16.3) 2 (4.5) 9 (10.3) 3 (7.1) 3 (6.8) 6 (7.0) 3 (7.0) 5 (11.6) 
8 (9.3) 
24 7 (16.3) 2 (4.5) 9 (10.3) 3 (7.1) 1 (2.3) 4 (4.7) 
0 (0.0) 4 (9.3) 4 (4.7) 
25 2 (4.7) 3 (6.8) 5 (5.7) 3 (7.1) 3 (6.8) 6 (7.0) 4 (9.3) 2 (4.7) 
6 (7.0) 
26 1 (2.3) 5 (11.4) 6 (6.9) 12 (28.6) 5 (11.4) 17 (19.8) 13 (30.2) 4 (9.3) 
17 (19.8) 




0.015 0.051 0.121 
* one set of data missing in each 
 
Table 5.14 reveals significant differences based on region with regard to education of 
patients with mild asthma (p=0.015). Asser physicians are more likely to provide 
asthma education to mild asthma patients than Riyadh physicians: for example, 
72.1% of Asser physicians scored 22 or more on a scale of 27, compared with 43.2% 
of Riyadh physicians, and 11.6% scored 18 or less, compared with 36.4% of Riyadh 
physicians. In contrast, for patients with moderate asthma, 25% of Riyadh physicians 
scored 18 or less, compared with only 2.4% of Asser physicians, while 81% of Asser 
physicians scored 22 and higher – a feat achieved by only 59.1% in Riyadh. There 




5.2.10 Total physicians’ scores  
The answers to the nine questions on education were scored for each level of asthma 
severity, as previously outlined. These scores were then summed to give a total score 
for each physician for all asthma severities. In this case, a score of 27 [(1+1+1) × 9] 
represents no information provided by physicians and 81 [(3+3+3) × 9] represents 
information provided across all cases without being requested by patients. Using 
these scores, physicians’ performance was rated as follows:  
 27–44: poor to fair;  
 45–62: fair to good;  
 63–81: good to excellent information provision.  
Table 5.15 Physicians’ educational performance across all severities of asthma. 







27 - 44 0 (0.0) 0 (0.0) 0 (0.0) 
45 - 62 7 (16.3) 17 (38.6) 24 (27.6) 
63 - 81 36 (83.7) 27 (61.4) 63 (72.4) 
Total 43 (100.0) 44 (100.0) 87 (100.0) 
P value 0. 020 
Total score = sum of the scores for each question and each severity of asthma. Minimum =27, maximum = 81 
 
Table 5.15 shows that the majority (72.4%) of physicians scored 63 or more on a 
scale of 81 in their provision of education to asthma patients. There were significant 
differences based on regions with severity (p=0.020). Asser physicians were better at 
providing asthma education on a routine basis with 36 (83.7%) scoring 63 or more 
on a scale of 81, compared with 27 (61.4%) of Riyadh physicians. In contrast, 17 
(38.6%) of Riyadh physicians scored 62 or less, while only 7 (16.3%) Asser 




5.2.11 Physicians’ overall asthma education performance with relation to 
physicians’ characteristics.  
Table 5.16 Physicians’ overall asthma education performance with relation to 
physicians’ characteristics  
Physicians’ 
characteristics 
 Physicians’ education total scores P value 
 45 to 62 63 to 81 Total  
Gender 
Male 14 (25.0%) 42 (75.0%) 56 (64.4%) 
0. 47 Female 10 (32.3%) 21 (67.7%) 31 (35.6%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
Specialization 
Family medicine 5 (17.2%) 24 (82.8%) 29 (33.3%) 
0. 3172 
General medicine 17 (32.7%) 35 (67.3%) 52 (59.8%) 
Other 2 (33.3%) 4 (66.7%) 6 (6.9%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
Age* 
31 to 39 years 12 (44.4%) 15 (55.6%) 27 (31.8%) 
0.087 
 0 to 49 years 8 (20.5%) 31 (79.5%) 39 (45.9%) 
Over 50 years 4 (21.1%) 15 (78.9%) 19 (22.4%) 









10 (23.3%) 33 (76.7%) 43 (49.4%) 
Community-based 
solo  
3 (27.3%) 8 (72.7%) 11 (12.6%) 
Other 2 (16.7%) 10 (83.3%) 12 (13.8%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
Medical practice 
duration 
0 to 10 year 12 (37.5%) 20 (62.5%) 32 (36.8%) 
0.17 
11 to 20 year 7 (17.9%) 32 (82.1%) 39 (44.8%) 
Over than 20 year 5 (31.3%) 11 (68.8%) 16 (18.4%) 




related to asthma 
management 
None or less than 
one every 5 years 
10 (32.3%) 21 (67.7%) 31 (35.6%) 
0.68 
Once at least every 
2 years 
10 (32.3%) 33 (76.7%) 43 (49.4%) 
Once a year or 
more 
4 (30.8%) 9 (69.2%) 13 (14.9%) 




Yes 8 (33.3%) 16 (66.7%) 24 (27.6%) 
0.46 No 16 (25.4%) 47 (74.6%) 63 (72.4%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
*Two data missing 
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The physicians’ performance based on the total scores shown in Table 5.16 was not 
influenced by gender, age, medical specialty, duration of practice or place of 
practice. Neither was it influenced by personal experience of asthma-like symptoms 
or the frequency of conference or seminar attendance. 
5.2.12  Physicians’ overall education performance with relation to access to 
guidelines and professional assistances. 
Table 5.17 Physicians’ overall education performance with relation to access to 
guidelines and professional assistance 
Question Response Physicians’ education total scores P 
value 
45 to 62 63 to 81 Total 
Access to The National 
Protocol for the 
Management of Asthma 
Yes 17 (25.0%) 51 (75.0%) 68 (78.2%) 0.31 
No 7 (36.8) 12 (63.2%) 19 (21.8%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
Type of access Hard copy 15 (29.4%) 36 (70.6%) 51 (75.0%) 0.35 
Internet 
access 
1 (11.1%) 8 (88.9%) 9 (13.2%) 
both 1 (12.5%) 7 (87.5%) 8 (11.8%) 
Total 17 (25.0%) 51 (75.0%) 68 (100.0%) 
Access to other guidelines 
for asthma management  
Yes 8  (24.2%) 2 (24.2%) 33 (37.9%) 0.59 
No 16 (29.6%) 38 (70.4%) 54 (62.1%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
Having a nurse or other 
health care professional to 
assist with care or education 
of patients with asthma 
Yes 12 (22.6%) 41 (77.4%) 53 (60.9%) 0.20 
No 12 (35.3%) 22 (64.7%) 34 (39.1%) 
Total 24 (27.6%) 63 (72.4%) 87 (100.0%) 
 
As shown in Table 5.17, physicians’ preferences based on their total scores was not 
significantly influenced by their access to the National Protocol for the Management 
of Asthma or to guidelines other than the National Protocol; nor by having a nurse or 
other health care provider to assist them.  
5.3 Treating Asthma 
Physicians were presented with six clinical vignettes (see Appendix B), with a 
number of actions to rate as either RECOMMENDED or NOT RECOMMENDED. 
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Physicians were deemed to agree with best practice if 75% or more of their responses 
matched the expected response.  
In regard to the six case scenarios, the third column was designed to show the first 
priority action, yet the majority of respondents did not answer, while some answered 
with a choice of more than one action. Both these responses were discarded. 
5.3.1 Vignette A  
‘Imagine that a patient of yours is usually free of asthma symptoms and is currently 
not taking any anti-asthma medication. He/ she experiences brief and infrequent 
episodes of asthma symptoms (about 2 times a week for less than 15 minutes). This 
morning the patient awoke feeling perfectly well, experiencing no symptoms. 
However, later in the day he/ she experienced some coughing, wheezing and 
shortness of breath after doing strenuous work around the house.’ 
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Table 5.18 Vignette A 
















Do not recommend 
N (%) 
Recommend  
 N (%) 





39 (90.7) 4 (9.3) 38 (86.4) 6 (13.6) 77 (88.5) 10 (11.5) 0.53 
Start an inhaled corticosteroid 37 (86) 6 (14) 36 (81.8) 8 (18.2) 73 (83.9) 14 (16.1) 0.59 
Add a non- steroid anti- 
inflammatory 
35 (81.4) 8 (18.6) 34 (77.3) 10 (22.7) 69 (79.3) 18 (20.7) 0.64 
Start an oral theophylline 39 (90.7) 4 (9.3) 41 (93.2) 3 (6.8) 80 (92) 7 (8.0) 0.67 
Start oral corticosteroid 41 (95.3) 2 (4.7) 42 (95.5) 2 (4.5) 83 (95.4) 4 (4.6) 0.98 
Wait and see (no medication 
needed at this time) 
32 (74.4) 11 (25.6) 36 (81.8) 8 (18.2) 68 (78.2) 19 (21.8) 0.40 
Outpatient visit (e.g. same day 
office visit or refer to Emergency 
Department ) 
39 (90.7) 4 (9.3) 31 (70.5) 13 (29.5) 70 (80.5) 17 (19.5) 0.017  
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The physicians’ responses in regards Vignette A are shown in Table 5.18. Nearly 90% of 
physicians recommended that a β2 agonist should be commenced (Riyadh 90.9%, Asser 88.4), 
while more than 75% of physicians from both regions did not recommended starting an 
ipratropium bromide, starting a corticosteroid, adding a non-steroid anti-inflammatory, 
starting an oral theophylline, or starting oral corticosteroid. Adopting an approach of wait and 
see was rejected by the majority of physicians in both Riyadh and Asser, as was the option to 
refer the patient to the Emergency Department, although significantly more physicians in 
Riyadh (29.5%) than in Asser supported this action (9.3%, p=0.017). Amongst all 
respondents, it was agreed to recommend starting an inhaled β2 agonist and not to recommend 
any other action. There were no significant differences based on gender, except in the same 
day office visit or referral to the Emergency Department (p=0.026), when female physicians 
recommended this action than males; see Appendix F.  
5.3.2 Vignette B 
‘Imagine that normally the patient’s asthma is well controlled using an inhaled β2 agonist on 
an as-needed basis. However, over the past 2 days, the patient notices an increase in cough, 
wheeze, and shortness of breath and an increase in the use of the inhaled β2 agonist (from 1-2 
times a day to every 4-6 hours.’  
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Table 5.19 Vignette B 




















Increase current use of the inhaled β2 
agonist 





31 (72.1) 12 (27.9) 30 (68.2) 14 (31.8) 61 (70.1) 26 (29.9) 0.69 
Start an inhaled corticosteroid 10 (23.3) 32 (74.4) 11 (25.0) 33 (75.0) 21 (24.1) 65 (75.6) 0.59 
Add a non- steroid anti- inflammatory 38 (88.4) 5 (11.6) 37 (84.1) 7 (15.9) 75 (86.20) 12 (13.8) 0.56 
Start an oral theophylline 37 (86%) 6 (14) 41 (93.2) 3 (6.8) 78 (89.7) 9 (10.3) 0.27 
Start oral corticosteroid 42 (97.7) 1 (2.3) 36 (81.8) 8 (18.2) 78 (89.7) 9 (10.3) 0.01 
Wait and see (no medication needed at this 
time) 
39 (90.7) 4 (9.3) 37 (84.1) 7 (15.9) 76 (87.4) 11 (12.6) 0.35 
Outpatient visit (e.g. Same day office visit 
or refer to Emergency Department ) 
33 (76.7) 10 (23.3) 24 (54.5) 20 (45.5) 57 (65.5) 30 (34.5) 0.029 
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The physicians’ responses to Vignette B are shown in Table 5.19. More than 75% of 
physicians in both regions would not add a non-steroid anti-inflammatory, start an 
oral theophylline, start oral corticosteroid, or recommend waiting and seeing. 
Seventy-five percent of Riyadh physicians and 74.4% of Asser physicians agreed 
with adding an inhaled corticosteroid. The proportion of Asser physicians who would 
not recommended an oral corticosteroid (97.7%) was significantly higher than that of 
Riyadh physicians (81.8%; p=0.015). Similarly, physicians in Asser were less likely 
to recommend the patient have an outpatients visit (23.3% vs. 45.5%; p=0.029).  
There was agreement (75% and over) among all study respondents regarding not 
recommending practices such as adding a non-steroid anti-inflammatory, starting an 
oral theophylline, starting oral corticosteroid, or waiting and seeing, but 
disagreement over whether to recommend or not recommend increasing the current 
use of the inhaled β2 agonist, starting inhaled ipratropium bromide, starting an 
inhaled corticosteroid, or suggesting an outpatient visit. There were no significant 
differences based on gender, except in the same day office visit or referral to the 
Emergency Department (p=0.042), where female physicians recommended this 
action than males; see Appendix F.  
5.3.3 Vignette C 
‘Imagine that a patient of yours, whose asthma is usually asymptomatic, has been 
experiencing an increase in symptoms (e.g. cough, wheeze, shortness of breath) over 
the past 3 days. For the past 2 nights, this patient has experienced nocturnal 
awakenings due to asthma symptoms, and last night awoke three times. Yesterday, 
the use of an inhaled β2 agonist controlled asthma symptoms for 3-4 hours. Today, 
the patient is using his/ her inhaled β2 agonist approximately every 1-2 hours. The 
patient’s usual activities were limited by these symptoms.’ 
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N= 87  








Do not recommend 
N (%) 
Recommend 
 N (%) 





19 (44. 2) 24 (55.8) 20 (45.5) 24 (54.5) 39 (44.8) 48 (55.2) 0.91 
Start an inhaled corticosteroid 2 (4.7) 41 (95.3) 8 (18.2) 36 (81.8) 10 (11.5) 77 (88.5) 0.046 
Add a non- steroid anti-inflammatory 30 (69.8) 13 (30.2) 36 (81.8) 8 (18.2) 66 (75.9) 21 (24.1) 0.19 
Start an oral theophylline 26 (60.5) 17 (39.5) 32 (72.7) 12 (27.3) 58 (66.7) 29 (33.3) 0.23 
Start oral corticosteroid 33 (76.7) 10 (23.3) 22 (50) 22 (50) 55 (63.2) 32 (36.8) 0.01  
Wait and see (no medication needed at this 
time) 
42 (97.7) 1 (2.3) 39 (88.6) 5 (11.4) 81 (93.1) 6 (6.9) 0.10 
Outpatient visit (e.g. Same day office visit or 
refer to Emergency Department) 




The physicians’ responses in regard to Vignette C are shown in Table 5.20. In this 
case there was strong support for increasing the patients’ asthma medications and 
seeking additional medical attention (Outpatient or Emergency Department visit). 
The option of waiting and seeing was rejected by almost all physicians from both 
Asser and Riyadh. The recommendation that gained the greatest support was the 
addition of an inhaled corticosteroid (Asser 95.3% vs. Riyadh 81.8%; p=0.048), 
more favoured by Asser physicians. In contrast, Riyadh physicians (50%) were more 
in favour of commencing an oral corticosteroid (Asser 23.3%, p=0.01). There was far 
less support for starting an inhaled non-steroid ant-inflammatory (24.1%) or oral 
theophylline (33.3%), although the addition of inhaled ipratropium bromide was 
recommended by 55.2% of physicians from both regions.  
There was agreement (75% and over) among all study respondents regarding 
recommending starting an inhaled corticosteroid, not recommending adding a non-
steroid anti-inflammatory or waiting and seeing (no medication needed at this time), 
but disagreement over increasing use of the current inhaled β2 agonist, starting 
inhaled ipratropium bromide, starting an oral theophylline, starting oral 
corticosteroid, or advising outpatient visits. There were no significant differences 
based on gender. 
5.3.4  Vignette D 
‘Imagine that a patient of yours felt fine yesterday. However, he/ she awoke early 
this morning experiencing wheezing and coughing which was incompletely relieved 
by an inhaled β2. One hour later, the patient is experiencing difficulty speaking and 
can only manage to speak 2-3 words before needing to take another breath.’ 
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Table 5.21 Vignette D 








 Potential action Do not recommend 
N (%) 
Recommend 
 N (%) 








Increase current use of the inhaled β2 
agonist 





15 (34.9) 28 (65.1) 15 (34.1) 29 (65.9) 30 (34.5) 57 (65.5) 0.94 
Start an inhaled corticosteroid 8 (18.6) 35 (81.4) 11 (25.0) 33 (75.0) 19 (21.8) 68 (78.2) 0.47 
Add a non-steroid anti- inflammatory 34 (79.1) 9 (20.9) 39 (88.6) 5 (11.4) 73 (83.9) 14 (16.1) 0.23 
Start an oral theophylline 29 (67.4) 14 (32.6) 32 (72.7) 12 (27.3) 61 (70.1) 26 (29.9) 0.59 
Start oral corticosteroid 20 (46.5) 23 (53.5) 16 (36.4) 28 (63.6) 36 (41.4) 51 (58.6) 0.34 
Wait and see (no medication needed at 
this time) 
42 (97.7) 1 (2.3) 40 (90.9) 4 (9.1) 82 (94.3) 5 (5.7) 0.18 
Outpatient visit (e.g. Same day office visit 
or refer to Emergency Department) 
12 (27.9) 31 (72.1) 6 (13.6) 38 (86.4) 18 (20.7) 69 (79.3) 0.17 
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Physicians’ recommendations in regard to Vignette D are shown in Table 5.21. In 
this instance there were no differences between regions. The majority favoured 
commencing an inhaled corticosteroid (78.2%). There was also strong support for 
commencing an oral corticosteroid (58.6%), starting ipratropium bromide (65.5%) 
and increasing the patient’s β2 agonist dose (56.3%). The patient’s attendance at an 
outpatient clinic or Emergency Department (79.3%) was also strongly favoured. 
‘Waiting and seeing’ was rejected by 94.3% of physicians. 
Agreement (75% and over) among all study respondents about starting an inhaled 
corticosteroid and recommending outpatient visits, but not adding a non-steroid anti- 
inflammatory or waiting and seeing, was demonstrated, while disagreement about 
increasing use of the current inhaled β2 agonist, starting inhaled ipratropium 
bromide, starting an oral theophylline, and starting oral corticosteroid was evidenced. 
There were no significant differences based on gender, except in the Start oral 
corticosteroid (p=0.028), when male physicians recommended this action than 
females; see Appendix F.  
5.3.5 Vignette E 
‘Imagine that a patient of yours is experiencing asthma symptoms daily despite use 
of an inhaled β2 agonist on an as-needed basis and an inhaled corticosteroid in a 
dosage <500g/ day (e.g. 2 puffs Beclovent
®
 QID or 1 puff Pulmicort
®
 BID). The 
patient’s activities are interrupted an average of 2-3 times a day due to asthma 
symptoms but are controlled by taking the inhaled β2 agonist. The patient is 




Table 5.22 Vignette E 

























18 (41.9) 25 (58.1) 24 (54.5) 20 (45.5) 42 (48.3) 45 (51.7) 0.24 
Increase an inhaled corticosteroid 12 (27.9) 31 (72.1) 20 (45.5) 24 (54.5) 32 (36.8) 55 (63.2) 0.09 
Add a non- steroid anti- inflammatory 24 (55.8) 19 (44.2) 33 (75.0) 11 (25.0) 57 (65.5) 30 (34.5) 0.06 
Start an oral theophylline 26 (60.5) 17 (39.5) 34 (77.3) 10 (22.7) 60 (69.0) 27 (31.0) 0.09 
Start oral corticosteroid 26 (60.5) 17 (39.5) 24 (55.8) 19 (44.2) 50 (58.1) 36 (41.9) 0.66 
Wait and see (no medication needed at this 
time) 
40 (93.0) 3 (7.0) 35 (79.5) 9 (20.5) 75 (86.2) 12 (13.8) 0.07 
Outpatient visit (e.g. Same day office visit or 
refer to Emergency Department) 
26 (60.5) 17 (39.5) 24 (54.5) 20 (45.5) 50 (57.5) 37 (42.5) 0.58 
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Physicians’ recommendations in regard to Vignette E are shown in Table 5.22. In 
this case there were some differences in the recommendations made by Asser and 
Riyadh physicians which just failed to reach statistical significance; for example, a 
greater proportion of Asser physicians recommended increasing the inhaled 
corticosteroid than did Riyadh physicians (72.1% versus 54.5%; p=0.09). This was 
also the case for an inhaled non-steroid anti-inflammatory (44.2% vs. 25.0%; 
p=0.06) and starting oral theophylline (39.5% vs. 22.7%; p=0.09). There was 
concordance about increasing the β2 agonist dose, starting inhaled ipratropium 
bromide, and starting an oral steroid. Physicians in Riyadh were more likely to 
favour the ‘wait and see’ approach than their Asser counterparts. Less than 50% of 
physicians from both regions favoured an Outpatient or Emergency Department visit.  
Agreement (75% and over) was not demonstrated among the respondents regarding 
recommended actions. Agreement was only seen with regard to not recommending 
‘wait and see’ of the offered management options. Disagreement was demonstrated 
for all other suggested actions. There were no significant differences based on 
gender.  
5.3.6 Vignette F 
‘Imagine a patient of yours has been experiencing flu-like symptoms for the past 2-3 
days. These symptoms include a sore throat, nasal and sinus congestion and 
rhinorrhoea. Additionally, the patient notices an increased cough productive of 
whitish-yellow sputum and increased wheezing and dyspnoea to the point of 
disrupting his/ her normal activities. The patient’s asthma is usually well controlled 
by using an inhaled β2 agonist in a dosage of 2 puffs QID and an inhaled 
corticosteroid at a dosage of 400 g/ day.’ 
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Table 5.23 Vignette F 












Do not recommend 
N (%) 
Recommend 
 N (%) 




Increase current use of the inhaled β2 
agonist 





26 (60.5) 17 (39.5) 29 (65.9) 15 (34.1) 55 (63.2) 32 (36.8) 0.60 
Increase an inhaled corticosteroid 19 (44.2) 24 (55.8) 23 (52.3) 21 (47.7) 42 (48.3) 45 (51.7) 0.45 
Add a non- steroid anti- inflammatory 26 (60.5) 17 (39.5) 32 (72.7) 12 (27.3) 58 (66.7) 29 (33.3) 0.23 
Start an oral theophylline 35 (81.4) 8 (18.6) 33 (75.0) 11 (25.0) 68 (78.2) 19 (21.8) 0.47 
Start oral corticosteroid 39 (90.7) 4 (9.3) 36 (81.8) 8 (18.2) 75 (86.2) 12 (13.8) 0.23 
Wait and see (no medication needed at 
this time) 
35 (81.4) 8 (18.6) 39 (88.6) 5 (11.4) 74 (85.1) 13 (14.9) 0.34 
Outpatient visit (e.g. Same day office visit 
or refer to Emergency Department) 
32 (74.4) 11 (25.6) 27 (61.4) 17 (38.6) 59 (67.8) 28 (32.2) 0.19 
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Physicians’ recommendations in regards to Vignette F are shown in Table 5.23. In 
this case there were no significant regional differences in the physicians’ 
recommendations. Increasing the inhaled corticosteroid dose was amongst the 
favoured recommendations, together with increasing the dose of the β2 agonist 
(47.1%) and starting ipratropium bromide (36.8%). The majority of physicians did 
not favour a ‘wait and see’ approach (85.1%) nor an Outpatient or Emergency 
Department visit (67.8%). In this case there was a clear focus on increasing all the 
patient’s medications.  
Agreement (75% and over) among all respondents was not demonstrated for any of 
the suggested actions; however, most physicians agreed about not starting an oral 
theophylline, starting oral corticosteroid, or waiting and seeing. There were no 
significant differences based on gender. 
5.4 Physicians’ Usual Approaches to Decision-making 
Physicians were asked about their usual practice in involving asthma patients in 
decisions about their disease management. 







Usually, in your practice, to what extent does the average 
patient with asthma get involved with management 
decisions about his/ her disease? 
N (%) N (%) N (%) 
I make the decisions, using all that is known about the 
treatment 
15 (34.9%) 18 (40.9%) 33 (37.9%) 
I make the decisions, but strongly consider the patient’s 
opinion 
23 (53.5%) 19 (43.2% 42 (48.3%) 
 The patient and I make the decisions together on an 
equal basis 
2 (4.7%) 5 (11.4%) 7 (8.0%) 
The patient makes the decisions, but strongly considers 
my opinion 
2 (4.7%) 2 (4.5%) 4 (4.6%) 
The patient makes the decisions using all the information 
he/ she knows about the treatments 
1 (2.3%) 0 (0.0%) 1 (1.1%) 
Difference between region p value 0.57 
Note: more detailed data are presented in Appendix F 
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The data in Table 5.24 illustrate the extent to which physicians usually involve 
patients in decisions about their management. There were no statistically significant 
differences based on region and gender, with physicians in both regions tending to 
make the decisions. More than one third (37.9%) of physicians from both regions 
usually made the decisions based on their knowledge of the treatment, while nearly 
half (48.3%) made the decisions but strongly considered the patient’s opinion; only 
8.0% shared decision-making with patients on an equal basis. Male physicians were 
more likely to make decisions than females in both regions: 25 (44.6%) and 26 
(46.4%) male physicians reported making the decisions based on their knowledge of 
the treatment, or making the decisions but considering the patient’s opinion, 
compared with 8 (25.8%) and 16 (51.6%) females respectively.  
5.5 Physicians’ Ideal Approaches to Decision-making 
Physicians were asked about their ideal practices in involving asthma patients in 
making decisions about their disease management. 







Ideally, in your practice, to what extent does the average 
patient with asthma get involved with management decisions 
about his/ her disease?  
N (%) N (%) N (%) 
































The patient makes the decisions using all the information he/ 
she knows about the treatment 
0 (0.0%) 0 (0.0%) 0 (0.0%) 
Difference between region p value 0.956 
Note: more detailed data are presented in Appendix F 
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The data presented in Table 5.25 illustrate the extent to which physicians ideally 
wish to involve patients in decisions about their management. There were no 
statistically significant differences based on region and gender, with physicians in 
both regions tending to make the decisions. More than one third (39.1%) of 
physicians from both regions usually made the decisions, based on their knowledge 
of the treatment, while nearly half (46.0%) of them made the decisions but strongly 
considered the patient’s opinion; only 11.5% shared the decision-making on an equal 
basis. Further, male physicians were more likely to make decisions than females in 
both regions, with 24 (42.9%) and 26 (46.4%) reporting that they made the decisions 
based on their knowledge of the treatment, or made the decisions but strongly 
considered the patient’s opinion, compared with 10 (32.2%) and 14 (45.2%) of 
females respectively.  
5.6 Discussion of Physicians’ Survey  
There was a gap between the physicians’ current asthma management practices and 
the optimal situation. Even though guidelines exist to guide health care providers and 
improve asthma management outcomes, studies conducted in both developed and 
developing countries have found that implementation and compliance with 
guidelines is not as expected (163, 166, 172, 184, 187, 190, 195, 261, 265, 266, 268). 
Furthermore, there is variation in physicians’ practices with both settings of care and 
physicians’ specialties. This is evident from studies of physicians or patients/ 
families, or both (38, 163, 186, 188, 194, 259, 264). Also contributing to suboptimal 
care is a lack of knowledge and understanding of some components of the guidelines 
(193, 195, 264). Doerschug et al. found in their study of physicians’ understanding of 
guideline components (assessment, diagnosis, patient education, pathology, 
pharmacology, prevention, severity, and therapy) that there were differences in the 
scores depending on the components and/ or physicians’ practice specialty, although 
the maximum mean of improved adherence by physicians was 60± 2% (mean ± 
SEM) (193). The degree of physicians’ lack of knowledge and confidence varied in 
regard to the guidelines’ components. Finkelstein et al. estimated that of 407 
children’s physicians practicing in three care organizations, most were 




Our study investigated primary health care physicians’ approaches to the practice of 
asthma management in three areas: providing education to patients/ family, asthma 
treatment, and patient-professional partnerships, in the Riyadh and Asser regions of 
Saudi Arabia. Overall there was a high response rate to the survey (88.3%), with no 
difference between Riyadh and Asser regions. A total of 87 physicians met the 
research criteria and were surveyed (Riyadh 44; Asser 43). The majority who 
responded were male (64.4%), aged less than 50 years (77.6%) and non-Saudi 
(94.3%). The distribution of specialties between physicians surveyed was similar in 
both Riyadh and Asser. Seventy-one (81.6%) had 20 years’ or less experience. A 
study by Gharagozlou et al. has found a lack of physicians’ continuing education 
(190), and our study revealed that more than one third (35.6%) of physicians 
surveyed had attended one or no conferences/ seminars in the previous five years, 
and only 14.9% attended at least one annually. Sixty-eight physicians (78.2%) 
reported having access to The National Protocol for the Management of Asthma and 
around one third (37.8%) had access to other guidelines. These data were consistent 
with Finkelstein et al., who found that 91% of their participants had the NAEPP 
guidelines and 75% had read them (264). However, it has been found that some 
physicians who have access to guidelines do not use them on a regular basis (190, 
268). Although most physicians reported being ‘aware’ of the guidelines, there were 
significant differences across groups. The authors concluded that guideline 
recommendations were not sufficiently read by physicians, less than half of whom 
reported having knowledge about guideline recommendations (163). 
Working in teams within health care mostly leads to better outcomes. Goeman et al. 
suggested that the presence of a professional educator would be an advantage, at 
least in circumventing the time-pressure barrier (165). In the current study, 53 
(60.9%) physicians (Asser 79.1% vs. Riyadh 43.2%, p=0.001) had access to the 
assistance of a nurse or other health care professional. Asser physicians were more 
likely to provide education than Riyadh physicians.  
Primary health care (PHC) was the main setting for treating and following asthma 
patients, and often patients were treated by general physicians; however, it is evident 
that most outpatients were not treated appropriately (184, 186, 187, 194, 248, 250, 
292). Lack of, or variation in, primary health care quality has been reported within 
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and between countries (247, 252). Specialists have been found more likely to adhere 
to treatment guidelines (186, 194, 195, 263). Laforest et al. found that quality of life 
and satisfaction among patients treated by specialists was better, and that patients 
were more likely to feel they had enough information regarding their disease. Diette 
et al. found that when patients were treated by specialists they were more likely to 
receive a controller medication (94% vs. 72%, p < .01), have AAPs (69% vs. 46%, p 
< .05), to be educated about their inhaler device (89% vs. 69%, p < .05), and have 
pulmonary function tests (86% vs. 48%, p < .05). These patients were more likely to 
adhere to daily medication use (68% vs. 36%, p < .01) in comparison with generalist 
physicians’ patients (186). In our study, most physicians were general medicine GPs 
(60%) and family physicians 33%, with the exception of one who was a specialist 
(pulmonologist); there was no significant difference between the two groups’ 
practices, although family physicians scored higher in their education performance 
(at 82.8% versus 67.3%, without statistical significance).  
5.6.1 Patients’ education 
Low adherence to some or all guideline components amongst Outpatient clinic 
physicians was reported. One of these components was the education of patients and 
their families, who are required to play a major role in asthma self-management and 
to be involved in decision-making. This requires those involved to have a basic 
knowledge of the disease and its treatment, as this may influence their behaviour; 
hence, education is recommended for all patients. However, lack of patients’ and 
their families’ knowledge, detrimental behaviours, and poor adherence in addition to 
misunderstanding, were noted (74, 179, 183, 212, 293-296). Haby et al. have 
reported that a high proportion of patients (51%) and family members (38%) believe 
they do not have an adequate amount of information (162). Health care providers are 
recognized as the main resource. A lack of physicians’ adherence to their duty to 
educate their patients in essential aspects of asthma and its management has also 
been stated (163, 186, 190). Gharagozlou et al. found that more than one third 
(42.2%) of the clinicians they surveyed reported giving no consideration to education 
or to providing action plans when treating their patients (190). Jin et al.’s study, 
conducted in Canada, found that although physicians believed they provided enough 
information and education to their patients regarding most aspects of the disease, in 
fact information about medications, triggers, signs of worsening asthma, and actions 
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that should be taken was deficient. Little over half (58%) of participants observed all 
or most of their patients demonstrating inhaler technique, and a lower proportion 
prepared written AAPs and referred patients to an asthma educator or an organization 
for asthma education. Variations were reported between physicians’ levels of 
specialization regarding these aspects (163). 
Our results were consistent with these findings. A lack of consistency in providing 
information and educating patients about some essential aspects of their disease and 
management was found. For some patients, information was not provided unless they 
asked for it. Physicians in this study also were likely to provide education mainly to 
patients with more severe asthma. Cicutto’s study found that physicians provided 
general information about asthma (87.1%–97.6%), explained the medication 
prescribed (90.2%–99.4%), demonstrated the proper use of an inhalation device 
(85.3%–94.5%), and defined signs of worsening asthma (74.8%–96.9%) to mild, 
moderate and severe asthma patients: figures consistently higher than in our study 
(72.4%–93.1% ; 63.2%–85.1%; 77%–88.5%, and 62%–90% respectively). Reeves et 
al. in their study reported that most of the children in the study sample (71%) 
acknowledged receiving some type of asthma education, with a majority of 99%, 
95% and 88.6% of respondents respectively reporting being educated about nebulizer 
use, medication treatment, and asthma triggers (187). Most physicians in our study 
reported that they demonstrated the use of an inhaler to their patients. Hussain et al. 
found a lack of knowledge and misconceptions by physicians about inhaler devices 
(184). 
Similar results were found regarding provision of AAPs. Receiving AAPs based on 
asthma severity (mild to severe) from their physicians occurred for 36.8%–69.0% of 
patients in our study, compared with 38% to 73.6% in Cicutto et al.’s (297). These 
findings are supported by data from several other studies which report a lack of 
asthma action plan development amongst asthma patients (158, 162, 163, 186, 187, 
264, 268). Goeman et al. found that while patient education was documented as the 
most important of six priorities to improve asthma care outcomes by six focus 
groups, including 49 GPs, written AAPs were not identified as a priority by five 
groups and were ranked third by the sixth group (165). In Jin et al.’s study, only 17% 
of physicians surveyed reported they provided an AAP for all or most of their 
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patients; differences were noted between physician specialties (163). Reeves et al. in 
their study, conducted in three Emergency Departments and including 197 patients 
aged between 2-17 years, found that less than half (43%) the participants had a 
written AAP (187). Similar findings were reported by Haby et al. in a study 
conducted in Melbourne involving 231 patients ranging from 2 to 5 years old. They 
found that only 52% of participants had an AAP (162). This may indicate the 
disagreement of physicians with the importance of AAPs (165); in any case, verbal 
plans are more likely to be used by physicians than written AAPs, and perhaps time 
constraints contribute to this. It has been suggested that self-management plans 
(SMPs) may not be appropriate to use with all patients, especially those with poorly 
controlled asthma (166). Physicians may believe that patients will not comply with 
their AAP. 
It has been reported worldwide that physicians are less likely to recommend home 
PFMs for their patients (163, 172, 187, 190, 264, 266, 268). Diette et al. found that 
58% and 83% of respondents who were treated by generalists and specialists 
respectively had been instructed about PFMs (186). In our study most physicians 
reported that they did not provide information about monitoring peak flow rate or 
using AAPs based on PFMs and symptoms to their patients with mild or moderate 
asthma. Despite this, the proportion of physicians providing their patients with this 
information was higher than that reported by Cicutto et al. (297) (36% vs. 10% and 
33% vs. 7% respectively) but for severe asthma patients was similar (62% vs. 60% 
for PFMs and 57% vs. 52% for AAP, based on symptoms and PFMs). This may be 
due to the unavailability of peak flow meters, poor PFM usage, and lack of 
knowledge. It has been reported that the reason behind the low use of spacers was 
unavailability, and the main reason behind the low recommendation of the lung 
function test by physicians was both lack of knowledge about how to interpret the 
test, and its unavailability (165, 187, 190). Liwarisakun et al. found that chest 
physicians answered 57% of the PEF variability correctly, compared with general 
doctors who answered only 9% correctly (195). 
 Haby et al. reported that 83% of parents had been informed about asthma triggers, 
but only 49% reported they had been advised on how to avoid them – although it has 
been suggested that these findings may not point to a gap in management as some 
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triggers cannot be avoided (162). In our study, physicians were found to be to be 
aware of this aspect of asthma management, with the majority reporting that they 
usually provided patients with information about avoiding asthma triggers and 
controlling their environmental. Our findings are inconsistent with those reported by 
Cicutto et al. (297). This may be attributed to physicians believing that most triggers 
in Saudi patients such as weather changes, contact with animals, and smoke 
generated by fires can be avoided.  
The results of this portion of the current study indicate a number of key points that 
need to be addressed. First is the variation among physicians’ performance of their 
duty to educate patients, which may reflect a lack of awareness about, or agreement 
with, patients’ issues, and limited application of the national guidelines. In addition, 
medical facilities may not always have all the educational and other equipment 
necessary. Morbidity and mortality have been reported among patients with mild 
asthma. Asthma severity is not stable, and mild forms may develop into moderate or 
severe asthma. This is pertinent to the second point, that physicians in the current 
study were more likely to give attention to severe cases than to mild cases of asthma 
with regard to providing education. This may be partly because it is usual practice in 
KSA to treat patients with mild asthma in PHCCs, while those with moderate and 
severe asthma are referred to secondary health care centres.  
A third key point in this part of current study is the low adherence to providing 
information about AAPs and PFMs. It was found that the reported provision of AAPs 
based on symptoms was low across the board, but especially lacking for patients with 
mild forms of the disease. The provision of information regarding monitoring peak 
flow rates was also found to be very low. Provision of AAPs based on symptoms and 
PFMs was reported to be lower than that of AAPs based on symptoms alone. This is 
reflective of the low use of PFMs, which may due to physicians’ lack of knowledge 
and familiarity with their use or to their unavailability, either of which may affect 
physicians’ practices. In addition, education is time-consuming, and shortage of time, 
lack of both suitable materials and community resources, and patients being 
unreceptive were common factors reported by participants in Jin et al.’s study (163). 
Education regarding asthma triggers was reported high across all severity 
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classifications. This indicates that physicians were highly aware of the importance of 
triggers in asthma management. 
Finally, in regard to community non-profit organizations, there was lack of patient 
guidance by providers to groups that could have offered further information. This 
finding is consistent with those of Robert et al. and Cicutto et al. (163, 297), and may 
be attributed either to providers’ being unaware of such organizations, to such bodies 
having no presence in KSA, to problems with language as most information is 
available only in English, or to a lack of access to resources such as the Internet.  
5.6.2 Physicians and treatment  
Diagnosing asthma and classifying its severity is an important issue facing 
physicians (266). Inaccurate assessment of the severity of asthma may contribute to 
inappropriate treatment (185, 189, 195, 262, 266) and may occur as a result of a lack 
of physician knowledge or an unawareness of asthma symptoms; from poor patient 
knowledge of and attitude towards asthma, or from a lack of communication between 
health care providers and patients and their families. Improvement in patients’ 
education and communication may increase adherence to guideline recommendations 
and improve the outcomes of asthma management. Halterman et al.’s study found 
that most respondents (60%) were incorrectly classified by their physicians, and of 
these only 28% had preventive anti-inflammatory medication prescribed (189). 
Physicians’ disagreement regarding asthma severity has also been reported (266) and 
may contribute to variations in or lack of treatment. Baker et al. asked 24 specialists 
to classify eight cases in addition to interpreting the pulmonary function test and 
indicating the main factor used in classification (daytime symptom, night-time 
symptom, pulmonary function or all) each case. They were also asked to recommend 
treatment. It was found that there was poor agreement amongst physicians in 
classifying asthma severity. There was better agreement on the main factor used to 
classify asthma amongst physicians and interpret pulmonary function, except in the 
case of asthma revealed by bronchodilator response. Although treatment was 
consistent with their classifications, it was often inappropriate as a result of incorrect 
classification. It was noted that while the majority of physicians recommended ICS, 
this proportion might differ in a larger sample (185). These findings may help 
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explain the variations between physicians’ recommendations in the six vignettes in 
our study. In our results, agreement with the six vignette options was considered at ≥ 
75% of the sample response. A lack of or variation in prescribing practices of 
physicians was reported by Jepson et al. in a study conducted in six European 
countries of adult and child patients (259), and almost the same results were found 
by another study performed in five European countries to estimate physicians’ 
knowledge, attitudes and prescribing behaviour (188). In our study, lack of 
physicians’ adherence to guidelines, and practice variations when treating asthma, 
were observed across all six clinical vignettes. Cicutto et al. (298), who used the 
same case studies, found that physicians were more likely to recommend the use of 
corticosteroids, either oral or inhaled (only 9% to 15% of Cicutto et al.’s participants 
did not recommend the use of corticosteroids) except for vignette D than the 
physicians in our study. In our study, the proportion of physicians who did not 
recommend corticosteroid use was higher than that reported by Cicutto et al. (range: 
6.9% to 43.7%) with the exception of vignette A. It has been reported that specialist 
physicians are more likely to prescribe controller medications than other physicians 
(163, 186, 195), which may explain the differences between these two results, as 
around half the participants in Cicutto et al.’s study were specialists, while nearly all 
(93%) of our participants were general and family physicians.  
It is concluded that although physicians report agreeing with ICS recommendations, 
in actual practice prescription of ICS is less than optimal (259, 266). Several studies 
have found that some physicians are less likely than others to prescribe ICS to their 
patients, and numerous reasons for non-ICS prescription have been offered, such as 
disagreement, cost, and side effect patterns (172, 184, 190, 194, 195). ICS 
recommendations in our study tended to be a bit high in some cases, although 
suboptimal within the recommendations of the guidelines’ recommendation usage 
rate from 16.1% to 88.5% among the six vignettes. This finding is consistent with 
data reported in the previous study (14.7 %– 87.7%) (298). However, physicians’ 
ICS recommendations in the two studies differ from vignette to vignette, with the 
exception of vignette A. For example, in our study 75.6%, 88.5%, 78.2%, 63.2% and 
51.7% of participants were reported agreeing to start or increase ICS dosage in 
vignettes B, C, D, E and F, compared with 87.7%, 71.8%, 40,5%, 80.9% and 71.8%; 
respectively in Cicutto et al.’s study (298). These are supported by Reeves et al.’s 
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finding that more than one third of respondents with persistent asthma are under-
treated, and that of these 51.3%, 36% and 22% had mild, moderate and severe 
asthma respectively p=0.03 (187). The current findings may also reflect variations 
between physicians’ practices. Gharagozlou et al. reported that a number of 
physicians may still disagree with the recommendation that ICS use is the 
cornerstone of asthma treatment, or may worry about the safety of long-term use 
(190). Hussain et al. in their study conducted in Pakistan found a significant lack of 
medication knowledge amongst physicians, combined with misconceptions about 
inhaler treatment, despite all respondents having participated in CME programs 
(184). In contrast, Finkelstein et al. reported a high awareness of the role of anti-
inflammatory agents in asthma treatment among physicians, but noted that they 
tended to hesitate before increasing dosages (264). This may support our findings. 
Physicians in our study were more likely to start ICS (except in vignette A) than to 
increase the dose of ICS that had been given in some vignettes. Furthermore, 
prescription of an anti-inflammatory agent may be affected by the severity of asthma 
(188). 
Inappropriate recommendations regarding the use of oral corticosteroids were 
identified amongst the physicians’ responses to most of the vignettes. Oral 
corticosteroids were recommended in some cases where they may not have been 
needed, as in vignettes A and E, while in other cases they were not recommended 
where they were needed, as in vignettes C and D.  
One of the asthma management goals is to reduce reliever use. However, it has been 
reported that utilizing bronchodilators is still commonly recommended by a large 
proportion of physicians (163, 184, 188, 190, 259). One study conducted in Canada 
with different specialty groups found that around 72.5% of participants almost 
always or often chose a trial course of inhaled β2 agonists as a method for 
diagnosing asthma in adults and children, compared with 61.9% and 60.3% who 
used a course of inhaled corticosteroids with adults and children respectively. 
Furthermore, β2 agonists’ use as first-line medication for adults and children were 
indicated by 71% and 65% respectively, while around 40% and 34% of participants 
reported regularly using β2 agonists (163). In our study, although patients in some 
vignettes were already using a high dose of β2 agonist, some physicians tended to 
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increase the dose. Increasing the β2 agonist dose was recommended by physicians 
more often in our study than in the Cicutto study (298): in our study, usage rate 
ranged from 30% to 57%, compared with 14% to 42% in the Cicutto study, again 
with the exception of vignette A, where similar levels were observed (90%) in both 
studies.  
On the other hand, starting inhaled ipratropium, or recommending oral theophylline 
and added non-steroid anti-inflammatories, varied across the physicians’ sample. 
Jepson et al. found that these agents were limited in their prescription (259). In our 
study, the recommendation to start these agents ranged from 11.5%–65.5% for 
inhaled ipratropium, 8%–33.3% for oral theophylline, and 13.8%–34.5% for adding 
a non-steroid anti-inflammatory across the six vignettes; in Cicutto’s study these 
medications were recommended in 5.5%–34.4%, 1.2%–14.9% and 3.7%–23.6% of 
cases respectively. It was reported that non-steroid anti-inflammatories had limited 
effects (50). 
In our study some physicians opted to ‘wait and see’, which may reflect a tendency 
to hesitate in prescribing medication or may be an effect of organization. Same-day 
office visits or referral to an ED were less likely to be recommended in our study 
than in Cicutto’s, in most vignettes. 
The lack of, or variations in, recommendations by physicians was noticeable in those 
vignettes that depicted more severe cases with exacerbation than in those of a lesser 
severity. This finding was consistent with those of other studies (188, 189). 
Inadequate management of worsening asthma has been reported, with wide 
discrepancies amongst five countries’ physicians. Physicians’ responses to the 
question, ‘Does yellow-green sputum always indicate a bacterial infection?’ varied 
widely (188). In Vignette F, for example, this variation was documented, and 
although antibiotics were not included in the answers option, over a third of 
respondents recommended adding antibiotics. Of these, 23.3% suggested adding only 
antibiotics. Slightly over half the respondents recommended starting or increasing 
corticosteroids, whether oral and/ or ICS; of these, 27.1% combined them with 
antibiotics. Laforest et al. found that general practitioners (GPs) and GP + specialist 
(SPE) groups were more likely to prescribe antibiotics for their adult patients than 
was a purely SPE group. The authors reported that the use of antibiotics was still 
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widespread in primary care (194). While adding antibiotics in this case may seem 
reasonable as the patient has an upper respiratory tract infection (URTI), infection 
signs may cause physicians concern that it could exacerbate the patient’s asthma. 
This action was not recommended in the other vignettes. This point may prove to be 
controversial. Around one third of respondents recommended starting ipratropium or 
adding a non-steroid anti-inflammatory agent, whilst 5.7% of respondents did not 
recommend any medication. These differences in treatment practices may be due to 
knowledge differences regarding the treatment of asthma (186). 
While some medications such as long-acting beta agonists (LABA), combinations of 
corticosteroids and LABA, and leukotriene receptor antagonists (LTRA) were not 
included in the vignettes’ management options in our study, physicians were asked to 
identify additional medications or actions that would apply. Consistently, these 
agents were either not recommended or least recommended by physicians. LABA 
were recommended only in vignettes B, C, D, and E in ≤ 4.6 % of cases. This result 
was mostly consistent with data from other studies where the use of LABA was 
reported in ≤ 8% of cases, although Robert et al. reported a slightly higher 
percentage of physicians recommending LABAs across their cases, in some 
instances inappropriately (163). In this study, combination formulations were 
recommended by 3.4% and 1.1% of physicians in Vignettes C and F respectively. 
Factors which may have contributed to this finding include physicians being unaware 
or having a lack of knowledge about asthma and its treatment, their level of 
agreement with recommended asthma treatments, and perceived agent unavailability 
or its cost. Hussain et al. in their study suggested that the low level of prescribed 
LABAs may be due to physicians’ lack of knowledge rather than to cost (184). 
Prescribing these agents may also be affected by physicians’ specialties: a study 
involving adult patients reported that respiratory physicians were more likely to 
prescribe LABA-ICS combinations to their patients (194). 
5.6.3 Patients’ involvement in decision-making 
Some evidence indicated that patient involvement in decision-making improved their 
adherence to at least some aspects of the guidelines. Sleath et al. reported that 
arthritis patients involved by their physicians in decisions about their treatment were 
more likely to provide and discuss health information and status (299). Possession of 
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a written action plan and adherence to daily preventer medication use has been 
reported to be significantly higher amongst patients who participated in decision-
making (158): Diette et al. reported that 91.2% and 77.9% of respondents treated by 
specialists and generalists respectively were involved in their treatment decisions 
(186). In the current study, physicians were less likely to involve patients, and fewer 
than 50% of those surveyed included patients in decision-making. There is no 
significant difference between physicians’ responses in actual and ideal cases. The 
severity of the disease and the level of communication between patients and 
professionals, in addition to patient characteristics such as age, education and income 
level, may affect these approaches (158). Given that nearly all the physicians were 
non-Saudi, a lack of relationship between physicians and their patients/ carers in this 
study may be involved in doctors’ preferences to make unilateral decisions. In 
particular, the physicians usually were not fluent in Arabic, and were unaware of the 
subtleties of Saudi culture and customs. This point is supported by Ferguson and 
Candib, who found that culture and language play a role in patient–physician 
relationships (201).  
5.6.4 Regional differences between physicians’ practices  
Regional differences between health care practices have been observed in other 
studies (87, 187, 188, 259), and our findings are consistent with these. Variations 
between practices in each region was reported. Asser physicians, for example, were 
more likely to provide education than their Riyadh counterparts. Reeves et al. have 
found a substantial difference between places in the possession of PFMs, with 
respondents from urban areas more likely to have a PFM than those elsewhere (187). 
In general, Asser physicians were more likely to provide all aspects of education 
(with the exception of recommending community non-profit organizations to 
moderate asthma patients) across the spectrum of asthma severity, although 
significant differences were still identified in the instruction of patients with mild and 
moderate severity in some aspects such as asthma warning signs, AAPs based on 
symptoms either with or without PFMs, and PFM information. For people with 
severe asthma, only providing information on PFMs was found to be significantly 
different between physicians from the two regions. This finding may indicate that 
Asser physicians are more likely to be compliant with the guideline 
recommendations related to patient education than are Riyadh physicians. Physicians 
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were found to give more attention to patients with severe asthma than to those with 
mild asthma. In addition, lack of adherence to AAPs and PFMs were reported.  
This finding may be an indication of awareness of the guidelines, with Asser 
physicians having greater access to them. It also may be a result of work overload, 
lack of time, and unavailability of professional assistance. Asser physicians were 
more likely to have a nurse or other health professional to assist them; they were also 
more likely to attend conferences or seminars, which might encourage a higher level 
of adherence to practice guidelines. Lack of professionals’ knowledge about devices 
such as PFMs, in addition to differences in facilities and their consequent 
availability, may also be factors. Furthermore, Riyadh’s physicians were less likely 
to involve patients in decisions about their treatment. In vignettes B and C a 
significant difference was noted between the groups’ recommendations to start oral 
corticosteroids, with Riyadh physicians more likely to recommend them. Asser 
physicians were more likely to recommend ICS than Riyadh physicians, as 
demonstrated in especially in Vignette C (P=0.048). Riyadh physicians also 
recommended same-day office or emergency visits, especially in Vignette A. This 
may be because of the large number of hospitals available locally. Although not 
significantly different, Asser physicians were more likely to recommend increased 
β2 agonists, oral theophylline, and adding non-steroid inflammatory agents than 
Riyadh physicians. Results for ipratropium bromide recommendations were similar 
across both regions. 
5.6.5 Gender influences  
Variations across gender were noticed in physicians’ practices. Male physicians were 
more experienced, and had a greater tendency to attend conferences. In addition, they 
had more access to guidelines and were more likely to have a nurse or other health 
professional (69.6% versus 45.2%; p=0.025) than their female counterparts. This 
finding may be why male physicians were more likely to provide education than 
female physicians in our study. Some statistically significant differences were noted: 
males were more likely to provide information about worsening asthma than female 
physicians to moderate/ severe patients (p=0.015); they also tended to supply their 
patients with moderate/ severe asthma with information about AAPs (p=0.037) and 
to discuss PFMs with moderate asthma patients (p=0.05). There were significant 
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differences between genders in the Riyadh region regarding education: male 
physicians were providing AAPs based on symptoms to patients with severe asthma, 
with or without PFM information, more than their female counterparts. Interestingly, 
significant differences were reported between female physicians in both regions 
regarding AAPs and PFMs. With regard to treatment, females were more likely to 
recommend β2 agonists and antibiotics; however, there were no significant 
differences in this area. They were also more likely to recommend corticosteroids in 
all vignettes, although the only significant difference appeared in Vignette E with 
their recommendation of oral corticosteroid. Female physicians were more likely to 
recommend ‘wait and see’ and same-day office visits or to refer the patient to an 
Emergency Department, in most of the vignettes. It was noticeable that male 
physicians’ recommendations regarding the use of oral theophylline in all vignettes 
was greater than females’ recommendations. The reason behind this is not clear, but 
it may be because males tend to recommend more than one drug.  
5.6.6 Barriers to adherence  
A number of barriers were reported affecting physicians’ approach to the treatment 
of people with asthma. Cabana et al. has grouped these barriers into three: 
‘Knowledge (lack of awareness and familiarity), attitudes (lack of agreement and 
self-efficacy, outcome expectancy and motivation/ previous practice) and behaviour 
(external barriers) barriers’ (265, p. 1460). In adult and children asthma patients, 
several studies have supported such findings (172, 191, 268); for instance, Robert et 
al. found a relationship between physician awareness and knowledge about guideline 
recommendations and their practice (163). 
It was reported that lack of familiarity more likely affected physicians’ practices than 
lack of awareness, and that one or more barriers may influence compliance with any 
recommendation in the guidelines (172, 265, 268). Cabana et al. estimated 
paediatrician physicians’ adherence to four components of the asthma guidelines 
(including ICS prescription and instruction in PFM daily use) and found that 88% of 
respondents were aware of the guidelines, but that lack of familiarity with all 
components was reported. The physicians’ adherence to these components ranged 
from 39% to 53% (172). Although our study was not designed to estimate barrier 
effects, some barriers can be deduced from the results. Physicians’ lack of 
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knowledge, and their misconceptions regarding some aspects of asthma treatment 
and tools, have been reported (184). Moffat et al. considered that lack of adherence 
to guidelines and to developing AAPs may contribute to poor communication 
between patients and health care providers (166). Lack of self-efficacy can be behind 
un-prescribing medication and failing to provide information about some devices. 
Low use of PFMs and AAPs by physicians contributes to the lack of physician self-
efficacy and unsatisfactory outcomes (172, 268). In addition to those barriers already 
mentioned, disagreement and cost effects have been implicated in the failure to 
achieve recommended PFM use by physicians (191). This may be deduced from the 
minimal information provided to patients regarding asthma, AAP and PFM as well 
as from the medication being prescribed. Physicians’ disagreement with the 
guideline recommendations, their lack of self-efficacy, and lack of outcome 
expectancy have all been reported as barriers resulting in low adherence to ICS 
prescriptions (172, 191, 268). Lagerlov et al. found a relationship between ICS 
prescribed and physicians’ knowledge and attitudes (188). These may join with many 
other elements and account for the inappropriate recommendation of corticosteroids 
and other variations in practice noted in our findings. In addition, patients’ 
knowledge, beliefs, perceptions and adherence to their regimen, as well as their ease 
of communication with their physicians, may be considered as another set of barriers 
influencing physicians’ practices (188, 191, 265, 268). Moffat et al. found that 
patients relate that such things as non-compliance and lack of concern, as well as 
poor communication, hinder their doctors’ ability to provide appropriate education to 
enable them to manage their asthma, arguing that good communications skills are 
essential if physicians are to supply patients with useful information that can improve 
their asthma control (166). The effect of both patients and their families on 
physicians’ practices that is revealed in our study is evident in physicians’ admission 
that, unless asked, they do not supply their patients with information. It may also 
account for the low number of physicians who involved their patients in decision-
making and explain the tendency of physicians to recommend oral corticosteroids 
where patients favour these over inhalers. At a pragmatic level, medication and 
device availability may limit physicians’ adherence: for example, PFMs may not be 
available in all health care centres and are not supplied free of charge, so while 
patients receive free health services there are some expensive agents such as 
leukotriene receptor antagonist (LTRA) and combination drugs that must be 
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purchased, or may not be available at least some of the time in PHCCs. These may 
be reasons for physicians not recommending their use. 
Most PHCC physicians are responsible about treating, following up and educating all 
their patients, not just their asthma patients; however, lack of time and work load 
pressure, combined with staff shortages, a lack of educational materials and lack of 
facilities were reported as working against best practice (163, 165, 166, 172, 186, 
191, 265, 268). 
Accessibility to and complication of guidelines can be considered barriers, especially 
for general physicians and professionals (191, 195, 265). Goeman et al. found that 
GPs’ concerns to achieve good levels of asthma care were not consistent with some 
aspects of the guidelines (165). 
The majority of respondents to our survey were non-Saudi. The differences in culture 
and language between physicians and patients is yet another barrier that may affect 
the quality of the relationship (201). 
5.6.7 Conclusion  
Although most physicians reported having access to guidelines, poor adherence 
among PHCC physicians was reported at least with several guideline components. 
There was a failure on the part of medical practitioners to provide essential asthma 
education, especially to mild asthma patients. Respondents were less likely to 
provide information about AAPs and PFMs to this group, indicating non-compliance 
with guideline recommendations to at least develop AAPs and recommend home 
PFMs. As far as establishing an equal partnership with their patients, physicians were 
unlikely to involve their patients or families in decisions about their treatment. The 
doctors in this study were likely to recommend controllers, which fall below the 
optimal prescription of corticosteroids. Inappropriate treatment choices were 
observed in the responses to the vignettes. Further, there were variations in practices 
between the two regions. Gender appears to be influential in some responses to 
guideline recommendations. In general, current practices fell short of adherence with 
the guidelines. An education program would improve physicians’ practices and 
increase compliance.  
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5.6.8  Recommendations 
The barriers affecting physicians’ practices and their adherence to management 
guidelines in Saudi Arabia should provide useful clues to where interventions will be 
most useful. Intervention programs can improve physicians’ understanding and 
change their behaviours, encouraging them to implement guideline recommendations 
(163, 165, 184, 187, 190, 193, 268). They go beyond medical issues, addressing non-
medical factors such as communication skills, which can produce a stronger 
partnership between patients and their health providers (165, 166, 187, 189). Cabana 
et al. state that in ten regions of the United States, a change in physicians’ behaviours 
and an improvement in patient outcomes in primary care resulted when physicians 
attended continuing medical education programs provided by their local peers (196). 
Continuing medical education was reported as one of the highest concerns by 49 
Australian GPs from metropolitan and rural sites, who considered it would help 
improve asthma care even though they recognized lack of time and access as 
limitation factors (165). 
It is recommended that education programs be developed to improve and update 
health care providers’ knowledge and behaviours. Workshops and seminars are 
preferable, in order to improve physicians’ self-efficacy by encouraging them to 
improve their communication approach, which will in turn assist them in developing 
their use of AAP and PFM with their patients. Specialist physicians are more likely 
to adhere to guideline components.  
It is also recommended that specialist asthma clinics be established in PHCCs, with 
appropriate facilities, equipment and education resources, and adequate staffing. As 
lack of time and shortage of staff lead to overload, they have a negative effect on 
physicians’ practices. Training educators to inform patients about the disease would 
be useful.  
Pharmacy staff should include educating patients and following up as part of their 
role, and develop educational materials and provide seminars, workshops, and group 
meetings to other professionals regarding optimal asthma management. 
Lastly, it is important to improve communication between healthcare professionals 
and their patients and families. 
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5.6.9 Limitations of physicians’ phase  
There are some limitations to this study that must be reported. Firstly, this study was 
reliant on self-reporting and as such may not reflect the physicians’ actual behaviour 
or practices. To avoid bias and limit this effect, and to gain accurate practice insight, 
the following actions were taken: 
 In the education section, usual practice regarding some essential aspects of 
asthma treatment was solicited across all three severity classifications to gain 
accurate and specific responses rather than a general catch-all reply. 
 Vignettes were used to elicit practical responses rather than knowledge; 
response options were unified across all vignettes to avoid any indication of 
which might be the ‘right’ answer.  
 Respondents were given the option to add any actions they felt had not been 
included in the options. 
It is believed that the surveys provide an accurate view of current practice, as 
physicians recorded even negative responses. Our finding is consistent with others 
studies’ findings in most aspects such as education (AAP, PFM) and variations in 
treatment (38, 187, 259, 261). 
Secondly, as only physicians from two regions were surveyed, generalizing the result 
across the other 11 regions in KSA may not be appropriate. However, these two 
regions reflect most of regional characteristics of the country, including urban, 
suburban, and rural areas, and a wide range of geographic and climactic conditions, 
heavy and light areas of population, and variations in customs.  
Thirdly, there was a lack of specialized asthma clinics in the PHCCs when the study 
was conducted, as is reflected in the shortage of specialist physicians in the research; 
only one respondent identified him/ herself as a pulmonologist. The shortage was 
also reflected in physicians’ lack of time and workload pressure, which resulted in 
responses generally being delayed, although overall the volume of responses is 
considered to be good.  
Fourthly, the shortage of female respondents may have been due to organizational 
systems, as females’ clinics are separate from males’ clinics, which creates contact 
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barriers: the researcher, being male, was blocked from access to female clinics and 




Chapter 6   
Phase 3: Barriers to the Optimal use of Inhaled 
Corticosteroids and to Patient Compliance – 
 Results and Discussion  
6.1 Administration of Survey 
6.1.1 Survey response 
A total of 230 questionnaires were administered to primary health care centres in 
Riyadh, KSA; 205 (89.1%) were returned. Of these, 28 (13.7%) were excluded 
because of the age of the respondent (under 5 or over 18) or because they were 
incomplete. Of the 177 eligible responses, 90 were from males and 87 from females. 
Table 6.1 Survey response 
Riyadh primary health cares in KSA 
Questionnaires administered 230 
Responses  205 (89.1%) 
Usable responses Male 90 (50.8%) 
Female 87 (49.2%) 




6.1.2 Person completing the survey 
Patients were asked to complete the survey by themselves, but if they could not, their 
carer could assist them.  
 
Figure 6.1 Persons completing the survey 
 
As Figure 6.1 illustrates, more than half (52%) of the questionnaires were completed 
by the patient. A significant difference was reported between genders. Male patients 
were more likely to prefer to complete their survey by themselves than were females: 
55 (61.1 %) male patients, compared with 37 (42.5%) females. Another 8 (8.9%) 
male and 18 (20.7%) female respondents had help from their parents (p=0.021).  
A significant difference was found among different age groups. Seventy-three 
respondents (86.9%)of the age group 15 to 18 years old completed their survey by 
themselves compared with 4 (4.8%) who completed the survey with their parents. In 
contrast, 34 (68%) of the returned surveys in the age group ‘over 5 but under 10’ 











Person Completing the Questionnaire  
Patient Parent/carers Patient with parent/carer
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6.1.3 Patients’ ages 
 
Figure 6.2 Patients’ ages 
 
Figure 6.2 illustrates that approximately half (47.5%) the participants were in the age 
group from 15 to 18 years; of these 56% were male. There was no significant 
difference based on gender.  
6.1.4 Patients’ education level  
Patients were asked about their education level. 
Table 6.2 Patients’ education level 







N % N % N % 
Primary school or less 24 13.6 41 23.2 65 36.7 
0.046 Secondary school 31 17.5 21 11.9 52 29.4 
High school  
27 19.8 25 14.1 60 33.9 
University level* 8 4.5 6 3.4 14 7.9  
Just enrolled  
 
The data in Table 6.2 show that most of the patients (36.7%) had a primary school or 
less level of education. Males were more educated than females. Twenty-four 
(13.6%) and 35 (19.8%) of the male respondents compared with 41 (23.2%) and 25 
(14.1%) of the female group had primary school or less and high school respectively 
(p=0.046).  
 11.30   16.90  
28.2 
 13.00   11.30  






















5 to less than 10 years 10 to less than 15 yr 15 years to less than 18.
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6.1.5 Parents’ education level 
Respondents were asked about their parents’ education level. 
 
Figure 6.3 Parents’ education level 
 
Figure 6.3 illustrates that a patient’s father was likely to have a higher level of 
education than the mother. A large proportion of mothers were primary school 
educated or less (35.6% females vs. 21.8% males), and fathers were more likely to 
have a university degree (31.0% males vs. 21.3% females, p=0.000).  
6.1.6 Monthly household income and health insurance 
Respondents were asked about their monthly household income and if they had 



















Table 6.3 Household’s monthly income and health insurance 
 Response  Male Female Total 
N % N % N % 
Monthly household income 
n=177 
Less than 5000 SR  42 23.7 38 21.5 80 45.2 
5001- 10000 SR 32 18.1 22 12.4 54 30.5 
10001- 15000 SR 10 5.6 23 13.0 33 18.6 
15001-20000 SR 6 3.4 4 2.3 10 5.6 
More than 20000 SR 0 0.0 0 0.0 0 0.0 
Have health insurance 
n=177 
Yes 23 13.0 15 8.5 38 21.5 
No 67 37.9 72 40.7 139 78.5 
 
Table 6.3 shows that in more than 45% of cases the patients’ monthly household 
income was less than 5000 SR (Au $1450); only 21% of respondents had health 
insurance. There was no significant difference regarding gender.  
6.1.7 Severity of disease 
Patients were asked to classify their asthma severity from very mild to severe, and to 




Table 6.4 Self-reported severity of disease  
Patients’ self-reported 
symptoms 
Responses  Male Female Total 












severity classified  
n=177 
Very Mild 5 2.8 7 4.0 12 6.8 
Mild 14 7.9 19 10.7 33 18.6 
Moderate 51 28.8 42 23.7 93 52.5 






















Difficulty Breathing)  
n=177 
Once per month or less 35 19.8 41 23.2 76 42.9 
Once per week  30 16.9 28 15.8 58 32.8 
Twice per week  15 8.5 11 6.2 26 14.7 
Daily 10 5.6 7 4.0 17 9.6 
Awoken at night  
n=175 
Not at all 23 13.1 28 16.0 51 29.1 
Less than once a week 30 17.1 35 20.0 65 37.1 
Once or twice a week 23 13.1 15 8.6 38 21.7 
Three or more times a 
week 
13 7.4 8 4.6 21 12.0 
missed school or 




Once per month or less 42 24.1 51 29.3 93 53.4 
Once per week 30 17.2 22 12.6 52 29.9 
Twice per week 11 6.3 7 4.0 18 10.3 
More than twice per week 6 3.4 5 2.9 11 6.3 
 
From Table 4 it can be seen that the majority of respondents (74.5%) of both genders 
classified their asthma as moderately severe or severe, and 101 (57.1%) reported they 
experienced asthma symptoms at least once per week. A large proportion of patients 
reported being woken by their asthma symptoms at more than once a week (33.7%), 
having a cough, wheeze or difficulty breathing (57.1%), or having missed school or 
been unable to do normal activities (46.5%) in the past four weeks. A statistically 
significant difference between genders was not found.  
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6.1.8 Inhaled corticosteroids 
Respondents were asked if they use inhaled corticosteroids (ICS). 
 
Figure 6.4 Respondents using inhaled corticosteroids 
 
Figure 4 illustrates that according to patients’ self-reporting, 118 (66.7%) used ICSs 
while 33.3% reported they did not or were unsure. There were no significant 
differences based on gender or age group, but females (34.5%) and those in the age 
group 10 to less than 15 (76.7%) reported using ICSs more than males from the same 
group and other age groups.  
6.1.9 Patients’ adherence to ICS use 
Respondents were asked about their level of compliance with daily ICS use. 
 
Figure 6.5 Patients’ adherence to ICS use 
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Figure 5 illustrates low levels of adherence reported by both genders. Only 30.5% 
from both genders used ICSs daily while the majority of the sample (69.5%) used 
them intermittently. There were no significant differences in the use of ICS 
according to gender and age, although males (33.3%) were marginally more 
compliant with ICS use than females (27.9%).  
6.1.10 Asthma self-management skills 
Respondents were asked if they had an Asthma Action Plan (AAP) and used a peak 
flow meter (PFM). 
Table 6.5 Asthma self-management skills  
Asthma management skill  Responses  Male Female Total 
N % N % N % 
Asthma Action Plan (AAP) 
n=177 
Unsure 8 4.5 8 4.5 16 9.0 
No 53 29.9 52 29.4 105 59.3 
Yes 29 16.4 27 15.3 56 31.7 
Peak Flow Meter (PFM) 
n=175 
Unsure 0 00 0 00 0 00 
No 78 44.1 71 40.1 149 84.2 
Yes 12 6.8 16 9.0 28 15.8 
 
The data presented in Table 5 illustrates that the majority of respondents did not have 
an AAP (68.3%), nor did they use a PFM (84.2%). No significant differences were 
identified across gender or age. 
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6.1.11 Education issues  
Respondents were asked whether they believed their medicines were useful in 
controlling asthma, that their doctor involved them in decision-making and that they 
had adequate access to information about asthma. Their responses are shown in 
Figure 6.6. 
 
Figure 6.6 Education issues 
 
There were no significant differences across gender and age; 38.4% and 44.1% of 
respondents believed their medication was unhelpful for controlling their disease and 
felt that their doctor did not involve them in decision-making. Fewer than 40% of 
respondents felt they had adequate access to asthma information.  
6.1.12 Factors in asthma management  
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Table 6.6 Factors in asthma management 











My medications have side effects that I really don’t like.  .65 .02 -.03 -.20 .03 
It’s hard for me to stay organized enough to keep track of medications or other things related 
to my illness 
.62 -.06 -.05 -.15 .25 
My treatment program causes changes to my body that I don’t like. .58 -.04 .09 .2 -.17 
It’s hard for me to plan things out carefully, so sometimes I don’t get around to following my 
treatment program.  
.52 -.03 -.05 -.09 .20 
I have difficulty taking my medication when I am not at home .52 .05 .21 .02 -.09 
Following my treatment program causes me physical pain or discomfort .46 .31 .05 .09 .04 
The doctors do a good job of explaining things to me. -.15 .72 .11 .01 -.10 
I don’t always trust the doctors and nurses.  .07 .62 .15 -.10 .14 
My doctors are friendly and easy to talk to. -.05 .55 -.12 .32 .10 
I have difficulty understanding the information the doctor tells me about my medications .28 .53 -.05 .18 .01 
The doctors don’t seem to understand how much my treatment program gets in the way of 
important things in my life.  
.12 .50 .18 -.06 .17 
My family gives me a lot of support to help me follow my treatment program. -.18 .49 -.21 .12 .09 
It feels like the doctors are too busy or rushed to talk to me about my illness and my 
treatment.  
.30 .42 .23 -.08 .11 
Sometimes I can’t remember everything I’m supposed to do about my illness.  .10 .07 .65 -.12 -.07 
When there are changes to my treatment program I sometimes get confused.  .20 .04 .64 .15 -.14 
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I try to forget that I have an illness -.27 -.08 .56 .10 .32 
I don’t want my friends to know about my illness -.11 -.05 .54 .21 .29 
When I feel nervous or worried, it’s hard to follow my treatment program.  .08 .18 .46 -.18 .03 
My regimen takes a lot of time and work.  .34 .04 .41 -.08 -.12 
I don’t mind if my friends bring up my illness or ask me questions about it.  -.31 .03 .20 .65 .07 
My illness is easier to take care of than a lot of other illnesses. -.00 -.11 .02 .63 -.01 
I believe that if I take care of myself and follow my treatment program, my health will 
improve.  
.09 .23 -.31 .58 .06 
I understand what I am supposed to do to care for my illness -.06 .25 -.06 .55 .13 
None of my friends have to deal with this, why do I?   .06 .00 .20 .72 
Nothing bad would happen to me if I didn’t follow my treatment program. -.07 .18 -.01 -.28 .65 
The doctors treat me like a little kid who can’t take care of her/ himself.  .11 .04 .06 .12 .48 




Table 6.6 shows the factor analysis loaded for IMS. In this study, the responses were 
grouped into either ‘strongly agree and agree’ or ‘strongly disagree and disagree’, 
after which the factor analysis for IMS was performed. The IMS items were 
subjected to principle components analysis (PCA) with varimax rotation using SPSS 
Version 17. The Kaiser-Meyer-Olkin value was .74, and, according to Bartlett’s Test 
of Sphericity, reached statistical significance; this supports the factorability of the 
correlation matrix. Based on the Scree plot test and eigenvalues greater than one, it 
was found that four to eight factors could explain the IMS. The loading for each 
barrier was >0.41. Five factors were considered by the researcher to be suitable for 
the current study, and accounted for 54.3% of the total variance in the responses. The 
five factors were labelled as follows: medication issues, consisting of 6 barriers 
(alpha=0.74); doctor and other relationships, with 7 barriers (alpha=0.76); adherence 
influences, with 6 barriers (alpha=0.64); self-efficacy, with 4 barriers (alpha=0.60); 
and negativity, with 4 barriers (alpha=0.55). 
6.1.13 Patients’/ carers’ responses: level of agreement 





Table 6.7 Patients’/ carers’ responses to IMS barriers 
Barriers  Count % 
My regimen takes a lot of time and work.  79 45.9% 
I have difficulty taking my medication when I am not at home 77 44.8% 
When I feel nervous or worried, it’s hard to follow my treatment program.  73 42.4% 
My medications have side effects that I really don’t like.  72 41.9% 
When there are changes to my treatment program I sometimes get confused.  69 40.1% 
It’s hard for me to stay organized enough to keep track of medications or other 
things related to my illness 
69 40.1% 
I try to forget that I have an illness 66 38.4% 
I hate the idea of giving up the things the doctors say I have to give up.  62 36.0% 
Sometimes I can’t remember everything I’m supposed to do about my illness.  56 32.6% 
I don’t mind if my friends bring up my illness or ask me questions about it.  54 31.4% 
I don’t want my friends to know about my illness. 53 30.8% 
My illness is easier to take care of than a lot of other illnesses. 48 27.9% 
My family doesn’t understand what it’s like to live with my illness.  48 27.9% 
I refuse to give up time with friends to take care of my illness.  44 25.6% 
It’s hard for me to plan things out carefully, so sometimes I don’t get around to 
following my treatment program.  
42 24.4% 
My treatment program causes changes to my body that I don’t like. 42 24.4% 
Following my treatment program causes me physical pain or discomfort. 40 23.3% 
Nothing bad would happen to me if I didn’t follow my treatment program. 40 23.3% 
It feels like the doctors are too busy or rushed to talk to me about my illness and 
my treatment.  
39 22.7% 
The doctors treat me like a little kid who can’t take care of her/ himself.  35 20.3% 
I have difficulty understanding the information the doctor tells me about my 
medications. 
35 20.3% 
My doctors are friendly and easy to talk to. 34 19.8% 
My family gives me a lot of support to help me follow my treatment program. 34 19.8% 
The doctors do a good job of explaining things to me. 33 19.2% 
The doctors don’t seem to understand how much my treatment program gets in the 
way of important things in my life.  
31 18.0% 
I believe that if I take care of myself and follow my treatment program, my health 
will improve.  
29 16.9% 
I understand what I am supposed to do to care for my illness. 29 16.9% 
None of my friends have to deal with this, why do I?  26 15.1% 




Table 6.7 shows that more than 40% of patients or their carers reported strongly 
agreeing or agreeing about being affected by the following barriers: My regimen 
takes a lot of time and work (45.9%); I have difficulty taking my medication when I 
am not at home (44.8%); When I feel nervous or worried, it’s hard to follow my 
treatment program (42.4%); My medications have side effects that I really don’t like 
(41.9%); When there are changes to my treatment program I sometimes get confused 
(40.1%); and It’s hard for me to stay organized enough to keep track of medications 
or other things related to my illness (40.1%). These barriers are related to issues with 
medication and compliance. The smallest barrier was ‘I don’t always trust the 
doctors and nurses’, reported by 14.0% of patients/ carers.  
6.1.14 Number of IMS barriers affecting patients. 
 
Figure 6.7 Number of IMS barriers affecting patients. 
 
Figure 6.7 illustrates that only 5.6% of participants reported one barrier, while more 
than two thirds or 72.9% reported being affected by five or more. The maximum 
number of barriers reported was 19. 
6.1.14.1 A summary of the relationship between IMS barriers and the patients’/ 
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Table 6.8 Relationship between IMS barriers and patients’/ families’ characteristics and disease severity 












PATIENT/ FAMILY CHARACTERISTICS  
 Gender 0.76 0.93 0.63 0.26 0.68 0.90 
 Age group 0.76 0.89 0.44 0.63 0.48 0.66 
 Health insurance 0.34 0.09 0.28 0.53 0.02* 0.30 
 Household’s monthly income 0.85 0.40 0.91 0.93 0.31 0.33 
 Patient’s education level 0.87 0.62 0.68 0.57 0.22 0.92 
 Parents’ education level 0.64 0.59 0.32 0.80 0.15 0.68 
DISEASE SEVERITY  
Asthma severity self-report 0.55 0,04* 0.49 0.43 0.49 0.47 
Asthma symptoms 0.68 0.003** 0.52 0.39 0.77 0.61 
Wake at night 0.30 0.03* 0.76 0.001*** 0.59 0.66 
Miss school or daily activity 0.10 0.001*** 0.65 0.32 0.96 0.57 
* P < .05. ** P≤ .01. *** P ≤ .001 
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Table 6. 8 shows the association between both total barriers and subclass factors for 
both patients’/ families’ characteristics and disease severity. There were no 
associations between patients’ gender, age, household income, or parents’ education 
level and the number of barriers or factors reported; however, significant associations 
were found between the self-efficacy factor and the possession of health insurance: 
patients who had health insurance reported higher mean scores (t (175) =2.269, p < 
0.05). Patients who had severe asthma or asthma symptoms, who woke at night and 
missed school or daily activities, were more likely to be affected by the medication 
factor and reported higher mean scores: f (3,173) = 2.78, p <0.05, f (3,173) = 4.93, p 
<0.05, f (3,171) = 3.14, p <0.05 and f (3,170) = 5.76, p <0.05, respectively. A 
significant association between waking at night and the adherence influences factor 
was found: patients who reported waking three times or more at night were likely to 
be affected by this factor: f (3,171) = 5.74, p <0.05. (For more detail see Appendix 
G).  
6.1.14.2 A summary of the relationship between IMS barriers and both asthma 
management skill and beliefs, and ICS adherence 
Table 6.9 Relationship between IMS barriers and both asthma management skills and 
beliefs, and compliance with ICS usage  






















Possession of AAP 0.93 0. 8 0.02* 0.36 0.03* 0.69 
Possession of PFM 0.07 0.69 0.19 0.22 0.12 0.16 
Adherence to PFM use 0.12 0.971 0.24 0.20 0.65 0.01** 
Patient’s/ carer’s beliefs 
and behaviours 
      
Medications useful 0.003** 0.000*** 0.005** 0.16 0.02* 0.01** 
Decision-making 
involvement 
0.015* 0.02* 0.000*** 0.15 0.60 0.03* 
Adequate information 0.782 0.01* 0.002** 0.40 0.58 0.02* 
ICS USE AND ADHERENCE 
Inhaled ICS 0.04* 0.04* 0.02* 0.87 0.59 0.83 
Adherence to ICS use 0.01** 0.001*** 0.02* 0.39 0.23 0.46 
* P < .05. ** P≤ .01. *** P ≤ .001 
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Table 6.9 shows no significant correlations between the number of barriers 
encountered and either possession of AAP and PFM or believing that the patient has 
adequate information; however, there are significant associations between patients’/ 
carer’s beliefs that their medications are useful and they are involved in making 
decisions about their health care, and both use of and adherence to ICS. Those who 
reported believing that medications were not useful and that they were not involved 
in decision-making were more likely to be affected by this barrier, and reported 
higher mean scores (t (175) =2.99, p < 0.05) and (t (175) =2.46, p < 0.05 
respectively). These barriers were also reported to be affecting patients who did not 
use, or did not know if they used, inhaled ICS and did not adhere to ICS daily use (t 
(175) =2.09, p < 0.05) and (t (116) =2.57, p < 0.05) respectively.  
Respondents who believed medications were not useful had higher mean scores with 
four factors: belief in the efficacy of medication and other medication issues (t (175) 
=4.01; doctor and other relationships, p < 0.05), (t (175) =2.85; self-efficacy, p < 
0.05), (t (175) =2.34; and negativity, p < 0.05) and (t (175) =2.47, p < 0.05). These 
associations are significant. There were also significant associations among those 
who believed they were not involved in decision-making and their evaluation of 
other issues, giving high mean scores to medication issues (t (175) =2.45, p < 0.05), 
doctor and other relationships (t (175) =2.23, p < 0.05), and negativity factors (t 
(175) =2.15, p < 0.05). Those who believed they had not been given adequate 
information also reported high mean scores for these factors: (t (175) =2.55, p < 
0.05), (t (175) =3.08, p < 0.05), and (t (175) =2.138, p < 0.05) respectively. There 
were also significant associations between both medication issues and doctor and 
other relationship factors, and inhaled ICS: patients who used ICS produced higher 
mean scores for medication issues factors (t (175) =2.05, p < 0.05) and lower mean 
scores for doctor and other relationships factors (t (175) =2.37, p < 0.05). Patients 
who reported irregular ICS use produced higher mean scores for the same factors (t 
(116) =3.39, p < 0.05) and (t (116) =2.42, p < 0.05) respectively. A significant 
association appears between doctor and other relationships and self-efficacy, and 
possession of AAP. Patients who did not have AAPs reported higher mean scores (t 
(175) =2.30, p < 0.05) than those who did. The self-efficacy factor also shows 
significant correlation with possession of an AAP: patients who had AAPs reported 
higher mean scores (t (175) =2.17, p < 0.05) than those who did not. A significant 
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relationship was reported between the negativity factor and adherence to PFM use. 
Patients who reported adherence also provided higher mean scores (t (26) =2.74, p < 
0.05).  
6.1.15 ICS Adherence factors 
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Table 6.10 ICS Adherence Factors 




concerns and fears 





Lack of reliable information sources  .79 .14 .13 .09 
Difficulty reading and understanding medication instruction  .68 .17 .28 .08 
Medication instruction language level .67 .06 .34 -.24 
Lack of understanding of the role of medication .63 .25 -.10 .37 
Lack of understanding the correct use of inhaler device  .62 .20 .15 .36 
Belief that medication is ineffective .61 .15 .27 .08 
Fear of side effects  .13 .87 .07 -.01 
Worry of addiction/ dependence .09 .81 .04 .03 
Forgetfulness .35 .60 .12 .16 
Different number of medication types (control and reliever medication) .17 .53 .41 .14 
Use of traditional therapy .08 .08 .75 -.10 
My relatives’ and friends’ awareness (concern) regarding my illness and 
medication 
.18 .11 .63 .10 
Belief that asthma is not a serious illness that need continued treatment  .24 -.05 .60 .15 
Embarrassment or discomfort using the medication.  .36 .28 .45 .24 
Cost of medication and/ or health services -.03 .04 .08 .76 
The inconvenience of scheduled visiting times (appointments) and waiting for 
refills  
.41 -.13 .34 .57 
Absence of warning signs (symptoms) means no medication is needed .34 .33 .09 .54 
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Table 6.10 shows the factor analysis loaded for ICS adherence barriers. The ICS 
items were subjected to principle components analysis (PCA) with varimax rotation 
using SPSS Version 17. The Kaiser-Meyer-Olkin value was .85, and according to 
Bartlett’s Test of Sphericity reached statistical significance; this supports the 
factorability of the correlation matrix. Based on the Scree plot test and eigenvalues 
greater than one, it was found that four to seven factors explained the ICS survey. 
The loading for each barrier was >0.41. Four factors were considered by the 
researcher to be suitable for the current study, accounting for 56.1% of the total 
variation in responses: Health and medication literacy, consisting of 6 barriers 
(alpha=0.82); Patient/ family concerns and fears, with 4 barriers (alpha=0.76); Peer 
influence and personal beliefs, with 4 barriers (alpha=0.67); and Treatment cost, 
convenience and need, with 3 barriers (alpha=0.57). 
6.1.15.1 Patients/ carers’ response agreement 
Responses to ICS barriers are sequenced in the tables by strength of agreement.  
Table 6.11 Responses to ICS barriers 
Barrier Count N % 
Worry of addiction/ dependence 102 59.3% 
Fear of side effects  99 57.6% 
Absence of warning signs (symptoms) means no medication is needed 97 56.4% 
Cost of medication and/ or health services 92 53.5% 
Forgetfulness 88 51.2% 
Lack of understanding of the role of medication 84 48.8% 
Different type of inhaler device 84 48.8% 
Lack of understanding of the correct use of inhaler device  75 43.6% 
Lack of reliable information sources  72 41.9% 
Inconvenience of scheduled visit times (appointments) and waiting for refills  72 41.9% 
Different medication types (control and reliever medication) 71 41.3% 
Embarrassment discomfort using the medication.  70 40.7% 
Medication instruction language level 69 40.1% 
Difficulty of reading and understanding medication instructions  60 34.9% 
Belief that asthma is not a serious illness that need continues treatment  59 34.3% 
Belief that medication is ineffective 58 33.7% 
Relatives’ and friends’ awareness of (concern) the illness and medication 40 23.3% 
Use of traditional therapy 36 20.9% 
 
185 
Table 6. 11 shows that more than half (51%) the patients/ carers reported being 
affected or strongly affected by the following factors: worry about addiction/ 
dependence, fear of side effects, absence of warning signs (symptoms), cost of 
medication and/ or health services, and forgetfulness. These barriers are related to the 
patient’s/ family’s concerns and fears regarding medication and treatment costs, and 
to convenience factors. The barriers least reported were nominated by 21.0% of 
patients/ carers.  
6.1.15.2 Number of ICS barriers affecting patients. 
 
Figure 6.8 Number of ICS barriers affecting patients. 
 
Figure 6.8 illustrates that more than two thirds (72.9%) of respondents reported being 
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6.1.15.3 A summary of the relationship between ICS barriers and both patient/ 
family characteristics and severity of disease  
Table 6.12 Relationship between ICS barriers and both patients/ family characteristic 
and disease severity  
 
 































 Gender 0.19 0.97 0.25 0.51 0.77 
 Age group 0.18 0.29 0.98 0,91 0.08 
 Health insurance 0.25 0.66 0.06 0.94 0.16 
 Household income 0.60 0.57 0.81 0.49 0.67 
 Patient’s education level 0.08 0.03* 0.24 0.40 0.78 
 Parents’ education level 0.22 0.24 0.04* 0.03* 0.80 
DISEASE SEVERITY  
 Asthma severity self-report 0.80 0.42 0.90 0.63 0.40 
 Asthma symptoms 0.70 0.18 0.43 0.91 0.96 
 Wake at night 0.61 0.88 0.48 0.17 0.56 
 Miss school or daily activity 0.55 0.04* 0.32 0.54 0.04* 
P < .05. ** P≤ .01. *** P ≤ .001 
 
Table 6.12 shows the associations between total ICS barrier scores and subclass 
factors with both patients’ family characteristics and severity of disease. There were 
no significant correlations between total barriers and patient/ family characteristics 
and disease severity, nor between patients’ gender, age group, possession of health 
insurance, household income, severity of asthma, asthma symptoms, waking at night, 
their or their parents’ education level and reported subclass factors. However, an 
association between the health and medication literacy factor and patients’ education 
level can be discerned. Patients at the primary school or less level were more likely 
to be affected, and to return a higher mean score, than respondents with higher 
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education levels: f (2,174) = 3.509, p < .05. Significants association is also evident 
between parents’ education levels and two factors of patient/ family concerns and 
fears, and peer influence and personal beliefs. Parents with secondary school 
qualifications were more likely to return high mean scores for these factors than 
others: f (2,171) = 3.174, p < .05, and f (2,171) = 3.433, p < .05 respectively. 
Significant associations between health and medication literacy, treatment cost, 
convenience factors, and missing school or daily activities are revealed. Patients who 
reported missing school or daily activity more than twice a week were more likely to 
be affected by the factors of health, medication literacy, treatment cost, and 
convenience, and to return higher mean scores: f (3,170) = 2.696, p < .05 and , f 
(3,170) = 2.725, p < .05 respectively (for more details see Appendix G). 
6.1.15.4 A summary of the relationship between ICS barriers and both asthma 
management skills and beliefs and ICS adherence 
Table 6.13 Relationship between ICS barriers and both asthma management skills and 
beliefs and ICS adherence  
   
      





























 Possession of AAP 0.25 0.021* 0.12 0.29 0.03* 
 Possession of PFM 0.92 0.31 0.18 0.82 0.51 





Medications useful 0.015* 0.32 0.007** 0.003** 0.18 
Decision-making involvement 0.42 0.29 0.036* 0.033* 0.18 
Adequate information 0.004** 0.094 0.038* 0.040* 0.036* 
ICS USE AND 
ADHERENCE 
 
Inhaled ICS 0.98 0.69 0.19 0.57 0.28 
Adherence to ICS use 0.89 0.038* 0.17 0.78 0.30 





Table 6.13 shows the relationship between ICS barriers and both asthma 
management skill, beliefs and ICS adherence. There were significant associations 
between total barriers and respondents’ beliefs about both the usefulness of 
medications and having adequate information. Those who reported believing that 
medications were not useful and they did not have adequate information returned 
higher mean scores than who did not: t (175) = 2.467, p < 0.05, t (175) = 2.913, p < 
0.05 respectively. Significant associations are evident between the factors of both 
health and medication literacy and treatment cost and convenience, and the 
possession of an AAP, with patients who did not have an AAP returning higher mean 
scores: t (175) = 2.347, p < 0.05 and t (175) = 2.330, p < 0.05 respectively. 
Significant associations were also found between the factor of patient/ family 
concerns and fears, and the responses regarding belief in the usefulness of the 
medication, being involved in making decisions, and having adequate information. 
Those who reported believing that medications were not useful, who felt they were 
not involved in decision-making and had inadequate information, were more likely to 
be affected by this factor, as indicated by the higher mean scores: t (175) = 2.785, p < 
0.05, t (175) = 2.115, p < 0.05 and t (175) = 2.095, p < 0.05 respectively. There were 
also significant associations between the factor of peer influence and personal beliefs 
and these same issues, which returned scores of t (175) = 2.988, p < 0.05, t (175) = -
2.157, p < 0.05 and t (175) = 2.087, p < 0.05 respectively. Another significant 
association was found between the responses regarding adequate information and the 
factor of treatment cost and convenience, with those who believed they did not have 
adequate information returning higher mean scores than others: (t (175) = 2.119, p < 
0.05). There was a further significant association between the factor of health and 
medication literacy and adherence to ICS. Patients with irregular ICS use returned 
lower mean scores for this factor: t (116) = 2.030, p < 0.05 (for more detail see 
Appendix G). 
6.2 Discussion  
Non-adherence to asthma management regimens became the most common factor 
influencing optimal management outcomes. The low adherence to asthma 
management amongst children and adolescents and/ or their families who attended 
primary health care centres (PHCC) in two regions of Saudi Arabia was reported in 
Phase One of this study, a finding consistent with those of several other studies 
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worldwide (74, 91, 183, 209, 300, 301). A number of studies have identified barriers 
that may influence adherence (204, 206-210, 218, 301). Some relate to the disease 
and its treatment, some to health care providers and some to patients and their 
families (34, 218). Barriers to compliance differ from one patient to another and 
across practice sites. Bender et al. found that there were differences both in the 
barriers reported and the emphasis placed on them, between adults and children (and/ 
or their parents) and between income groups. Concern about medication side effects 
was reported among all groups and was one of the most common barriers (204). 
The current phase of this study was conducted to identify the barriers affecting 
asthma management amongst child and adolescent asthma patients and/ or their 
families in Riyadh, KSA. In particular, the barriers affecting usage of and adherence 
to ICS was examined, and correlations between these barriers and participants’ 
characteristics, severity of disease, possession of an AAP and PFM, beliefs and 
behaviours were evaluated. One hundred and seventy seven respondents took part in 
the survey, 50.8% males, nearly half aged 15–18 years, and 36.7% having completed 
primary education or less. Male patients and older age groups were more likely to 
complete the survey themselves. Patients’ fathers were likely to a have higher level 
of education than their mothers. Most participants reported a monthly income of less 
than 5000 SR (Au $1450). One hundred and thirty two (74.5%) participants 
classified their asthma as moderate or severe. A large proportion reported having a 
cough, wheeze or breathing difficulty (57.1 %), 33.7% reported being woken by their 
asthma symptoms, 46.5% had missed school or been unable to undertake normal 
daily activities at least once a week in the four weeks prior to the survey. 
Undertreatment and low adherence to regimens were observed. In this third phase, 
66.7% of participants reported using an ICS, but of these only 30.5% used it daily; 
these figures were 49.6% and 25.9% respectively in Phase One of this study among 
Riyadh patients. The majority of respondents did not have AAPs (59.3%) or PFMs 
(84.2%). The rate of possession of AAPs in Phase Three was reported as less than in 
Phase One for the same region. These anomalies support our suggestion that patients 
may be confused about verbal instructions and written AAPs.  
Around 40% of participants believed their medications were unhelpful and claimed 
their doctor did not involve them in making decisions about their treatment. Fewer 
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than 40% felt they had adequate access to asthma information. Chambers et al. found 
a relationship between patients’ beliefs about their health and the seriousness of their 
asthma, and their adherence to treatment (177). The current study’s findings are 
consistent with this.  
Patients may be affected by more than one barrier to compliance (93, 207, 208). In 
the current study, the IMS scale revealed a range of barriers affecting self-
management. Rhee et al. found 46% of participants reporting five or more barriers on 
the IMS scale (207). Our findings were consistent with this, with 73% of the sample 
reporting five or more barriers. McQuaid et al. found that older children were less 
likely to be compliant with medication regimens, but that adherence was not affected 
by gender, asthma severity or socioeconomic status (91). Logan et al. found a 
correlation between IMS total scores and age, with older adolescents reporting more 
barriers (206). This was not established in our study, which found no significant 
difference across age groups; results similar to ours were found by Rhee et al. (207). 
Male patients in Rhee et al.’s study returned higher mean scores in the total IMS 
barriers and with some factors; however, significant differences were found only 
with denial factors (207). In this study, with the exception of factor four (adherence 
influence), male participants returned higher mean scores than females, but there 
were no significant correlations between gender and either IMS total scores or 
factors: a finding consistent with Logan et al. and Rhee et al. (206, 207). It should be 
noted that both those studies and this one used the same instrument, although the age 
range differed. Negative significant correlations between both parents’ education, 
household income and IMS total scores were reported by Rhee et al. (207). 
Responses in this current study are not consistent with this finding: whilst 
respondents with high income and parents with high levels of education reported 
more barriers, there are no significant differences. This may be due to health care 
being provided free of charge in KSA at present, so that participants did not think 
about cost and it did not affect their responses. It may also be due to the uneven 
distribution of groups, as a large minority of participants had low incomes (45.2%) 
and the majority of parents had attended high school or higher (61.5%). Blais et al. 
found that socioeconomic status did not impact on adolescents’ adherence, but did 
have a small effect in younger children (213). 
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Logan et al. and Rhee et al. in their studies found significant correlations between 
severity and IMS scale scores (206, 207). In the current study, patients with severe 
asthma and those who suffered from asthma symptoms, such as being woken at night 
and missing school or normal activities, returned high IMS mean scores. However, 
there were no significant correlations observed between asthma symptoms and 
severity, and IMS total scores. On the other hand, there were significant correlations 
between both asthma symptoms and severity and the factor of medication issues. 
There were no significant correlations detected between IMS total mean scores and 
possession of both AAPs and PFMs, but significant correlations with participants’ 
beliefs, behaviours, and ICS use. As predicted, patients and their families who 
believed that the medicine(s) prescribed were useful for controlling asthma, and/ or 
who had been involved in making treatment decisions, were more likely to return 
lower mean scores. The same was found with patients who reported daily adherence 
with ICS use. Modi et al. found that there was a lack of knowledge among children 
and parents regarding their disease and its treatment. They did not observe any 
relationship between participants’ knowledge and their adherence, although they 
noted that their sample size was small (208). Our findings are not consistent with 
this, as effects of respondents’ knowledge, attitudes, behaviours, and self-efficacy on 
adherence was observed, in line with Rhee et al.’s findings (207). 
6.2.1 The five factors of the IMS scale  
6.2.1.1 IMS Factor 1: Medication issues  
This relates to patients’ and/ or their carers’ beliefs in, fears about, concerns with, 
confidence in, and perceptions of the treatment regimen, and their adherence to it. 
Adherence with medication use over a long time may not be easy. This may be due 
to misunderstanding the need and function of asthma medication –a common finding 
in several studies (175, 179, 212, 218). It may also be due to patients’ 
misconceptions and concerns about medication side effects. Boulet found that 43% 
of participants did not know the role of corticosteroid and 59% were worried about 
side effects; interestingly, 75% of the sample did not discuss their concerns with their 
health provider (179). It is not surprising that misconceptions, lack of confidence and 
fear of side effects lead to lack of adherence and poor management outcomes. The 
factor of medication issues has positive correlation with asthma severity and 
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symptoms. Patients who had severe asthma (p < 0.05), a high frequency of symptoms 
(p≤0.01), who woke at night (p < 0.05) and missed school or daily activities 
(p≤0.001) were more likely to be affected by this factor and return higher mean 
scores. This is supported by the negative correlation between this factor and 
respondents’ belief that their medication is useful in controlling the disease 
(p≤0.001), that they are involved in decision-making (p < 0.05), and that they have 
adequate information (p≤0.01). This factor has positive correlations with the 
responses concerning ICS use (p < 0.05), but a strong negative correlation with 
responses about daily use (p≤0.001). This may be because patients who use ICS and/ 
or their families are most concerned about the medication, which may affect 
adherence.  
6.2.1.2  IMS Factor 2: Doctor and other relationships  
The second factor relates to the barriers perceived by respondents to affect their 
relationship with their health care provider in areas such as communication, 
relationship, faith, ability of the patient to understand the provided information, 
patient motivation, and social support. Bender reported that patients’ motivation is 
one of the most common barriers to adherence to medical regimens (218); others 
have noted that the nature of the relationship between patients/ carers and health 
professionals, and the clearness of communications, affected adherence (34, 93, 132, 
208, 209, 218, 302, 303). Buston and Wood found that patients who failed to comply 
with their medication believed that their health provider’s awareness of their disease 
was limited (209). Lack of a good working relationship and poor communication, in 
addition to lack of social support, contributed to their having inadequate knowledge, 
insufficient confidence to undertake behaviour changes, and little motivation to 
adhere to self-management plans. It was also found that a relationship of trust 
between diabetes patients and physicians reduced costs related to the patients’ failure 
to adhere to medication routines (302). In the current study, this can be explained by 
the negative correlation between this factor and the possession of an AAP, belief in 
the value of the medication, participation in decision-making, and having adequate 
information. Patients with AAPs returned lower mean scores than those who did not; 
and those who used ICS on a regular, daily basis were less likely to report problems 
with their medical advisors. This finding may indicate that poor communication and 
lack of support affects ICS use and adherence. Cultural differences and language 
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may also influence the relationship, as trouble with communication between patients 
and their health care provider may affect asthma management outcomes (132). In this 
study, both the lack of a satisfactory relationship and poor communication were 
linked with problems about trust as well as with language and cultural differences 
between respondents and health professionals. Phase Two of this study showed that 
the majority of physicians were non-Saudi, with different languages and cultures.  
6.2.1.3  IMS Factor 3: Adherence influences,  
 Factor three relates to barriers that influence adherence to medication routines, 
whether intentional or unintentional cognitive barriers, such as memory failure, 
confusion, psychological issues, trying to forget, and stigmatization. Bender et al. 
found stigma to be the barrier most emphasized in child patients, who did not report 
forgetfulness; nor did their parents (204). A number of studies have reported 
forgetfulness as a common barrier (208, 209); Piette et.al. found that symptoms were 
likely to be twice as influential as costs on adherence (302).  
There was a significant correlation between adherence and participants’ responses to 
being woken at night by symptoms. Patients who reported waking at least once a 
week were more likely to be affected by adherence issues than those who did not: for 
unclear reasons, they returned higher mean scores than those who were woken once 
or more a week. This may be because patients with severe asthma are more educated 
than patients with mild symptoms, so that they feel more confident and succumb less 
to stress or worry.  
6.2.1.4  IMS Factor 4: Self-efficacy  
Factor four relates to perceptions of being in control, such as believing that asthma is 
not serious and understanding how to deal with it. If patients have appropriate 
knowledge, good care, and a comfortable relationship with their doctor, these may 
encourage behaviour changes and improve self-efficacy. This assertion is supported 
by the following results: this factor had a significant correlation with the possession 
of health insurance: patients who have private health insurance have more choices in 
their health care, such as access to private clinics. Possession of AAPs also seems to 
improve communication between patients and health professionals, and so may lead 
to behaviour changes and improved self-efficacy. In this study, patients who did not 
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have AAPs returned higher mean scores for this factor; it also had a negative 
correlation with patients’ beliefs that their medication was useful for controlling 
asthma.  
6.2.1.5 IMS Factor 5: Negativity  
The last factor relates to beliefs, behaviours and emotional barriers, such as finding 
one’s situation uncomfortable, showing unconcern about management outcomes, 
being dissatisfied with the health care provider’s attitude, and lacking motivation and 
support. The negativity factor had significant correlation with PFM adherence, 
indicating that patients who used PFMs were more affected by this factor. However, 
it had a negative correlation with patients’ beliefs about the degree of their 
involvement and the availability of suitable information about their asthma.  
Bender and Bender in their review found differences in the barriers reported and 
emphasized by adults and children (and/ or their parents), as well as by those in low 
income groups (204). 
In Phase One of this study, differences in responses appeared when controller or 
preventer expressions were used and when ‘ICS’ was used in the questions. In this 
phase, using IMS and ICS surveys, different responses were found, as were 
differences in the sequences of some barriers. The IMS survey, which evaluated 
asthma management in general, revealed that the five most common barriers, 
reported by at least 40% of participants (Table 6.7), were unpremeditated: 
psychological and social issues, and time pressures. The ICS survey revealed the five 
most common barriers, reported by at least 51% of participants (Table 6.11), were 
premeditated attitudes: worry, fears, and beliefs.  
While ICSs are considered the cornerstone of asthma treatment, patients’ use of them 
and adherence to daily use remains suboptimal. These medications may raise more 
argument than other medications: Modi et al. found that parents and their children 
with asthma documented more barriers to ICS use than they did to other medications 
(208). Farber et al. in their study of parents of children with asthma, which evaluated 
their understanding of the role of medications, found a significant level of 
misunderstanding: 23% of 571 parents misunderstood role of ICS, while the same 
was true for only 7% of 1432 of participants regarding quick reliever medication 
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(212). Barriers to adherence to ICS were estimated in the current study using the ICS 
scale. As mentioned previously, patients may be affected by more than one barrier, 
and in the current phase of the study, the ICS scale revealed that participants indeed 
reported a range of barriers affecting their adherence to ICS regimens: more than 
72% of participants identified five or more barriers. There were negative correlations 
between total ICS scale scores and beliefs about the usefulness of the medication and 
the adequacy of information about it. Patients and their families who believed they 
had access to adequate information and that the medicine(s) prescribed were useful 
on controlling their asthma returned lower mean scores than those who did not, or 
who were unsure. 
6.2.2 The four factors of the ICS scale 
The ICS scale in this study revealed four subclasses relating to patients’ and/ or their 
carers’ beliefs, knowledge, behaviour, concerns, attitudes, and self-efficacy regarding 
ICS use and adherence.  
6.2.2.1 ICS Factor 1: Health and medication literacy  
The first factor indicates the reliability of information, the understanding of 
instruction in medication, and the awareness of the role and use of inhaler devices, in 
addition to the value of medication, amongst patients and carers. It has been reported 
that not understanding the role of medication is one of the common barriers to ICS 
adherence (179, 212). Suboptimal use and inadequate technique in using the inhaler 
have been reported in many studies, even amongst patients who had been educated in 
its use (116, 120, 121, 124, 304). As previously mentioned, Farber et al. found nearly 
a quarter of parents whose children had persistent asthma misunderstood the function 
of their child’s medication, with only 24% of these parents reporting that their child 
complied with daily medication use; this compared with 64% of 442 parents who did 
understand the role of the medication (212). In this study, the effect of medication 
literacy on adherence to ICS can be observed in the significant negative correlation 
between this factor and the participants’ daily adherence to ICS use (p<0.05). 
Patients with primary school education level or less were more likely to be affected 
by this factor than patients with higher education levels. This factor also correlated 
with missing school or daily activities, indicating that this group and their carers 
lacked either knowledge or willingness, or had not been provided with good health 
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care. Boulet found that 75% of participants did not discuss their concerns about ICS 
with their health care providers. Good communication and relationships with health 
professionals, as well as education and follow-up, may reduce the effect of this 
factor, as can be seen in the negative correlation between it and the possession of an 
AAP. Patients who had AAPs returned lower mean scores for this factor (p<0.05).  
6.2.2.2 ICS Factor 2: Patient/ family concerns and fears  
The second factor relates to corticosteroid phobia, forgetfulness, and the number of 
medications prescribed. Several studies have reported that steroid phobia is the most 
common barrier behind the lack of adherence (34, 177, 179, 303, 305, 306). This 
affects not only the patient’s attitude, but also that of their family or carers. Mothers 
who believe or fear that corticosteroids have dangerous side effects are less likely to 
let their children use ICS and more likely to reduce the dose (215). Two recent 
studies have found that patients were more likely to be tolerant of a single inhaler for 
combination drug use (ICS and LABA) than of separate inhalers (129, 131): Janson 
et al. found that about half the patients who used two medications were adherent with 
only one of them (210), while Farber et al. found that misunderstanding the role of 
medication was higher amongst parents with low levels of education and whose child 
did not visit a specialist (212). In the current study, this factor had strong correlation 
with parents’ education level. Parents with secondary school level education were 
more likely to return higher mean scores with this factor. Forgetfulness has also been 
reported as an adherence barrier. Culture and social beliefs can play major role in the 
use of traditional therapy (93, 307).  
 It has been found that negative patient/ carer beliefs about medication affect 
adherence, even if it is believed that the medication is necessary for asthma treatment 
(34, 183, 300, 301, 308). Availability of adequate information, appropriate patient 
education, and improved patient/ carer–health care provider relationships may prove 
helpful in changing these beliefs and behaviours, contributing to a decrease in the 
effect of the fear factor. This is supported by the negative correlation seen between 
this factor and participants’ responses regarding the usefulness of medication, 




6.2.2.3 ICS Factor 3: Peer influence and personal beliefs  
The third factor relates to peer influence, misconceptions, unease with having a 
disease and/ or its management, believing asthma is not a serious disease, and the use 
of traditional therapy. Bender and Bender found that the belief that asthma is not 
serious is low amongst adult patients and absent among children and their parents 
(204). More important for the cohort in this current study are peer influence and 
personal beliefs, which are found to have a significant correlation with parents’ 
education level. Parents with secondary school education returned higher mean 
scores than other groups. This factor had negative correlation with patients’ beliefs in 
the usefulness of their medication, the suitability of the information they had 
received, and satisfaction with their involvement in decision-making. This finding 
indicates that intervention should be provided to all patients, carers, and peers/ 
relatives, for example through school intervention programs. Improving social 
support may be effective in minimizing the effect of this factor.  
6.2.2.4 ICS Factor 4: Treatment cost, convenience, and need  
The last factor relates to treatment costs, visit schedules and time wasted, and lack of 
adherence caused by misunderstanding and lack of knowledge. The cost of health 
services and medication may negatively influence adherence, especially amongst 
those on low incomes or without health insurance (34, 132, 303). This factor 
correlated with missing school or daily activities. Improving health care and 
adherence to asthma management protocols instituted by the professionals, in 
addition to building good communication and relationships with patients/ carers, may 
reduce costs and so reduce the effect of this factor. This can be predicted from the 
negative correlation between this factor and both possession of AAPs and access to 
adequate information. Patients who had AAPs returned lower mean scores with this 
factor (p<0.05) than those without. A similar finding was observed regarding access 
to information.  
It is interesting that although health services and medication are provided free in 
Saudi Arabia, the cost of medication and/ or health services was still reported as a 
barrier by 53.5% of participants. This may indicate that the more effective 
medications are not readily available in the PHCCs, or the respondents were 
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dissatisfied with the quality of the services provided by PHCCs, inclining them to 
use private health care services. 
There were no correlations found between possession of PFMs and all factors of both 
surveys. This may be due to the low number of patients reporting the use of PFMs 
(15.8%); it may equally be due to the low prescription of PFMs and lack of 
motivation to increase PFM use.  
A limitation of this study was the lack of a database where one could double-check 
patient medication use patterns to assess levels of adherence. To overcome this, 
patients were asked to list their medications and a visual list was produced to make it 
easier for them to identify their medication.  
6.2.3 Conclusion 
Low use of both AAPs and PFMs, combined with inappropriate treatment, were 
observed among participants in this study. Adherence to ICS use in this phase was 
low, consistent with Phase One findings of patients from the same region. 
Participants reported a number of factors affecting their adherence to asthma 
management in general and ICS use in particular, with a majority reporting more 
than five barriers. Chapman et al. have argued that most patients are affected by 
more than one barrier and that this makes it impossible to find one solution that can 
be generalized to enhance compliance amongst all patients (93). Furthermore, there 
were differences between the barriers revealed in the IMS and ICS scales, although 
most barriers in both scales were related to asthma medication. Information 
availability and access, beliefs about medication usefulness, involvement in decision-
making, and possession of AAPs and use of ICS correlated with a number of these 
factors. Lack of knowledge, negative behaviours, erroneous attitudes, poor self-
efficacy, misconceptions, misunderstanding by patients/ carers, poor communication 
with health care providers, lack of motivation, and inadequate social support 
contributed to problems with medication.  
Effective interventions should embrace all components of asthma management, with 
emphasis on the use of terminology such as controlling expression. Interventions 
should encourage partnerships between patients/ carers and health care providers and 
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be provided to all affected parties, whether patients, relatives, carers, or health 
professionals.  
6.2.4 Recommendations 
Prepared intervention programs should be delivered in clinics, schools and 
community centres and cover asthma disease and its management; however, the 
barriers discussed above should be considered.  
Physicians should be motivated to develop and prescribe AAPs, as they play an 
important positive role in compliance.  
There should be stronger focus on improving patient knowledge, promoting 
behaviour changes, and correcting misconceptions such as steroid phobia. 
Pharmacy departments should play a larger role in reducing the effect of barriers, 
which mostly relate to medication. 




Chapter 7   
Phase 4: Impact of an Education Program and Provision of 
Asthma Action Plans on the Knowledge and Health 
Outcomes of Asthmatic Patients – 
 Results and Discussion 
7.1 Results 
7.1.1 Group A (Education and asthma action plan) 
In this portion of the study, patients and/ or their carers were given asthma education 
and an asthma action plan (AAP) as intervention. They were surveyed pre- and post-
individual intervention to identify any changes in a wide range of issues, including 
knowledge, beliefs, perceptions, behaviours, adherence, self-efficacy, and asthma 
control. The results of the intervention are shown below.  
7.1.2  Survey response 
Table 7.1 shows that 135 questionnaires were administered to group A. The 
participants in this study were made up of 90 males and 45 females. Of these, 105 
(78.7%) completed the study (69 males and 36 females). Most respondents were 
aged 15 to less than 18 years in both stages of this phase: 40.7% pre-intervention and 
40.0% post-intervention respectively. 
Table 7.1 Survey response 
Intervention 
stages 
                       Gender 
Age group  
Male Female Total 




5 - < 10 yrs. 30 22.2 15 11.1 45 33.3 
10 - <15 yrs. 22 16.2 13 9.6 35 25.9 
15 - <18 yrs. 38 28.1 17 12.6 55 40.7 




5 - < 10 yrs. 24 22.9 11 10.5 35 33.3 
10 - <15 yrs. 16 15.2 12 11.4 28 26.7 
15 - <18 yrs. 29 27.6 13 12.4 42 40.0 
Total 69 65.7 36 34.3 105 100.0 
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7.1.3 Patients’ seasonal asthma symptoms  
Respondents were asked if their asthma symptoms differed across seasons. 
Table 7.2 Patients’ seasonal asthma symptoms 
Stage Response 
option 
Winter Spring Summer Fall 




none 5 3.7 16 11.9 11 8.1 46 34.1 
A little 50 37.0 65 48.1 67 49.6 73 54.1 
A lot 80 59.3 54 40.0 57 42.2 16 11.9 




none 2 1.9 8 7.6 9 8.6 33 31.4 
A little 39 37.1 54 51.4 51 48.6 59 56.2 
A lot 64 61.0 43 41.0 45 42.9 13 12.4 
Total 105 100.0 105 100.0 105 100.0 105 100.0 
p value 0.000 0.000 0.001 0.000 
 
The data in Table 2 illustrate that participants in both stages of the study reported 
increased symptoms during the winter season and reduced symptoms in the fall. No 





7.1.4 Severity of disease  
7.1.4.1 Self-assessment of severity of asthma  
Respondents were asked to classify their or their child’s severity of asthma in a range 
from very mild to severe. 









N % N % 
0.000 
Patient self-assessment  
Very mild 2 1.5 3 2.9 
Mild 39 28.9 69 65.7 
Moderate 70 51.9 31 29.5 
Severe 24 17.8 2 1.9 
 
The majority (82.2% and 98.1%) of respondents from both stages, pre- and post-, 
classified their asthma as moderately severe or less. Of these, 41 (30.4%) and 72 
(68.6%) reported their asthma as very mild or mild in both stages, while 70 (51.9%) 
and 31 (29.5%) reported their asthma severity as moderate. There was a significant 
difference reported between both stages (p=0.000). Pre-intervention patients’ asthma 
severity was more likely to be classified as severe than post-intervention patients’. 
Thirty-nine (28.9%) and 24 (17.8%) pre-intervention patients classified their asthma 
severity as mild and severe compared, with 69 (65.7%) and 2 (1.9%) post-
intervention patients. There were no statistically significant differences observed 




7.1.4.2 Self-reported asthma symptoms  
Respondents were asked about the frequency of asthma symptoms over the past four 
weeks. 









during the day 
when not 
exercising 
















None 9 6.7 19 14.1 16 11.9 32 23.7 21 15.6 
1 to 3 57 42.2 97 71.9 82 60.7 76 56.3 68 50.4 
4 to 7 61 45.2 14 10.4 36 26.7 25 18.5 35 25.9 
over 7 8 5.9 5 3.7 1 .7 2 1.5 11 8.1 




None 33 31.4 83 79.0 50 47.6 75 71.4 51 48.6 
1 to 3 64 61.0 21 20.0 54 51.4 29 27.6 51 48.6 
4 to 7 8 7.6 1 1.0 1 1.0 1 1.0 3 2.9 
over 7 0 00 0 00 0 00 0 00 0 00 
Total 105 100.0 105 100.0 105 100.0 105 100.0 105 100.0 
p value 0.000 0.000 0.000 0.000 0.000 
 
Table 7.4 shows the patients’ asthma symptoms in the four weeks previous to the 
survey, for both pre- and post-intervention stages. Significant differences between all 
pre- and post-intervention stage symptoms were noted. Pre-intervention patients 
were more likely to be suffering from asthma symptoms than post-intervention 
patients. Across all the symptoms listed there was a dramatic increase in the 
proportion of patients who were symptom-free post-intervention; for example, the 
proportion increased from 4.6% to 31.5 in the case of wheezing or difficulty 
breathing when exercising (p=0.000) and from 14.1% to 79.0% for wheezing during 
the day when not exercising (p=0.000). Response rates in both stages were 
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influenced neither by age nor by gender, except in pre-intervention patients with 
wheezing during the day when not exercising. Pre-intervention female patients were 
more likely to suffer from this symptom than males (p=0.034); see Appendix H. 
7.1.4.3 Self-reported asthma severity classification according to patient answers to 
symptoms question (at least one symptom) 
Based on the respondents’ replies to a series of five questions, the patients’ asthma 
severity score was calculated. The score ranged from 3 to 18, where a score of 3 
represented very mild, 8 mild, 13 moderate, and 18 severe, asthma.  
 
Figure 7.1 Self-reported asthma severity 
 
Figure 7.1 illustrates asthma severity based on symptom scores. A significant 
difference between both stages was found. Pre-intervention patients’ asthma severity 
was more likely to be severe than post-intervention patients’. Fifty-five (40.7%) pre-
intervention respondents classified their asthma severity as very mild or mild, 
compared with 111 (96.2%) post-intervention respondents, while 78 (57.8%) and 4 
(3.8 %) respondents from the pre- and post-intervention stages respectively reported 
their asthma severity as ‘moderate’ (p=0.000). There were no significant differences 
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7.1.5 Patient beliefs, perceptions, behaviours, attitudes, involvement and self-
confidence (self-report) 
Respondents were asked about their beliefs, perception, behaviour, attitude, 
practices, self-confidence, and involvement in decisions regarding asthma 
management issues.  
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From the data presented in Table 7.5 it can be seen that there were statistically 
significant differences between respondents’ beliefs in both stages. Only 28.9% of 
respondents pre-intervention believed their asthma had been well controlled over the 
previous four weeks, compared with 73.3% of post-intervention respondents 
(p=0.000), and were more likely to believe their medications were useful for 
controlling their asthma than post-intervention respondents (48.1% vs. 88.6%, 
p=0.000). Post-intervention respondents felt they were involved in decision-making, 
and their belief that they had had a say in their medication choices regarding asthma 
treatment was nearly twice that of pre-intervention respondents (100.0% and 99.0% 
vs. 52.6% and 51.9%; p=0.000 respectively). A significant difference between each 
stage’s self-confidence was found in pre-intervention respondents feeling less able to 
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manage changes in their asthma (57.8%) and administer their asthma medication by 
themselves (64.5%) than those in the post-intervention stage (8.9% and 28.6%, 
p=0.000). 
7.1.6 Disease management 
7.1.6.1 Medication used in past 12 months 
Respondents were asked if they had used an asthma medication over the past 12 
months, and all responded yes. 
7.1.6.2 Quick relief medication  
Respondents were asked if they had used medication as a reliever for their disease 
symptoms.  
All patients in both stages reported they had used a quick reliever. The highest 
number of times in one day that patients used a quick reliever, in the previous four 
weeks and 12 months during both stages, can be seen in Table 7.5. 










N=105 p value 
N % N % 
In the previous four 
weeks 
None 2 1.5 38 36.2 0.000 
1 to 2 84 62.2 65 61.9 
3 to 4 46 34.1 2 1.9 
5 to 6 2 1.5 0 00 
over 6 1 .7 0 00 
In the past 12 
months 
None 7 5.2 3 2.9 NS 
1 to 2 45 33.3 26 24.8 
3 to 4 57 42.2 49 46.7 
5 to 6 20 14.8 23 21.9 
over 6 6 4.4 4 3.8 
 
Data in Table 6 illustrate the frequency of reliever use in the 4 weeks before the 
survey declined post-intervention. Thirty-eight (36.2%) post-intervention patients 
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reported no use of a reliever, compared with 2 (1.5%) pre-intervention patients, while 
46 (34.1%) from the pre-intervention stage reported the use of a reliever three to four 
times daily compared with 2 (1.9%) in post-intervention (p=0.000). No significant 
differences were observed based on age in either stage; however, a significant post-
intervention difference was seen with gender, where male patients were less likely to 
have used a reliever than females. Of the 69 males, 32 (46.4%) reported no use of a 
reliever inhaler in the past four weeks compared to 6 of 36 females (16.7%), while 
53.6% of males had used a reliever 1 to 2, or 2 to 3 times, compared with 83.4% of 
females (p=0.011); see Appendix H. No significant differences were observed based 
on gender or age in the use of quick relievers in the past 12 months, in either stage. 
7.1.6.3 Control medication (self-report)  
Respondents were asked if they had used any control medication, for example 
corticosteroids. 








Use of control medication Unsure 35 (25.9) 0 (0.00) 
No 8 (5.9) 0 (0.00) 
Yes 92 (68.1) 105 (100.0) 
Difference between stage p value 0.000 
 
Table 7 shows self-reported use of controller medications. There was a significant 
difference between stages: 92 (68.1%) of per intervention stage chose ‘Yes’ 
compared with 105 (100%) of post-intervention (p=0.000). A significant difference 
was seen between genders in the pre-intervention stage, with male patients more 
likely to use control medications than females: 65 (n=90; 72.2%) of males reported 
they used a controller compared to 27 (45; 60%) of females p=0.004. There was no 
significant difference between gender in the post-intervention stage, and no 
significant differences associated with age in either stage 
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7.1.6.4 Self-assessment of adherence to control medications 
 Respondents were asked about their level adherence to daily control medication use. 
Table 7.8 Patients’ self-assessments of adherence to control medications 






N % N % 
Takes it every day 28 30.4 72 68.6 
0.000 
Takes it some days, but not other days 22 23.9 25 23.8 
Used to take it, but now does not 12 13 2 1.9 
Only takes it when having symptoms 28 30.4 6 5.7 
Never took it 2 2.2 0 0.00 
Total 92 68.1 105 100 
 
Table 8 shows patients’ self-reported adherence to the use of their control 
medications. Post-intervention patients were more likely to use their medication. 
More than two thirds (68.6%) of patients post-intervention who used a control 
medication reported taking it daily, compared with less than one third (30.4%) of 
pre-intervention respondents, while 69.6% pre-intervention used it intermittently 
compared with 31.4% post-intervention (p=0.000). No significant differences were 
seen in gender or age in either stage. 
7.1.6.5 Inhaled corticosteroid (ICS) (self-report) 
Patients were asked if they used an inhaled corticosteroid (ICS). 
Table 7.9 Inhaled corticosteroid (ICS) 
Use of an inhaled 
corticosteroid 





N % N % 
Don’t know 56 
 




23.0 3 2.9 
Yes 48 
 
35.6 98 93.3 
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Table 9 shows a significant difference across stages. Patients pre-intervention 
reported they used ICS 2.6 times less often than post-intervention. Forty eight 
(35.6%) and 87 (63.5%) pre-intervention chose ‘Yes’ and ‘No/ Don’t know’, 
compared with 98 (93.3%) and 7 (6.7%) post-intervention, respectively (p=0.000). 
There were no significant differences observed based on gender or age. 
7.1.6.6  Patients’ adherence to ICS daily use 
Respondents were asked about their level of adherence to recommended ICS use. 
Table 7.10 Patients’ adherence to inhaled corticosteroid 





N=98 p value 
N % N % 
Every day  15 31.3 71 72.4 
0.000 
Less often  11 22.9 13 13.3 
Several times a week  7 14.5 11 11.2 
When having asthma symptoms 15 31.3 3 3.1 
 
Table 10 presents patients’ self-reported adherence to ICS use. Post-intervention 
patients were 2.3 times more likely to be adhering to their medical regimen than pre-




7.1.6.7 Medication use 
 Respondents were asked to list their asthma medications. This list was grouped and 
classified by the researcher as shown in Table 7.11. 
Table 7.11 Medication use 





N % N % 
β2 agonist  No 4 3.0 0 0.00 NS 
Yes 131 97.0 105 100.0 
Inhaler corticosteroid  No 0 0.00 0 0.00 0.068 
ICS alone  70 51.9 42 40.0 
ICS Combination 65 48.1 63 60.0 
Oral corticosteroid No 124 91.9 103 97.1 NS 
Yes 11 8.1 3 2.9 
LABA No 117 86.7 88 83.8 NS 
Yes 18 13.3 17 16.2 
Montelukast (Singular)  No 131 97.0 104 99 NS 
Yes 4 3.0 1 1.0 
Other medications  No 127 94.1 105 100.0 NS 
Yes 8 5.9 0 0.00 
 
The data presented in Table 11 illustrate the use of asthma-related medications in 
both pre- and post-intervention stages of the study. Almost all participants in both 
stages were using a β2 agonist, and all patients were using ICS; however, post-
intervention participants were more likely to use an ICS combination (60%) than pre-
intervention participants (48.1%). Use of oral corticosteroids was reduced amongst 
post-intervention patients. However, there were no significant differences, and the 
responses were not influenced by age or gender.  
7.1.6.8 Comparison of self-reported control medication use and investigator 
assessment  
 The questionnaire asked the patients or their family member if they (or their child) 
used a control medication and an inhaled corticosteroid. To validate their responses 
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the primary researcher asked the respondents to list their medications, to determine if 
they used an ICS.  
Table 7.12 Comparison of patients’ versus investigator’s assessment of controller use. 































































Data in Table 7.12 illustrate how differences appear in patients’ responses to similar 
actions or questions. Patients in the post-intervention stage were more likely to 
choose similar answers for such questions, and to more accurately report their 
medications, than pre-intervention respondents. However, based on the medication 
list provided, all patients used either an ICS alone or in combination in both stages.  
7.1.6.9 Peak flow meter (PFM) and spacer use 
Respondents were asked if they had used a PFM and spacer. 





















Uses a peak flow 
meter to monitor 
asthma 
2 (1.5) 126 (93.3) 7 (5.2) 37 (35.2) 13 (12.4) 55 (52.4) 0.000 
Uses a spacer when 
using an inhaler 
10 (7.4) 102 (75.6) 23 (17.0) 15 (14.3) 58 (55.2) 32 (30.5) 0.004 
 
Table 13 shows the use of PFM for monitoring asthma and the use of spacers. 
Patients in the post-intervention stage were more familiar with PFM and spacer use 
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than in the pre-intervention stage. The majority (93.3%) of respondents pre-
intervention did not use a PFM to monitor their asthma, compared with just over half 
(52.4%) post-intervention (p=0.000). There were no significant differences reported 
across gender or age.  
In general there was a low level of spacer use in both stages. Around one third 
(30.5%) of post-intervention patients chose ‘Yes’ for spacer use, compared with 
17.0% pre-intervention (p=0.004). There were no significant differences across 
gender; but a significant difference was observed between different groups. In the 
pre-intervention stage, patients aged 10 and under 15 were more likely to use a 
spacer than other age groups. Ten of 45 (22.2%), patients aged 5 to under 10, 11 of 
35 (31.4%) of those 10 to under 15, and 2 of 55 (3.6%) of those 15 to under 18 years 
chose ‘Yes’ to using a spacer, compared with 35 (77.8%), 24 (68.6%) and 53 
(96.4%) who answered ‘No/ Unsure’ (p=0.005). In the post-intervention stage, the 
same was observed: the 10 and under 15 age group was more likely to use a spacer 
than the older age group. However, an increase in the use of spacers was seen in the 
youngest age group: 16 out of 35 patients aged 5 to less than 10 (45.7%), 13 out of 
28 aged 10 to under 15 (46.4%), and 3 out of 42 aged 15 to under 18 (7.1%) 
answered ‘Yes’ to using a spacer, compared with 19 (54.3%), 15 (53.6%), and 39 
(92.9%) who answered ‘No/ Unsure’ (p=0.000; see Appendix H.  
7.1.7 Patient education and follow-up 
Respondents were asked if they had access to adequate information and if their 
health carers followed up about how to use asthma medications. In addition, 




























41 (30.4) 60 (44.4) 34 (25.2) 9 (8.6) 2 (1.9) 94 (89.5) 0.000 
Medication usage 
follow-up over the 
past 12 months 
18 (13.3) 39 (28.9) 78 (57.8) 0 00 105 (100.0) 0.000 
Peak flow meter 
usage education 
0 118 (87.4) 17 (12.6) 5 (4.8) 1 (1.00) 99 (94.3) 0.000 
 
The data in Table 14 show that patients in the post-intervention stage were 3.6 times 
more likely to believe they had access to enough information to help them control 
their asthma than they had been in the pre-intervention stage (89.5% vs. 25.2%; 
p=0.000). There was no significant difference observed across gender in either stage, 
but pre-intervention data show significant differences based on age. Younger patients 
were more satisfied with the information available than older age groups. Eighteen of 
45 aged 5 to under 10 (40.0%), 9 of 35 aged 10 to under 15 (25.7%), and 7 of 55 
aged 15 to under 18 (12.7%) answered ‘Yes’ to having access to enough information, 
compared with 27 (60.0%), 26 (74.3%) and 48 (87.3%) who replied ‘No/ unsure’ 
(p=0.035). No significant difference was seen between age groups in the post-
intervention stage; see Appendix H. 
Patient follow-up also increased in the post-intervention stage, where all patients 
reported they had received follow-up regarding their medication use, compared with 
57.8% in the pre-intervention stage (p=0.000). No significant differences were seen 
based on gender or age in either stage. 
Pre-intervention patients were less educated about PFM use. Only 12.6% reported 
they were educated about PFM use, compared with a majority of 99 post-intervention 
respondents (94.3%); 118 (87.4%) and six (6%) pre-and post-intervention patients 
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were not educated or unsure (p=0.000). There were no significant differences 
observed across age groups in either stage, but post-intervention patients showed 
significant differences by gender, with male patients more likely to have been 
educated about PFM use than females: 68 (98.6%) males and 31 (86.1%) females 
reported they had been educated (p=0.031); see Appendix H. 
7.1.7.1 Rating the quality of information (self-report) 
Respondents were asked to evaluate the quality of information regarding their 
disease received from their health providers. 
Table 7.15 Ratings of the quality of information 
Question Responses Pre-intervention 
N=135 
Post-intervention 
N=105 p value 
N % N % 
Rate the quality of 
the information 
provided  
None 3 2.2 0 0.00 0.000 
Bad 29 21.5 0 0.00 
OK 43 31.9 2 1.9 
Good 46 34.1 45 42.9 
Very good 14 10.4 58 55.2 
 
The data in Table 15 show that the information quality improved in the post-
intervention stage. The majority of patients post-intervention (98.1%) evaluated the 
quality of information they received from their health care provider about asthma as 
‘very good’ or ‘good’, compared with 44.5% and 55.5% of patients pre-intervention, 
who classified the quality of information as good or higher and ‘OK’,’ bad’ or ‘none’ 
(p =0.000). No statistically significant differences were observed across gender or 
age. 
7.1.8 Quality of life 




Table 7.16 Patients’ quality of life 








Never Some of the 
time 
Often  Always 
(Daily) 
Never Some of the 
time 
Often  Always 
(Daily) 
N % N % N % N % N % N % N % N % 
in trouble  69 51.1 56 41.5 9 6.7 1 .7 90 85.7 15 14.3 0 00 0 00 0.000 
worried, anxious or afraid  39 28.9 59 43.7 33 24.4 4 3.0 69 65.7 36 34.3 0 00 0 00 0.000 
annoyed or angry  37 27.4 57 42.2 36 26.7 5 3.7 66 62.9 38 36.2 1 1.0 0 00 0.000 




The data in Table 7.16 illustrate the quality of life elements for both stages. The 
quality of patients’ life improved in the post-intervention stage. Significant 
differences were reported between both QOL elements (p=0.000). Ninety (85.7%), 
69 (65.7%), and 66 (62.9%) patients post-intervention were not in trouble, worried or 
anxious, afraid or annoyed or angry because of their disease, compared with 69 
(51.1%), 39 (28.9%), and 37 (27.4%) of pre-intervention patients (p=0.000). Further, 
post-intervention participant’s regular activities increased by 18% (p=0.000). No 
statistically significant differences were observed across gender or age. 
7.1.8.1 Patients bothered by asthma symptoms  
Respondents were asked if they suffered from asthma symptoms including coughing, 
chest tightness, and wheezing over the previous four weeks. 
 Table 7.17 Frequency of asthma symptoms in the previous four weeks 








N % N % 
0.000 
Patient bothered by the 
following symptoms: coughing, 
chest tightness, wheezing, in the 
previous four weeks 
Never 1 0.7 42 40.0 
Once a week or less 67 49.6 59 56.2 
2 to 3 times a week 50 37.0 4 3.8 
4 to 5 times a week 15 11.1 0 00 
Daily 2 1.5 0 00 
 
Table 7.17 shows the frequency of patients’ symptom intervention over the previous 
four weeks. According to self-reporting, the majority of respondents in the post-
intervention stage reported either no symptoms (40.0%) or symptoms only once 
weekly (56.2%), whereas of pre-intervention patients only 0.7% and 49.6% reported 
the same (p=0.000). Response rates were not influenced by gender or age. 
7.1.8.2 Avoiding severe asthma attacks 




Table 7.18 Ability to avoid severe asthma attack 











Easy 10 7.4 0 0 
0.000 
Moderate 68 50.4 21 20.0 
Difficult 52 38.5 79 75.2 
Very 
difficult 
5 3.7 5 4.8 
 
Data in Table 18 show patients’ ability, based on self-evaluation, to avoid having a 
severe asthma attack. More than half (57.8%) the patients in the pre-intervention 
stage reported their ability to avoid asthma attacks to be ‘easy to moderate’, 
compared with 21 (20%) of those post-intervention, 80% of whom described their 
ability as difficult or very difficult (compared to 42.2% pre-intervention p=0.000). 
There were no significant differences observed across age groups in either stage, but 
post-intervention responses revealed significant differences based on gender, with 
male patients feeling more likely to be able to avoid an asthma attack than females. 
Nineteen (27.5%) and 47 (68.1%) of 69 males reported their ability to avoid an 
asthma attack as ‘easy’ or ‘moderate’, compared with two (2.6%) and 32 (88.9%) 
female patients respectively; (p=0.028). No significant differences across age in 
either stage were discerned see Appendix H.  
7.1.8.3 Hospital or emergency room visiting 
Respondents were asked if they had been admitted to hospital or attended an 
Emergency Room at the hospital in the previous three months; and if so, how many 
times.  
Table 7.19 Number of patients admitted to hospital or attending ER 
Question Responses  Pre-intervention 
N=135 
Post-intervention 
N=105 p value 
N % N % 
Hospital & ER visits No 58 43.0 74 70.5 0.000 




The data presented in Table 19 illustrate patients’ hospital admissions and 
Emergency Room attendances in the previous three months. Admissions to hospital 
or attendances at ERs decreased among post-intervention patients, with 29.5% 
admitted to hospital or attending the ER compared with 57% during the pre-
intervention stage (p=0.000). There were no statistically significant differences 
across gender or age in either stage. 
Table 7.20 Times patients were admitted to hospital or attended ER 
Number of admissions or attendances  Pre-intervention 
N=77 
Post-intervention 
N=31 p value 
N % N % 
1 to 3 times 
 
59 76.6 30 96.8 
0.044 
4 to 6 times 
 
15 19.5 1 3.2 
7 to 9 times 
 
3 3.9 00 00  
 
Data in Table 20 illustrate the number of times patients were admitted to hospital or 
attended ER. The number of visits to hospital or ER decreased in the post-
intervention stage. Fifty-nine post-intervention (76.6%) and 30 (96.8%) post-
intervention patients visited hospital or ER one to three times, compared with 15 
(19.5%) and one (3.2%) who visited four to six times (p=0.044). There were no 
statistically significant differences across gender or age in either stage.  
7.2 Adverse Effects 
Patients and their carers were asked if they or their child had suffered from any 
adverse effects such as weight gain, change of mood, diabetes, or slowed growth rate 




Figure 7.2 self-reported adverse effects 
 
As shown in Figure 2, adverse effects were reported in both stages. Significant 
differences were reported in both stages in weight gain and change of mood. Thirty-
four (25.2%) pre-intervention patients reported weight gain and 26 (19.3%) reported 
change of mood, compared with 6 (5.7%) and 7 (6.7%) post-intervention patients. 
No significant differences in diabetes or slowed growth rate were discerned. 
7.2.1 Asthma medication management (clinical category) 
Respondents were asked about their asthma management, in particular their use of 
reliever and controller medication: ‘Does your child use an inhaler or nebulizer for 
quick relief from asthma symptoms?’ and ‘Has your child ever had a prescription for 
asthma medicine that is NOT used for quick relief, but is used to control your child’s 
asthma?’ The responses are shown in Table 7.21. Reported levels of use of the 
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Use of a quick 
reliever and has 
a controller 
92 (68.1) 105 (100.0) 
 
 













Use of a control medication. 




















every day  
Controller used 
daily 
28 (30.4) 72 (68.2) 
 
All patients were on asthma medications, with eight pre-intervention patients (5.9%) 
reporting using only a reliever and 92 (68.1%) using reliever with control 
medication; all patients in post-intervention stage reported both using a quick reliever 
and having a controller medication. These patients were more likely to use their 
controller medication on a daily basis than those in the pre-intervention stage (68.2% 
vs. 30.4%; p=0.0001).  
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7.2.2 Patients’ asthma control levels  
Using the Therapy Assessment Questionnaire (ATAQ), which scores patients’ 
responses to a series of three questions, individual patient’s control levels were 
determined. Patient with a score of zero were deemed well controlled whilst those 
with a score of seven were classified as poorly controlled (see Appendix A: Scoring 
Instructions). 
 
Figure 7.3 Patients’ asthma control level 
 
As illustrated in Figure 3, post-intervention patients had significantly better asthma 
control than pre-intervention: for example, 18.1% of the post-intervention cohort 
reported well controlled asthma compared with zero in the pre-intervention stage 
(p=0.000).  
No significant differences across age in either stage were observed; however, there 
was a significant difference based on gender in the post-intervention stage with 
female patients less likely to report good asthma control than males. More than half 
the 69 males (58.0%) reported their asthma was well controlled or that they had 
mostly one control problem, while 10 (27.8%) of 36 female patients (p=0.012) did 
so. No significant difference across gender in the pre-intervention stage was 
observed (see Appendix H).   
0.0% 10.0% 20.0% 30.0% 40.0%
Poor control
Have six control problems
Have five control problems
Have four control…
Have three control…
Have two control problems
Have one control problem
Well control
Responses % 
Asthma control level 
p=0.000 
post responses pre responses
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7.2.3 Patients’ behaviours/ attitudes  
Using the ATAQ and a series of two questions, individual patients’ behaviours/ 
attitudes were determined. Patient with a score of zero were deemed to have no 
behaviour/ attitude barriers whilst those with score of two were classified as having 
two barriers (see Appendix A: Scoring Instructions)..  
 
Figure 7.4 Patients’ behaviour/ attitude (Domain) 
 
Significant differences between stages were revealed, with 40.7% pre-intervention 
patients reporting no behaviour barriers compared with 72 (68.6%) post-intervention. 
More than half (59.3%) the pre-intervention patients reported one or two barriers, 
compared with 31.4% post-intervention (p=0.000). No statistically significant 
differences were observed across gender or age in either stage. 
7.2.4 Patients’ knowledge (Domain) 
Using ATAQ and a series of three questions, individual patients’ knowledge about 
their disease and medication was determined. Patients with a score of zero were 
deemed to have good knowledge, whilst those with a score of three were classified as 




























Figure 7.5 Patients’ knowledge (Domain) 
 
The data presented in Figure 7.5 illustrate patients’ knowledge levels in both stages. 
Patients’ knowledge increased in the post-intervention stage: pre-intervention, 71.1% 
reported they had good knowledge, compared with 83.8% post-intervention, while 
28.9% pre-intervention reported a lack of or poor knowledge, compared with 16.2% 
(p=0.047) post-intervention. Responses in neither stage were influenced by gender. 
No significant differences were based on age in the pre-intervention group, but there 
was a significant difference noted between age groups post-intervention, where the 
middle group was more likely to claim good knowledge: 30 of 35 (85.7%) patients 
aged 5 to under 10, 19 of 28 (67.9%) aged 10 to under 15, and 39 of 42 (92.9%) of 
those aged 15 to under18 believed they had a good knowledge level, compared with 
5 (14.3%), 9 (32.1%), and 3 (7.1%), who felt they lacked knowledge (p=0.019; see 
Appendix H). 
7.2.5 Communication (Domain) 
Using ATAQ and a series of five questions, the level of communication between 
individual patients and their health providers was determined. Patients with a score 
of zero were deemed to have high communication levels, whilst those with a score of 
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Figure 7.6 Communication (Domain)  
 
The data presented in 7.6 illustrate the level of communication between patients and 
their health care providers in both intervention stages. In the pre-intervention stage, 
there was lack of communication, with around half (48.9%) classifying 
communication with their health providers as medium or fair. Post-intervention 
patients tended to report a higher level of communication (99.0% vs. 33.3%, 
p=0.000). There were no significant differences observed based on gender or age. 
7.2.6 Self-efficacy (Domain) 
Using ATAQ and a series of three questions, patients’ self-efficacy was determined. 
Patients with a score of zero were deemed to have high self-efficacy, whilst those 
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Figure 7.7 Self-efficacy (Domain) 
 
Figure 7.7 shows the differences in self-efficacy in pre- and post-intervention 
responses. Patients in the post-intervention stage (66.7%) were more likely to have 
high self-efficacy than in the pre-intervention (9.6%). Furthermore, patients in the 
pre-intervention stage reported poor self-efficacy 6.5 times more often than patients 
in the post-intervention stage (31.1% vs. 4.8%, p=0.000). There were no significant 
differences observed based on age or gender. 
7.3 Group B (Education Only) Result 
In group B, patients and/ or their carers were given asthma education as an 
intervention. They were surveyed pre- and post-intervention to identify any changes 
in a wide range of issues including knowledge, beliefs, perceptions, behaviour, 
adherence, self-efficacy, and asthma control. The results appear below.  
7.3.1  Survey response 
One hundred and thirty-five questionnaires were administered in group B, to 82 
males and 53 females. Of these, 99 (73.3%) completed the study (62 males and 37 
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Table 7.23 Survey response 
Intervention 
stage 
                  Gender 
Age group  
Male Female Total 




5 - < 10 yrs. 21 15.6 17 12.6 38 28.1 
10 - <15 yrs. 21 15.6 16 11.9 37 27.4 
 15 - <18 yrs. 40 29.6 20 14.8 60 44.4 




5 - < 10 yrs. 18 18.2 12 12.1 30 30.3 
10 - <15 yrs. 16 16.2 12 12.1 28 28.3 
 15 - <18 yrs. 28 28.3 13 13.1 41 41.4 
Total 62 62.6 37 37.4 99 100 
 
7.3.2 Patients’ seasonal asthma symptoms  
Respondents were asked if their asthma symptoms differed across seasons. 





Winter Spring Summer Autumn 
N % N % N % N % 
Pre-intervention 
N=135 
none 4 3.0 26 19.3 18 13.3 54 40.0 
A little 44 32.6 66 48.9 63 46.7 64 47.4 
A lot 87 64.4 43 31.9 54 40.0 17 12.6 




none 2 2.0 18 18.2 11 11.1 38 38.4 
A little 31 31.3 48 48.5 46 46.5 45 45.5 
A lot 66 66.7 33 33.3 42 42.4 16 16.2 
Total 99 100.0 99 100.0 99 100.0 99 100.0 




The data presented in Table 2 illustrate that the participants reported increased 
symptoms during the winter season in both stages of the study, with reduced 
symptoms in autumn. No statistically significant differences were observed across 
gender or age groups in either stage.  
7.3.3 Severity of disease  
7.3.3.1 Self-assessment of the severity of asthma 
Respondents were asked to classify their or their child’s asthma in a range from very 
mild to severe. 












Very Mild 7 5.2 5 5.1 
Mild 44 32.6 54 54.5 
Moderate 64 47.4 37 37.4 
Severe 20 14.8 3 3.0 
 
Table 7.25 shows that the majority of respondents from both stages (85.2% pre- and 
97% post-intervention) classified their asthma as moderately severe or less. Of these, 
51 (37.8%) and 59 (59.6%) reported their asthma as very mild or mild, compared 
with 64 (47.4%) pre-intervention and 37 (37.4%) post-intervention who reported 
their asthma as moderate. There was a significant difference between the two stages 
(p=0.001): Pre-intervention patients’ asthma was more likely to be considered severe 
than post-intervention patients’. Forty-four (32.6%) and 20 (14.8%) pre-intervention 
patients classified their asthma as mild or severe, compared with 55 (54.5%) and 3 
(3.0%) post-intervention. There were no statistically significant differences across 




7.3.3.2 Self-reported asthma symptoms  
Respondents were asked about the frequency of asthma symptoms in the previous 
four weeks. 































None 12 8.9 23 17.0 21 15.6 34 25.2 25 18.5 
1 to 3 67 49.6 93 68.9 81 60.0 79 58.5 80 59.3 
4 to 7 44 32.6 17 12.6 30 22.2 18 13.3 23 17.0 
over 7 12 8.9 2 1.5 3 2.2 4 3.0 7 5.2 




None 25 25.3 62 62.6 38 38.4 55 55.6 34 34.3 
1 to 3 65 65.7 35 35.4 58 58.6 41 41.4 59 59.6 
4 to 7 9 9.1 2 2.0 3 3.0 3 3.0 6 6.1 
over 7 0 0 0 0 0 0 0 0 0 0 
Total 99 100.0 99 100.0 99 100.0 99 100.0 99 100.0 
p value 0.000 0.000 0.000 0.000 0.000 
 
Table 7.4 shows both pre-intervention and post-intervention patients’ asthma 
symptoms in the previous four weeks. Significant differences between all pre-
intervention and post-intervention symptoms were reported (p=0.000). Pre-
intervention patients were more likely to suffer asthma symptoms than post-
intervention patients. Across all the symptoms listed there was a dramatic increase in 
the proportion of patients who were symptom-free in the post-intervention segment: 
for example, the symptom-free proportion increased from 8.9% to 25.3% in the case 
of wheezing or difficulty breathing when exercising (p=0.000), and from 17.0% to 
62.6% for wheezing during the day when not exercising (p=0.000). Response rates 
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were not influenced by age and gender in either stage, with the exception of 
wheezing during the day when exercising. Pre-intervention female patients were 
more likely to suffer from this symptom than their male counterparts (p=0.034). 
7.3.3.3 Self-reported asthma severity classification regarding symptoms (at least 
one symptom) 
Based on responses to a series of five questions, each patient’s asthma severity score 
was calculated. The score ranged from 3 to 18, where a score of 3 represented very 
mild, 8 mild, 13 moderate and 18 severe asthma.  
Figure 7.8 Self-reported asthma severity 
 
Figure 7.8 illustrates asthma severity scores based on symptoms. A significant 
difference between stages was observed. Pre-intervention patients were more likely 
to report their asthma severe than post-intervention patients. Seventy-four (54.8%) 
respondents pre-intervention classified their asthma as very mild or mild, compared 
with 89 (89.9%) post-intervention, while 55 (40.7%) pre-and 10 (10.1 %) post-
intervention respondents considered their asthma moderate (p=0.000). There were no 
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7.3.4 Patients’ beliefs, perceptions, behaviours, attitudes, involvement, and 
self-confidence 
Respondents were asked about their beliefs, perceptions, behaviours, attitudes, 
practices, self-confidence, and involvement in making decisions about asthma 
management issues.  
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The data presented in Table 7.27 indicate statistically significant differences between 
respondents’ beliefs in each stage. Only 33.3% of pre-intervention respondents 
believed their asthma had been well controlled in the past four weeks, compared with 
67.7% of post-intervention respondents (p=0.000). Post-intervention respondents 
were more likely to believe their medications were useful for controlling their asthma 
than pre-intervention (51.9% vs. 73.7%, p=0.001). They felt involved in decision-
making more than pre-intervention respondents (63.6% vs. 43.0%, p=0.003) and that 
their choice of medication was taken into consideration (61.6% vs. 39.3%; p=0.000). 
Another significant difference in self-confidence was that pre-intervention 
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respondents felt less able to manage changes in their asthma (54.8%) or administer 
their medication themselves (57.1%) (20.2%, p =0.000 and 36.3%, p=0.003). 
7.3.5 Disease management 
7.3.5.1 Medication used in the previous 12 months 
Respondents were asked if they had used an asthma medication over the past 12 
months. 
Table 7.28 Medication used in the previous 12 months 
Asthma medication use over the 











N % N % 
Yes 132 97.8 99 100.0 NS 
No 3 2.2 0 0 
 
The data presented in Table 7.28 illustrate that the majority of patients (>97%) in 
both stages had used asthma related medications in the past 12 months. There were 
no significant differences in medication use between genders or across age groups.  
7.3.5.2 Quick relief medication  
Respondents were asked if they had used medication as a reliever for their 
symptoms. 










N % N % 
Use of an inhaler or nebulizer for 
quick relief from asthma symptoms 
Yes 124 91.9 99 100.0 0.015 
No 6 4.4 0 0 
Unsure 5 3.7 0 0 
 
Table 7.29 shows the respondents’ responses to quick reliever use. There was a high 
level of use of an inhaler or nebulizer as a quick reliever in both stages. All patients 
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post-intervention and 124 (91.9%) pre-intervention had used inhalers for quick relief 
(p=0.015). There was no significant difference in the use of an inhaler or nebulizer 
based on age in either stage, but there was a significant difference across gender in 
the pre-intervention stage. Pre-intervention males were more likely to use relievers 
than females. Seventy-nine (96.3%) and 3 (3.7%) out of 82 pre-intervention males 
chose ‘Yes’ or ‘No/ unsure’ about using quick relief inhalers, compared with 45 
(84.9%) and 8 (15.1%) of 53 female patients (p=0.014; see Appendix H). 
7.3.5.3 Frequency of quick reliever use in the previous four weeks and 12 months.  
The highest number of times in one day a patient used a quick reliever for asthma 
symptoms in both stages of study can be seen in Table 7.30 







N=99 p value 
N % N % 
In the previous four weeks None 10 7.4 20 20.2 
0.000 
1 to 2 75 55.6 73 73.7 
3 to 4 43 31.9 6 6.1 
5 to 6 5 3.7 0 0.00 
over 6 2 1.5 0 0.00 
In the past 12 months None 9 6.7 1 1.0 
0.028 
1 to 2 55 40.7 27 27.3 
3 to 4 50 37.0 52 52.5 
5 to 6 16 11.9 14 14.1 
over 6 5 3.7 5 5.1 
 
The maximum daily use of reliever medication fell post-intervention: 20 (20.2%) of 
post-intervention patients reported no use of relievers in the previous four weeks, 
compared with 10 (7.4%) pre-intervention patients; but 43 (31.9%) pre-intervention 
respondents reported the use of relievers three or four times daily, compared with 6 
(6.1%) post-intervention (p=0.000). No significant differences were observed across 
gender or age. 
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7.3.5.4 Control medication (self-reported)  
Respondents were asked if they had used any control medication, such as 
corticosteroids. 












N % N % 
Use of control medication Unsure 50 37 11 11.1 0.000 
No 36 26.7 12 12.1 
Yes 49 36.3 76 76.8 
 
There was a significant difference between both stages: 76 (76.8%) post-intervention 
respondents chose ‘Yes’ compared with 49 (36.3%) pre-intervention, and 23 (23.2%) 
chose ‘No/ Unsure’ compared with 86 (63.7%) pre-intervention (p=0.000).  
The response rate was not influenced by gender in either stage, although significant 
differences by age were noted in both stages. Pre-intervention, older patients (those 
15 to under 18) were more likely to use controllers than other groups. Twenty-eight 
of 60 (46.7%) patients aged 15 to under 18, 8 of 37 (21.6%) aged 10 to under 15, and 
13 of 38 (34.2%) aged 5 to under 10 years said ‘Yes’ to using controllers, compared 
with 32 (53.3%), 29 (78.4%) and 25 (65.8%) who replied ‘No/ Unsure’ respectively 
(p=0.042). Amongst post-intervention patients, these aged 10 to under 15 years were 
more likely to use controller medication than other groups. Twenty-four of 28 
(85.7%) patients aged 10 to under 15, 24 of 30 (80.0%), aged 5 to under 10, and 28 
of 41 (68.3%) aged 15 to under 18 chose ‘Yes’ for using controllers, compared with 
4 (14.3%), 6 (20.0%) and 13 (31.7%) in each group who answered ‘No/ unsure’ 
( p=0.006; see Appendix H). 
7.3.5.5 Self-assessment of adherence to control medications 




Table 7.32 Self-assessment of adherence to control medications 





N % N % 
Takes it every day 7 14.3 39 51.3 
0.000 
 
Takes it some days, but not other days 21 42.9 22 28.9 
Used to take it, but now does not 2 4 4 5.3 
Only takes it when having symptoms 19 38.8 11 14.5 
Never takes it 0 0.00 0 0.00 
 
Low adherence in both stages was reported, but post-intervention patients were more 
likely to use their medication. Just over half (51.3%) patients post-intervention who 
used controller medication reported taking it daily, compared with 7 (14.3%) pre-
intervention, while 85.7% pre-intervention used it intermittently compared with 
48.7% post-intervention (p=0.000). There were no significant differences based on 
gender or age in either stage. 
7.3.5.6 Inhaled corticosteroid (ICS) (self reported) 
Patients were asked if they used an inhaled corticosteroid (ICS). 
Table 7.33 Inhaled corticosteroid (ICS) 
Use of an inhaled 
corticosteroid 





N % N % 
Don’t know 65 48.1 16 16.2 
0.000 
 
No 38 28.1 11 11.1 
Yes 32 23.7 72 72.7 
 
There was a significant difference in the use of inhaled corticosteroids between each 
stage. Patients post-intervention reported they used ICSs 3.1 times more than those 
pre-intervention. Seventy-two (72.7%) and 27 (27.3%) post-intervention respondents 
chose ‘Yes’ and ‘No/ Don’t know’ compared with 32 (23.7%) and 103 pre-
intervention (76.3%) (p=0.000). 
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 Amongst pre-intervention patients no significant differences across gender or age 
were observed. In post-intervention there was no significant difference based on 
gender but a significant difference by age: the middle age group (10 to under 15) 
were more likely to use an ICS than the other groups. Twenty-three of 28 (82.1%) 
patients aged 10 years to under 15 years, 24 of 30 (80.0%) aged 5 to under 10, and 25 
of 41 (61.0%) aged 15 to under 18 answered ‘Yes’ to using a controller, compared 
with 5 (17.9%), 6 (20.0%) and 16 (39.0%) who answered No/ Unsure’ respectively 
(p=0.003; see Appendix H).  
7.3.5.7 Patients’ adherence to inhaled corticosteroid use 
Respondents were asked about their level of adherence to daily ICS use. 
Table 7.34 Patients’ adherence to daily use of inhaled corticosteroid 





N=72 p value 
N % N % 
Every day  5 15.6 37 51.4 
0.003 
Less than every day  8 25 15 20.8 
Several times a week 4 12.5 7 9.7 
When having asthma symptoms 15 46.9 13 18.1 
 
Post-intervention respondents were more likely to adhere to their medication than 
pre-intervention. Post-intervention, 72 of 105 reported they had used ICS, and of 
these more than half (51.4%) reported they had used ICS daily, compared with 5 
(15.6%) of 32 pre-intervention respondents who answered ‘Yes’ to using ICS 
(p=0.003). Responses were not influenced by gender or age. 
7.3.5.8 Medication usage 
 Respondents were asked to list their asthma medications. This list was grouped and 




Table 7.35 Medication usage 





N % N % 
β2 agonist  No 4 3.0 6 6.1 NS 
Yes 131 97.0 93 93.9 
Inhaler corticosteroid  No 39 28.9 12 12.1 0.009 
ICS alone  50 37.0 47 47.5 
ICS Combination 46 34.1 40 40.4 
Oral corticosteroid No 126 93.3 91 91.9 NS 
Yes 9 6.7 8 8.1 
LABA No 125 92.6 82 82.8 0.021 
Yes 10 7.4 17 17.2 
Montelukast (Singular)  No 133 98.5 99 1.00 NS 
Yes 2 1.5 0 0 
Other medications  No 127 94.1 96 97.0 NS 
Yes 8 5.9 3 3.0 
 
The data presented in Table 7.35 illustrates the use of asthma-related medications in 
both stages of this phase. The majority (>93%) of participants in both stages were 
using a β2 agonist, and most were using ICS; however, a significant difference was 
reported between stages regarding ICS use. Participants post-intervention were more 
likely to use ICS (87.9%) than pre-intervention (71.1%): only 12 (12.1%) post-
intervention respondents answered ‘No’ to this option, compared with 39 (28.9%) 
pre-intervention (p=0.009). Use of LABL increased from 7.4% pre-intervention to 
17.2% post-intervention (p=0.021). Use of oral corticosteroids was similar in both 
stages. There were no significant differences across gender or age in either stage.  
7.3.5.9 Patients’ vs. investigator’s assessment of use of control medication  
The questionnaire asked the patients or their carers if they (the child) used a control 
medication and an inhaled corticosteroid. To validate their responses the primary 
researcher asked the respondents to list the medication used, to determine if they 
used an ICS.  
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Table 7.36 Patients’ vs. investigator’s assessment of use of control medication  

















































27 (27.3) 47 
(47.5) 
40 (40.4) 8 (8.1) 17 
(17.7) 
 
Post- intervention patients proved more knowledgeable about their intervention and 
more able to answer correctly if they were on an ICS.  
7.3.5.10 Peak flow meter (PFM) and spacer use 
Respondents were asked if they (their child) used a PFM and/ or a spacer. 




















Uses a peak flow 
meter to monitor 
asthma 
4 (3.0) 128 (94.8) 3 (2.2) 3 (3.0) 82 (82.8) 14 (14.1) p=0.002 
Uses a spacer 
when using an 
inhaler 
5 (3.7) 111 (82.2) 19 (14.1) 3 (3.0) 75 (75.8) 21 (21.2) NS 
 
There was low use of PFMs pre- and post-intervention, but a significant difference 
was observed post-intervention, where patients were more familiar with PFM use 
than pre-intervention. Only three (2.2%) of the pre-intervention respondents used a 
PFM to monitor their asthma, compared with 14 (14.1%) post-intervention 
(p=0.002). No significant differences were seen across gender or age groups. 
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In general there was a low level of spacer usage in both stages. Only 19 (14.1%) pre-
intervention respondents said they used a spacer, and 21 (21.2%) post-intervention. 
There were no significant differences across stages, but a significant gender 
difference was observed pre-intervention, with male patients slightly more likely to 
use a spacer than females: 7 (13.2%), 41 (77.4%) and 5 (9.4%) of 53 pre-intervention 
females answered ‘Yes’, ‘No’ and ‘Unsure’ to using spacers, compared with 12 
(14.6%) and 70 (85.4%) of 82 males (p=0.018; see Appendix H). 
Significant differences across age were also noted both pre- and post-intervention. 
Pre-intervention young patients (5 to under 10) were more likely to use spacers than 
older respondents. Twelve of 38 (31.6%) aged 5 to under 10, 4 of 37 (10.8%) aged 
10 to under 15, and 3 of 60 (5.0%) aged 15 to under 18 answered ‘Yes’ to using 
spacers, compared with 26 (68.4%), 33 (89.2%) and 57 (95%) who said ‘No/ Unsure’ 
(p=0.006). The same was observed post-intervention, with younger patients more 
likely to use spacers than their older counterparts. However, an increase in the 
percentage of patients using spacers especially was noticeable in the middle age 
group. Eleven of 30 (36.7%) aged 5 to under 10, 7 of 28 (25.0%) aged 10 to under 
15, and 3 of 41 (7.3%) aged 15 to under 18 answered ‘Yes’ to using spacers, 
compared with 19 (63.3%), 21 (75.0%) and 38 (92.6%) who answered ‘No/ Unsure’ 
(p=0.017; see Appendix H). 
7.3.6 Patient education and follow-up 
7.3.6.1 Patient education and follow-up  







































































Patients’ satisfaction with their access to adequate information about asthma grew 
significantly post-intervention (28.9% vs. 76.8%; p=0.000). There was no significant 
difference observed by gender in either stage, but post-intervention patients 
demonstrated differences by age, with patients in the middle age group more satisfied 
than others. Twenty-six of 30 (86.7%) aged 5 to under 10, 25 of 28 (89.3%) aged 10 
to under 15, and 25 of 41 (61.0%) aged 15 to under 18 answered ‘Yes’ to having 
access to enough information, while 4 (13.3%), 3 (10.7%) and 16 (39.0%) answered 
‘No/ Unsure’ (p=0.036). No significant differences based on age were seen in the 
pre-intervention stage (see Appendix H). 
Patient follow-up increased. The majority (89.9%) post-intervention reported they 
had received follow-up regarding their medication use, compared with 59 (43.7%) 
pre-intervention (p=0.000). Pre-intervention patients felt less educated about PFM 
use than post-intervention patients. There was no significant difference observed 
across gender in either stage; but in pre-intervention there were differences based on 
age: patients in the group 5 to less than 10 were more likely to be followed up than 
other age groups. Twenty-one of 38 (55.3%) aged 5 to under 10, 17 of 37 (45.9%) 
aged 10 to under 15, and 21 of 60 (35.0%) aged 15 to under 18 answered ‘Yes’ to 
having had follow-up, compared with 17 (44.7%), 20 (10.7%) and 39 (65.0%) who 
replied ‘No/ Unsure’ (p=0.033; see Appendix H). Moreover, the majority of post-
intervention respondents (85.9%) reported they were educated about PFM use, 
compared with 13 (9.6) pre-intervention, while 122 (90.4%) and 11 (15.1%) of pre- 
and post-intervention patients felt they were not educated or were unsure (p=0.000). 




7.3.6.2 Rating the quality of information  
Respondents were asked to evaluate the quality of the information they received 
from their health providers about their disease.  
Table 7.39 Rating of the quality of information (self-reported) 
Question Responses  Pre-intervention 
N=135 
Post-intervention 
N=99 p value 
N  % N  % 
Rate the quality of the 
information provided 
None 4 3.0 0 0.00 
000 
Bad 22 16.3 0 0.00 
OK 42 31.1 10 10.1 
Good 51 37.8 57 57.6 
Very good 16 11.9 32 32.3 
 
Post-intervention participants rated the provided information highly. The majority 
(89.9% and 10.1%) evaluated the quality of information as ‘very good or good’ and 
‘OK’, compared with 49.7% and 31.1% of patients pre-intervention (p =0.000). The 
responses were not influenced by gender or age. 
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7.3.7 Quality of life 
7.3.7.1 Patients’ quality of life 
Respondents were asked to evaluate the quality of their life over the past four weeks. 







p value In the past four 
weeks have you 
felt…  
Never 
Some of the 
time 
Often  Always (Daily) Never Some of the time Often  
Always 
(Daily) 
N  % N  % N  % N  % N  % N  % N  % N  % 
Troubled 55 40.7 68 50.4 8 5.9 4 3.0 79 79.8 20 20.2 0 00 0 00 0.000 
Worried, anxious 
or afraid  
43 31.9 58 43.0 25 18.5 9 6.7 54 54.5 42 42.4 3 3.0 0 00 0.000 
Annoyed or 
angry  
47 34.8 56 41.5 25 18.5 7 5.2 63 63.6 36 36.4 0 00 0 00 0.000 
Normal  26 19.3 59 43.7 32 23.7 18 13.3 34 34.3 58 58.6 7 7.1 0 00 0.000 
 
242 
The quality of patients’ life improved in the post-intervention stage. Significant 
differences were reported between both stages’ QOL elements (p=0.000). Seventy-
nine (79.8%), 54 (54.5%) and 63 (63.6%) post-intervention stage were not troubled, 
worried or anxious, afraid, annoyed, or angry because of their disease, compared 
with 55 (40.7%), 43 (31.9%) and 47 (34.8%) pre-intervention. Post-intervention 
participants’ regular activities increased 1.8 times over pre-intervention (p=0.000). 
No statistically significant differences were observed across gender or age. 
7.3.7.2 Patients experiencing asthma symptoms  
Respondents were asked if they had suffered from asthma symptoms including 
coughing, chest tightness, or wheezing in the previous four weeks. 








N  % N  % 0.000 
Patient bothered by the following 
symptoms: coughing, chest 
tightness, wheezing, in the past 
four weeks. 
Never 4 3.0 29 29.3 
Once a week or less 70 51.9 61 61.6 
2 to 3 times a week 46 34.1 9 9.1 
4 to 5 times a week 9 6.7 00 00 
Daily 6 4.4 00 00 
 
The majority of post-intervention respondents reported either no symptoms (29.3%) 
or once-weekly symptoms (61.6%), whereas only 3.0% and 51.9% of pre-
intervention respondents did so (p=0.000). Response rates were not influenced by 




7.3.7.3 Avoiding severe asthma attacks 
Respondents were asked to rate their ability to avoid an asthma attack. 
 








N  % N  % 
Ability to avoid having 
severe asthma attacks 
Easy 29 21.5 11 11.1 0.000 
Moderate 60 44.4 75 75.8 
Difficult 40 29.6 13 13.1 
Very difficult 6 4.4 0 0.00 
 
More than two thirds (65.9%) of pre-intervention patients reported their ability to 
avoid asthma attacks to be easy to moderate, compared with 86.9% post-intervention 
(p=0.000). Response rates were not influenced by gender or age. 
7.3.7.4 Hospital or emergency room visiting 
Respondents were asked if they had been admitted to hospital or attended the 
Emergency Room at the hospital during the last 3 months, and if so, how many 
times.  
Table 7.43 Number of patients admitted to hospital or attending ER 





N  % N  % 0.000 
Hospital & ER visits No 45 33.3 60 60.6 
Yes 90 66.7 39 39.4 
 
Admissions to hospital or ER attendances decreased amongst post-intervention 
patients, with 39.4% admitted to hospital or attending the ER compared with 66.7% 
of pre-intervention patients (p=0.000). No statistical significance across gender was 
observed in either stage, but significant differences based on age were noted among 
the pre-intervention cohort. Young patients were more likely to be admitted to 
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hospital or attend ER than those who were older. Thirty-three of 38 (86.8 %), 
patients aged 5 to under 10, 23 of 37 (62.2%) aged 10 to under 15, and 34 of 60 
(56.7%) aged15 to under 18 answered ‘Yes’ to hospital or ER admission, compared 
with 5 (13.2%), 14 (37.8%) and 26 (43.3%) who replied ‘No’ (p=0.007). No 
significant difference was seen between age groups in the post-intervention stage 
(see Appendix H). 
Table 7.44 Number of times patients were admitted to hospital or attended ER 





N  % N  % 
1 to 3 times 67 74.4 37 94 0.025 
4 to 6 times 19 21.1 2 5.1 
7 to 9 times 4 4.4 0 0  
 
Visits to hospital or ER decreased amongst post-intervention patients. Sixty-seven 
(74.4%) and 37 (94.0%) of pre- and post-intervention patients respectively visited 
hospital or ER one to three times in the previous three months, compared with 19 
(21.1%) and two (5.1%) who visited four to six times (p=0.025). Response rates 
were not influenced by gender or age. 
7.3.7.5 Adverse effects 
Patients and their carers were asked if they or their child had suffered from any 
adverse effects, particularly weight gain, change of mood, diabetes, or slowed 




Figure 7.9 self-reported side effects 
 
Significant differences were noted between the stages in weight gain and change of 
mood. More than one quarter of pre-intervention patients reported weight gain 
(28.1%) and changes of mood (25.9%), compared with 12 (12.1%, p=0.000) and 14 
(14.1%, p=0.005) post-intervention. No significant differences were observed 
regarding diabetes or slower growth rate. 
7.3.8 Asthma medication management (Clinical category) 
Respondents were asked about their medication management and in particular their 
use of reliever and controller medication. The two questions were: ‘Does your child 
use an inhaler or nebulizer for quick relief from asthma symptoms?’ and ‘Has your 
child ever had a prescription for asthma medicine that is NOT used for quick relief, 
but is used to control your child’s asthma?’ Responses are shown in Table 7.45. 
Participants were also asked about their level of use of their controller medication if 
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Yes- No- Unsure 
Clinical 
category 






Use of an inhaler or 
nebulizer for quick 
relief from asthma 
symptoms  












Use of quick 
reliever only 
  




Use of a quick 
reliever and a 
controller 
45 (33.3) 76 (76.8) 
 
 
Table 7.46 Patients’ adherence controller medication 
Questions 
Answer option 
Yes- No- Unsure 
Clinical 
category 






Use of a control 
medication: 






(not daily)  
42 (85.8) 37 (48.7) 
Yes 
AND 
Never took it 
Controller 
prescribed but 
never taken  
0 (0.00) 0 (0.00) 
Yes  
AND 




7 (14.3) 39 (51.3) 
 
Almost all patients were on asthma medications, although 34 (25.0%) and 45 
(33.3%) pre-intervention patients reported using only a reliever or a reliever with 
control medication, compared with 12 (12.1%) and 76 (76.8%) post-intervention. 
Post-intervention patients were more likely to use a controller medication on a daily 
basis than were pre-intervention patients (14.3% vs. 51.3%, p=0.0001)  
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7.3.9 Patients’ asthma control level (Domain) 
Using ATAQ and a series of seven questions, individual patients’ asthma control 
levels were determined. Patients with a score of zero were deemed well controlled 
whilst these with a score of seven were classified as poorly controlled (see Appendix 
A: Scoring Instructions).  
 
Figure 7.10 Patients’ asthma control levels 
 
Post-intervention patients had significantly better asthma control than pre-
intervention patients: for example, 10.1% of patients post-intervention reported well 
controlled asthma, compared with 1.55 pre-intervention (p=0.000). The response 
rates were not influenced by gender or age in either stage. 
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7.3.10 Patients’ behaviours/ attitudes (Domain) 
Using ATAQ and a series of three questions, individual patients’ behaviours and 
attitudes were determined. Patients with a score of zero were deemed to have no 
behaviour or attitude barriers, whilst those with a score of two were classified as 
having two barriers (see Appendix A: Scoring Instructions).  
 
Figure 7.11 Patients’ behaviours and attitudes (Domain) 
 
Figure 7.11 illustrates patients’/ relatives’ behaviours and attitudes. There was no 
significant difference between the stages, although post-intervention patients were 
less likely to have behaviour barriers than pre-intervention patients. Fifty-nine 
(59.6%) post-intervention patients reported no behaviour barriers, compared with 64 
(47.4%) pre-intervention. More than half the pre-intervention patients (52.6%) 
reported one or two barriers, as did 40.4% post-intervention (p=0.052). No 
statistically significant differences were reported across gender or age in either stage. 
7.3.11 Patients’ knowledge (Domain) 
Using ATAQ and a series of three questions, individual patients’ asthma knowledge 
was determined. Patients with a score of zero were deemed to have good knowledge, 



























Figure 7.12 Patients’ knowledge (Domain) 
 
Patients’ knowledge increased in the post-intervention stage: pre-intervention, 58.5% 
reported they had a good knowledge; this rose to 77.8% of patients in the post-
intervention stage (p=0.006). The responses were not influenced by gender or age in 
either stage.  
7.3.12 Communication (Domain) 
Using ATAQ and a series of five questions, the level of communication between 
patients and their health care providers was determined. Patients with a score of zero 
were deemed to have a high communication level with their health care provider, 
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Figure 7.13 Communication (Domain) 
 
In the pre-intervention stage there was a lack of communication. Nearly half (48.9%) 
and one third (33.3%) of pre-intervention patients classified their communication 
with their health providers as medium. fair or poor, compared with 39.4% and 5.1% 
post-intervention, who tended to return a ‘good’ or ‘high’ response (55.5% vs. 17.8% 
pre-intervention, p=0.000). There were no significant differences observed based on 
gender or age. 
7.3.13 Self-efficacy (Domain) 
Using ATAQ and a series of three questions, patients’ individual self-efficacy was 
determined. Patients with a score of zero were deemed to have high self-efficacy, 
whilst those with a score of three were classified as poor having self-efficacy (see 
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Figure 7.14 Patients’ self-efficacy (Domain) 
 
Post-intervention patients reported higher self-efficacy levels, with more than half 
(51.5%) reporting high self-efficacy compared with only 16 (11.9%) of pre-
intervention patients, who were more likely to have poor self-efficacy (27.4% vs. 
12.1% post-intervention, p=0.000). No significant differences were observed based 
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7.4 Comparisons of group A and B responses  
7.4.1 Comparison of pre-intervention in both groups 
Table 7.47 Comparison of pre-intervention responses regarding patients’/ carers’ 




 (n = 135) 
Group B 







Uses an inhaler or nebulizer as reliever 2.00 0.00 1.88 0.42 0.001 
Uses controller medication  1.42 0.88 0.99 0.86 0.000 
Adheres to controller use 1.70 1.57 0.97 1.46 0.000 
Uses an inhaled corticosteroid (ICS) 1.48 0.50 1.05 0.79 0.000 
Able to avoid severe asthma attacks 1.38 0.68 1.17 0.81 0.02 
Has limitations on activities because of 
asthma 
1.58 0.88 1.31 0.93 0.02 
Physicians pays attention to patients’ 
medication preferences 
1.31 0.80 1.08 0.84 0.02 
Patient knowledge (Domain) 0.3037 0.49 0.45 0.58 0.02 
Communication (Domain) 1.40 1.19 3.72 1.11 0.000 
 
Group A patients/ carers were more likely to use quick relievers, controller 
medication and ICS than those in Group B, and reported higher mean scores (t (268) 
= 3.247, p < 0.05), (t (268) = 4.066, p < 0.05) and (t (268) = 5.312, p < 0.05) 
respectively. They also reported asthma attacks were difficult to avoid (t (268) = 
2.351, p < 0.05) and that daily activities had been limited in the last four weeks (t 
(268) = 2.408, p < 0.05) more than Group B. However, lack of knowledge and poor 
communication were more frequently observed amongst pre-intervention 




7.4.2 Comparison of post-intervention responses in both groups 
7.4.2.1 Comparison of post-intervention responses regarding patients’/ carers’ 
beliefs, perceptions, behaviours, attitudes, and self-efficacy from both 
groups 
Table 7.48 Comparison of post-intervention responses regarding patients’/ carers’ 




 (n = 105) 
Group B 







Patients’/ carers’ belief in ability to 
administer medication 
1.51 0.81 1.42 0.82 .432 
Adequate access to asthma management 
information  
1.81 0.57 1.58 0.80 0.02 
Patients/ carers belief in usefulness of 
medication 
1.77 0.64 1.59 0.74 0.05 
Patients’/ carers’ belief in ability to control 
asthma in the previous four weeks  
1.51 0.83 1.50 0.79 0.06 
Ability to avoid severe asthma attacks 0.85 0.48 1.02 0. 50 0.012 
Use of a peak flow meter to monitor asthma 1.26 0.44 1.07 0.26 0.000 
Use of a spacer when using an inhaler  1.23 0.42 1.17 0.38 0.11 
Ability to mange asthma attacks 1.83 0.56 1.64 0.75 0.039 
Do you feel that you may have suffered 
weight gain from your medication? 
1.06 0.23 1.12 0.33 0.11 
Do you feel that you may have suffered 
change of mood (e.g. depression) from your 
medication? 
1.07 0.25 1.14 0.35 
0.07 
 
Do you feel that you may have suffered 
diabetes from your medication? 
1.02 0.137 1.02 0.14 0.95 
Do you feel that you may have suffered 
slowed growth rate from your medication? 





Patients’/ carers’ belief in the usefulness of medication and the availability of 
information improved more in Group A than in Group B, with higher reported mean 
scores: (t (202) = 1.916, p < 0.05) and (t (202) = 2.416, p < 0.05) respectively. 
Asthma control patients’/ carers’ beliefs did not show significant differences between 
groups, although Group A patients believed they controlled their asthma more than 
Group B patients did. Positive behaviours and confidence developed more in Group 
A than in Group B. A higher proportion of Group A respondents were likely to use a 
PFM to monitor asthma, and felt better able to manage changes than Group B (t 
(202) = 5.588, p < 0.05) and (t (202) = 2.081, p < 0.05). Further, Group A tended to 
self-administer medication(s) and use a spacer more than Group B, although there 
was no significant difference.  
7.4.2.2 Comparison of post-intervention responses regarding patients’/ carers’ 
education by and communication with health care providers in two groups 
Table 7.49 Comparison between post-intervention responses regarding patients’/ 




 (n = 105) 
Group B 







Involvement in decisions about asthma 
treatment  
2.00 0.00 1.54 0.67 0.000 
Physicians’ attentiveness to patients’ 
medication preferences 
1.98 0.20 1.51 0.69 0.000 
Medication use followed up in the past 12 
months 
2.00 0.00 1. 80 0.61 0.001 
Peak flow meter usage education 1.90 0.44 1.77 0.60 .084 
Quality of information provided 3.53 0.54 3.22 0.62 0.000 
 
More Group A patients/ carers felt they were involved in making decisions and in 
having a say in medication choices in the post-intervention stage than those in Group 
B, and recorded higher mean scores (t (202) = 7.057, p < 0.05) and (t (202) = 6.780, 
p < 0.05 respectively). They believed they had been educated and followed up about 
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medications, and rated the quality of information higher, than those in Group B (t 
(202) = 3.418, p < 0.05) and (t (202) = 3.849, p < 0.05 respectively).  
7.4.2.3 Comparison of post-intervention responses regarding patients’ asthma 
severity and quality of life in both groups 
Table 7.50 Comparison of post-intervention responses regarding asthma severity and 
quality of life  
Questions Post-intervention 
Group A 
(n = 105) 
Group B 
 (n = 99) 
Mean Std dev Mean Std. dev P value 
Asthma severity  1.30 0.56 1.38 0.63 0.34 
Suffering coughing, chest tightness, wheezing 0.64 0.56 0.80 0.59 0.044 
Wheezing or having difficulty breathing when 
exercising 
0.76 0.58 0.84 0.57 0.34 
Wheezing during the day when not exercising 0.22 0.44 0.39 0.53 0.011 
Waking up at night with wheezing or difficult 
breathing 
0.53 0.52 0.65 0.54 0.13 
Missing days of school because of asthma 0.30 0.48 0.47 0.56 0.014 
Missing daily activities (e.g. playing, visiting 
friends) 
0.54 0.56 0.72 0.57 0.028 
Asthma symptoms during winter 1.60 0.53 1.65 0.52 0.45 
Asthma symptoms during spring 1.33 0.61 1.15 0.71 0.052 
Asthma symptoms during summer 1.34 0.63 1.31 0.66 0.74 
Asthma symptoms during fall 0.81 0.64 0.78 0.71 0.74 
Frequency of quick reliever use in the previous 
four weeks 
0.66 0.52 0.86 0.50 0.005 
Frequency of quick reliever use in the past 12 
months 
1.99 0.86 1.95 0.81 0.73 
Admitted to hospital or attended ER 1.30 0.46 1.39 0.49 0.14 
Number of admission or attendances 1.65 0.71 1.90 0.82 0.17 
Feeling in trouble during the last four weeks 
because of asthma 
.143 0.35 0.20 0.40 0.27 
Feeling worried, anxious or afraid in the last 
four weeks because of asthma 
0.34 0.48 0.48 0.56 0.052 
Feeling annoyed or angry because of asthma .038 0.51 0.36 0.48 0.80 




In general asthma symptoms were less severe amongst post-intervention respondents 
in Group A than in Group B, and quality of life was better; but significant differences 
were only found with coughing and chest tightness, wheezing during the day when 
not exercising, and missing days of school or daily activities due to asthma (t (202) = 
-1.994, p < 0.05), (t (202) = -2.572, p < 0.05), (t (202) = -2.466, p < 0.05) and (t 
(202) = -2.208, p < 0.05 respectively). The frequency of quick reliever usage in the 
previous four weeks was lower amongst post-intervention respondents in Group A (t 
(202) = -2.843, p < 0.05). Quality of life indicators were better in Group A, and 
fewer symptoms were reported, as were lower rescue medication use, lower 
frequency of hospital admissions, higher activity levels, and strong emotional and 
psychological states; none of these differences were statistically significant.  
7.4.2.4 Comparison of post-intervention responses regarding medication used by 
two groups 
Table 7.51 Comparison of post-intervention responses regarding medication used by 




 (n = 105) 
Group B 






Use of control medication 2.00 0.00 1.66 0.67 0.000 
Adherence to controller 1.45 0.80 1.83 1.06 0.006 
Use of an inhaled steroid for asthma 1.90 0.41 1.57 0.76 0.000 
Adherence to ICS daily use 1.45 0.82 1.94 1.16 0.002 
Short Beta agonist (β2) use according to 
medication list 
1.00 0.00 0.94 0.24 0.01 
Inhaled corticosteroid (ICS) use according 
to medication list 
1.60 0.49 1.28 0.68 0.000 
Steroid use according to medication list 0.03 0.17 0.08 0.27 0.10 
Montelukast (singular) use according to 
medication list 
0.015 0.10 0.00 0.00 0.32 
LABA use according to medication list 0.16 0.37 0.17 0.38 0.85 
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Post-intervention patients/ carers in Group A were more likely to use medication and 
adhere to regular daily use than those in Group B. Reported controller and ICS use 
were higher in Group A (t (202) = 5.234, p < 0.05) and (t (202) = 3.883, p < 0.05 
respectively). ICS usage, obtained from medication lists, was found to be higher in 
Group A and was consistent with patients’/ carers’ self-reported responses. Group A 
respondents’ adherence to these agents was much better, returning higher mean 
scores (t (202) =, p < 0.05) and (t (202) = 7.057, p < 0.05 respectively). In addition, 
β2 usage was found to be higher amongst Group A post-intervention patients (t (202) 
= 2.590, p < 0.05).  
7.4.2.5 Comparison of post-intervention patients’/ carers’ knowledge, behaviours/ 
attitudes, self-efficacy, communication, and asthma control levels between 
groups 
Using ATAQ and a series of three questions, individual patients’ knowledge and 
self-efficacy were determined. Two, five and seven questions were used to determine 
individual patients’ behaviours, communication and control levels as well.  
Table 7.52 Comparison between post-intervention patients’/ carers’ knowledge, 
behaviours/ attitudes, self-efficacy, communication, and asthma control levels between 
groups 
Domains Post-intervention  
Group A 
 (n = 105) 
Group B 






Patient knowledge  0.16 0.37 0.23 0.45 0.22 
Behaviours/ attitudes  0.31 0.47 0.41 0.52 0.15 
Communication  0.01 0.10 2.79 1.08 0.000 
Self-efficacy  0.50 0.83 0.86 1.06 0.008 
Asthma control level  1.93 1.59 2.34 1.53 0.06 
 
Patients’ asthma control tended to be better in group A than in group B, but did not 
reach statistical significance due to the high standard deviation. There were 
significant differences found regarding self-efficacy and communication, with Group 
 
258 
A respondents claim greater self-efficacy and a better level of communication than 
those in Group B, as demonstrated by higher mean scores (t (202) = -2.659, p < 0.05) 
and (t (202) = -26.224, p < 0.05 respectively).  
7.5 Phase Four Discussion 
The previous phases of the study have shown that the current management of asthma 
in KSA is suboptimal. Lack of adherence to asthma management protocols was 
reported by respondents. These included inappropriate medication usage, low use of 
AAPs and PFMs, and low levels of asthma control. A number of barriers were 
reported by patients / carers that affected their adherence to asthma management in 
general and ICS use in particular, especially in Phase Three of this study. Most of 
these barriers proved to have significant correlations, either positive or negative, with 
the severity and symptoms of asthma, patients’ or their carers’ beliefs in the efficacy 
of the regimen, their involvement in decision-making, their possession of an AAP, 
and their use of medication. It was observed that the lack of current management and 
barriers resulted from inadequacies in patients’ or carers’ knowledge, their 
misconceptions, poor attitudes and negative behaviours, and their lack of self-
efficacy. In addition, poor communication between participants and their health care 
providers and the shortage of education provided, as well as a lack of social support 
and motivation, were implicated. McGhan et al. have found that the main education 
sources reported by participants (40%) were their physicians and other health care 
providers, but 65.8% of the participants reported that their education in asthma and 
its treatment and control had been received five years earlier (232). 
As asthma patients spend most of their time away from health care sites, they and 
their carers are required to take a large share of responsibility for the daily 
management of the disease. Success in doing this is based on the patients’/ carers’ 
knowledge, attitudes, and self-efficacy, and on the availability of both collaborative 
care and social support.  
The fourth phase of this study was conducted to estimate the impact of an 
intervention program and the impact of AAP use. It involved two groups: both 
received intervention programs but Group A was provided with AAPs as well. 
Participants’ responses were estimated before and after intervention. One hundred 
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and thirty-five patients were involved in each group in the pre-intervention stage, and 
105 and 99 participants completed the post-intervention stage in Groups A and B 
respectively. Around one-third of participants in each group were female. Most 
patients in both groups were aged between 15 and under 18. The majority of 
participants from both groups had asthma classified as moderately severe or less. It 
was observed that their symptoms increased during winter and decreased in autumn, 
perhaps due to weather changes. 
A number of studies have found that intervention programs improve patients’ and/ or 
carers’ knowledge, behaviours, self-efficacy, and involvement in treatment decisions, 
all of which enhance asthma management outcomes (35, 67, 135, 173, 203, 225, 
227-235) and reduce costs and hospital admissions (241, 242). In addition, the school 
performance of educated patients improves (227). The current study’s findings 
accord with these. Patients’ and/ or carer’s knowledge, behaviours, self-efficacy, and 
beliefs about their involvement in treatment decisions improved in both post-
intervention groups, and is evident in the comparison of pre- and post-intervention 
responses regarding the identification of medication and recognition of its role. For 
example, in the pre-intervention stage in both Groups A and B, 26% and 37% were 
unsure if they had used a control medication, but these percentages decreased by 
26% in the post-intervention stage in both groups. A similar reduction was found 
with ICS use: the unsure response in the post-intervention stage decreased by 37.7% 
in Group A and 31.9% in Group B. It can also be seen that post-intervention 
responses to medication questions had a high consistency with actual medication 
usage, indicating that patients/ carers had become more knowledgeable and 
understanding about their medication after attending the intervention program.  
Changes in patients’ beliefs about the seriousness of their disease (in the case of 
asthma, acceptance that it is chronic), and about the efficacy of their medication are 
other indicators that an intervention program can bring about improvements in 
knowledge. The percentage of patients/ carers believing their medications were 
useful for controlling their asthma increased from 48.1% to 88.6% (p=0.000) in 
group A and from 51.9% to73.7% (p=0.001) in group B. The improvement in 
knowledge, attitude, and beliefs is also reflected in the change in respondents’ beliefs 
regarding their access to adequate asthma management information: 25.2% pre- vs. 
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89.5% post-intervention (p=0.000) in group A and 28.9% pre- vs. 76.8% post- 
(p=0.000) in group B; and it is evident in the altered perception of the ease of 
control. In the pre-intervention stage most believed that avoiding an asthma attack 
was easy; after the intervention program they believed that the task was not so easy. 
This indicates that patients’ awareness of their disease had increased, and was more 
realistic.  
In Phase Three of this study, it was found that patients’/ carers’ concerns about 
medication side effects, and misconceptions about the role of asthma medication, 
were the main common factors influencing compliance. After intervention 
respondents’ behaviours changed, reflected in the increased use of ICS and better 
adherence to medication regimens. It has been reported that intervention programs 
may increase medication compliance and improve inhaler technique (135, 173, 223, 
232, 233, 237, 239, 241). In our study, an increase in the use of controller medication 
and a decrease in the use of quick relievers were observed in the post-intervention 
stage. Most patients, during the education program, did not correctly perform all the 
inhaler technique steps, but in the post-intervention stage these were more likely to 
be performed correctly. Furthermore, ICS usage based on self-report improved from 
35.6% to 93.3% in Group A and from 23.7% to 72.7% in Group B. The percentage 
of adherence to ICS daily use increased by 41.1% (p=0.000) and 35.8%, (p=0.003) in 
the post-intervention stage in Groups A and B respectively. These results are 
supported by Prabhakaran et al.’s findings that participants’ beliefs in using ICS 
daily as a control drug increased from 58.8% to 91.8%, and that correct inhaler 
technique improved from 38.2% to 95.6% after an intervention program (173). Kelly 
et al. found that using anti-inflammatory drugs increased from 34% at baseline to 
95% a year after an intervention program, compared with 60% to 65% in the control 
group, although the control group reported a higher percentage of usage at baseline 
(241).  
Respondents were found to be unfamiliar with PFM use. The use of PFMs at pre- 
intervention stages was very low in both groups, which was consistent with the 
findings in Phases One and Three of this study and supported by the findings of other 
studies (38, 89, 118, 284, 287). In Phase Two it was found that physicians were not 
very likely to educate patients about PFMs, perhaps because of the lack of PFM 
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accessibility and the cost; physicians may also lack confidence that the patients will 
adhere to PFM use, as is indicated by patients’ attitudes and the reliability of their 
diary keeping. In any case, physicians tend to depend on FEV1measures if they are 
available. However, in the current study, the use of PFMs increased in the post- 
intervention stage by 47.2% and 11.9% in Groups A and B respectively. It should be 
noted that in this study PFMs were provided to all patients by the researcher.  
Patients’ assessment of both training and education as well as the quality of 
information improved in the post-intervention stage. This may be attributed to either 
the effectiveness of the program and/ or the improvement in interaction between 
patients and their health care providers. It is observed that in the post-intervention 
stage communication between patients and health care providers increased, and 
respondents believed that they were more involved in decisions about their 
treatment; the belief that they were involved in both decisions about their treatment 
and in choosing medication grew two-fold in Group A and about 1.5-fold in Group 
B. 
Self-efficacy improved, indicated by changes in both behaviour and knowledge. 
Post-intervention patients were more confident about managing changes in their 
asthma and in adhering to specific medication instructions Pre-intervention 
respondents demonstrated less confidence in these matters: 57.8% and 54.8% in 
Groups A and B pre-, compared with 8.9% and 20.2% post-intervention respectively. 
Furthermore, the ability to administer medication as directed increased after the 
intervention by more than one third (35.8% in Group A and 34.7 in Group B). The 
improvement in self-efficacy is clearly indicated by the ATAQ self-efficacy domain 
response: post-intervention, 66.7% and 51.5% of respondents in Groups A and B 
were likely to have high self-efficacy, compared with 9.65% and 11.9% pre-
intervention.  
As a result of the intervention program’s positive impact on patients’ and/ or carers’ 
knowledge, behaviours, communication with health care providers, and self-efficacy, 
asthma management outcomes progressed positively in the current study. In the post-
intervention stage, medication use and adherence improved amongst patients in both 
groups. Based upon the use of reliever and controller medication, the percentage of 
patients who used relievers and had controllers increased by 31.9% and 43.5% in 
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Groups A and B respectively. In addition, patients’ adherence to controller regimens 
improved by more than one third in both groups. The frequency and severity of 
asthma symptoms were reported as less in the post-intervention stage. In both 
groups, across all the symptoms listed, there was a dramatic increase in the 
proportion of patients who were symptom-free in the post-intervention stage, and 
who reported being more in control of their disease. In the responses regarding the 
domain of asthma control level, Group A reported their asthma to be well controlled, 
from 0 in pre- to 18.1% in post- intervention; this compared with a rise from1.5 to 
10.1% in Group B. Evans et al. similarly found improvements in self-efficacy, 
asthma management skills, and frequency of episodic asthma after intervention, 
although they did not establish a significant relationship between school attendance 
and the intervention program, suggesting that this may be because their sample 
tended to be of mild severity (227). However, other studies have found that 
intervention results in a reduction in absenteeism (228, 232, 237). 
Quality of life also improved in both groups. This can be reflected by the increased 
proportion of patients who were not suffering from either psychological or physical 
aspects such as anxiety, worries, anger, or limitations to their daily activity as a result 
of their diseases in the post-intervention stage. In addition, the frequency of 
symptoms was reported as less, and emergency attendances and hospital admissions 
were reduced in both groups. These improvements, found in the current study, are 
consistent with several other studies’ findings (134, 223, 227, 228, 230-239, 241).  
7.5.1 Response comparison between Group A and Group B 
AAPs and education with follow-up are recognized as major factors affecting asthma 
treatment outcomes. Patients’ and/ or their carers’ medication knowledge, self-
efficacy, and behaviours may be improved by intervention programs and self-
management plans (134, 135, 225, 234). Several studies have suggested that while 
education influences knowledge, health outcomes are improved by sharing decisions 
with the patient/ carer and providing AAPs, resulting in better compliance with 
recommended asthma management (203, 235, 244). For both groups during the pre-
intervention stage, differences were found in the response to the use of controllers, 
ICS and quick relievers, agents more commonly used among Group A patients than 
those in Group B. Group A patients and their carers were more likely to report that 
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asthma limited their daily activity than were Group B patients The reasons are not 
fully clear; it may because Group A reported asthma that was more severe, with 
slightly higher symptoms, than did group B, although there were no statistically 
significant differences. It may also be that Group A patients and their carers were 
more concerned about their disease, and that they believed their asthma attacks were 
more difficult to avoid than Group B did. In general, the most likely reasons are the 
lack of knowledge and poor communication with health care providers among group 
B. This can be supported by the significant differences in level of knowledge and 
communication between the groups, as those in Group A were found to be more 
knowledgeable about asthma and to have better communication with their health 
providers than Group B. Only in these aspects was a significant difference between 
groups’ responses in the pre-intervention stage found. 
In the post-intervention stage, several significant differences were observed between 
both groups. Patients in Group A were more likely to be knowledgeable, to have the 
ability to change their attitudes and behaviours, to be more confident, and to 
demonstrate high self-efficacy. They were more involved in making treatment 
decisions and had better communication with their health care providers. The belief 
of involvement in decision-making and medication choice in the post-intervention 
stage doubled in Group A and increased 1.5 times in Group B, resulting in different 
asthma management outcomes. Group A participants were more likely to have better 
management outcomes. Patients in Group B were less likely to use controller 
medications or to adhere to routines, and used more quick relievers than Group A. In 
addition, Group B patients suffered from asthma symptoms such as wheezing during 
the day, missing school or daily activities, and being bothered by coughing and chest 
tightness; and they had more control problems than Group A patients. They also 
showed less improvement in both their levels of asthma control and in their quality 
of life than Group A. Group B participants returned higher mean scores in the 
domains of patient knowledge and behaviours/ attitudes than Group A, although 
without significant differences. Group B had lower knowledge and more behaviour/ 
attitude barriers than Group A. However, Group B’s knowledge level improved by 
19.3%, compared with 12.7 % in Group A. It may be that at the pre-intervention 
stage, Group A was initially higher than Group B (71.1 5 vs. 58.5%). In the domain 
of behaviours/ attitudes (no barriers) they improved by 27.9%, compared with 
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12.2 % in Group B in post-intervention. This suggests that prescribed AAPs are more 
likely to affect behaviours and attitudes than knowledge; and this in turn makes it 
clear that the use of education programs improves asthma management outcomes, 
but when coupled with AAPs it will have more influence – at least on patients’ 
behaviours, attitudes, self-efficacy, and communication, which will enhance self-
asthma management and outcomes.  
Shah et al. found that females and 10-year-olds were more affected by intervention 
than others, with significant improvement found in both the activity and emotions 
domains of male subjects (228). Gender and age effects were not clearly observed in 
this study, but there were significant associations reported between some aspects and 
both gender and age, in both groups. In regard to gender in Group A, all significant 
associations were found in the post-intervention responses with the exception of the 
element of controller use. Post-intervention male patients were less likely to have 
used quick relievers in the last four weeks, and more likely to be educated about 
PFMs (98.6% vs. 86.1%, p=0.000); to have the ability to avoid asthma attacks 
(p=0.028) and to have asthma control than females. Group A male patients in the 
pre-intervention stage were more likely to use controller medications than females 
(72.2 % vs. 60%, p= 0.004). Boulet found that male patients were more likely to use 
ICSs than females (179). In Phase Two of this study, it was found that male 
physicians were more likely to provide education for their patients than females. 
Perhaps poor communication during the intervention delivery to female patients, the 
cultural separation of the sexes and the structure of the health care department 
limiting contact between members from different genders, contributes to this. On the 
other hand, Group B’s significant differences were reported in the pre-intervention 
stage, with females more likely to report wheezing during daily exercise than males. 
Males were more likely to use quick relievers (96.3% vs. 84.9%, p=0.014) and 
spacers. In Group B post-intervention, there were no significant differences 
compared with Group A.  
In the current study, it was observed that children aged under 15 were more likely to 
reflect improvements and benefits from the intervention program. McQuaid et al. 
found that asthma knowledge had a positive relationship with gender, age, reasoning 
about asthma, and disease management responsibility; they also found that there was 
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a correlation between disease management responsibility and age, but that aspects 
relating to medication adherence did not correlate with asthma knowledge, 
reasoning, or management responsibility; adherence instead was negatively 
associated with age (91).  
 In Group A, both pre- and post-intervention patients aged 10 to under 15 were more 
likely to use spacers than other age groups, although the greatest improvement 
affecting spacer usage was observed in the younger aged group, where it was found 
that 22.2% of the group in the pre-intervention stage used spacers compared with 
45.7% in the post-intervention stage. In Group B, younger patients (i.e. those under 
ten) were more likely to use spacers than older groups in both the pre- and post-
intervention stages, although spacer use increased most in the middle group, from 
10.8% pre-intervention to 25.0% post-intervention. Further, the post-intervention 
middle group in Group A were more likely to have good knowledge. In the post-
intervention stage, Group B middle patients were more likely to use ICS medication 
and to be more satisfied with available information than the older group, while 
younger patients were more likely to be followed up, were less frequently admitted 
to hospital, and attended ER less often than the older group. This may be attributed 
to the role of carers in intervention delivery. It was found that in young children, 
parents’ knowledge, beliefs, worries, and psychosocial state were factors that could 
affect asthma management (134, 181-183, 301, 309); moreover, younger children 
were more likely to change behaviours and be influenced by the intervention than 
older participants. It is likely, too, that some elements of asthma control such as 
spacer use may be more suitable for younger children than for others.  
7.5.2 Limitations 
In most clinics there was no suitable venue available for intervention delivery. Other 
limitations were the communication barrier between the sexes due to religious and 
cultural restrictions, evidenced in KSA by the health department structure where 
female clinics are separate from male, with a same-gender staff policy. Moreover, 
most children are most likely to be accompanied by their mother. In addition, there 
was a lack of access to good patient records or databases across all service providers. 
Patients’ records were not up to date in regard to personal information and contact 
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details, which made it very difficult for the investigator to clarify some aspects of the 
research such as double-checking severity and medication use.  
7.5.3 Recommendations 
It is clear from the results of this study that intervention programs play an effective 
role in improving asthma management outcomes. To achieving optimal outcomes 
from an intervention, a number of issues should be addressed. It is a necessity to 
have qualified staff, a well-equipped venue and well prepared materials and delivery 
methods in each clinic. Furthermore, the intervention should include the supply of an 
AAP, as it was observed that providing AAPs is useful, at the very least helping to 
change behaviour positively, improve communication between patients/ carers and 
health care providers, and increase self-efficacy, all of which contribute to improved 
self-asthma management and outcomes. Involving the patient’s family in an 
intervention programme will be helpful, especially with younger patients.  
Culture, religion, and language are factors that may act as barriers to meeting the full 
objectives of intervention programs in KSA, especially as most physicians and 
professionals are non-Saudis and may have different cultural and linguistic 
backgrounds. In addition, a high proportion of patients and their carers have low 
education levels, and most asthma materials, including instructions in how to use 
devices, equipment, and medication, are written in languages not known to most 
KSA citizens, or are highly technical and inaccessible. The communication 
difficulties created by these factors demonstrate the need for an educator who is a 
separate staff member who, in addition to being able to avoid such barriers, has the 
time that effective education and intervention programs require.  
Asthma education in schools has reported positive effects. Peer education is likely to 
have a strong effect especially on adolescent patients, making intervention programs 
delivered through schools, and peer education, highly effective. It is strongly 
recommended that programs for health care providers are developed, addressing 





The intervention program outlined in this survey improved patients’/ carers’ 
knowledge, behaviours, and attitudes, increased their self-efficacy, and enhanced 
communication with their health providers, resulting in improved asthma 
management outcomes. When patients and carers were treated as partners in the 
management of asthma, increases in their knowledge and changes in their 
behaviours, as well as improvement in their self-efficacy, resulted in better 
communication. Use of controller adherence amongst patients increased. There were 
significant differences found in the use of inhaled corticosteroid between pre- and 
post-intervention responses. ICS in post-intervention respondents increased by 
57.7% and 49% in Groups A and B respectively, while adherence increased by 
41.1% and 35.8%. Patients reported fewer asthma symptoms and felt more in control 
of their disease, which resulted in a better quality of life. When the intervention was 
coupled with the provision of AAPs and follow-ups it produced better results in 
patients’/ carers’ knowledge, behaviours, attitudes, and self-efficacy, as well as in 
their communication with health providers, leading to an overall enhancement of 
asthma management outcomes.  
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Chapter 8   
 Summary of Findings, Limitations, and Recommendations 
This study investigated asthma management practices amongst children and 
adolescents under primary health care in two regions (Asser and Riyadh) of KSA. It 
evaluated the practices of physicians prescribing for mild to severe asthma in 
primary health care centres in these regions against the guidelines of the Saudi 
National Protocol for Management of Asthma and identified barriers affecting 
adherence to asthma management and ICS use among young and adolescent 
asthmatic patients and their families. Adherence to national and international asthma 
management guidelines, such as the use of ICS, was found to be suboptimal; AAP 
prescription, the use of home PFMs and patients’ and/or carers’ education were all 
found to be unsatisfactory. 
An education intervention and the provision of AAPs was evaluated for its effect on 
patients’/ carers’ knowledge, behaviours/ attitudes, communication and ability to 
affect asthma management outcomes.  
8.1 Phase One: Patient/ Carer Survey  
8.1.1 Aims 
The aims of Phase One of the study were as follows: 
 To compare asthma management practices in KSA PHCCs against the 
national protocol. 
 To document asthma management in children and adolescents in KSA. 
 To assess the appropriateness of corticosteroid use in childhood asthma.  
 To assess patient’s/ relatives’ understanding of asthma management. 
Questionnaires were distributed to chronic asthma patients or their carers. Of 200 
each, 152 (77.5%) and 162 (81%) from Asser and Riyadh were returned, 
respectively. A total of 230 (57.5%) were useable (56.1 % from male respondents 





Low levels of the use of ICS, PFM, and AAP were found, together with poor levels 
of patient/ carer education. Poor knowledge, attitudes, behaviours, and levels of self-
efficacy were found amongst patients and their carers. A lack of communication 
between care-providers and their patients was evident. Respondents’ feedback 
revealed that generally the severity of asthma was underestimated, whereas the level 
of control was overestimated. During winter, respondents reported increased 
symptoms. Riyadh patients suffered more symptoms in spring than those in Asser 
(p=0.001), perhaps due to their different weathers in this season. Over three months, 
79 of 230 patients had been hospitalized and 35.4% had utilized health services three 
or more times. In Asser 57.5%, and in Riyadh 43.6% of patients (p=0.035) reported 
their asthma to be well-controlled in the month prior to the survey; however, 
according to the ATAQ responses, only 14.3% of patients had well-controlled 
asthma, with the remaining 85.7% having one or more control problems indicative of 
poorly-controlled asthma. Within Phase One the use of corticosteroids was 
suboptimal at 34.8%. Use of 2 agonists was high at 93.4%, but in combination with 
ICS was low. Although a high proportion of respondents reported having AAPs, a 
lack of understanding and adherence was observed, with 20% reporting having PFMs 
and 36% using a spacer. Few respondents reported the use of PFMs to monitor 
asthma. In total, 28.2% of respondents did not have access to information, 33.5% 
were not educated about inhaler use, and 35% had not been observed by a provider 
when using an inhaler. A lack of knowledge among both patients and carers was 
found. Lack of adherence with controller medication and PFM use reflected poor 
attitudes/ behaviours. More than 75% of respondents had one or more behavioural 
barriers, with poor communication evident in two-thirds and low self-efficacy in 
46.9% of the responses.  
8.1.3 Conclusions  
Management of PHCC patients with asthma (children and adolescents) in KSA fell 
short of national and international guidelines. Many forms of non-adherence with 
guidelines were reported, and a majority of participants had at least one or more 
control problems. Low use of preventative and/ or self-management skills such as 
use of PFMs and spacers was reported. Use of ICS was suboptimal, given that the 
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National Guidelines recommend the use of corticosteroids as first-line treatment of 
chronic asthma. Use of LABA amongst patients with asthma was very low; this may 
indicate their unavailability at PPCCs or the cost of this agent. Lack of adherence 
with medications, AAP use, and PFMs was significant amongst both regions’ 
patients/ carers. Variations in PHC practices were found between regions.  
8.2 Phase Two: Physicians’ Survey  
8.2.1 Aims 
The aims of Phase Two of the study were as follows: 
 To identify physicians’ practices for asthma management in KSA. 
 To compare practice for asthma management in KSA PHCCs with the 
National Protocol for the Management of Asthma. 
 To assess patterns and appropriateness of medication prescription.  
The aims were accomplished through distribution of a three-scale questionnaire to 
physicians in PHCCs in Asser and Riyadh. The response rate was 72.5% (87/120); 
52.8% of respondents were male. A majority (94.3%) of participating physicians 
were non-Saudi; a majority (95.4%) also worked in government centres. Most 
physicians (60%) were general specialists; 44.8% had 11 to 20 years’ experience. 
Continuing medical education amongst respondents was low: only 14.9% of 
participants attended one or more programs a year. Female physicians were less 
frequent conference attendees and tended to be less experienced than their male 
counterparts. Asser physicians reported greater access to national guidelines (93.0%) 
and to assistance (79.1%) than Riyadh physicians (63.6% and 43.2%). Over a third 
of all physicians reported having access to alternative guidelines such as British, 
Australia and GINA guidelines. A gap between physicians’ asthma management 
practices and national and international guideline recommendations was evident.  
Physicians were likely to provide education to patients with severe asthma, but 
provided unsatisfactory education to milder cases. Asser physicians were more likely 
to provide education, perhaps due to a low load of patients or the availability of 
assistants. Variations in the provision of education are attributable to lack of 
awareness of and/ or agreement with the guidelines, lack of knowledge about PFM 
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use, and/or the unavailability of PFMs. A lack of adherence to guidelines, and 
variations in practice when treating asthma, were observed across six clinical 
vignettes.  
The usage rate of ICSs was revealed to vary from 16.1% to 88.5% across six 
vignettes. Prescription of anti-inflammatory agents may be affected by the severity of 
the asthma. Low prescription rates of ICS may be attributed to physicians’ 
disagreement with the recommendation that ICS be the cornerstone of asthma 
treatment, or to their concerns about the safety of long-term use, the cost of 
medication, and the perceptions of corticosteroids held by patients or their carers. 
Physicians’ responses in most vignettes included the use of oral corticosteroids, but 
recommendations were sometimes inappropriate. While reducing reliever use is one 
of the goals of the asthma guidelines, utilization of bronchodilators remains 
unsatisfactory. The practice of starting with inhaled ipratropium or oral theophylline 
and adding non-steroid anti-inflammatory recommendations varied the across the 
sample; physicians tended to ‘wait and see’, reflecting hesitation in prescribing 
medication. While antibiotics were not included in answer options, over one third of 
respondents recommended adding antibiotics. Few physicians recommended LABA, 
which may due to cost, its availability in PHCCs, and referral requirements. 
Fewer than 50% of the physicians surveyed involved patients in decision-making. 
Nearly all physicians were non-Saudi and not fluent in Arabic, and a lack of 
relationship between physicians/ patients was clearly evident. Physicians’ 
unawareness of and unfamiliarity with aspects of asthma and tools for treatment were 
observed; misconceptions were evident. Lack of self-efficacy and inadequate 
outcomes expected by physicians may be related to the under-prescription of 
medication and under-provision of information regarding asthma devices. 
Physicians’ disagreement with guidelines, lack of self-efficacy, and/ or low 
expectations of outcomes may be perceived as barriers to adherence with ICS 
prescribing. The availability of medication and devices may also limit adherence. 
Lack of time and work load pressures, a shortage of staff in organizational roles, a 





Although most PHCC physicians reported having access to guidelines, there was 
poor adherence to several guideline components. Failure to provide essential asthma 
education, especially to patients with mild asthma, was observed. Physicians were 
unlikely to involve patients or their families in decisions about treatment. They were 
likely to recommend relievers rather than preventers; suboptimal use of ICS resulted. 
Inappropriate treatment was observed in the responses to the study vignettes.  
8.3 Phase Three: Barriers Affecting ICS Use and Patient 
Adherence  
8.3.1 Aims 
The aim of Phase Three of the study was as follows: 
 To identify barriers affecting Saudi asthma patients’ management adherence 
in general, and to ICS use in Riyadh PHCCs in particular.  
This was accomplished through a questionnaire distributed to patients/ carers in 
Riyadh PHCCs. Two hundred and thirty questionnaires were administered; the 
overall response rate was 89.1% (205/230). Of 177 eligible responses, 87 (49.2%) 
were from females. Questionnaires included two parts: IMS and ICS scales. Most 
patients (36.7%) had primary school education or less. Nearly half the patients were 
from households where the monthly income was less than 5000 SR; less than one 
quarter of respondents had health insurance. The majority of respondents (74.5%) 
had asthma classified as moderately severe or severe. One hundred and eighteen 
respondents (65.5%) reported using ICS. A majority of the sample (78.4%) used 
ICSs intermittently. Most respondents did not have an AAP (61%) or use a PFM 
(84.6%). Around 40% of participants believed medications were unhelpful and that 
the doctor did not involve patients in decision-making. Less than 40% of respondents 
had adequate access to appropriate information (either hard copy or internet).  
8.3.2 Findings 
Relevant components in the IMS survey were medication issues, doctor–patient 
relationships, adherence influences, self-efficacy, and negativity factors (54.3% total 
variance). The ICS survey revealed four factors: health and medication literacy, 
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patient and family concerns and fears, peer influence and personal beliefs, and 
treatment cost, convenience and needs (56.1% total variance). In both IMS and ICS, 
72.9% of patients/ carers reported being affected by five or more barriers. Positive 
and negative associations between IMS and ICS scales, both of total barriers and of 
sub-class factor scores, with patients’/ carers’ characteristics and disease severity, as 
well as asthma management skills, beliefs, and ICS adherence, were observed. While 
ICS was considered a cornerstone of asthma treatment, patients’ and carers’ 
adherence to routines remained suboptimal. In this phase, the IMS and ICS surveys 
produced different responses, and differences in the sequences of barrier effects were 
observed. In the IMS survey results the five most common barriers reported by 
patients/ carers were unintentional, such as confusion; the ICS survey revealed that 
the five most common barriers indicated by patients/carers were intentional, such as 
fear of side effects. However, medication barriers, such as misunderstanding the need 
and function of asthma medication, having concerns or misconceptions about the 
medication and its side effects, failing to establish a good relationship or adequate 
communication with health providers, or lacking social support, were the most 
common. Cultural differences and language may play a major role in the relationship 
of and communications between patients and providers, possibly affecting asthma 
management outcomes. Involving patients/ carers in decision-making and providing 
AAPs may improve communication between patients and health professionals, 
leading to behavioural changes and improved self-efficacy.  
8.3.3 Conclusions  
Low use of AAPs and PFMs with inappropriate treatment was observed among 
participants. Reported adherence to ICS use in this phase was low. Participants 
identified a number of factors affecting adherence with asthma management in 
general and ICS use in particular, with a majority noting more than five barriers. 
These included lack of knowledge, negative behaviours and attitudes, low self-
efficacy, misconceptions, misunderstandings on the part of patients/ carers, poor 




8.4 Phase Four: Impact of an Education Program and Provision of 
AAPs on Knowledge and Health Outcomes of Asthmatic 
Patients  
8.4.1 Aims 
The aims of Phase Four of the study were as follows: 
 To assess the impact of an education program and the provision of an AAP on 
Saudi asthma patients’ and carers’ knowledge, self-efficacy, and behaviours. 
 To assess the impact of an education program and the provision of an AAP on 
asthma management outcomes among Saudi asthma patients and carers. 
 To assess the impact of an education program and the provision of an AAP on 
patient/carer adherence. 
 To compare the impact of an education program combined with the provision 
of an AAP, as opposed to education alone, on patients’ and carers’ asthma 
management.  
The aims were accomplished through a questionnaire distributed to two groups of 
patients/ carers. In Group A, patients/ carers were given asthma education and an 
Asthma Action Plan, while Group B patients/ carers were given only education. Both 
groups were surveyed pre- and post-intervention to identify changes in a wide range 
of issues, including knowledge, beliefs, perceptions, behaviours, adherence, self-
efficacy, and asthma control.  
One hundred and thirty five questionnaires were issued to each Group. In Group A, 
105/135 (78.7%) completed the study; of these, 69 were males. In Group B, 99/135 
(73.3%) completed study; 62 were males. Around 40% of respondents in both groups 
were aged between 15 years and under 18. In both groups, a majority of respondents 
in both pre- and post-intervention stages had asthma classified as moderately severe 
or less; post-intervention patients’ asthma severity was less likely to be severe than 





The proportion of patients who were symptom-free in the post-intervention stages 
increased dramatically, and a significant improvement in patients’/ carers’ beliefs, 
behaviours, attitudes, self-efficacy, and involvement in decisions regarding 
management were observed. The frequency of reliever use declined significantly in 
the post-intervention stages. Post-intervention patients/ carers were more 
knowledgeable about and more likely to use, as well as to adhere to, medication than 
in the pre-intervention stages. Self-reported ICS use more than doubled amongst 
post-intervention patients in both groups, and the use of PFMs and spacers improved. 
Satisfaction with access to information also improved significantly.  
Quality of life improved in the post-intervention stages, reflected by a significant 
decrease in asthma symptoms, reliever use, hospital admissions and Emergency 
Room attendance. Patients’/ carers’ knowledge, behaviours and attitudes, self-
efficacy, communication with health care providers, and asthma control all improved 
significantly. While intervention programs were provided to all group participants, 
Group A also received AAPs.  
A comparison of Group A and Group B indicted some significant differences during 
the pre-intervention stage: controller, ICS and quick reliever use were more 
commonly used among Group A patients, possibly due to the severity of asthma 
among this group. In the post-intervention stage, patients in Group A were more 
likely to be knowledgeable, to have the ability to change their attitudes and 
behaviours, be more confident, have higher self-efficacy, communicate better, and be 
more involved in decision-making. They were more likely to use controller 
medication, to adhere to regimens, and to suffer less from symptoms. Patients in 
Group B showed less improvement in control levels and quality of life.  
Gender and age effects were not clearly observed in this study, but significant 
associations between management aspects and both gender and age in groups were 
found. Male patients and younger age groups were more likely to reflect 




8.4.3 Conclusions  
An intervention program improved patients’ and carers’ knowledge, behaviours and 
attitudes, and self-efficacy, as well as their communication with health providers, 
resulting in improved asthma management and quality of life; when coupled with 
AAPs and follow-up, all these elements improved even more, and enhanced asthma 
management outcomes.  
8.5 Limitations  
8.5.1 Self-reported data of patients as an accurate representation of 
circumstances and behaviours  
The data collected from patients and analysed within this study came from self-
reports, which may limit the extent to which they accurately represent the 
circumstances and behaviours of the patients and their support network. However, 
the questionnaire had been previously validated and by this study also. To alleviate 
the problem of relying on memory in the self-reported data, the self-report was 
limited to the previous four-week period, the time when respondents would best 
remember details of the circumstances and behaviours being questioned. Repeating 
the themes of questions using re-wording with different styles ensured that patient’s 
responses were consistent and evaluated the effect of using different expressions. 
Allowing respondents to record positive and negative responses aided comparisons 
between the findings of this study and of other studies in similar contexts; these 
mechanisms were adopted to ensure data quality. There was no coercion placed upon 
respondents, who were free to refuse to participate or to answer specific questions. 
8.5.2 Self-reported data of physicians as an accurate representation of 
circumstances and behaviours 
The reliance on physician self-reports is similarly a limitation of this study. To 
minimize the effect of respondent bias on the quality of the data and findings of the 
investigation, several techniques were used. Physicians were asked about their usual 
practice in relation to essential aspects of asthma management across three severity 
classifications, for the purposes of gaining very specific responses. Vignettes were 
used to reflect actual responses rather than knowledge; the response options in these 
were unified across all vignettes to avoid any suggestion of the ‘most suitable’ 
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choice. In addition, physicians were given the option to add any actions they felt had 
not been included in the items. 
Physicians were found to provide negative responses, which argue for the validity 
and reliability of this category of self-reported data to some extent. The findings of 
this study regarding patient education, provision of AAPs, and the recommendation 
of PFM are congruent with the findings of similar investigations conducted 
nationally and internationally. 
8.5.3 A lack of validation of research variables 
The researcher did not access electronic medical records of patients in the PHCCs, 
which might have been done to verify that the asthma severity triggers, medication, 
adherence to best practice, and other relevant medical circumstances and behaviours 
provided by patients/carers were accurate. This was not attempted because the 
records were often not up to date. 
8.5.4 Language as a limitation on the generalizability of the findings  
Linguistic problems may limit the generalizability of the findings of this research. 
Adherence to best practice, specifically, may have been affected by the extraneous 
variable in this study of language proficiency. It was difficult to double-check patient 
medication use patterns to assess adherence, because medications were prescribed in 
written English, which is not the main language of the patients or their carers. To 
counter this problem, coloured photographs of asthma medications were attached to 
questionnaires, to help patients identify their medication.  
8.5.5 The lack of specialized asthma clinics  
Another limitation recognized in the study was that no specialized asthma clinics 
were included: the proportion of specialist physicians in the study was very low, with 
only one pulmonologist identified.  
8.5.6 Separation of genders limiting investigation communication 
A limitation arose concerning the communication barriers between genders due to 
religious and cultural habits prevailing in KSA, including the structure of the health 
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system in which female clinics are separated from male clinics and a same-gender 
staff policy obtains.  
8.6 Recommendations 
8.6.1 Establish specialized asthma clinics in PHCCs 
The availability of specialized clinics within PHCCs would improve the general 
outcomes of treatment for the following reasons: 
 Diagnoses would be more accurate if performed by specialists. 
 Drugs would be more uniformly prescribed and available in the PHCCs. 
 There would be improved patient adherence and follow-up through control of 
prescriptions and re-fill supplies. 
 There would be improved patient awareness of the chronic nature of the 
disease and the need for regular follow-up and discipline in its management. 
 It would enhance patient and family involvement in the treatment process. 
8.6.2 Improve the pharmacy’s role in asthma care 
The area of pharmaceutical science plays a vital role in developing medicines, yet at 
the heart of the problem of poor health outcomes lies the failure of the system to 
ensure adherence to medication regimens. The literature and commentary indicate a 
positive correlation between education programs provided by pharmacists and 
increased adherence to medication usage. Pharmacists can play an important role in 
addressing the misunderstandings, beliefs, and misperceptions of patients and carers 
regarding asthma medications and drug side effects. They can also facilitate better 
communication between patients and carers and their health care providers, and in 
doing so address many of the factors negatively influencing compliance. Further, as 
most KSA pharmacists and pharmacy assistants are Saudis while the physicians are 
often non-Saudis, they can help eliminate problems of language, custom and culture 
on the communication process. The availability of female pharmacy staff also helps 
in improving communication with asthma patients.  
Pharmacy staff should also play an active role in delivering workshops for asthma 
sufferers and lectures for other health care providers, and in maintaining strong links 
with drug and equipment manufacturers. 
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8.6.3 Better funding for intervention programs 
Intervention programs must have better funding, but more importantly they need 
better evaluation mechanisms so that care providers and patients get what they need 
from these initiatives. Well-developed education programs based on proven social 
theories have been shown to have positive effects on management outcomes; 
therefore, education programs for both patients and providers regarding asthma, 
asthma medication, and management, are desirable. Given that many physicians in 
the KSA are non-Saudi, education focusing on communication skills must be 
provided to them together with programs on cultural awareness and safety. For 
programs delivered to patients and their families, different methods should be used, 
such as face-to-face consultations, DVDs, or online information sites; these should 
be tailored to the different education levels of patients and their families. 
Implementing programs based on peer education are recommended, as these have 
proven to lead to satisfactory outcomes, especially amongst young sufferers. Such 
programs could be delivered in schools to ease the pressure on physicians and avoid 
the problems associated with dealing with non-Saudi doctors; they will be delivered 
by people with the same language, culture and gender as the recipients. Intervention 
programs also may reduce negative social impacts by improving knowledge and 
attitudes about the disease and medications. It is important to acknowledge that 
carers’ knowledge, beliefs, and attitudes, and behaviours affect patients’ practices, 
especially those of children; carers’ involvement in any intervention is essential.  
8.6.4 Increased provision of Asthma Action Plans and recommendations for 
Peak Flow Monitoring  
Physicians must be encouraged to prescribe AAPs as this may increase patient 
motivation and improve the communication process, leading to a better patient–
physician relationship and patient adherence. Further, increased use of PFMs may 
help patients monitor the severity of their disease and become more actively involved 
in its treatment. 
8.6.5 Improved access to National Asthma Management Guidelines 
Access to the National Asthma Management Guidelines must be dramatically and 
immediately increased through its provision in electronic and hard copy. Access to 
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guidelines can significantly influence practice, and should be supported by 
continuing education programs. Initiatives at the PHCC level, such as workshops and 
group meetings, need to be put in place to help change provider attitudes, behaviours, 
and self-efficacy in regard to the implementation of the national guidelines. 
Based on observations during the study, a further recommendation follows: 
8.6.6 Improving quality of record-keeping  
Developing awareness of the need to keep documents updated will assist both health 
care providers and patients in easing the process of follow-up, determining a 
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Appendix A:  
Phase One Patients’ Questionnaire (English)  
 
Consent (English version) 
 
I agree to participate in the study having complete understanding of the following: 
 Participation is voluntary, and I am free to withdraw at any time, without 
having to give any excuse whatsoever. 
 The full purpose of the study/research has been explained to me, and all 
my questions have been answered to my satisfaction. 
 I may benefit from the study by learning more about my asthma, and 
others may be helped by the outcomes of the research. 
 All information obtained during this study is confidential and my identity 
will be protected at all times. It will be stored separately in locked filing 
cabinets in the School of pharmacy, Curtin University, and will be 
available only to the researcher and the study supervisor. 
I have read and I understand the consent form for this study. By signing this consent 
form, I am indicating that I agree to participate in the study. 
Patient Signature        
Date 







1. What is your child’s gender? (Mark one 
box.)  
 [   ] Male   
[   ] Female 
2. How old is your child?  
 
[   ]   less than 5 years  
[   ]   5 to less than10 years 
[   ]   10 to less than 15 years 
[   ]   l5 years to less than 18 
3. Has a doctor or medical provider ever told 
you that your child has asthma?  
 
[   ] Yes 
[   ] No (If no, please stop here 
and return the questionnaire) 
4. For each season of the year, to what extent 
does your child usually have asthma 
symptoms? 
(Mark one box on each line.)  
                 A lot       A little      None  
Winter        [   ]         [   ]           [   ] 
 Spring        [   ]         [   ]           [   ] 
Summer      [   ]         [   ]           [   ] 
Fall             [   ]         [   ]           [   ] 
 5. In the past 4 weeks, how many days did 
your child...  
a) Have wheezing or difficulty breathing when 
exercising?  
b) Have wheezing during the day when not 
exercising?  
c) Wake up at night with wheezing or difficult 
breathing?  
d) Miss days of school because of his/her asthma?  
e) Miss any daily activities (such as playing, 
going to a friend’s house, or any family 
activity) because of his/her asthma? 
None   1 to3   4 to 7  over 7 
  
[   ]     [   ]    [   ]             [   ] 
 
 [   ]     [   ]    [   ]             [   ] 
 
 [   ]     [   ]    [   ]             [   ]  
 
[   ]     [   ]    [   ]             [   ] 
 
[   ]   [   ]    [   ]             [   ] 
6. Are you dissatisfied with any part of your 
child’s current asthma treatment?  
Yes    [   ]  




 Unsure     [   ] 
(If yes, please explain)  
 
 
7. In the past 12 months, has your child taken 
any medicine for his/her asthma?  
Yes    [   ]   
No  [   ] 
8. Do you believe...  
a) Your child’s asthma was well controlled in the 
past 4 weeks? ` 
b) Your child is able to administer his/her asthma 
medicine(s) as directed?   
You have access to enough information to help 
your child control his/her asthma?  
d) The medicine(s) your child takes are useful in 
controlling his/her asthma? 
Yes      No    Unsure  
[   ]       [   ]      .[   ] 
 
[   ]       [   ]      .[   ] 
[   ]       [   ]      .[   ] 
 
[   ]       [   ]      .[   ] 
9. Does your child’s doctor or medical 
provider...  
a) Involve you and your child in making decisions 
about your child’s asthma treatment? 
 b) Know how your child prefers to take his/her 
asthma medicine(s) (such as by chewable 
tablet, liquid or inhaler)? 
Yes         No    Unsure  
 
 [   ]       [   ]      .[   ] 
 
[   ]       [   ]      .[   ] 
 
10. In the past 12 months, has your child’s 
doctor or medical provider gone over with you  
or your child how to take his/her asthma 
medicine(s)?  
 
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
 
11. Do you or your child have/has written 
instructions from his/her doctor or medical 






a)  On what to do if he/she is having an asthma 
attack? 
 b) On how to take his/her medicine(s) on days 
when he/she is not having an asthma attack?
  
 
 [   ]       [   ]      .[   ] 
 
[   ]       [   ]      .[   ]  
12. Does your child use an inhaler or nebulizer 
(blue inhaler) for quick relief from asthma 
symptoms? 
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
A. If yes, In the past 4 weeks, what was the 
highest number of times in one day your 
child used this inhaler/nebulizer (blue 
inhaler)? 
0                [   ] 
1 to 2        [   ]  
 3 to 4        [   ]  
 5 to 6         [   ]  
 over 6        [   ] 
B- In the past 12 months, on days your child 
used an inhaler/nebulizer for quick relief, how 
many times a day did he/she usually use it 
(blue inhaler)? 
0                 [   ] 
1 to 2         [   ]  
 3 to 4         [   ]  
 5 to 6          [   ]  
 over 6         [   ] 
13. Has your child ever had a prescription for 
asthma medicine that is NOT used for quick 
relief, but is used to control your child’s 
asthma? 
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
  
If you answered yes to the question above, 
what best describes how your child takes this 
medicine? 
[   ] Takes it every day  
[  ] Takes it some days, but not 
other days 
[   ] Used to take it, but now does 
not 
[ ] Only takes it when having 
symptoms 
[   ] Never took it  





In this section, we would like to find out how often your asthma has bothered you 
DURING THE PAST 4 WEEKS. 




2. Once a week or less 
3. 2 to 3 times a week 
4. 4 to 5 times a week 
5. Daily 
b. Sputum (phlegm or mucus when coughing) 
1. Never 
2. Once a week or less 
3. 2 to 3 times a week 
4. 4 to 5 times a week 
5. Daily 
c. Chest tightness (difficulty taking a deep breath) 
1. Never 
2. Once a week or less 
3. 2 to 3 times a week 
4. 4 to 5 times a week 
5. Daily 
 






d. Wheezy or whistling sound in the chest 
1. Never 
2. Once a week or less 
3. 2 to 3 times a week 
4. 4 to 5 times a week 
5. Daily 
2. In the past 4 weeks, on average, how often did your child’s asthma awaken 
them at night? 
1. Not at all 
2. Less than once a week 
3. Once or twice a week 
4. Three or more times a week 
3. In the past 4 weeks, on average, how often did your child have asthma 
attacks? (“Asthma attack” means increased difficulty breathing that may be 
accompanied by increased coughing, wheezing, chest tightness or other 
symptoms). 
1. Not at all 
2. Less than once a week 
3. Once or twice a week 







The next questions ask about various experiences your child may have had with 
asthma. 
 
1. In general, would you say your child asthma is (circle the appropriate 
answer):  
Very mild           Mild           Moderate             Severe            Very severe                    
                1                      2                   3                        4                          5 
 
2. How easy is it for your child to avoid having severe asthma attacks (flare-ups 
worse than usual asthma symptoms)? (Circle the appropriate answer) 
Very easy       Easy       Moderate      Difficult       Very difficult 
1                   2                  3                   4                       5 
 
3a. Does your child use inhaled steroids (such as Beclomethasone (Becotide, 
Viarex), Budesonide (Pulmicort), Fluticasone/salmeterol (Seretide), 
Budesonide/formoterol (Symbicort), or others for his/her asthma? 
1. Yes                  IF YES, please answer Question 3b below. 
2. No                    Please go on to Section IV, Question 1. 
3. Don’t know     Please go on to Section IV, Question 1. 
 
3b. If you answered “yes” to question 3a above, which of the following best 
describes how your child’s uses his/her inhaled steroid medication? (please 
circle only ONE) 
1. He/she uses inhaled steroids every day, whether or not he/ she has asthma 
symptoms. 
2. Even though the doctor wants inhaled steroids to be used every day, he/she uses 
them less often than that. 
3. He/she uses inhaled steroids several times a week. 





The next two questions ask about peak flow meters (a peak flow meter is a hand-held 
device that measures how much air you can blow out of your lungs) and inhalers, and 
education about medicine and how adjust it . 
 
1. Which of the following is true for your child? (Please tick only ONE) 
1. He/she does not have a home peak flow meter.  
2. He/she has a home peak flow meter and uses it regularly. Please answer Question 
2 below 
3. he/she has a home peak flow meter, but ALMOST never uses it. Please answer 
Question 2 below 
 
IF YOU TICKED 2 OR 3 ABOVE, please answer question 2. 
2. Which of the following are true for your child? (Please mark one box in each 
row.)                                                                             
 YES NO 
1. He/she has been taught how to use a peak flow meter by their doctor 
or nurse. 
  
2. He/she knows their personal best reading on their home peak flow 
meter 
  
3. He/she keeps a peak flow meter diary   
4. He/she alters their medications based on their home peak flow meter 
reading. 
  




3. Has your child been shown the correct way to use their inhaler by your 
doctor, nurse or other health care provider? 
1. He/she does not use an inhaler for their asthma.  [   ] 
2. Yes        [   ] 






4. During an office visit, has your child’s doctor, nurse or other health care 
provider watched your child use the inhaler to check that he/ she is using it 
correctly? 
1. He/she does not use an inhaler for their asthma.   [   ] 
2. Yes         [   ] 
3. No         [   ] 
 
5. Has your child been given written directions by a doctor, nurse or other 
health care provider about how to take their asthma medicine and what to do in 
a severe asthma attack? 
1. Yes, and he/she (I) understand completely.   [   ] 
2. Yes, and he/she (I) understand pretty well.   [   ] 
3. Yes, but he/she (I) am still confused.    [   ] 
4. No, not at all.       [   ] 
 
Has a doctor or nurse explained each of the following to your child: 
6. What to do when your child has a severe asthma attack? 
1. Yes, and he/she (I) understand completely.   [   ] 
2. Yes, and he/she (I ) understand pretty well.   [   ] 
3. Yes, but he/she (I) am still confused.    [   ] 
4. No, not at all.       [   ] 
 
7. How to adjust his/her medication when their asthma gets worse? 
1. Yes, and he/she (I) understand completely.   [   ] 
2. Yes, and he/she (I) understand pretty well.   [   ] 
3. Yes, but he/she (I) am still confused.    [   ] 
4. No, not at all.       [   ] 
5. Does not apply       [   ] 
 
8.  Do you know what things can make your child’s asthma worse and how to 
avoid them? 
1. Yes, and he/she (I) understand completely.   [   ] 
2. Yes, and he/she (I) understand pretty well.   [   ] 
3. Yes, but he/she (I) am still confused.    [   ] 






9. How would you rate the quality of the information given to your child about 
their asthma by their doctor, nurse or other health care provider: 
None Very bad Bad OK Good Very good 
      
 
10. Which of the following are true for your child? 
(Please mark one box in each row.)                                                          YES     NO 
1. He/she usually uses a spacer when using an inhaler for asthma.             [   ]   [   ]  
2. He/she uses a peak flow meter to monitor their asthma           [   ]     [   ]                                           
3. He/she is able to manage changes in their asthma themselves most of the time. 
                    [   ]    [   ] 
 4. He/she follows the care plan given by the current doctor or nurse.        [   ]     [   ]  
5. He/she recognizes things that make their asthma worse.                     [   ]     [   ]  
6. I know what to do during an asthma attack.             [   ]    [   ]  
7. He/she takes asthma medicines when they are appropriate.  [   ]    [   ]  





In this section, we ask you to rate your satisfaction with the health care your child 
has received for their asthma. 
 
1. The quality of the education your child has been given to help them manage 
their asthma daily 
Poor Fair Good Very good Excellent 
     
 
2. How well your child’s doctors and nurses have listened to their/your concerns 
about your child’s asthma 
Poor Fair Good Very good Excellent 
     
 
3. Overall, how would you rate the quality of health care your child has received 
for their asthma during the past 12 months? 
(0 =Very poor, as bad as health care can be;  5= Average ; 10= Excellent)  
0 1 2 3 4 5 6 7 8 9 10 
           
 
4. Could you please list your child’s medicines’ name, frequency of dosage, 
dosage form and dose: 
Drug name  
Dose  (i.e. number of  tablets, puffs per day)  




Dosage form    (e.g. tablet, inhaler)    
 
5.Has your child suffered any of the following problems since commencing 
treatment for asthma:  
Yes           No 
1- weight gain        [   ]           [   ]                                                          
2- change of mood (e.g. depression)     [   ]           [   ]                                   
3- diabetes        [   ]           [   ]             
4- slowed growth rate      [   ]           [   ]   
 
6. Has your child been admitted to hospital or attended the Emergency Room at 
the hospital during the last 3 months 
   Yes  [      ]      how many times (              ) number 






Permission to use FACCT questionnaire 
Josh Lemieux <lmx@omnimedix.org>  Thu, Sep 8, 2005 at 11:45 PM  
To: salthagfan@gmail.com  
Cc: Kathleen DeCarlo <KDeCarlo@markle.org>  
Hello Sultan:  
As long as you cite FACCT - Foundation for Accountability as the author, you are 
free to use the asthma measurements survey in your post-grad research.   FACCT is 
no longer in business, but the Markle Foundation has graciously made key FACCT 
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Appendix B:  






PATIENT EDUCATION STRATEGIES  
In this section, we will be asking you about your usual approach in providing asthma 
information to patients with mild, moderate and severe asthma. 
INSTRUCTIONS 
The information below is to provide you with some general guidelines for classifying 
asthma severity.  
 
Mild intermittent asthma  
intermittent & infrequent (days with symptoms < 2 times/ week and nights with 
symptoms<2/month ) asthma symptoms (wheeze, cough, dyspnoea)  
PEF > 80% of predicted lung function  
 
Mild persistent asthma  
intermittent & infrequent (days with symptoms  >2 times/ week and nights with 
symptoms>2/month ) asthma symptoms (wheeze, cough, dyspnoea)  
PEF tests > 80% of predicted lung function  
 
Moderate asthma  
symptoms (wheeze, cough, dyspnoea) experienced daily and >1/month during nights  





Severe asthma  
symptoms (wheeze, cough, dyspnoea) experienced daily, and frequently during 
nights   
PEF tests <60% of predicted lung function  
On the next few pages you will be presented with several different educational 
strategies that you may or may not provide or use with your patients. For each 
educational strategy, please indicate which statement most closely reflects your usual 
approach for providing information to patients with mild, moderate, and severe 






What is your usual approach for providing general information about asthma (e.g. structure of the respiratory system, mechanisms of asthma, 
inflammation, common triggers) to patients with… 
a- Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
              this information.           only if the patient asks.            waiting for the patient to ask. 
 
b- moderate asthma; 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
              this information.           only if the patient asks.               waiting for the patient to ask. 
 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
              this information.           only if the patient asks.            waiting for the patient to ask. 
 
2. What is your usual approach to providing information about prescribed asthma medication (e.g. mode of action, proper dose, side effects) to 
patients with… 
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
b-  moderate asthma; 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  





3. What is your usual approach to demonstrating the proper use of inhalational devices (e.g. metered dose inhaler, spacer device, turbuhaler) to 
patients with…. 
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
b-  Moderate asthma; 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
c-  Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
4. What is your usual approach to providing information on the avoidance of asthma triggers an environmental control (e.g. control of house 
dust mites, mould, etc.….) to patients with… 
a-   Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.                waiting for the patient to ask. 
 
b-   Moderate asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
c-   Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  




5. What is your usual approach to providing information on the warning sings of worsening or uncontrolled asthma to patients with… 
 
a-   Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           Only if the patient asks.            waiting for the patient to ask. 
 
b-   Moderate asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           Only if the patient asks.            waiting for the patient to ask. 
c-   Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.                waiting for the patient to ask. 
 
 
6. What is your usual approach to providing an asthma action plan based upon symptoms (e.g. written plan that outlines steps to control/regain 
control of asthma including increasing dosage of drug) to patients with… 
 
a-   Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           Only if the patient asks.            waiting for the patient to ask. 
b-   Moderate asthma; 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
c-   Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  






7. What is your usual approach to providing information about monitoring peak flow rates (e.g. purpose, use of peak flow meters and proper 
recording of peak flow rates) to patients with… 
 
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
b-  Moderate asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           Only if the patient asks.            waiting for the patient to ask. 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.               waiting for the patient to ask. 
 
8. What is your usual approach to providing an asthma action plan that is based upon peak expiratory flow rates in conjunction with symptoms 
(e.g. written plan that outlines steps to control asthma) to patients with… 
 
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.        only if the patient asks.               waiting for the patient to ask. 
b-  Moderate asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.                waiting for the patient to ask. 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  






9. What is your usual approach to providing information about community non-profit organizations that provide further information about asthma  
(e.g. The National Scientific Committee of Bronchial Asthma ) to patients with…  
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
             this information.           only if the patient asks.                waiting for the patient to ask. 
b-  Moderate asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           only if the patient asks.            waiting for the patient to ask. 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
                 this information.           only if the patient asks.            waiting for the patient to ask. 
 
10. What is your usual approach to providing other information ( please specify the information) 
___________________________________________________________) to patients with… 
 
a-  Mild asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
               this information.           only if the patient asks.            waiting for the patient to ask. 
b-  Moderate asthma; 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
               this information.           only if the patient asks.            waiting for the patient to ask. 
c- Severe asthma: 
       [   ] I do not provide     [   ] I provide this information     [   ] I provide this information without  
              this information.           only if the patient asks.            waiting for the patient to ask. 





TREATING ASTHMA  
In this section, we will ask you to select the treatment options you would recommend 
to patient with differing degrees of asthma severity. 
INSTRUCTIONS  
You will be presented with six different clinical profiles. Each profile describes an 
asthma patient whom you may treat. For each profile, you will be asked to indicate 
which treatment action(s) you would or would not recommend to patients. The 
therapeutic actions may include the following:  
1. Inhaled B2 agonists (e.g. Ventolin, Bricanyl) 
2. Inhaled Ipratropium bromide (Atrovent) 
3. Inhaled corticosteroids (e.g. Beclomethasone (Becotide, Viarex), Budesonide 
(Pulmicort),  Fluticasone/salmeterol (Seretide), Budesonide/formoterol 
(Symbicort). 
4. Non-steroidal anti-inflammatories (these include the following medications:  
Intal   (cromolyn), Tilade (nedocromil), & Zaditen (ketotifen))  
5. Oral corticosteroids  
6. Wait and see: at this time the patient does not need to take any asthma 
medication(s)  
7. Outpatient visit –– including seeing the patient in your office on the same day or 
referring the patient to an emergency department  
 
Please indicate for each therapeutic action listed whether or not you would 
recommend the action by placing a check mark in the appropriate column. A check 
mark in Column A indicates that you would not recommend the action and a check 
mark in Column B indicates that you would recommend the action. If you indicate 
that you would recommend more than one action, please go on to Column C: First 
Priority Action and indicate which of the actions that you selected is the most 





When indicating whether or not you would recommend each action, please keep in 
mind these two points:  
(1) Ensure your response reflects what you do in your normal practice.  
(2) Assume that the individual can obtain or purchase these medications without 
difficulty.  
Clinical Profile A: Imagine that a patient of yours is usually free of asthma 
symptoms and is currently not taking any anti-asthma medication. He/she 
experiences brief and infrequent episodes of asthma symptoms (about 2 times a week 
for less than 15 minutes). This morning the patient awoke feeling perfectly well, 
experiencing no symptoms. However, later in the day he/she experienced some 
coughing, wheezing and shortness of breath after doing strenuous work around the 
house.  
Potential Action Column A 









1. Starting an inhaled B2 agonist    
2. Starting inhaled Atrovent 
(ipratropium bromide)  
   
3. Starting an inhaled 
corticosteroid  
   
4. Adding a non- steroid anti-
inflammatory 
   
5. Starting an oral theophylline     
6. Starting oral corticosteroid    
7. Waiting and seeing (no 
medication needed at this time) 
   
8. Outpatient visit (e.g. same day 
office visit or refer to 
Emergency Department ) 
   






Clinical profile B: Imagine that normally the patient’s asthma is well controlled 
using an inhaled B2 agonist on an as-needed basis. However, over the past 2 days, 
the patient notices an increase in cough, wheeze and shortness of breath and an 
increase in the use of the inhaled B2 agonist (from 1-2 times a day to every 4-6 
hours).  
 
Potential Action Column A 









1. Increasing current use of the 
inhaled B2 agonist 
   
2.  Adding inhaled Atrovent 
(ipratropium bromide) 
   
3. .Starting an inhaled 
corticosteroid 
   
4.  Adding a non- steroid anti- 
inflammatory 
   
5.  Starting an oral 
theophylline  
   
6. Starting an oral 
corticosteroid 
   
7.  Waiting and seeing (no 
medication needed at this 
time) 
   
8. Outpatient visit (e.g. same 
day office visit or refer to 
Emergency Department ) 
   
9. Other (please specify) 
 





Clinical Profile C: Imagine that a patient of yours, whose asthma is usually 
asymptomatic, has been experiencing an increase in symptoms (e.g. cough, wheeze, 
shortness of breath ) over the past 3 days. For the past 2 nights, this patient has 
experienced nocturnal awakenings due to asthma symptoms and last night woke 3 
times. Yesterday, the use of an inhaled B2 agonist controlled asthma symptoms for 
3-4 hours. Today, the patient is using his/her inhaled B2 agonist approximately every 
1-2 hours. The patient’s usual activities are limited by these symptoms.  
 
Potential Action Column A 









1.  Increasing current use of the   
inhaled B2 agonist 
   
2.  Adding inhaled Atrovent 
(ipratropium bromide) 
   
3.  Starting an inhaled 
corticosteroid 
   
4.  Adding a non- steroid anti- 
inflammatory 
   
5.  Starting an oral theophylline     
6. Starting an oral 
corticosteroid 
   
7.  Waiting and seeing ( no 
medication needed at this 
time) 
   
8. Outpatient visit (e.g. Same 
day office visit or refer to 
Emergency Department ) 
   








Clinical profile D: Imagine that a patient of yours felt fine yesterday. However, 
he/she awoke early this morning experiencing wheezing and coughing which was 
incompletely relived by an inhaled B2.One hour later, the patient was experiencing 
difficulty speaking and could only manage to speak 2-3 words before needing to take 
another breath. 
 
Potential Action Column A 









1.  Increasing current use 
of the inhaled B2 
agonist 
   
2.  Adding inhaled 
Atrovent (ipratropium 
bromide) 
   
3.  Starting an inhaled 
corticosteroid 
   
4.  Adding a non- steroid 
anti- inflammatory 
   
5.  Starting an oral 
theophylline  
   
6. Starting an oral 
corticosteroid 
   
7.  Waiting and seeing (no 
medication needed at 
this time) 
   
8. Outpatient visit (e.g. 
same day office visit or 
refer to Emergency 
Department ) 
   
9. Other (please specify) 
 






Clinical profile E: Imagine that a patient of yours is experiencing asthma 
symptoms daily despite use of an inhaled B2 agonist on an as-needed basis and an 
inhaled corticosteroid in a dosage <500g/day (e.g. 2 puffs Beclovent QID or1 puff 
Pulmicort BID). The patient’s activities are interrupted an average of 2-3 times a day 
due to asthma symptoms but are controlled by taking the inhaled B2 agonist. The 
patient is experiencing no nocturnal awakenings. 
 
Potential Action Column A 









1.  Increasing current use of the 
inhaled B2 agonist 
   
2.  Adding inhaled Atrovent 
(ipratropium bromide) 
   
3.  Increasing an inhaled 
corticosteroid 
   
4.  Adding a non-steroid anti- 
inflammatory 
   
5.  Starting an oral theophylline     
6. Starting an oral corticosteroid    
7. Waiting and seeing (no 
medication needed at this time) 
   
8. Outpatient visit (e.g. same day 
office visit or refer to 
Emergency Department ) 
   





Clinical Profile F: Imagine a patient of yours has been experiencing flu-like 
symptoms for the past 2-3 days. These symptoms include a sore throat, nasal and 
sinus congestion and rhinorrhea. Additionally, the patient notices an increased cough 
productive of whitish-yellow sputum and increased wheezing and dyspnea to the 
point of disrupting his/her normal activities. The patient’s asthma is usually well 
controlled by using an inhaled B2 agonist in a dosage of 2 puffs QID and an inhaled 
corticosteroid at a dosage of 400 g/day. 
 
Potential Action Column A 









1.  Increasing current use of 
the inhaled B2 agonist 
   
2.  Adding inhaled Atrovent 
(ipratropium bromide) 
   
3.  Increasing an inhaled 
corticosteroid 
   
4.  Adding a non- steroid 
anti- inflammatory 
   
5.  Starting an oral 
theophylline  
   
6.  Starting an oral 
corticosteroid 
   
7.  Waiting and seeing (no 
medication needed at this 
time) 
   
8. Outpatient visit (e.g. 
same day office visit or 
refer to Emergency 
Department ) 
   
9. Other (please specify) 
 
   
 
 







In this section, we will ask for your opinions about the management of asthma 
1. Usually, in your practice, to what extent does the average patient with asthma 
get involved with the management decisions about his/her disease? 
 
[   ]  I make the decisions using all that is known about the treatments. 
[   ]  I make the decisions, but strongly consider the patient’s opinion. 
[   ]  The patient and I make the decisions together on an equal basis. 
[   ]  The patent makes the decisions, but strongly considers my opinion. 
[   ] The patient makes the decisions using all the information he/she knows about the 
treatments. 
 
2. Ideally, in your practice, to what extent does the average patient with asthma get 
involved      with the management decisions about his/her disease? (Please check (  ) 
the statement that most accurately reflects your opinion). 
  
 [  ] I make the decisions using all that is known about the treatments.  
 [  ] I make the decisions, but strongly consider the patient’s opinion.  
 [  ] The patient and I make the decisions together on an equal basis.  
 [   ] The patient should make the decisions, but strongly consider my opinion.  






3. If there are any other areas or aspects of your management approach to asthma that 
have not been covered in this questionnaire, please take a minute to highlight them in 



















SECTION  4  
PRACTICE CHARACTERISTICS  
 
In this section, we will ask you some general questions about yourself and your 




Please place a check mark in the appropriate box.  
a- Working place: government centre  [   ]   
        Private centre   [   ] 
b- Nationality:      Saudi    [   ] 
                             Non Saudi    [   ] 
  1. I am a/an:  
                       [   ]  Allergist/ Immunologist  
              [   ]  Family Physician  
              [   ]  General Internist  
              [   ]  Respirologist/Respiratory physician  
              [   ]  Other (please specify)-------------------------------------- 
  
2. I have been in medical practice for: 
                   [   ] 0 to 5 years  
                  [   ] 6 to 10 years  
                      [   ] 11to 15 years  
                    [   ] 16 to 20 years  





3. I am:  
             [   ] Female                [   ]  Male  
4. My birth date is ………/……….(month / year ) 
 
5. My practice is predominantly: 
              [   ] University associated  
                     [   ] Community-based group practice  
                        [   ] Community-based solo practice  
                        [   ] Other (please specify) --------------------------------------------  
 
6. I attend conferences or seminars that have at least one session related to 
asthma management:  
                        [   ] less than every 5 years  
                        [   ] less than every 2-4 years  
                        [   ] once every 2 years  
                        [   ] once a year  
                        [   ] 2 to 4 times a year  
                        [   ] 5 or more times a year  
 
7. Have you, personally, ever experienced asthma-like symptoms?  
                        [   ] yes                [  ] No  
 
8. Do you have a nurse or other health care professional to assist you with care 
or education of patients with asthma?  





9. Please fill in the blanks below.  
Over the past year,-------- % of my practice has been managing patients with asthma.  
In an average month, I see a total of--------_ (number please) asthma patients.  
Of these patients, I would say that:  
                  ---------%    have mild asthma  
                  ---------%    have moderate asthma  
                 ----------%    have severe asthma  
Do you have any access to The National Protocol for the Management of 
Asthma?  
[    ] Yes                        [   ]  No   Please go to question 11 
Which is the type of access? 
 [   ] Hard copy              [   ] Internet access 
 
9. Do you have access to any another guidelines for asthma management? 
 
[   ] Yes  (Please specify) 
____________________________________________________________________ 
 [   ] No 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE AND 
PARTICIPATING IN THE STUDY 
Please use the space below to make comments about this questionnaire. Your input is 








Permission to use ‘A Survey of Asthma Management: the 
Physician’s Perspective’  
Wed, Oct 5, 2005 at 12:55 AM  
To: sultans.althagfan@postgrad.curtin.edu.au  
Our Reference No.: 23419 
Dear Sultan Al-Thagfan: 
Thank you for your recent inquiry regarding questionnaires used in the thesis “ A 
survey of asthma management: the physician’s perspective” by Lisa Chantelle 
Cicutto. 
The pages containing the questionnaires are in Appendix B of the study (pages 217 
to 241). Other pages in the study are related directly to those questionnaires; they 
might be of interest to you. We suggest, for copyright reasons, that you either buy a 
copy of that thesis or borrow it through interlibrary loan by making arrangements 
with your university library. If you decide to buy a copy, you can contact ProQuest 
Information and Learning: by e-mail at: info@umi.com   by telephone at: 1-800-521-
3042 (toll free in North America)  or by fax at: 1-800-864-0019.  For further 
information on their services you can visit their website at:   www.umi.com 
If you prefer, you can borrow the microform copy of that item from Library and 
Archives Canada’s collection. Information on our service can be found from our 
website at: http://www.collectionscanada.ca/ill/index-e.html. 
We hope this information will prove useful and best of luck with your research. 
Francine Falardeau 
Reference and Genealogy Division 





Appendix C:  
Phase Three Questionnaire  (English) 




Attached is the measure and some scoring information.  You are welcome to use it, 
there are no costs involved.   
Best, 
Deirdre Logan  
Deirdre Logan, Ph.D. 
Psychologist, Pain Treatment Service  
Children’s Hospital Boston  
333 Longwood Avenue 5th Floor  









I agree to participate in the study having complete understanding of the following: 
 Participation is voluntary, and I am free to withdraw at any time, without 
having to give any reason whatsoever. 
 The full purpose of the study/research has been explained to me, and all 
my questions have been answered to my satisfaction. 
 I may benefit from the study by learning more about my asthma, and that 
others may be helped by the outcomes of the research. 
 Al1 information obtained during this study is confidential and my identity 
will be protected at all times. It will be stored separately in locked filing 
cabinets in the School of Pharmacy, Curtin University, and will be 
available only to the researcher and the study supervisor. 
 
I have read and I understand the consent form of this study. By signing this consent 
form, I am indicating that I agree to participate in the study. 
 
 
Patient’s  Signature       Date 
 
 






Questionnaire completed by:   
Child       
Parent/carer     
Child with parent/carer   
 
PART 1: GENERAL INFORMATION 
1. Child’s gender?    
Male     
Female    
2. Child’s age? 
Less than 5 years    
5 to less than 10 years   
10 to less than 15 years  
15 years to less than 18   
3. What is the highest education level obtained by… 
 Primary 







Child     
Child’s father     
Child’s mother     
 
4. What is your household’s income monthly? 
   Less than 5000 SR    
   5001- 10000 SR   
   10001- 15000 SR   
   15001-20000 SR   




5. Do you have health insurance? 
Yes     
No     
 
6.  In general, how severe is the child’s asthma? 
Very mild     
Mild      
Moderate    
Severe     
 
7. How often did the child suffer from asthma symptoms (Cough, Wheeze, 
Difficulty Breathing) in the last month?                       
Once or less    
Once per week   
Twice per week   
Daily     
 
8.In the past 4 weeks, on average, how often did the child’s asthma awaken 
him/her at night? 
Not at all    
Less than once a week  
Once or twice a week   






9. How often did the child miss school or was unable to do normal daily 
activities because of his/her asthma?     
Once per month or less  
Once per week   
Twice per week   
More than twice per week   
 
10. Which of the following are TRUE about the child?  
  Yes No Unsure 
A Does the child have written instructions on how to 
manage their from his/her doctor or medical provider 
(i.e. an asthma action plan)? 
   
B Does the child have a peak flow meter and use it 
regularly? 
   
C Does the child use inhaled corticosteroids (e.g. 
Becotide, Flixotide, Pulmicort, Symbicort or Seretide) ? 
   
D Are the medicines the child takes useful for controlling 
his/her asthma? 
   
E Does the doctor involve the child or his/her parents in 
making decisions about their asthma treatment? 
   
F Does the child or his/her parents have access to enough 
information to help the child control his/her asthma? 
   
 
11. IF YOU ANSWERED “YES” TO QUESTION 10C ABOVE (inhaled 
corticosteroid), What best describes how the child takes this medicine? (please 
tick only ONE) 
Uses the inhaler every day, even when he/she is symptom free  
Uses the inhaler regularly, but not every day     





PART 2: HEALTH BELIEFS 
Directions:  We are interested in what can make it difficult to take care of children 
with asthma.  Below is a list of things that some children (or their parents) think or 
feel about what they have to do to take care of their illness.  When you read the 
words “my treatment program” please think about what you as a child (or parent) 
have to do to take care of your asthma on a daily basis.  This includes taking pills or 
other medicines, limiting your activities, things you have to avoid (like dust, animals, 
cigarette smoke or certain foods), having to come to doctor’s visits or to the hospital, 
etc.  
After each statement, please circle the answer that best says how the child feels 
SD =  Strongly Disagree  (This is definitely NOT true for me/my child) 
D =  Disagree   (This is not really true for me/my child) 
N =  Neutral   (This is neither true nor untrue for me/my child) 
A =  Agree    (This is somewhat true for me/my child) 





1. I hate the idea of giving up the things the doctors say I have to give 
up.  
2. I believe that if I take care of myself and follow my treatment 
program, my health will improve.  
3. I try to forget that I have an illness.  
4. My regimen takes a lot of time and work.  
5. Sometimes I can’t remember everything I’m supposed to do about 
my illness.  
6. I don’t want my friends to know about my illness.  
7. When there are changes to my treatment program I sometimes get 
confused.  
8. When I feel nervous or worried, it’s hard to follow my treatment 
program.  
9. None of my friends have to deal with this, why do I?  
10. My illness is easier to take care of than a lot of other illnesses.  
11. I understand what I am supposed to do to care for my illness.  
12. The doctors treat me like a little kid who can’t take care of myself.  
13. I have difficulty understanding the information the doctor tells me 
about my medications 
14. I don’t always trust the doctors and nurses.  
15. Following my treatment program causes me physical pain or 
discomfort.  
16. Nothing bad would happen to me if I didn’t follow my treatment 
program.  
17. My doctors are friendly and easy to talk to.  
18. It’s hard for me to plan things out carefully, so sometimes I don’t 
get around to following my treatment program.  
19. My medications have side effects that I really don’t like.  
20. I have difficulty taking my medication when I am not at home 
21. My family doesn’t understand what it’s like to live with my illness.  
22. I don’t mind if my friends bring up my illness or ask me questions 
about it.  
SD   D   N   A   SA 
 
SD   D   N   A   SA 
 
SD   D   N   A   SA 
SD   D   N   A   SA 
SD   D   N   A   SA 
 
SD   D   N   A   SA 
SD   D   N   A   SA 
 
SD   D   N   A   SA 
 
SD   D   N   A   SA 
SD   D   N   A   SA 
SD   D   N   A   SA 
SD   D   N   A   SA 
SD   D   N   A  SA 
 
SD   D   N   A  SA 
SD   D   N   A  SA 
 
SD   D   N   A  SA 
 
SD   D   N   A  SA 
SD   D   N   A  SA 
 
SD   D   N   A  SA  
SD   D   N   A  SA  
SD   D   N   A  SA 
 





23. The doctors don’t seem to understand how much my treatment 
program gets in the way of important things in my life.  
24. My family gives me a lot of support to help me follow my 
treatment program.  
25. The doctors do a good job of explaining things to me.  
26. It’s hard for me to stay organized enough to keep track of 
medications or other things related to my illness.  
27. I refuse to give up time with friends to take care of my illness.  
28. It feels like the doctors are too busy or rushed to talk to me about 
my illness and my treatment.  
29. My treatment program causes changes to my body that I don’t like. 
SD   D   N   A  SA  
 
SD   D   N   A  SA  
 
SD   D   N   A  SA  
SD   D   N   A  SA  
 
SD   D   N   A  SA  
SD   D   N   A  SA  
 






PART 3: CORTICOSTEROIDS ADHERENCE BARRIERS 
In your opinion, to what extent are the following barriers to the child’s daily use of corticosteroids? (Rate on a scale of 1 to 5, where 1 = strong 
effect and 5 = no effect) 
 















Forgetfulness      
Fear of side effects       
worry of addiction/ dependence      
Cost of medication and /or health services      
Lack of understanding the role of medication      
Lack of understanding the correct use of inhaler device       
Lack of reliable information sources       
Difficulty in reading and understanding medication instruction       
Belief that medication is ineffective      
Absence of warning signs (symptoms) means no medication is needed      



















Use of traditional therapy      
Different types of inhaler devices      
Different numbers of medication types (control and reliever medication)      
Embarrassment or discomfort      
Asthma is not a serious illness that need continuous treatment       
The inconvenience of scheduled appointment times and waiting times for refills       





Appendix D:  




I agree to participate in the study having complete understanding of the following: 
 Participating is voluntary, and I am free to withdraw at any time, without 
having to give any reason whatsoever. 
 The full purpose of the study/research has been explained to me, and all 
my questions have been answered to my satisfaction. 
 I may benefit from the study by learning more about my asthma, and 
others may be helped by the outcomes of the research. 
 Al1 information obtained during this study is confidential and my identity 
will be protected at all times. It will be stored separately in locked filing 
cabinets in the School of Pharmacy, Curtin University, and will be 
available only to the researcher and the study supervisor. 
 
I have read and I understand the consent form of this study. By signing this consent 
form, I am indicating that I agree to participate in the study. 
 
 
Patient’s Signature       Date 
 
 







1. What is your child’s gender? (mark one 
box.)  
 [   ] Male   
[   ] Female 
2. How old is your child?  
 
[   ]   less than 5 years  
[   ]   5 to less than10 years 
[   ]   10 to less than 15 years 
[   ]   l5 years to less than 18 
3. Has a doctor or medical provider ever told 
you that your child has asthma?  
 
[   ] Yes 
[   ]  No - (If no, please stop here 
and return the questionnaire) 
4. For each season of the year, to what extent 
does your child usually have asthma 
symptoms? 
(Mark one box on each line)  
                 A lot       A little      None  
Winter        [   ]         [   ]           [   ] 
Spring        [   ]         [   ]           [   ] 
Summer      [   ]         [   ]           [   ] 
Fall             [   ]         [   ]           [   ] 
 5. In the past 4 weeks, how many days did 
your child...  
a) Have wheezing or difficulty breathing when 
exercising?  
b) Have wheezing during the day when not 
exercising?  
c) Wake up at night with wheezing or difficult 
breathing?  
d) Miss days of school because of his/her asthma?  
e) Miss any daily activities (such as playing, 
going to a friend’s house, or any family 
activity) because of his/her asthma? 
None   1 to3  4 to 7  over 7 
  
[   ]   [   ]    [   ]    [   ] 
 
[   ]   [   ]    [   ]    [   ] 
 
[   ]   [   ]    [   ]    [   ] 
  
[   ]   [   ]    [   ]    [   ] 
 
[   ]   [   ]    [   ]    [   ] 
6. Are you dissatisfied with any part of your 
child’s current asthma treatment?  
Yes    [ ]  




 Unsure              [   ] 
(If yes, please explain)  
 
7. In the past 12 months, has your child taken 
any medicine for his/her asthma?  
Yes       [   ]   
No  [   ] 
8. Do you believe...  
a) Your child’s asthma was well controlled in the 
past 4 weeks? ` 
b) Your child is able to administer his/her asthma 
medicine(s) as directed?   
You have access to enough information to help 
your child control his/her asthma?  
d) The medicine(s) your child takes are useful in 
controlling his/her asthma? 
Yes      No    Unsure  
[   ]       [   ]      .[   ]  
 
[   ]       [   ]      .[   ] 
[   ]       [   ]      .[   ] 
 [   ]       [   ]      .[   ] 
9. Does your child’s doctor or medical 
provider...  
a) Involve you and your child in making decisions 
about your child’s asthma treatment? 
 b) Know how your child prefers to take his/her 
asthma medicine(s) (such as by chewable 
tablet, liquid or inhaler)? 
Yes         No    Unsure  
 
[   ]       [   ]      .[   ] 
 
[   ]       [   ]      .[   ] 
 
10. In the past 12 months, has your child’s 
doctor or medical provider gone over with you  
or your child how to take his/her asthma 
medicine(s)?  
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
 
11. Do you or your child have written 
instructions from his/her doctor or medical 
provider...  
a)  On what to do if he/she is having an asthma 
attack? 
 b) On how to take his/her medicine(s) on days 
when he/she is not having an asthma attack? 
Yes         No    Unsure  
 
 
 [   ]       [   ]      .[   ] 
 




12. Does your child use an inhaler or nebulizer 
(blue inhaler) for quick relief from asthma 
symptoms? 
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
A. If yes) In the past 4 weeks, what was the 
highest number of times in one day your 
child used this inhaler/nebulizer (blue 
inhaler)? 
0              [   ] 
1 to 2     [   ]  
 3 to 4     [   ]  
 5 to 6      [   ]  
 over 6    [   ] 
B. In the past 12 months, on days your child 
used an inhaler/nebulizer for quick relief, 
how many times a day did he/she usually 
use it (blue inhaler)  ? 
0              [   ] 
1 to 2     [   ]  
 3 to 4     [   ]  
 5 to 6      [   ]  
 over 6     [   ] 
13. Has your child ever had a prescription for 
asthma medicine that is NOT used for quick 
relief, but is used to control your child’s 
asthma? 
Yes         No    Unsure  
 [   ]       [   ]      .[   ] 
If you answered yes to the question above, 
what best describes how your child takes this 
medicine 
[   ] Takes it every day  
[  ] Takes it some days, but not 
other days 
[   ] Used to take it, but now does 
not 
[ ] Only takes it when having 
symptoms 
[   ] Never took it  
14. Thank you for completing this section of the questionnaire! Is there anything 






In this section, we would like to find out how often your child’s asthma has bothered 
him/her DURING THE PAST FOUR WEEKS. 
1. Over the past 4 weeks, how often has your child been bothered by the 
following symptoms: coughing, chest tightness, wheezing? 
1. Never 
2. Once a week or less 
3. 2 to 3 times a week 
4. 4 to 5 times a week 
5. Daily 
Section III:  
The next questions ask about various experiences your child may have had with 
asthma. 
1. In general, how severe is your child’s asthma? 
Very mild     
Mild      
Moderate    
Severe     
 
2. How easy is it for your child to avoid having severe asthma attacks (flare-ups 
worse than the usual asthma symptoms)? (Circle the appropriate answer) 
Easy       Moderate      Difficult       Very difficult 






3a. Does your child use an inhaled steroid (such as Beclomethasone (Becotide, 
Viarex), Budesonide (Pulmicort), Fluticasone/salmeterol (Seretide), 
Budesonide/formoterol (Symbicort), or others) for his/her asthma? 
1. Yes     IF YES, please answer Question 3b below. 
2. No     Please go on to Section IV. 
3.Don’t know Please go on to Section IV. 
 
3b. If you answered “yes” to question 3a above, which of the following best 
describes how your child’s uses his/her inhaled steroid medication? ( please tick 
only ONE) 
1. He/she uses an inhaled steroids every day, whether or not he/she has asthma 
symptoms. 
2. Even though his/her doctor wants them to use inhaled steroids every day, he/she 
uses them less often. 
3. He/she uses inhaled steroids several times a week. 





A. The next two questions ask about peak flow meters. A peak flow meter is a hand-
held device that measures how much air you can blow out of your lungs. And inhaler 
and education about medicine and how adjust it  
 Yes No Unsure 
1. He/she has been taught how to use a peak flow meter by 
their doctor or nurse 
   
2. He/she uses a peak flow meter to monitor the asthma.     
3. He/she usually uses a spacer when using an inhaler for 
the asthma.  
   
4. He/she is able to manage changes in their asthma 
themselves most of the time.   
   
 
B. How would you rate the quality of the information given to your child about 
their asthma by their doctor, nurse or other health care provider: 




5. Very bad 
6. None 
 
C. Could you please list your child’s medicines’ names, frequency, dosage form 
and dose? 
Drug name Dosage form (e.g. 
tablet, inhaler, 
nebulizer) 
Dose (i.e. number 
of tablets/puffs) 
Frequency (i.e. 
times used per 
day) 
    
    







D. Has your child suffered any of the following problems since commencing 
treatment for their asthma:  
                                                                                Yes           No 
5- weight gain      [   ]           [   ]                                                          
6- change of mood (e.g. depression)  [   ]           [   ]                                   
7- diabetes                                                               [   ]           [   ]             
8- slowed growth rate    [   ]           [   ]                                                           
 
E. Has your child been admitted to hospital or attended the Emergency Room at 
the hospital during the last 3 months? 
   Yes  [   ]      how many times? (              ) number   






Section V:  Quality of life 
The following questions relate to the impact of your child’s asthma on their general 
well being. 
Q1- Have you feel in trouble during the last four weeks because of your asthma?  
1. Never 
2. Some of the time (Once a week or less) 
3. Often (2 to 4 times a week) 
 4. Always (Daily)  
 
Q2- Did you feel worried, anxious or afraid in the last four weeks because your 
asthma? 
1. Never 
2. Some of the time 
3. Often  
4. Always (Daily) 
 
Q3- In the last four weeks did you feel annoyed or angry because of your 
asthma? 
1. Never 
2. Some of the time 
3. Often  
4. Always (Daily) 
 
Q4- In the last four weeks how often could you do your regular activities 
because of your asthma? 
1. Never 
2. Some of the time 
3. Often  







Appendix E:  
Phase One Results (Patients) 
This appendix reflects the association between asthma management aspects and 
gender. 
Table E 1 Patients’ self-assessment of severity 
















 Very mild  Male 4 (6.9) 1 (1.4) 5 (3.9) 
Female 8 (14.5) 1 (2.2) 9 (8.9) 
Total 12 (10.2) 2 (1.7) 14 (6.1) 
Mild Male 19 (32.8) 16 (22.5) 35 (27.1) 
Female 20 (36.4) 7 (15.2) 27 (26.7) 
Total 39 (34.5) 23 (19.7) 62 (27.0) 
 Moderate 
  
Male 30 (51.7) 39 (54.9) 69 (53.5) 
Female 24 (43.6) 28 (60.9) 52 (51.2) 
Total 54 (47.8) 67 (57.3) 121 (52.6) 
 Severe 
  
Male 5 (6.6) 15 (21.1) 20 (15.5) 
Female 3 (5.5) 10 (21.7) 13 (12.9) 























Winter None 5 (8.8) 5 (9.1) 4 (5.6) 0 (0.0) 
NS A little 24 (42.1) 21 (38.2) 26 (36.6) 13 (28.3) 
A lot 28 (49.1) 29 (52.7) 41 (57.7) 33 (71.7) 
Summer 
 
None 10 (17.5) 15 (27.3) 20 (28.2) 12 (26.1) NS 
A little 28 (49.1) 24 (43.6) 40 (56.3) 23 (23.9) 
A lot 19 (33.3) 16 (29.1) 11 (15.5) 11 (23.9) 
Spring 
 
None 5 (8.8) 5 (9.1) 12 (16.9) 9 (19.6) NS 
A little 38 (66.7) 40 (72.7) 32 (45.1) 20 (43.5) 
A lot 14 (24.6 10 (18.2) 27 (38.0) 17 (37.0) 
Fall None 12 (21.1) 17 (30.9) 14 (19.7) 10 (21.7) NS 
A little 34 (59.6) 25 (45.5) 35 (49.3) 25 (54.3) 
A lot 11 (19.3) 13 (23.6) 22 (31.0) 11 (23.9) 














Male 56(96.6) 2(3.4) 58(100.0) 
Female 53(96.4) 2(3.6) 55(100.0) 
Total 109(96.5) 4(3.5) 113(100.0) 
Riyadh 
Male 69(97.2) 2(2.8) 71(100.0) 
Female 43(93.5) 3(6.5) 46(100.0) 
Total 112(95.7) 5(4.3) 117(100.0) 
Total 
Male 125(96.9) 4(3.1) 129(100.0) 
Female 96(95.0) 5(5.0) 101(100.0) 
Total 221(96.1%) 9(3.9) 230(100.0) 
 Difference between 





Table E 4 Number of patients using an inhaler or nebulizer for quick relief from 
asthma symptoms.  
Region Gender 
Use of an inhaler or nebulizer for quick relief from asthma symptoms. 
Yes No Unsure Total 




45(77.6) 11(19.0) 2(3.4) 58(100.0) 
Female 
N=55 
34(61.8) 20(36.4) 1(1.8) 55(100.0) 
Total 
N=113 




59(83.1) 12(16.9) 0(0.0) 71(100.0) 
Female 
N=46 
36(78.3) 9(19.6) 1(2.2) 46(100.0) 
Total 
N=117 




104(80.6) 23(17.8) 2(1.6) 129(100.0) 
Female 
N=101 
70(69.3) 29(28.7) 2(2.0) 101(100.0) 
Total 
N=230 
174(75.70 52(22.6) 4(1.7) 230(100.0) 
 Difference in Gender p value NS 
 
Table E 5 Number of patients using control medication 
Number of patients using 



















Male 42 (72.4) 47 (66.2) 89 (69.0) 
Female 42 (76.4) 35 (76.1) 77 (76.2) 
Total 84 (74.3) 82 (70.1) 166 (72.2) 
No Male 16 (27.6) 24 (33.8) 40 (31.0) 
Female 13 (23.6) 11 (23.9) 24 (23.8) 






Table E 6 Classes of medication used 
Class of medication used Gender 
  
 Response option 
P value 
Yes No 
N (%) N (%) 
 NS  
 Adrenoceptor Agonist (select β2 
Agonist)  
Male 124 (96.1) 5 (3.9) 
Female 93 (92.1) 8 (7.9) 
Total 217 (94.3) 13 (5.7) 
 Anticholinergic 
Male 4 (3.1) 125 (96.9) 
  
  
Female 1 (1.0) 100 (99.0) 
Total 5 (2.2) 225 (97.8) 
  
Corticosteroid  
Male 36 (27.9) 93 (72.1) 
 NS 
  
Female 32 (31.7) 69 (68.3) 
Total 68 (29.6) 162 (70.4) 
  
Theophylline  
Male 3 (2.3) 126 (97.7) 
NS 
Female 3 (3.0) 98 (97.0) 
Total 6 (2.6) 224 (97.4) 
Anti-Histamine 
Male 9 (7.0) 120 (93.0) 
NS 
Female 2 (2.0) 99 (98.0) 
Total 11 (4.8) 219 (95.2) 
Sodium cromoglycate 
Male 2 (1.6) 127 (98.49) 
NS 
Female 3 (3.0) 98 (97.0) 
Total 5 (2.2) 225 (97.8) 
Anti-leukotriene receptor 
Male 1 (0.8) 128 (99.2) 
NS 
Female 5 (5.0) 96 (95.0) 
Total 6 (2.6) 224 (97.4) 
Antibiotics 
Male 1 (0.8) 128 (99.2) 
NS 
Female 0 (0.0) 101 (100.0) 






Table E 7 Medication usage 
Medication usage Gender Regions  P value 
Asser Riyadh  Total 




 β2 agonist only 
 
Male 41 (70.7) 38 (53.3) 79 (61.2) 
Female 39 (70.9) 22 (47.8) 61 (60.4) 
Total 80 (70.8) 60 (51.3) 140 (60.9) 
 β2 agonist + Corticosteroid 
Male 7 (12.1) 19 (26.8) 26 (20.2) 
  NS 
   
Female 7 (12.7) 15 (32.6) 22 (21.8) 
Total 14 (12.4) 34 (29.1) 48 (20.9) 
 β2 agonist +Corticosteroid + 
others 
Male 1 (1.7) 5 (7.0) 6 (4.7) 
 NS  
Female 0 (00.0) 3 (6.5) 3 (3.0) 
Total 1 (0.9) 8 (6.8) 9 (3.9) 
 β2 agonist + other (Non-
Corticosteroid ) 
Male 7 (12.1) 7 (9.9) 14 (10.9) 
NS 
Female 5 (9.1) 3 (6.5) 8 (7.9) 
Total 12 (10.6) 10 (8.5) 22 (9.6) 
Corticosteroid  only 
Male 2 (3.4) 2 (2.8) 4 (3.1) 
NS 
Female 2 (3.6) 3 (6.5) 5 (5.0) 
Total 4 (3.5) 5 (4.3) 9 (3.9) 
Corticosteroid + other (non β2 
agonist) 
Male 0 (00.0) 0 (00.0) 0 (00.0) 
NS 
Female 2 (3.6) 0 (00.0) 2 (2.0) 












Yes No I do not know Total 
N (%) N (%) N (%) N (%) 
Asser 
Male 12(20.7) 39(67.2) 7(12.1) 58(100.0) 
Female 10(18.2) 41(74.5) 4(7.3) 55(100.0) 
Total 22(19.5) 80(70.8) 11(9.7) 113(100.0) 
Riyadh 
Male 32(45.1) 27(38.0) 12(16.9) 71(100.0) 
Female 26(56.5) 14(30.4) 6(13.4) 46(100.0) 
Total 58(49.6) 41(35.0) 18(15.4) 117(100.0) 
Total 
Male 44(34.1) 66(51.2) 19(14.7) 129(100.0) 
Female 36(35.6) 55(54.5) 10(9.9) 101(100.0) 
Total 80(34.8) 121(52.6) 29(12.6) 230(100.0) 




Table E 9 Patients’ adherence to ICS daily usage 








value Gender N (%) N (%) N (%) 







Female 3(13.6) 6(10.3) 9(11.3) 
Total 9(40.9) 15(25.9) 24(30.0) 
 Inhaled steroids less often.   Male 3(13.6) 8(13.8) 11(13.8) 
Female 2(9.1) 2(3.4) 4(5.0) 
Total 5(22.7) 10(17.2) 15(18.8) 
Inhaled steroids several times a week.   Male 0(0.0) 2(3.4) 2(2.5) 
Female 1(4.5) 3(5.2) 4(5.0) 
Total 1(4.5) 5(8.6) 6(7.5) 
Inhaled steroids when having asthma 
symptoms.  
Male 3(13.6) 13(22.4) 16(20.0) 
Female 4(18.2) 15(25.9) 19(23.8) 






Table E 10 Self-reported side effects 












A. Weight gain Yes Male 5(8.8) 16(22.9) 21(16.5) NS 
Female 10(18.2) 8(17.4) 18(17.8) 
Total 15(13.4) 24(20.7) 39(17.1) 
No Male 52(91.2) 54(77.1) 106(83.5) 
Female 45(81.8) 38(82.6) 83(82.2) 
Total 97(86.6) 92(79.30 189(82.9) 
B. Change of 
mood 
Yes Male 13(22.4) 27(38.6) 40(31.3) NS 
Female 23(41.8) 20(44.4) 43(43.0) 
Total 36(31.9) 47(40.9) 83(36.4) 
No Male 88(38.6) 43(61.4) 88(68.8) 
Female 57(25.0) 25(55.6) 57(57.0) 
Total 145(63.6) 68(59.1) 145(63.6) 
C. Diabetes Yes Male 1(1.8) 1(1.4) 2(1.6) NS 
Female 0(0.0) 0(0.00 0(0.0) 
Total 1(0.9) 1(0.9) 2(0.9) 
No Male 56(98.2) 68(98.6) 124(98.4) 
Female 54(100.0) 46(100.0) 100(100.0) 
Total 110(99.1) 114(99.1) 224(99.1) 
D. Slowed 
growth rate 
Yes Male 11(19.3) 17(24.3) 28(22.0) NS 
Female 10(18.2) 8(17.4) 18(17.8) 
Total 21(18.8) 25(21.6) 46(20.2) 
No Male 46(80.7) 53(75.7) 99(78.0) 
Female 45(81.8) 38(82.6) 83(82.2) 






Table E 11 Number of patients admitted to hospital or attending ER. 
Patients admitted to hospital 







































Table E 12 Number of patients with written instructions (AAPs) 
AAP availability, on what to do 











Yes Male 49 (94.2) 50 (75.8) 99 (83.9) NS 
Female 49 (92.5) 36 (80.0) 85 (86.7) 
Total 98 (93.3) 86 (77.5) 184(85.2) 
No Male 3 (5.8) 16 (24.2) 19 (16.1) 
Female 4 (7.5) 9 (20.0) 13 (13.3) 
Total 7(6.7) 25 (22.5) 32 (14.8) 
*Eight data missing 
**Six data missing 





Table E 13 Respondents’ taking of medicine(s) on days when not having an asthma 
attack. 
AAP availability, on how to take 










N (%) N (%) N (%) 
 Yes 
  





Female 44(80.0) 30(66.6) 74(74) 
Total 91(80.5) 80(69.6) 171(75.0) 
 No 
  
Male 5(8.6) 16(22.9) 21(16.4) 
Female 6(10.9) 7(15.6) 13(13) 
Total 11(9.7) 23(20.0) 34(14.9) 
 Unsure 
  
Male 6(10.4) 4(5.7) 10(7.8) 
Female 5(9.1) 8(17.8) 13(13) 
Total 11(9.7) 12(10.4) 23(10.1) 
*Two data missing 
**Two data missing 
 
Table E 14 Respondents’ understanding of AAP instructions on how to use their 
medications when not having a severe asthma attack 
Level of AAP understanding on how 















1. Yes, and completely understood 
Male 41(70.7) 53(74.7) 94(72.8) 
Female 37(67.3) 31(67.4) 68(67.3) 
Total 78(69.0) 84(71.8) 162(70.4) 
2. Yes, well understood 
 
Male 14(24.1) 11(15.5) 25(19.4) 
Female 15(27.3) 8(17.4) 23(22.8) 
Total 29(25.7) 19(16.2) 48(20.9) 
3. Yes, confused 
 
Male 1(1.7) 3(4.2) 4(3.1) 
Female 2(3.6) 1(2.2) 3(3.0) 
Total 3(2.7) 4(3.4) 7(3.0) 
4. No, not at all 
 
Male 2(3.5) 4(5.6) 6(4.7) 
Female 1(1.8) 6(13.0) 7(6.9) 




Table E 15 Respondents’ understanding of AAP instructions on how to use their 
medications when having a severe asthma attack 
Level of AAP understanding on what 











  N (%) N (%) N (%) 
  
 1. Yes, and completely understood  
Male 39(67.3) 47(66.2) 86(66.7) 
NS 
Female 42(76.4) 29(63.0) 71(70.3) 
Total 81(71.7) 76(65.0) 157(68.3) 
 2. Yes, well understood 
  
Male 14(24.1) 11(15.5) 25(19.4) 
Female 12(21.8) 7(15.2) 19(18.8) 
Total 26(23.0) 18(15.4) 44(19.1) 
 3. Yes, confused 
  
Male 0(0.0) 3(4.2) 3(2.3) 
Female 1(1.8) 1(2.2) 2(2.0) 
Total 1(0.9) 4(3.4) 5(2.2) 
 4. No, not at all 
  
Male 5(8.6) 10(14.1) 15(11.6) 
Female 0(0.0) 9(19.6) 9(8.9) 
Total 5(4.4) 19(16.2) 24(10.4) 
 
Table E 16 Number of patients with a peak flow meter 













Male 52(89.7) 51(71.8) 103(79.8) 
NS 
Female 49(89.0) 32(69.6) 81(80.2) 
Total 101(89.4) 83(70.9) 184(80.0) 
 Yes and uses it regularly.  
  
Male 0(0.0) 9(12.7) 9(7.0) 
NS 
Female 3(5.5) 7(15.2) 10(9.9) 
Total 3(2.7) 16(13.7) 19(8.3) 
 Yes, but almost never used  
  
Male 6(10.3) 11(15.5) 17(13.2) 
Female 35.5) 7(15.2) 10(4.3) 




Table E 17 Number of patients using a spacer when taking medication. 








  N (%) N (%) N (%) 
 Yes 
  





Female 14(25.9) 21(46.7) 35(35.4) 
Total 27(24.1) 55(47.8) 82(36.1) 
No 
  
Male 45(77.6) 36(51.4) 81(63.3) 
Female 40(74.1) 24(53.3) 64(64.6) 
Total 85(75.9) 60(52.2) 145(63.9) 
*One data missing 
**Two data missing 
*** Three data missing 
 
Table E 18 Accessibility of information across gender and region 
Access to adequate asthma 













Male 46(79.3) 48(67.6) 94(72.9) 
Female 42(77.8) 27(61.3) 69(70.4) 
Total 88(78.6) 75(65.2) 163(71.8) 
 No 
  
Male 7(12.1) 13(18.3) 20(15.5) 
Female 6(11.1) 12(27.2) 18(18.4) 
Total 13(11.6) 25(21.7) 38(16.7) 
 Unsure 
  
Male 5(8.6) 10(14.1) 15(11.6) 
Female 6(11.1) 5(11.4) 11(11.2) 
Total 11(9.8) 15(13.0) 26(11.5) 
*One data missing 
**Two data missing 






Table E 19 Respondents’ inhaler usage education 
Correct inhaler use 









p value  
  No N (%) N (%) N (%) 
 Yes 
  
Male 42(72.4) 47(67.1) 89(69.5) 
NS 
   
Female 33(62.3) 29(63.0) 62(62.6) 
Total 75(67.6) 76(65.5) 151(66.5) 
 No 
  
Male 16(27.6) 23(32.9) 39(30.5) 
Female 20(37.7) 17(37.0) 37(37.4) 
Total 36(32.4) 40(34.5) 76(33.5) 
*Two data missing 
**One data missing 
*** Three data missing 
 




 Regions P 
value 
Asser* Riyadh * 
Total 






Male 6 (10.3) 17 (24.0) 23 (17.9) 
Female 2 (3.7) 8 (17.8) 10 (10.1) 
Total 8 (7.1) 25 (21.6) 33 (14.5) 
 Good 
Male 28 (48.3) 26 (36.6) 54 (41.9) 
  NS 
   
Female 30 (55.6) 23 (51.1) 53 (53.5) 
Total 58 (51.8) 49 (42.2) 107 (46.9) 
  
Very Good 
Male 17 (29.3) 18 (25.4) 35 (27.1) 
 NS 
  
Female 16 (29.6) 6 (13.3) 22 (22.2) 
Total 33 (29.5) 24 (20.7) 57 (25.0) 
  
Excellent 
Male 7 (12.1) 10 (14.1) 17 (13.2) 
NS 
Female 6 (11.1) 8 (17.8) 14 (14.1) 
Total 13 (11.6) 18 (15.5) 31 (13.6) 





Table E 21 Patients’ involvement in treatment across gender and region 
Involvement in asthma treatment 










   N (%) N (%) N (%) 
   
 Yes 
  






Female 36(65.5) 34(73.9) 70(69.3) 
Total 83(73.5) 83(70.9) 166(72.2) 
 No 
  
Male 4(6.9) 18(25.4) 22(17.0) 
Female 12(21.8) 11(23.9) 23(22.8) 
Total 16(14.2) 29(24.8) 45(19.6) 
 Unsure 
  
Male 7(12.1) 4(5.6) 11(0.8) 
Female 7(12.7) 1(2.2) 8(7.9) 
Total 14(12.4) 5(4.3) 19(8.3) 
 
Table E 22 Level of health care provider’s attention to patient concerns 
Level of health care provider 
attention to patient concern 
Gender 
  
 Regions P 
value 
Asser* Riyadh * 
Total** 










Male 4 (7.2) 11 (15.5) 15 (11.8) 
Female 4 (7.4) 6 (14.0) 10 (10.3) 
Total 8 (7.3) 17 (14.9) 25 (11.2) 
 Good 
Male 21 (37.5) 20 (28.2) 41 (32.3) 
Female 24 (44.4) 23 (53.5) 47 (48.5) 
Total 45 (40.9) 43 (37.7) 88 (39.3) 
  
Very good 
Male 16 (28.6) 18 (25.4) 34 (26.8) 
Female 15 (27.8) 5 (11.6) 20 (20.6) 
Total 31 (28.2) 23 (20.2) 54 (24.1) 
  
Excellent 
Male 15 (26.8) 22 (31.0) 37 (29.1) 
Female 11 (20.4) 9 (20.9) 20 (20.6) 
Total 26 (23.6) 31 (27.2) 57 (25.4) 
*Three data missing 





Table E 23 Patients’ perceptions of physicians’ medication recommendations  
Physician’s attentiveness to 
























Male 47(81.0) 55(77.5) 102(79.1) 
Female 49(89.1) 37(80.4) 86(85.1) 




Male 2(3.5) 8(11.2) 10(7.8) 
Female 4(7.3) 5(10.9) 9(9.0) 




Male 9(15.5) 8(11.2) 17(7.4) 
Female 2(3.6) 4(8.7) 6(5.9) 
Total 11(9.7) 12(10.3) 23(10.0) 
Table E 24 Number of respondents coached about medication usage over the past 12 
months 






N=230 p value 
N (%) N (%) N (%) 
 Yes 
  








Female 52(94.5) 34(73.9) 86(85.1) 




Male 3(5.2) 14(19.7) 17(13.2) 
Female 3(5.5) 8(17.4) 11(10.9) 




Male 3(5.2) 1(1.4) 4(3.1) 
Female 0(0.0) 4(8.7) 4(4.0) 





Table E 25 Number of respondents observed by their health care providers while using 
their inhaler 

























Female 30(57.7) 32(71.1) 62(63.9) 




Male 19(32.8) 25(35.2) 44(34.1) 
Female 22(42.3) 13(28.9) 35(36.1) 
Total 41(37.3) 38(32.8) 79(35.0) 
*Three data missing 
**One data missing 
*** Four data missing 
Table E 26 Number of patients able to administer medicine as directed 
Patients believe they can administer 
























Female 51(92.7) 36(78.3) 87(86.1) 




Male 3(5.2) 7(9.9) 10(7.8) 
Female 1(1.8) 8(17.4) 9(8.9) 




Male 3(5.2) 3(4.2) 6(4.7) 
Female 3(5.5) 2(4.3) 5(5.0) 






Table E 27 Respondents’ perceptions about medication effectiveness 























Male 36(62.1) 40(57.1) 76(59.3) 
Female 45(81.8) 29(64.5) 74(74.0) 




Male 5(8.6) 11(15.7) 16(12.5) 
Female 3(5.5) 6(13.3) 9(9.0) 




Male 17(29.3) 19(27.2) 36(28.2) 
Female 7(12.7) 10(22.2) 17(17.0) 
Total 24(21.2) 29(25.2) 53(23.2) 
*Two data missing 
Table E 28 Patients’ and their families’ self-efficacy 


















 High self-efficacy 
No (%) 
Male 31 (53.4) 33 (47.1) 64 (50.0) 
Female 
37(68.5) 19 (43.2) 56 (57.1) 
 Good  
No (%) 
Male 17 (29.3) 18 (25.7) 35 (27.3) 
Female 11 (20.4) 12 (27.3) 23 (23.5) 
Total    
 Low 
N (%) 
Male 7 (12.1) 14 (20.0) 21 (16.4) 
Female 
4 (7.4) 8 (18.2) 12 (12.2) 
Poor 
N (%) 
Male 3 (5.2) 5 (7.1) 8 (6.3) 
Female 
2 (3.7) 5 (11.4) 7 (7.1) 
*One data missing 
**Three data missing 




Table E 29 Patients’ and their families’ behaviours/ attitudes 

























Male 14 (24.1) 19 (26.8) 33 (25.6) 
Female 16 (29.1) 8 (17.4) 24 (23.8) 




Male 31 (53.4) 41 (57.7) 72 (55.8) 
Female 33 (60.0) 26 (56.5) 59 (58.4) 






Male 13 (22.4) 11 (15.5) 24 (18.6) 
Female 6 (10.9) 12 (26.1) 18 (17.8) 






Table E 30 Patients’ asthma control levels 
Asthma control 
level 
Asser Riyadh Total P value 
Male (58) 
No (%) 
















8(13.8) 11 (20.0) 8 (11.3) 5 (10.9) 16 (12.4) 16 (15.8) 
Two control 
problems 
9 (15.5) 16 (29.1) 18 (25.4) 6 (13.0) 27 (20.9) 22 (21.8) 
Three control 
problems 
7 (12.1) 9 (16.4) 17 (23.9) 9 (19.6) 24 (18.6) 18 (17.8) 
Four control 
problems 
12 (20.7) 4 (7.3) 13 (18.3) 10 (21.7) 25 (19.4) 14 (13.9) 
Five control 
problems 
4 (6.9) 2 (3.6) 5 (7.0) 8 (17.4) 9 (7.0) 10 (9.9) 
Six control 
problems 
4 (6.9) 2 (3.6) 5 (7.0) 3 (6.5) 9 (7.0) 5 (5.0) 
Poor control 0 (0.00) 1 (0.9) 1 (1.4) 0 (0.00) 1 (0.8) 1 (1.00) 
 
Table E 31 Patients’ and their health care providers’ communication levels 
Communication 
level 
Asser (113) Riyadh (115) Total (228) P 















Poor 35 (60.3) 30 (54.5) 28 (40.0) 22 (48.9) 63 (49.2) 52 (52.0) 
NS 
Low 9(15.5) 15 (27.3) 19 (27.1) 9 (20.0) 28 (21.9) 24 (24.0) 
Fair 6 (10.3) 6 (10.9) 9 (12.9) 5 (11.1) 15 (11.7) 11 (11.0) 
Medium 6 (10.3) 1 (1.8) 4 (5.7) 2 (4.4) 10 (7.8) 3 (3.0) 
Good  1 (1.7) 0 (0.00) 5 (7.1) 3 (6.7) 6 (4.7) 3 (3.0) 





Appendix F:  
Phase Two Results  (Physicians) 
This appendix reflects the association between asthma management’s aspects and gender. 
Section 1: Patient education strategies  
Table F 1 Asthma: general information  
What is your usual approach to 
providing general information 
about asthma (e.g. structure of the 
respiratory system, mechanisms of 
asthma, inflammation, common 
triggers) to patients? 
 Asser 
N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56Male and 31 female) 













Mild             
N (%) 





I do not provide this information 
  
Male 
0 (0.0) 0 (0.0) 0 (0.0) 2 (7.7) 1(3.8) 1(3.8) 2 (3.6) 1 (1.8) 1 (1.8) 
Female 1 (7.7) 0 (0.0) 1 (7.7) 
0 (0.0) 0 (0.0) 0 (0.0) 1 (3.2) 0 (0.0) 1 (3.2) 
Total 1 (2.3) 0 (0.0)  1 (2.3) 2 (4.5) 1(2.3) 1(2.3%) 3 (3.4) 1 (1.1) 
2 (2.3) 
 I provide this information  only if 
the patient asks 
Male 7 (23.3) 4 (13.3) 1 (3.3) 2 (7.7) 2 (7.7) 0 (0.0) 9 (16.1) 6 (10.7) 
1 (1.8) 






Total 10 (23.3) 5 (11.6) 1 (2.3) 11 (25.0) 6 (13.6) 3 (6.8) 21 (24.1) 11 (12.6) 
4 (4.6) 
 I provide this information without 
waiting for the patient to ask.  
Male 23 (76.7) 26 (86.7) 29 (96.7) 22 (84.6) 23 (88.5) 25 (96.2) 45 (80.4) 49 (87.5) 
54 (96.4) 
Female 9 (69.2) 12 (92.3) 12 (92.3) 9 (50.0) 14 (77.8) 15 (83.3) 18 (58.1) 26 (83.9) 27 (87.1) 
Total 32 (74.4%) 38 (88.4) 41 (95.4) 31 (70.5) 37 (84.1) 40 (90.9) 63 (72.4) 75 (86.2) 81 (93.1) 
 Difference between Gender p 
value   
 0.305  0.596 0.252  0.004  0.289 0.074 0.060 0.593   0.216 
Difference between Region p 
value 










N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56Male and 31 female) 
What is your usual approach to 
providing information about 
prescribed asthma medication (e.g. 
mode of action, proper dose, side 
effects) to patients? 
Gender 








N (%)  
Moderate 
 N (%) 
Severe 
N (%) 
Mild             
N (%) 
Moderate   
N (%) 
Severe    
   N (%) 
I do not provide  this information 
Male 0 (0.0) 0 (0.0) 1 (3.3) 2 (7.7) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 1 (1.8) 
Female 0 (0.0) 0 (0.0) 1 (7.7) 2 (11.1) 1(5.6) 1(5.6) 2 (6.5) 1 (1.1%) 2 (6.5) 
Total 0 (0.0) 0 (0.0) 2 (4.7) 4 (9.1) 1(2.3) 1(2.3) 4 (4.6) 1 (1.1%) 3 (3.4) 
 
I provide this information  only if 
the patient asks 
Male 10(33.3) 5(16.7) 2 (6.7) 9(34.6) 9(34.6) 6 (23.1) 19 (33.9) 14 (16.1%) 8 (14.3) 
Female 3 (23.1) 0 (0.0) 0 (0.0) 6 (33.3) 4 (22.2) 2 (11.1) 9 (29.0) 4 (4.6%) 2 (6.5) 
Total 13 (30.3) 5 (11.6) 2 (4.7) 15 (34.1) 13 (29.5) 8 (18.2) 28 (32.2) 18 (20.7%) 10 (11.5) 
I provide this information without 
waiting for the patient to ask.  
Male 20 (66.7) 25 (83.3) 27 (90.0) 15 (57.7) 17 (65.4) 20 (76.9) 35 (62.5) 42 (48.3%) 47 (83.9) 
Female 10 (76.9) 13 (100.0) 12 (92.3) 10 (55.6) 13 (72.2) 15 (83.3) 20 (64.5) 26 (29.9%) 27 (87.1) 
Total 30 (69.7) 38 (88.4%) 39 (90.7) 25 (56.8) 30 (68.2) 35 (79.5) 55 (63.2) 68 (78.2%) 74 (85.1) 
Difference in Gender p value  0.501 0.117 0.537 0.928 0.355 0.311 0.770 0.181 0.309 




Table F 3 Demonstrating the proper use of inhalation devices 
Q   
Asser 
N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56 Male and31 female) 
What is your usual approach to 
demonstrating the proper use of 
inhalational device (e.g. metered 
dose inhaler, spacer device, 
turbuhaler) to patients?  Gender 













Mild             
N (%) 
Moderate   
N (%) 
Severe      
N (%) 
  
I do not provide  this information  
Male 
1 (3.3) 0 (0.0) 1 (3.3) 1(3.8) 0 (0.0) 0 (0.0) 2 (3.6) 0 (0.0) 1 (1.8) 
Female 
1 (7.7) 0 (0.0) 1 (7.7) 1(5.6) 1(5.6) 1(5.6) 2 (6.5) 1 (3.2) 2 (6.5) 
Total 
2 (4.7%) 0 (0.0) 2 (4.7) 2 (4.5) 1(2.3) 1(2.3) 4 (4.6) 1 (1.1) 3 (3.4) 
  
I provide this information  only if 
the patient asks  
Male 
2 (6.7) 1 (3.3) 2 (6.7) 6 (23.1) 4 (15.4) 2 (7.7) 8 (14.3) 5 (8.9) 4 (7.1) 
Female 
3 (23.1) 2 (15.4) 1 (7.7) 5 (27.8) 2 (11.1) 2 (11.1) 8 (25.8) 4 (12.9) 3 (9.7) 
Total 
5(11.6) 3 (7.0) 3 (7.0) 11 (25.0) 6 (13.6) 4 (9.1) 16 (18.4) 9 (10.3) 7 (8.0) 
  
I provide this information without 
waiting for the patient to ask.  
Male 
27 (90.0) 29 (96.7) 27 (90.0) 19 (73.1) 22 (84.6) 24 (92.3) 46 (82.1) 51 (91.1) 51 (91.1) 
Female 
9 (69.2) 11 (84.6) 11 (84.6) 12 (66.7) 15 (83.3) 15 (83.3) 21 (67.7) 26 (83.9) 26 (83.9) 
Total 
36 (83.7) 40 (93.0) 38 (88.3) 31 (70.5) 37 (84.1) 39 (88.6) 67 (77.0) 77 (88.5) 77 (88.5) 
 Difference in Gender p value 
 
0.230 0.154 0.813 0.894 0.452 0.432 0.311 0.328 0.464 




Table F 4 Information about asthma triggers  
Q  Asser 
N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56 Male and31 female) 
What is your usual approach to providing 
information on avoidance of asthma triggers 
and environmental control (e.g. control of 
house dust mites, mould, etc.….) to patients? 
Gender Asthma Severity Asthma Severity Asthma Severity 




Severe    N 
(%) 




Severe    N 
(%) 
Mild             
N (%) 
Moderate   
N (%) 
Severe      
N (%) 
 
I do not provide this information 
 
Male 0 (0.0) 0 (0.0) 1 (3.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 
Female 0 (0.0) 0 (0.0) 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (3.2) 
Total 0 (0.0) 0 (0.0) 2 (4.7%) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (2.3%) 
 
I provide this information only if the patient 
asks 
 
Male 2 (6.7) 2 (6.7) 0 (0.0) 2 (7.7) 3 (11.5) 2 (7.7) 4 (7.1) 5 (8.9) 2 (3.6) 
Female 1 (7.7) 0 (0.0) 0 (0.0) 2 (11.1) 1(5.6) 1(5.6) 3 (9.7) 1 (3.2) 1 (3.2) 
Total 3 (7.0) 2 (4.7) 0 (0.0) 4 (9.1) 4 (9.1) 3 (6.8) 7 (8.0) 6 (6.9) 3 (3.4) 
 
I provide this information without waiting 
for the patient to ask 
 
Male 28 (93.3) 28 (93.3) 29 (96.7) 24 (92.3) 23 (88.5) 24 (92.3) 52 (92.9) 51 (91.1) 53 (94.6) 
Female 12 (92.3) 13 (100.0) 12 (92.3) 16 (88.9) 17 (94.4) 17 (94.4) 28 (60.3) 30 (96.8) 29 (93.5) 
Total 40 (93.0) 41 (95.3) 41 (95.3) 40 (90.9) 40 (90.9) 41 (93.2) 80 (92.0) 81 (93.1) 82 (94.3) 
Difference in Gender p value  0.903 0.340 0.533 0.698 0.497 0.782 0.677 0.316 0.910 








N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56 Male and31 female) 
What is your usual approach to 
providing information on the 
warning sings of worsening or 
uncontrolled asthma to patients? Gender 













Mild             
N (%)  
Moderate 
N (%)  
Severe 
N (%) 
I do not provide  this information 
  
Male 1 (3.3) 0 (0.0) 0 (0.0) 5 (19.2) 1(3.8) 1(3.8) 6 (10.7) 1 (1.8) 1 (1.8) 
Female 0 (0.0) 0 (0.0) 0 (0.0) 4 (22.2) 5 (27.7) 4 (22.2) 4 (12.9) 5 (16.1) 4 (12.9) 
Total 1 (2.3) 0 (0.0) 0 (0.0) 9 (20.5%) 6 (13.6) 5 (11.4%) 10 (11.5) 6 (6.9) 5 (5.7) 
  
I provide this information  only if 
the patient asks 
  
Male 10 (33.3) 5(16.7) 0 (0.0) 4 (15.4) 3 (11.5) 2 (7.7) 14 (25.0) 8 (14.3) 2 (3.6) 
Female 3 (23.1) 0 (0.0) 1 (7.7) 6 (33.3) 1(5.6) 0 (0.0) 9 (29.0) 1 (3.2) 1 (3.2) 
Total 13 (30.2) 5(11.6) 1 (2.3) 10 (22.7) 4 (9.1) 2 (4.5) 23 (26.4) 9 (10.3) 3 (3.4) 
 I provide this information without 
waiting for the patient to ask. 
  
Male 19 (63.3) 25 (83.3) 30 (100.0) 17 (65.4) 22 (84.6) 23 (88.5) 36 (64.3) 47 (83.9) 53 (94.6) 
Female 10 (76.9) 13 (100.0) 12 (92.3) 8 (44.4) 12 (66.7) 14 (77.8 18 (58.1) 25 (80.6) 26 (83.9) 
Total 29 (67.4) 38 (88.4) 42 (97.7) 25 (56.8) 34 (77.3) 37(84.1) 54 (62.1) 72 (82.8) 79 (90.8) 
 Difference in Gender p value   0.607 0.117 0.124 0.305 0.070 0.096 0.848 0.015 0.103 






Table F 6 Asthma action plans based upon symptom information  
What is your usual approach to 
providing an asthma action plan 
based upon symptoms (e.g. written 
plan that outlines steps to 
control/regain control of asthma 
including changing dose of drug)? 
 
**Asser N=43 
(30 male and 13 female) 
Riyadh N=44 
(26 male and18 female) 
*Total N=87 
(56 male and 31 female) 












N (%) * 
Mild             
N (%) 
Moderate   
N (%) N= 
86* 
Severe 
N (%)  
I do not provide  this information 
 
Male 4 (13.3) 2 (6.7) 2 (6.7) 10 (38.5) 5 (19.2) 3 (11.5) 14 (25.0) 7 (12.5) 5 (8.9) 
Female 2 (15.4) 1 (8.3) 2 (15.4) 9 (50.0) 7 (38.9) 6 (33.3) 11 (35.5) 8 (26.7) 8 (25.8) 
Total 6 (14.0%) 3 (7.1%) 4 (9.3%) 19 (43.2%) 12 (27.3%) 9 (20.5%) 25 (28.7) 15 (17.4) 13 (14.9) 
I provide this information  only if 
the patient asks 
 
Male 14 (46.7) 7 (23.3) 4 (13.3) 7 (29.9) 9 (43.6) 8 (30.8) 21 (37.5) 16 (28.6) 12 (21.4) 
Female 7 (53.3) 4 (33.3) 2 (15.4) 2 (11.1) 3 (16.7) 0 (0.0%) 9 (29.0) 7 (23.3%) 2 (6.5) 
Total 21 (48.8) 11 (26.2) 6 (14.0) 9 (20.5) 12 (27.3) 8 (18.2) 30 (34.5%) 23 (26.7%) 14 (16.1%) 
I provide this information without 
waiting for the patient to ask.  
Male 12 (40) 21 (70.0) 24 (80.0) 9 (34.6) 12 (46.2) 15 (57.7) 21 (37.5) 33 (58.9) 39 (69.6) 
Female 4 (30.8) 7 (58.3) 9 (69.2) 7 (38.9) 8 (44.4) 12 (66.7) 11 (35.5) 15 (50.0) 21( 67.7) 
Total 16 (37.2) 28 (66.7) 33 (76.7) 16 (36.4) 20 (45.5) 27 (61.4) 32 (36.8%) 48 (55.8%) 60 (69.0%) 
Difference in Gender p value  0.848 0.765 0.636 0.431 0.250 0.017 0.549 0.256 0.037 
Difference in Region p value   ---- ---- ---- ---- ---- ---- ---- 0.003 0.034 0.247 








N=43(30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87(56 Male and31 female) 
What is your usual approach to providing 
information about monitoring peak flow rates 
(e.g. purpose, purpose use of peak flow meters 
and proper recording of peak flow rates) to 
patients? 
Gender 













Mild             
N (%) 
Moderate   
N (%)  
Severe      
N (%)  
  
I do not provide  this information 
  
Male 6 (20.0) 4 (13.3) 3 (10.0) 8 (30.8) 7 (26.9) 6 (23.1) 14 (25.0) 11 (19.6) 9 (16.1) 
Female 3 (23.1) 1 (7.7) 1 (7.7) 11 (61.1) 7 (38.9) 6 (33.3) 14 (45.2) 8 (25.8) 7 (22.6) 
Total 9 (20.9) 5(11.6) 4 (9.3) 19 (43.2) 14 (31.8) 12 (27.3) 28 (32.2) 19 (21.8) 16 (18.4) 
  
I provide this information  only if the patient 
asks 
  
Male 11 (36.7) 3 (10.0) 4 (13.3) 9 (34.6) 6 (23.1) 4 (15.4) 20 (35.7) 9 (16.1) 8 (14.3) 
Female 4 (30.8) 3 (23.1) 3 (23.1) 4 (22.2) 8 (44.4) 6 (33.3) 8 (25.8) 11 (35.5) 9 (29.0) 
Total 15 (34.9) 6 (14.0) 7 (16.3) 13 (29.5) 14 (31.8) 10 (22.7) 28 (32.2) 20 (23.0) 17 (19.5) 
  
I provide this information without waiting for 
the patient to ask. 
  
Male 13 (43.3) 23 (76.7) 23 (76.7) 9 (34.6) 13 (50.0) 16 (61.5) 22 (39.3) 36 (64.3) 39 (69.6) 
Female 6 (46.2) 9 (69.2) 9 (69.2) 3 (16.7) 3 (16.7) 6 (33.3) 9 (29.0) 12 (38.7) 15 (48.4) 
Total 19 (44.2) 32 (74.4) 32 (74.4) 12 (27.3) 16 (36.4) 22 (50.0) 31(35.6) 48 (55.2) 54 (62.1) 
 Difference in Gender p value  0.929 0.490 0.723 0.130 0.072 0.164 0.156 0.050 0.127 




Table F 8 Asthma action plan based upon peak exploratory flow rates in conjunction with symptoms 
What is your usual approach to 
providing an asthma action plan that 
is based upon peak exploratory flow 
rates in conjunction with symptoms 
(e.g. written plan that outlines steps to 
control asthma) to patients?  
 
Asser 
N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56Male and 31 female) 
Gender 










N (%) * 
Severe 
N (%) 
Mild             
N (%)  
Moderate   
N (%)  
Severe 
N (%) N=86  
  
I do not provide  this information 
  
Male 7 (23.3) 7 (23.3) 7 (23.3) 11 (42.3) 6 (23.1) 4 (15.4) 18 (32.1) 13 (23.2) 11 (19.6) 
Female 2 (15.4) 1 (7.7) 2 (15.4) 12 (66.7) 11 (61.1) 10 (58.8) 14 (45.2) 12 (38.7) 12 (40.0) 
Total 9 (20.9) 8 (18.6) 9 (20.9) 23 (52.3) 17 (38.6) 14 (32.6) 32 (36.8) 25 (28.7) 23 (26.7) 
  
I provide this information  only if the 
patient asks  
Male 11 (36.7) 5(16.7) 3 (10.0) 6 (23.1) 10 (38.5) 7 (26.9) 17 (30.4) 15 (26.8) 10 (17.9) 
Female 4 (30.8) 3 (23.1) 2 (15.4) 5 (27.8) 3 (16.7) 2 (11.8) 9 (29.0) 6 (19.4) 4 (13.3) 
Total 15 (34.9) 8 (18.6) 5(11.6) 11 (25.0) 13 (29.5) 9 (20.9) 26 (29.9) 21( 24.1) 14 (16.3) 
  
I provide this information without 
waiting for the patient to ask.  
Male 12 (40.0) 18 (60.0) 20 (66.7) 9 (34.6) 10 (38.5) 15 (57.7) 21( 37.5) 28 (50.0) 35 (62.5) 
Female 7 (53.8) 9 (69.2) 9 (69.2) 1(5.6) 4 (22.2) 5 (29.4) 8 (25.8) 13 (41.9) 14 (46.6) 
Total 19 (44.2) 27 (62.8) 29 (67.4) 10 (22.7) 14 (31.8) 20 (46.5) 29 (33.3%) 41 (47.1%) 49 (57.0%) 
 Difference in Gender p value   0.685  0.469  0.775 0.072 0.037 0.012 0.417 .301 0.127 
Difference in Region p value   ----     ----    ----    ---- ----    ----  0.009 0.041 0.143 




Table F 9 Information about community non-profit organizations  
Q 
 Asser 
N=43 (30 Male and13 female) 
Riyadh 
N=44 (26 Male and18 female) 
Total 
N=87 (56 Male and31 female) 
What is your usual approach to providing 
information about community non-profit 
organizations that provide further information about 
asthma  (e.g. The National Scientific Committee of 
Bronchial Asthma ) to patients?  
Gender Asthma Severity Asthma Severity Asthma Severity 
Mild 











Mild             
N (%)  
Moderate   
N (%) 
Severe      
N (%) 
  
I do not provide this information  
Male 
8 (26.7) 7 (23.3) 7 (23.3) 12 (46.2) 9 (34.6) 7 (26.9) 20 (35.7) 16 (28.6) 14 (25.0) 
Female 
3 (23.1) 2 (15.4) 2 (15.4) 11 (61.1) 10 (55.6) 10(55.6) 14 (45.2) 12 (38.7) 12 (38.7) 
Total 
11 (25.6) 9 (20.9) 9 (20.9) 23 (52.3) 19 (43.2) 17 (38.6) 34 (39.1) 28 (32.2) 26 (29.9) 
  
I provide this information only if the patient asks  
Male 
17 (56.7) 16 (53.3) 12 (40.0) 8 (30.8) 7 (26.9) 8 (30.8) 25 (44.6) 23 (41.1) 20 (35.7) 
Female 
3 (23.1) 4 (30.8) 3 (23.1) 4 (22.2) 2 (11.1) 1(5.6) 7 (22.6) 6 (19.4) 4 (12.9) 
Total 
20 (46.5) 20 (46.5) 15 (34.9) 12 (27.3) 9 (20.5) 9 (20.5) 32 (36.8) 29 (33.3) 24 (27.6) 
  
I provide this information without waiting for the 
patient to ask.  
Male 
5(16.7) 7 (23.3) 11 (36.7) 6 (23.1) 10 (38.5) 11 (42.3) 11 (19.6) 17 (30.4) 22 (39.3) 
Female 
7 (53.8) 7 (53.8) 8 (61.5) 3 (16.7) 6 (33.3) 7 (38.9) 10 (32.3) 13 (41.9) 15 (48.4) 
Total 
12 (27.9) 14 (32.6) 19 (44.2) 9 (20.5) 16 (36.4) 18 (40.9) 21( 24.1) 30 (34.5) 37 (42.5) 
 Difference in Gender p value 
 0.034 0.145 0.319 0.621 0.293 0.061 0.110 0.120 0.067 
Difference in Region p value 




Section 2: Treatment 




















 N (%) 
Start an inhaled β2 agonist 1(3.2) 30(96.8) 8(14.3) 48(85.7) 9(10.3) 78(89.7) 0.105 
Start inhaled Atrovent (ipratropium 
bromide) 
28(90.3) 3(9.7) 49(87.5) 7(12.5) 10(11.5) 10(11.5) 0.693 
Start an inhaled corticosteroid 23(74.2) 8(25.8) 50(89.3) 6(10.7) 73(83.9) 14(16.1) 0.067 
Add a non-steroid anti- inflammatory 25(80.6) 6(19.4) 44(78.6) 12(21.4) 69(79.30 18(20.7) 0.819 
Start an oral theophylline 29(93.5) 2(6.5) 51(91.1) 5(8.9) 80(92.0) 7(8.0) 0.684 
Start oral corticosteroid 30(96.8) 1(3.2) 53(94.6) 3(5.4) 83(95.4) 4(4.6) 0.649 
Wait and see (no medication needed at 
this time) 
22(71.0) 9(29.0) 46(82.1) 10(17.9) 68(78.2) 19(21.8) 0.227 
Outpatient visit (e.g. same day office visit 
or refer to Emergency Department) 




Table F 11 Vignette B 




















Increase current use of the inhaled β2 
agonist 
13(42) 18(58) 28(50.0) 28(50.0) 41(47.1) 46(52.9) 
NS 
Start inhaled Atrovent (ipratropium 
bromide) 
22(71.0) 9(29.0) 39(69.6) 17(30.4) 61(70.1) 26(29.9) NS 
Start an inhaled corticosteroid 
5(16.1) 26(83.9) 16(28.6) 40(71.4) 21(24.1) 66(75.9) NS 
Add a non- steroid anti- inflammatory 
27(87.1) 4(12.9) 48(85.7) 8(14.3) 75(86.2) 12(13.8) NS 
Start an oral theophylline 
29(93.5) 2(6.5) 49(87.5) 7(12.5) 78(89.7) 9(10.3) NS 
Start oral corticosteroid 
28(90.3) 3(9.7) 50(89.3) 6(10.7) 78(89.7) 9(10.3) NS 
Wait and see (no medication needed at 
this time) 
25(80.6) 6(19.4) 51(91.1) 5(8.9) 76(87.4) 11(12.6) NS 
Outpatient visit (e.g. same day office visit 
or refer to Emergency Department) 





Table F 12 Vignette C 


















 N (%) 
Recommend N 
(%) 
Increase current use of the inhaled β2 agonist 23(74.2) 8(25.8) 38(67.9) 18(32.1) 61(70.1) 26(29.9) Ns 
Start inhaled Atrovent (ipratropium bromide) 13(41.9) 18(58.1) 26(46.4) 30(53.6) 39(44.8) 48(55.2) Ns 
Start an inhaled corticosteroid 1(3.2) 30(96.8) 9(16.1) 47(83.9) 10(11.5) 77(88.5) 0.072 
Add a non-steroid anti-inflammatory 22(71.0) 9(29.0) 44(78.6) 12(21.4) 66(75.9) 21(24.1) Ns 
Start an oral theophylline 23(74.2) 8(25.8) 35(62.5) 21(37.5) 58(66.7) 29(33.3) Ns 
Start oral corticosteroid 20(64.5) 11(35.5) 35(62.5) 21(37.5) 55(63.2) 32(36.8) Ns 
Wait and see (no medication needed at this 
time) 
28(90.3) 3(9.7) 53(94.6) 3(5.4) 81(93.1) 6(6.9) Ns 
Outpatient visit (e.g. same day office visit or 
refer to Emergency Department) 






Table F 13 Vignette D 





















Increase current use of the inhaled β2 
agonist 
13(41.9) 18(58.1) 25(44.6) 31(55.4) 38(43.7) 49(56.3) NS 
Start inhaled Atrovent (ipratropium 
bromide) 
12(38.7) 19(61.3) 18(32.1) 38(67.9) 30(34.5) 57(65.5) NS 
Start an inhaled corticosteroid 5(16.1) 26(83.9) 14(25.0) 42(75.0) 19(21.8) 68(78.2) NS 
Add a non- steroid anti- inflammatory 26(83.9) 5(16.1) 47(83.9) 9(16.1) 73(83.9) 14(16.1) NS 
Start an oral theophylline 24(77.4) 7(22.6) 37(66.1) 19(33.9) 61(70.1) 26(29.9) NS 
Start oral corticosteroid 8(25.8) 23(74.2) 28(50.0) 28(50.0) 36(41.4) 51(58.6) 0.028 
Wait and see (no medication needed at this 
time) 
30(96.8) 1(3.2) 52(92.9) 4(7.1) 82(94.3) 5(5.7) NS 
Outpatient visit (e.g. Same day office visit 
or refer to Emergency Department) 





Table F 14 Vignette E 
























Increase current use of the inhaled β2 agonist 16(51.6) 15(48.4) 22(39.3) 34(60.7) 38(43.7) 49(56.3) NS 
Start inhaled Atrovent (ipratropium bromide) 17(54.8) 14(45.2) 25(44.6) 31(55.4) 42(48.3) 45(51.7) NS 
Increase an inhaled corticosteroid 11(35.5) 20(64.5) 21(37.5) 35(62.5) 32(36.8) 55(63.2) NS 
Add a non- steroid anti- inflammatory 20(64.5) 11(35.5) 37(66.1) 19(33.9) 57(65.5) 30(34.5) NS 
Start an oral theophylline 25(80.6) 6(19.4) 35(62.5) 21(37.5) 60(69.0) 27(31.0) 0.080 
Start oral corticosteroid 18(58.1) 13(41.9) 33(58.9) 23(41.1) 51(58.6) 36(41.4) NS 
Wait and see  no medication needed at this time) 27(87.1) 4(12.9) 48(85.7) 8(14.3) 75(86.2) 12(13.8) NS 
Outpatient visit (e.g. same day office visit or refer 
to Emergency Department) 







Table F 15 Vignette F 




















Increase current use of the inhaled β2 agonist 15(48.4) 16(51.6) 31(55.4) 25(44.6) 46(52.9) 41(47.1) NS 
Start inhaled Atrovent (ipratropium bromide) 21(67.7) 10(32.3) 34(60.7) 22(39.3) 55(63.2) 32(36.8) NS 
Increase an inhaled corticosteroid 12(38.7) 19(61.3) 30(53.6) 26(46.4) 42(48.3) 45(51.7) NS 
Add a non-steroid anti- inflammatory 21(67.7) 10(32.3) 37(66.1) 19(33.9) 58(66.7) 29(33.3) NS 
Start an oral theophylline 26(83.9) 5(16.1) 42(75.0) 14(25.0) 68(78.2) 19(21.8) NS 
Start oral corticosteroid 26(83.9) 5(16.1) 49(87.5) 7(12.5) 75(86.2) 12(13.8) NS 
Antibiotics  19(61.3) 12(38.7) 38(67.9) 18(32.1) 57(65.5) 30(34.5) NS 
Wait and see (no medication needed at this time) 25(80.6) 6(19.4) 49(87.5) 7(12.5) 74(85.1) 13(14.9) NS 
Outpatient visit (e.g. same day office visit or 
refer to Emergency Department ) 




Section 3: Patients’/ carers’ involvement  
Table F 16 Usual practices regarding patients’ involvement in decision-making 



















Usually, in your practice, to what extent does the 
average patient with asthma get involved with 
the management decisions about his/her disease? 
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
I make the decisions using all that is known 
about the treatment 
12(40) 3(23) 15 (34.9) 13 (50%) 5(27) 18(40.9) 25(44.4) 8(25.8) 33(37.9) 
I make the decisions, but strongly consider the 
patient’s opinion 
15(10.5) 8(61.5) 23 (53.5) 11 (43.3) 8(44.4) 19(43.2) 26(46.4) 16(51.6) 42(48.3) 
 The patient and I make the decisions together 
on an equal basis 
1(3.3) 1(7.7) 2 (4.7) 2 (7.7) 3(16.7) 5(11.4) 3(5.4) 4(12.9) 7(8.0) 
The patent makes the decisions, but strongly 
considers my opinion 
2(6.7) 0(0.0) 2(4.7) 0(0.0) 2(11.1) 2(4.5) 2(3.6) 2(6.5) 4(4.6) 
The patient makes the decisions using all the 
information he/she knows about the treatments 
0(0.0) 1(7.7) 1(2.3) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 1(3.2) 1(1.1) 
 Difference in Gender p value 0.341 0.176 0.235 






Table F 17 Ideal practices regarding patients’ involvement in decision making 





















Ideally, in your practice, to what extent does the 
average patient with asthma get involved   with 
the management decisions about his/her disease?  
N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
I make the decisions using all that is known 
about the treatment 
11(36.7) 6(46.2) 17(39.5) 13(50) 4(22.2) 17(38.6) 24(42.9) 10(32.3) 34(39.1) 
I make the decisions, but strongly consider the 
patient’s opinion 
15(10.5) 5(38.5) 20(46.5) 11(43.3) 9(50.0) 20(45.5) 26(46.4) 14(45.2) 40(46.0) 
 The patient and I make the decisions together 
on an equal basis 
3(10.0) 2(15.4) 5(11.6) 1(3.8) 4(22.2) 5(11.4) 4(7.1) 6(19.4) 10(11.5) 
The patent makes the decisions, but strongly 
considers my opinion 
1(3.3) 0(0.0) 1(2.3) 1(3.8) 1(5.6) 2(4.5) 2(3.6) 1(3.2) 3(3.4) 
The patient makes the decisions using all the 
information he/she knows about the treatments 
0(0.0) 0(0.0) 0(0.0) 0(0.0) 0(0.0%) 0(0.0) 0(0.0) 0(0.0) 0(0.0) 
 Difference in Gender p value 0.771 0.139 
0.395 





Appendix G:  
Phase Three Results 
Section 1: IMS Barriers  
Table G 1 Relationship between IMS barriers and both patients’ gender and possession of health insurance 
IMS total scores and factors Gender Health insurance 
Male (90) Female (87)  Yes (38) No (139)  
mean SD mean SD P mean SD mean SD P 
Total barriers scores 2.24 .43 2.26 .44 0.76 2.32 .47 2.24 .43 0.34 
Medication issues factor 1.97 .46 1.98 .49 0.93 2.09 .43 1.94 .48 0.09 
Doctor and other relationship factor 1.66 .45 1.70 .44 0.63 1.61 .48 1.69 .43 0.28 
Adherence influences factor 2.09 .48 2.01 .46 0.26 2.10 .47 2.04 .47 0.53 
Self-efficacy factor 1.75 .53 1.78 .50 0.68 1.94 .45 1.72 .52 0.02 




Table G 2 Relationship between IMS barriers and possession of both AAP and PFM 
IMS total scores and factors Possession AAP Possession PFM Adherence to PFM use 
Yes   
N =56 





 N =28 
No or unsure 
N=149 






mean SD mean SD mean SD mean SD mean SD mean SD 
Total barriers 2.25 .44 2.26 .44 0.93 2.40 .50 2.23 .42 0.07 2.63 .52 2.30 .47 0.12 
Medication issues factor 1.96 .46 1.98 .48 0.80 2.01 .54 1.97 .46 0.69 2.00 .53 2.00 .56 0.97 
Doctor and other relationship factor 1.57 .44 1.73 .44 0.02 1.78 .37 1.66 .45 0.19 1.64 .43 1.83 .35 0.24 
Adherences influences factor 2.10 .50 2.03 .46 0.36 2.15 .46 2.03 .47 0.22 2.33 .52 2.08 .43 0.20 
Self-efficacy factor 1. 71 .51 1.8 .50 0.03 1.90 .48 1.74 .51 0.117 1.97 .59 1.88 .45 0.7 






Table G 3 Relationship between IMS barriers and inhaled ICS 
IMS total scores and factors Inhaled ICS Adherence to ICS use 
Yes  
 N =118 
No / unsure 
N = 59 
P value Daily use 
 N =36 
Irregular use  
N =82 
P value 
mean SD mean SD mean SD mean SD 
Total barriers 2.20 .40 2.36 .48 0.04 2.08 .28 2.26 .44 0.01 
Medication issues factor 2.02 .46 1.87 .48 0.04 1.81 .43 2.11 .45 0.001 
Doctor and other relationship factor 1.62 .44 1.78 .44 0.02 1.48 .44 1.68 .42 0.02 
Adherences influences factor 2.06 .45 2.05 .50 0.87 2.12 .50 2.03 .43 0.39 
Self-efficacy factor 1.75 .53 1.79 .47 0.59 1.66 .54 1.79 .52 0.23 






Table G 4 Relationship between IMS barriers and patient’s/ carers’ beliefs 
IMS total scores and factors Medications useful Decision making involvement Adequate of information 
Yes 
 N =109 




No / unsure 
N = 78 
 Yes 
 N =66 
No / unsure  
 N = 111 
 
mean SD mean SD P mean SD mean SD P mean SD mean SD P 
Total barriers 2.17 .38 2.38 .49 0.003 2.18 .39 2.35 .48 0.02 2.24 .43 2.26 .44 0.78 
Medication issues factor 1.86 .47 2.14 .42 0.000 1.90 .45 2.07 .48 0.02 1.86 .51 2.04 .44 0.01 
Doctor and other relationship 
factor 
1.60 .43 1.8 .43 0.005 1.56 .46 1.82 .37 0.000 1.55 .47 1.75 .41 0.002 
Adherences Influences factor 2.02 .48 2.12 .45 0.16 2.10 .47 1.99 .47 0.15 2.02 .51 2.08 .44 0.40 
Self-efficacy factor 1.69 .48 1.88 .54 0.02 1.74 .50 1.79 .53 0.60 1.73 .47 1.78 .54 0.58 






Table G 5 Relationship between IMS barriers and both age groups and household income  
IMS total scores and factors Age group N=177 Household monthly income N=177 
 Responses N Mean Std. Dev P Responses N Mean Std. Dev P 
IMS Total barriers score 5 to less than 10 years 50 53.96 7.84  
.76 
 
Less than 5000 SR 80 53.49 7.34 .85 
10 to less than 15 years 43 52.81 7.46 5001- 10000 SR 54 53.09 7.14 
15 years to less than 18 84 53.55 7.21 10001-  20000 SR 43 53.98 8.04 
Factor a1 
Medication issues factor 
5 to less than 10 years 50 1.97 .47 .89 Less than 5000 SR 80 1.92 .46 .40 
10 to less than 15 years 43 1.95 .47 5001- 10000 SR 54 2.00 .45 
15 years to less than 18 84 1.99 .48 10001-  20000 SR 43 2.03 .52 
Factor a2 
Doctor and other relationship factor 
5 to less than 10 years 50 1.74 .49 .44 Less than 5000 SR 80 1.69 .46 .91 
10 to less than 15 years 43 1.63 .44 5001- 10000 SR 54 1.66 .45 
15 years to less than 18 84 1.66 .41 10001-  20000 SR 43 1.67 .42 
Factor a3 
Adherences influences factor 
5 to less than 10 years 50 2.02 .47 .63 Less than 5000 SR 80 2.04 .47 .93 
10 to less than 15 years 43 2.11 .45 5001- 10000 SR 54 2.07 .47 
15 years to less than 18 84 2.04 .48 10001-  20000 SR 43 2.06 .48 
Factor a4 
Self-efficacy factor 
5 to less than 10 years 50 1.800 .52 .48 Less than 5000 SR 80 1.75 .53 .31 
10 to less than 15 years 43 1.68 .42 5001- 10000 SR 54 1.70 .53 
15 years to less than 18 84 1.79 .55 10001-  20000 SR 43 1.86 .45 
factora5 
Negativity factor 
5 to less than 10 years 50 1.73 .49 .66 Less than 5000 SR 80 1.74 .51 .33 
10 to less than 15 years 43 1.63 .54 5001- 10000 SR 54 1.61 .45 






Table G 6 Relationship between IMS barriers and both patients’ and parents’ education level 
IMS total scores and factors  Patients’ education level N=177 Parents’ education level N=1774 
Responses N Mean Std. Dev P N Mean Std. Dev P 
IMS Total barriers score Primary school or less 65 53.17 7.75 .87 
 
33 52.82 7.57 .64 
 Secondary school 52 53.44 7.68 34 54.44 6.95 
High school or higher 60 53.87 6.92 107 53.27 7.50 
Factor a1 
Medication issues factor 
Primary school or less 65 1.96 .49 .62 
 
33 1.89 .56 .59 
 
 
Secondary school 52 1.93 .51 34 1.99 .34 
High school or higher 60 2.027 .42 107 1.99 .48 
Factor a2 
Doctor and other relationship factor 
Primary school or less 65 1.71 .45 .68 33 1.62 .44  
.32 
 
Secondary school 52 1.63 .43 34 1.77 .43 
High school or higher 60 1.67 .45 107 1.66 .44 
Factor a3 
Adherences Influences factor 
Primary school or less 65 2.01 .48 .57 
 
33 2.02 .51 .80 
 Secondary school 52 2.07 .46 34 2.02 .47 
High school or higher 60 2.09 .47 107 2.07 .45 
Factor a4 
Self-efficacy factor 
Primary school or less 65 1.73 .51 .22 33 1.92 .44 .15 
Secondary school 52 1.87 .50 34 1.76 .62 
High school or higher 60 1.70 .52 107 1.73 .49 
Factor a5 
Negativity factor 
Primary school or less 65 1.70 .51 .92 33 1.64 .51 .68 
Secondary school 52 1.66 .49 34 1.74 .467 






Table G 7 (A) Relationship between IMS barriers and asthma severity 
IMS total scores and factors Asthma severity (self-report)  N=177 Average times asthma awakens patients at night (self-report) N =17 
Responses N Mean Std. 
Deviation 
P Responses N Mean Std. 
Deviation 
P 
IMS Total barriers score Very Mild 12 53.58 7.56 .55 Not at all 51 52.08 7.21 .30 
Mild 33 53.00 7.45 Less than once a week 65 53.80 7.99 
Moderate 93 53.01 7.68 Once or twice a week 38 53.53 6.91 
Severe 39 55.00 6.76 Three or more times a week 21 55.67 7.16 
Factor a1 
Medication issues factor 
Very Mild 12 1.88 .55 .04 Not at all 51 1.87 .47 .03 
Mild 33 1.87 .40 Less than once a week 65 1.93 .50 
Moderate 93 1.94 .50 Once or twice a week 38 2.06 .44 
Severe 39 2.15 .41 Three or more times a week 21 2.21 .47 
Factor a2 
Doctor and other relationship 
Very Mild 12 1.85 .57 .49 Not at all 51 1.73 .40 .76 
Mild 33 1.70 .43 Less than once a week 65 1.66 .48 
Moderate 93 1.64 .45 Once or twice a week 38 1.64 .46 
Severe 39 1.68 .39 Three or more times a week 21 1.64 .41 
Factor a3 
Adherences influences factor 
Very Mild 12 1.96 .38 .43 Not at all 51 1.84 .43 .001 
Mild 33 1.98 .53 Less than once a week 65 2.18 .49 
Moderate 93 2.05 .48 Once or twice a week 38 2.11 .45 
Severe 39 2.15 .41 Three or more times a week 21 2.11 .39 
Factor a4 
Self-efficacy factor 
Very Mild 12 1.90 .45 .49 Not at all 51 1.74 .50 .59 
Mild 33 1.80 .47 Less than once a week 65 1.79 .50 
Moderate 93 1.78 .53 Once or twice a week 38 1.68 .48 
Severe 39 1.67 .51 Three or more times a week 21 1.84 .57 
Factor a5 
Negativity factor 
Very Mild 12 1.65 .45 .47 Not at all 51 1.76 .52 .66 
Mild 33 1.67 .569 Less than once a week 65 1.65 .52 
Moderate 93 1.69 .52 Once or twice a week 38 1.64 .52 






Table G 7 (B) Relationship between IMS barriers and asthma severity 
IMS total scores and factors Asthma symptoms (self-report)  N=177 Patients miss school or are unable to do normal daily activities (self-report)  N=174 
Responses N Mean Std. 
Deviation 
P Responses N Mean Std. 
Deviation 
P 
IMS Total barriers score Once per month 
or less 
76 52.96 7.44659 .68 
 
Once per month or less 93 52.69 7.74 .10 
 
Once per week 58 53.29 7.68916 Once per week 52 53.23 7.70 
Twice per week 26 54.81 5.89250 Twice per week 18 57.39 5.62 
Daily 17 54.47 8.71147 More than twice per week 11 54.73 5.10 
Factor a1 
Medication issues factor 
Once per month 
or less 
76 1.85 .46025 .003 
 
 
Once per month or less 93 1.86 .46 .001 
 
 Once per week 58 1.97 .45612 Once per week 52 2.02 .48 
Twice per week 26 2.21 .34499 Twice per week 18 2.20 .41 
Daily 17 2.15 .58000 More than twice per week 11 2.33 .43 
Factor a2 
Doctor and other relationship 
Once per month 
or less 




Once per month or less 93 1.69 .45 .65 
 
Once per week 58 1.63 .46422 Once per week 52 1.62 .45 
Twice per week 26 1.62 .41555 Twice per week 18 1.75 .41 
Daily 17 1.68 .40573 More than twice per week 11 1.68 .43 
Factor a3 
Adherences influences factor 
Once per month 
or less 
76 1.99 .49174 .39 
 
Once per month or less 93 2.01 .48 .32 
 
Once per week 58 2.10 .49267 Once per week 52 2.09 .50 
Twice per week 26 2.15 .34616 Twice per week 18 2.20 .39 
Daily 17 2.02 .44050  More than twice per week 11 1.94 .27 
Factor a4 
Self-efficacy factor 
Once per month 
or less 
76 1.73 .46068 .77 Once per month or less 93 1.74 .491 .96 
Once per week 58 1.81 .56644 Once per week 52 1.77 .53838 
Twice per week 26 1.79 .56 Twice per week 18 1.79 .52 
Daily 17 1.69 .48 More than twice per week 11 1.73 .52 
Factor a5 
Negativity factor 
Once per month 
or less 
76 1.71 .55 .61 Once per month or less 93 1.67 .539 .57 
Once per week 58 1.67 .50 Once per week 52 1.68 .53 
Twice per week 26 1.59 .40 Twice per week 18 1.85 .46 





Section 2: ICS Barriers  
Table G 8 Relationship between ICS barriers and both patients’ gender and possession of health insurance 
Total ICS scores and 
factors 
Gender Health insurance 
Male (90) Female (87)  Yes (38) No (139)  
mean SD mean SD P mean SD mean SD P 
Total barriers 38.67 7.97 37.05 8.40 0.2 39.13 7.39 37.53 8.40 0.25 
Factor 1 Health and 
medication literacy  
.0030 .97 .0031 1.04 0.97 .065 .56 -.018 1.09 0.66 
Factor 2 
Patients’ concerns and 
fears 
.085 .93 .088 1.07 0.25 .27 .83 -.08 1.03 0.056 
 
Factor 3’ 
Peer influence and 
personal beliefs  
.049 .90 .051 1.10 0.51 -.011 . 90 .003 1.03 0.94 
 
Factor 4  
Treatment cost, 
convenience and need 




Table G 9 Relationship between ICS barriers and possession of both AAP and PFM 
Total ICS scores and factors Possession  of AAP Possession  of PFM Adherence to PFM use 
Yes 
 N =56 
No / unsure 
N = 121 
P Yes 
 N =28 
No / unsure 
N =149 





mean SD mean SD mean SD mean SD mean SD mean SD 
Total barriers 36.82 9.03 38.36 7.77 0.25 37.75 6.93 37.89 8.44 0.92 37.25 8.53 37.95 6.42 0.84 
Factor 1 Health and medication 
literacy  
-.26 1.04 .12 .96 0.021 .16 .87 -.03 1.02 0.31 .40 .94 .064 .84 0.40 
Factor 2 
Patients’ concerns and fears 
.16 .87 -.08 1.05 0.12 -.27 1.18 .05 .96 0.18 -.65 
 
1.07 -.12 1.21 0.27 
Factor 3 
Peer influence and personal 
beliefs  
.12 1.04 -.06 .98 0.29 -.04 .87 .010 1.03 0. 82 .05 .78 -.07 .92 0.75 
Factor 4  
Treatment cost, convenience 
and need 
-.24 1.02 .11 .98 0.030 -.10 .79 .02 1.04 0.51 -.08 
 






Table G 10 Relationship between ICS barriers and Inhaled ICS 
Total ICS scores and 
factors 
Inhaled ICS Adherence to ICS use 
Yes  N =118 No / unsure  
N = 59 
P Daily use   
N =36 
Irregular use  
N =82 
P 
mean SD mean SD mean SD mean SD 
Total barriers 37.88 8.07 37.85 8.51 0.98 38.03 7.91 37.82 8.19 0.89 
Factor 1 Health and 
medication literacy  
-.021 1.01 .04 1.00 0.69 .26 .95 -.12 1.04 0.038 
Factor 2 
Patients’ concerns and 
fears 
.07 1.00 -.14 1.00 0.19 -.13 1.05 .16 .97 0.17 
Factor 3 
Peer influence and 
personal beliefs  
.03 .97 -.06 1.06 0.57 .07 .97 .01 .98 0.78 
Factor 4  
Treatment cost, 
convenience and need 






Table G 11 Relationship between ICS barriers and patients’/ carer’s beliefs 
Total ICS scores 
and factors 
Medications useful Decision making involvement Adequacy of information 
Yes   
N =109 
No / unsure  
N = 68 
P Yes   
N =99 
No / unsure  
N = 78 
P Yes   
N =66 
No / unsure  
N = 111 
P 
mean SD mean SD mean SD mean SD mean SD mean SD 
Total barriers 36.68 8.0 39.78 8.22 0.015 37.42 8.23 38.44 8.18 0.42 35.56 8.29 39.24 7.86 0.004 
Factor 1 Health 
and medication 
literacy  




-.16 .96 .26 1.01 0.007 .14 .93 .18 1.07 0.036 -.12 .97 
 
.20 1.02 0.038 
Factor 3 
Peer influence and 
personal beliefs  
-.17 .98 .28 .98 0.003 -.15 .90 .12 1.09 0.033 -.12 0.97 .20 1.02 0.040 









Table G 12 Relationship between ICS barriers and both age group and household income 
Total ICS scores and 
factors 
Age group N=177 Household’s monthly income N=177 
Responses N Mean Std. Dev P Responses N Mean Std. Dev P 
IMS Total barriers score 5 to less than 10 years 50 39.70 8.38 0.18 Less than 5000 SR 80 38.49 9.34 0.60 
10 to less than 15 years 43 37.02 7.44 5001- 10000 SR 54 37.03 7.25 
15 years to less than 18  84 37.21 8.38 10001-  20000 SR 43 37.77 7.03 
Factor 1-  Health and 
medication literacy 
5 to less than 10 years 50 .18 1.002 0.29 Less than 5000 SR 80 .065 1.21 0.57 
10 to less than 15 years 43 -.06 .85 5001- 10000 SR 54 -.015 .75 
15 years to less than 18  84 -.08 1.07 10001-  20000 SR 43 -.10 .85 
Factor 2  Patients’ 
concerns and fears 
5 to less than 10 years 50 -.005 .93 0.98 Less than 5000 SR 80 -.04 1.11 0.81 
10 to less than 15 years 43 .021 .95 5001- 10000 SR 54 -.01 .86 
15 years to less than 18  84 -.01 1.07 10001-  20000 SR 43 .08 .95 
Factor 3 Peer influence 
and personal beliefs 
5 to less than 10 years 50 .03 1.05 0.91 Less than 5000 SR 80 .09 1.11 0.49 
10 to less than 15 years 43 -.06 .88 5001- 10000 SR 54 -.12 .96 
15 years to less than 18  84 .015 1.03 10001-  20000 SR 43 -.003 .83 
Factor 4Treatment cost, 
convenience and need 
 
5 to less than 10 years 50 .15 .86 0.077 Less than 5000 SR 80 .07 1.00 0.67 
10 to less than 15 years 43 -.29 1.02 5001- 10000 SR 54 -.08 1.01 




Table G 13 Relationship between ICS barriers and both patients’ and parents’ education level 
Total ICS scores and factors Patients’ education level     N=177 Parents’ education level    N=1774 
Responses N Mean 
Std. 
Deviation 
P N Mean Std. Deviation P 
IMS Total barriers score Primary school or less 65 39.69 8.02 
0.078 
33 39.42 9.23 
0.22 Secondary school 52 36.75 8.50 34 38.85 7.95 
High school or higher 60 36.87 7.92 107 36.95 7.89 
Factor 1 Health and 
medication literacy 
Primary school or less 65 .23 1.06 
0.032 
33 .27 1.24 
0.24 Secondary school 52 -.01 .92 34 .00 .98 
High school or higher 60 -.24 .96 107 -.07 .91 
Factor 2  Patients’ concerns 
and fears 
Primary school or less 65 .13 .93 
0.24 
33 .00 1.09 
0.042 Secondary school 52 -.18 1.04 34 .35 .99 
High school or higher 60 .01 1.03 107 -.13 .99 
Factor 3 Peer influence and 
personal beliefs 
Primary school or less 65 -.05 1.15 
0.40 
33 -.00 1.12 
0.034 Secondary school 52 -.10 .83 34 .37 1.00 
High school or higher 60 .14 .96 107 -.14 .93 
Factor 4 Treatment cost, 
convenience and need 
Primary school or less 65 -.02 .95 
0.78 
33 -.074 1.25 
0.80 Secondary school 52 -.03 1.03 34 .09 .97 






Table G 14 (A) Relationship between ICS barriers and asthma severity 
Total ICS scores and 
factors 
Asthma severity (self-report)  N=177 Average times  asthma awakens patients at night (self-report)  N=175 
Responses N Mean Std. Dev P Responses N Mean Std. Devi P 
IMS Total barriers score Very Mild 12 38.42 9.26 .80 Not at all 51 38.06 8.38 .70 
Mild 33 36.67 8.76 Less than once a week 65 36.98 8.68 
Moderate 93 37.96 8.27 Once or twice a week 38 38.42 7.28 
Severe 39 38.51 7.38 Three or more times a week 21 39.10 7.50 
Factor 1 Health and 
medication literacy 
Very Mild 12 -.01 1.02 .42 Not at all 51 .14 .92 .18 
Mild 33 .07 1.09 Less than once a week 65 -.17 .99 
Moderate 93 -.11 .88 Once or twice a week 38 -.06 .97 
Severe 39 .20 1.19 Three or more times a week 21 .31 1.24 
Factor 2 Patients’ concerns 
and fears 
Very Mild 12 -.17 1.12 .90 Not at all 51 -.17 .88 .43 
Mild 33 -.05 .99 Less than once a week 65 .02 1.07 
Moderate 93 .004 .94 Once or twice a week 38 .11 .93 
Severe 39 .08 1.13 Three or more times a week 21 .19 1.15 
Factor 3 Peer influence and 
personal beliefs 
Very Mild 12 .29 1.14 .63 Not at all 51 .06 1.11 .91 
Mild 33 -.10 1.1 Less than once a week 65 -.02 1.03 
Moderate 93 .04 .95 Once or twice a week 38 -.00 .79 
Severe 39 -.09 .99 Three or more times a week 21 -.13 .98 
Factor 4 Treatment cost, 
convenience and need 
Very Mild 12 .10 1.23 .40 Not at all 51 -.05 1.05 .96 
Mild 33 -.27 1.03 Less than once a week 65 -.00 .96 
Moderate 93 .06 .90 Once or twice a week 38 .06 1.06 






Table G 14 (B) Relationship between ICS barriers and asthma severity 
Total ICS scores and 
factors 
Asthma symptoms (self-report)  N=177 Patients miss school or are unable to do normal daily activities (self-report)  
N=174 
Responses N Mean Std. Dev P Responses N Mean Std. Dev P 
IMS Total Barriers 
score 
Once per month or less 76 37.38 8.33 .61 
 
Once per month or less 93 37.48 8.03 .55 
 Once per week 58 37.74 8.34 Once per week 52 37.85 9.24 
Twice per week 26 39.85 7.19 Twice per week 18 37.61 6.88 
Daily 17 37.47 8.81 More than twice per week 11 41.27 5.27 
Factor 1 Health and 
medication literacy 
Once per month or less 76 -.02 1.01 .88 
 
 
Once per month or less 93 .03 1.00 .04 
 
 
Once per week 58 -.04 .90 Once per week 52 -.16 .99 
Twice per week 26 .03 .95 Twice per week 18 -.12 .77 
Daily 17 .18 1.38 More than twice per week 11 .73 1.29 
Factor 2  Patients’ 
concerns and fears 




Once per month or less 93 -.09 .91 .32 
 Once per week 58 -.03 1.03 Once per week 52 .16 1.11 
Twice per week 26 .26 .99 Twice per week 18 -.20 . 90 
Daily 17 .10 1. 20 More than twice per week 11 .27 1.19 
Factor 3 Peer influence 
and personal beliefs 
Once per month or less 76 .09 1.15 .17 
 
Once per month or less 93 -.02 1.12 .54 
 Once per week 58 -.08 .82 Once per week 52 .10 .82 
Twice per week 26 .19 .75 Twice per week 18 -.03 .63 
Daily 17 -.43 1.90  More than twice per week 11 -.38 1.15 
Factor 4 Treatment cost, 
convenience and need 
Once per month or less 76 -.11 1.10 .56 Once per month or less 93 -.05 1.04 .04 
 Once per week 58 .12 .91 Once per week 52 -.12 .87 
Twice per week 26 .10 .97 Twice per week 18 .58 .92 




Appendix H:  
Phase Four Results 
This appendix reflects the significant association between aspects and both gender 
and age groups. 
Group A: Education and AAPs 
Table H 1 Self-reported asthma symptoms 
Stage 
Asthma symptoms  
Wheezing during the day when not exercising Asthma symptoms P value 
                     gender 
Response  
Male (90) Female (45) Total (135) 





None 11  12.2 8 17.8 19 14.1 
1 to 3 71 78.9 26 57.8 97 71.9 
4 to 7 5 5.6 9 20.0 14 10.4 
over 7 3 3.3 2 4.4 5 3.7 
Total 90 66.7 45 33.3 135 100.0 
 
Table H 2 Maximum frequency of quick reliever use in past 4 weeks 
Stage 
Maximum daily use (Times of Day) P value 
                     Gender 
Response  
Male (69) Female (36) Total (105)  





None 32 46.4 6 16.7 38 36.2 
1 to 2 36 52.2 29 80.6 65 61.9 
3 to 4 1 1.4 1 2.8 2 1.9 
5 to 6 0 00.0 0 00.0 0 00.0 
over 6 0 00.0 0 00.0 0 00.0 






Table H 3 Number of patients using control medication 
Stage 
Use of control medication P value 
                     Gender 
Response  
Male (90) Female (45) Total (135) 





Unsure 24 26.7 11 24.4 35 25.9 
No 1 1.1 7 15.6 8 5.9 
Yes 65 72.2 27 60.0 92 68.1 
Total 90 66.7 45 33.3 135 100.0 
Table H 4 Peak flow meter (PFM) and spacer usage 
Stage 
Spacer usage P 
value                      
Age 
Response  
5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Unsure 5 11.1 2 5.7 3 5.5 10 7.4 
No 30 66.7 22 62.9 50 90.9 102 75.6 
Yes 10 22.2 11 31.4 2 3.6 23 17.0 




Unsure 7 20.0 5 17.9 3 7.1 15 14.3 0.000 
No 12 34.3 10 35.7 36 85.7 58 55.2 
Yes 16 45.7 13 46.4 3 7.1 32 30.5 
Total 35 33.3 28 26.7 42 40.0 105 100.0 
Table H 5 Accessible information 
Stage 




                     
Age 
Response  
5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Unsure 12 26.7 9 25.7 20 36.4 41 30.4 
No 15 33.3 17 48.6 28 50.9 60 44.4 
Yes 18 40.0 9 25.7 7 12.7 34 25.2 





Table H 6 Peak flow meter usage education 
Stage 
Peak flow meter usage education 
 
P value 
                     Gender 
Response  
Male (90) Female (45) Total (135) 





Unsure 1 1.4 4 11.1 5 4.8 
No 0 00.0 1 2.8 1 1.0 
Yes 68 98.6 31 86.1 99 94.3 
Total 69 65.7 36 34.3 105 100.0 
 
Table H 7 Avoiding severe asthma attack 
Stage 
Peak flow meter usage education 
 
P value 
                     Gender 
Response  
Male (90) Female (45) Total (135) 





Easy 19 27.5 2 5.6 21 20.0 
Moderate 47 68.1 32 88.9 79 75.2 
Difficult 3 4.3 2 5.6 5 4.8 
Very difficult 0 00.0 0 00.0 0 00.0 
Total 69 65.7 36 34.3 105 100.0 
 
Table H 8 Patient knowledge domain 
Stage 
Patient knowledge level P 
value                      
Age 
Response  
5 to less 
than 10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Patient has good 
knowledge 
30 85.7 19 67.9 39 92.9 88 83.8 
Has a lack of 
knowledge 
5 14.3 9 32.1 3 7.1 17 16.2 







Group B: Education only 
Table H 9 Quick relief medication use 
Stage 
Quick relief medication use P value 
                     Gender 
Response  
Male (82) Female (53) Total (135) 





Unsure 0 00.0 5 9.4 5 3.7 
No 3 3.7 3 5.7 6 4.4 
Yes 79 96.3 45 84.9 124 91.9 
Total 82 60.7 53 39.3 135 100.0 
Table H 10 Number of patients using control medication 
Stage 
Use of control medication P 
value                      
Age 
Response  
5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Unsure 16 42.1 13 35.1 21 35.0 50 37.0 
No 9 23.7 16 43.2 11 18.3 36 16.7 
Yes 13 34.2 8 21.6 28 46.7 49 36.3 




Unsure 0 00.0 1 3.6 10 24.4 11 11.1 0.006 
No 6 20.0 3 10.7 3 7.3 12 12.1 
Yes 24 80.0 24 85.7 28 68.3 76 76.8 
Total 30 30.3 28 28.3 41 41.4 99 100.0 
 
Table H 11 Inhaled corticosteroid (ICS) 
Stage 
Use of an inhaled corticosteroid P 
value                      
Age 
Response  
5 to less than 
10 yrs. 
10 to less than 
15 yrs. 
15 to less than 
18 yrs. 
Total  





Don’t know 0 00.0 3 10.7 13 31.7 16 16.2 
No 6 20.0 2 7.1 3 7.3 11 11.1 
Yes 24 80.0 23 82.1 25 61.0 72 72.2 




Table H 12 Spacer use and gender 
Stage 
Spacer use P value 
                     Gender 
Response  
Male (82) Female (53) Total (135) 





Unsure 0 00.0 5 9.4 5 3.7 
No 70 85.4 41 77.4 111 82.2 
Yes 12 14.6 7 13.2 19 14.1 
Total 82 60.7 53 39.3 135 100.0 
 
Table H 13 Spacer use and age 
Stages 





Spacer use P 
value 5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Unsure 1 2.6 1 2.7 3 5.0 5 3.7 
No 25 65.8 32 86.5 54 90.0 11
1 
82.2 
Yes 12 31.6 4 10.8 3 5.0 19 14.1 







Unsure 2 6.7 0 00.0 1 2.4 3 3.0 0.017 
No 17 56.7 21 75.0 37 90.2 75 75.8 
Yes 11 36.7 7 25.0 3 7.3 21 21.2 







Table H 14 Follow up 
Stages 




                     
Age 
Response  
5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





Unsure 9 21.1 5 13.5 7 11.7 21 15.6 
No 8 21.1 15 40.5 32 53.3 55 40.7 
Yes 21 55.3 17 45.9 21 35.0 59 43.7 





Table H 15 Accessibility of information 
Stage 







5 to less than 
10 yrs. 
10 to less than 
15 yrs. 
15 to less than 
18 yrs. 
Total  





Unsure 3 10.0 3 10.7 13 31.7 1
9 
19.2 
No 1 3.3 0 00.0 3 7.3 4 4.0 
Yes 26 86.7 25 89.3 25 61.0 7
6 
76.8 




Table H 16 Number of patients admitted to hospital or who attended ER 
Stage 




5 to less than 
10 yrs. 
10 to less 
than 15 yrs. 
15 to less 
than 18 yrs. 
Total  





No 5 13.2 14 37.8 26 43.3 45 33.3 
Yes 33 86.6 23 62.2 34 56.7 90 66.7 
















































































Appendix M:  
Questionnaires in Arabic  
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